# 60th EASD Annual Meeting

<table>
<thead>
<tr>
<th>Content</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Address</td>
<td>2</td>
</tr>
<tr>
<td>About EASD</td>
<td>4</td>
</tr>
<tr>
<td>About EFSD</td>
<td>5</td>
</tr>
<tr>
<td>General Information</td>
<td>6</td>
</tr>
<tr>
<td>Registration</td>
<td>7</td>
</tr>
<tr>
<td>Certificates</td>
<td>7</td>
</tr>
<tr>
<td>In person attendance onsite in Madrid</td>
<td>8</td>
</tr>
<tr>
<td>Floorplan</td>
<td>10</td>
</tr>
<tr>
<td>Online attendance via Virtual Meeting platform</td>
<td>13</td>
</tr>
<tr>
<td>Virtual Meeting App</td>
<td>13</td>
</tr>
<tr>
<td>Speakers and Chairpersons</td>
<td>16</td>
</tr>
<tr>
<td>Programme</td>
<td>18</td>
</tr>
<tr>
<td>Programme Committee</td>
<td>18</td>
</tr>
<tr>
<td>Abstract Review</td>
<td>19</td>
</tr>
<tr>
<td>Programme Overview</td>
<td>20</td>
</tr>
<tr>
<td><strong>Tuesday, 10 September 2024</strong></td>
<td>28</td>
</tr>
<tr>
<td>Claude Bernard Lecture</td>
<td>28</td>
</tr>
<tr>
<td>Short Oral Discussions Event A</td>
<td>35</td>
</tr>
<tr>
<td>Short Oral Discussions Event B</td>
<td>37</td>
</tr>
<tr>
<td>Camillo Golgi Lecture</td>
<td>44</td>
</tr>
<tr>
<td><strong>Wednesday, 11 September 2024</strong></td>
<td>48</td>
</tr>
<tr>
<td>Albert Renold Lecture</td>
<td>48</td>
</tr>
<tr>
<td>Short Oral Discussions Event C</td>
<td>57</td>
</tr>
<tr>
<td>Short Oral Discussions Event D</td>
<td>59</td>
</tr>
<tr>
<td>Minkowski Lecture</td>
<td>68</td>
</tr>
<tr>
<td><strong>Thursday, 12 September 2024</strong></td>
<td>72</td>
</tr>
<tr>
<td>Rising Star Symposium</td>
<td>73</td>
</tr>
<tr>
<td>Short Oral Discussions Event E</td>
<td>83</td>
</tr>
<tr>
<td>Short Oral Discussions Event F</td>
<td>85</td>
</tr>
<tr>
<td>Diabetes Prize for Excellence Lecture</td>
<td>93</td>
</tr>
<tr>
<td><strong>Friday, 13 September 2024</strong></td>
<td>98</td>
</tr>
<tr>
<td>Short Oral Discussions</td>
<td>115</td>
</tr>
<tr>
<td>Abstract Presenter Index - Orals and Short Orals</td>
<td>220</td>
</tr>
<tr>
<td>Invited Speaker Index</td>
<td>232</td>
</tr>
<tr>
<td>Satellite Symposia on the occasion of EASD 2024</td>
<td>235</td>
</tr>
<tr>
<td>Industry Sessions on the occasion of EASD 2024</td>
<td>255</td>
</tr>
<tr>
<td>EASD and EFSD Acknowledgements</td>
<td>308</td>
</tr>
</tbody>
</table>
Dear Members and Guests,

On behalf of the European Association for the Study of Diabetes, it is my honour and pleasure to welcome you to Madrid for the 60th EASD Annual Meeting.

Joining us in Madrid is an excellent opportunity to stay up to date with recent developments in the diabetes field. You will be at the interface between discovery science and clinical practice, where key discussions take place that will move the field forward.

You can look forward to an exceptional scientific programme that extensively covers scientific research, current treatments, technologies, and care. The EASD Annual Meeting provides the perfect setting to exchange ideas and network with peers from all over the world, connecting the global diabetes community, sharing groundbreaking diabetes science and research, and offering educational opportunities.

Celebrate with us the 60th anniversary of EASD’s Annual Meetings: I warmly invite you to register for a welcome reception in the Plaza de Toros de las Ventas - the bullring – on the evening of Tuesday, 10 September 2024.

Madrid, Spain’s vibrant capital, offers great options outside of the scientific programme hours. Its rich history, stunning architecture, diverse culture, exquisite gastronomy, and lively entertainment provide a variety of choices for how to spend your evenings.

The EASD Board and the entire EASD team look forward to welcoming all of you in Madrid. For those who might not be able to travel, we invite you to join us virtually.

Join us in our mission to promote excellence in diabetes care through research, networking, and education!

**Chantal Mathieu**
President EASD/EFSD
Dear Colleagues and Friends,

On behalf of the Scientific Programme Committee, I am delighted to welcome you to the EASD Annual Meeting 2024 in Madrid, Spain.

The Scientific Programme Committee, together with the Abstract Review Committee, reviewed more than 2,000 submitted abstracts and selected over 1,000 to create the backbone of the scientific programme. For the first time in the history of EASD Annual Meetings, we have included late-breaking abstracts to ensure we capture the latest hot topics in diabetes research and care.

The programme comprises seven parallel streams featuring inspiring symposia, oral and short oral presentations, award lectures, debates, and discussions. It will undoubtedly provide a great opportunity for participants to update their knowledge about the latest innovations and developments in the treatment of type 1 and type 2 diabetes and their associated complications.

Whether you are a clinician, basic scientist, nurse, healthcare professional, or young academic, I sincerely hope that the scientific programme of the EASD Annual Meeting 2024 will offer everyone interesting topics and an abundance of new knowledge.

Attending the Annual Meeting is more than just following the scientific programme – it is also a unique opportunity to communicate with colleagues from all over the world and learn from each other’s experiences and expertise.

We look forward to welcoming you to an exceptional meeting from 9 - 13 September 2024 in Madrid.

Tina Vilsbøll
Honorary Secretary EASD
About EASD

The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany.

EASD is a network with active members from all over the world. Membership is open to scientists, physicians, students, postdocs and fellows, allied health professionals and nurses who are interested in the field of diabetes or related diseases.

The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific programme includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research.

EASD is also a leading player in postgraduate education having trained thousands of healthcare professionals through dedicated training courses and online education activities.

The Association is actively involved in producing and endorsing statements and guidelines translating the latest results from diabetes research into best practices in diabetes management.

By creating the Early Career Academy, EASD has increased its commitment to support, train, mentor, and create opportunities for scientists, clinicians, and students who are at an early or intermediate stage of their career.

EASD is the publisher of the journal *Diabetologia*, a major monthly international diabetes journal with a high and rising impact factor.

For more information, please visit: [www.easd.org](http://www.easd.org).
About EFSD

The European Foundation for the Study of Diabetes (EFSD) was created by EASD to stimulate diabetes research in Europe. EFSD was founded in 2000 and has become a significant European funding agency for diabetes research, and is continually striving to enhance diabetes awareness in Europe.

The Foundation offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives. Awards are strictly competitive and decisions are based upon a rigorous and fully independent peer-review process.

Funding streams are available throughout the year and since inception, EFSD has committed over €130 million to European diabetes research by way of a wide range of grant and fellowship funding initiatives.

For more information about EFSD and the funding programmes, please visit: www.europeandiabetesfoundation.org.

EFSD Scientific Board:

H. Al-Hasani, Germany
M. Blüher, Germany
F. Bosch, Spain
A. Boulton, UK
M. Donath, Switzerland
G.P. Fadini, Italy
M. Federici, Italy
N. Lalic, Serbia
M. Nauck, Germany
F. Pociot, Denmark
U. Smith, Sweden
**General Information**

**Format**

The 60th EASD Annual Meeting will take place as a hybrid event from 9 to 13 September 2024, providing the option to join us in person in Madrid, Spain or online via the Virtual Meeting platform.

All sessions in the scientific programme will take place onsite at the meeting venue in Madrid, Spain at the times indicated in the programme and will be live-streamed for delegates attending the meeting virtually.

Recordings of all sessions will be available, access to recordings will be limited to registered delegates until 11 October 2024.

**Meeting venue**

The in person meeting will take place in halls 9 & 10 and the North Convention Centre at:

**IFEMA Convention Center - Feria de Madrid**

Avda. del Partenón, 5, 28042 Madrid, Spain

---

**Advisory Note**

Please be aware of ‘fraudulent’ websites and companies offering EASD services e.g. registration or hotel accommodation.

EASD is the official registration provider and all activities are handled via the official EASD website: [www.easd.org](http://www.easd.org).
For online attendance, the Virtual Meeting platform can be accessed directly or via the EASD website www.easd.org.

**Registration**

Children under the age of 18 are not permitted to access the 60th EASD Annual Meeting.

**Types of registration for the Annual Meeting:**

**In person attendance** to join onsite at the meeting venue in Madrid, Spain. In person attendees receive:

- Name Badge / Congress Material
- Access to the Scientific Programme
- Access to the Exhibition
- Public transportation ticket valid for 5 days
- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates in person and / or virtual attendance

**Virtual attendance** to follow the Annual Meeting online. Virtual attendees receive:

- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates watch time

All registrations prior to the EASD Annual Meeting dates have to be made by means of the secured online registration system. For more information, please visit: www.easd.org/annual-meeting/easd-2024.html.

During the EASD Annual Meeting dates, in person registrations can be made by the online registration system or at the onsite registration counter at the venue in Madrid, Spain.

Virtual registrations can only be made by the online registration system.

**Certificates**

Certificates will be available for download via your / the delegate’s MyEASD account. It will be mandatory to complete the congress evaluation survey to receive certification.

In person attendance will be checked. Virtual watch time will be monitored via the MyEASD account. This data will be the basis for certification.
Certificate of Attendance

The Certificate of Attendance will be available online from 16 September 2024, 10:00 hrs CEST.

A minimum watch time / attendance of 60 minutes from 9 September 2024, 9:00 hrs CEST to 11 October 2024, 23:59 hrs CEST (in person / live stream and on demand sessions) is required to be entitled to receive the Certificate of Attendance.

Information for in person attendance onsite in Madrid

Registration counters are open:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8 September 2024</td>
<td>12:00 - 18:00</td>
</tr>
<tr>
<td>Monday</td>
<td>9 September 2024</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>10 September 2024</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>11 September 2024</td>
<td>07:30 - 19:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>12 September 2024</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Friday</td>
<td>13 September 2024</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

Badges:

The delegates’ name badges serve as an admission pass to all scientific sessions and the exhibition. Delegates are asked to keep their name badges displayed at all times during the meeting. Badges can be replaced and will be charged for.

First Aid:

The First Aid is located on the Mezzanine floor between Halls 7 and Hall 9. In case of emergency, please contact the nearest security or staff member or call the emergency number +34 91 722 54 00
Restaurants:
There are various eateries located along the Avenida.

Cloakroom/Lost and Found Counter:
A cloakroom with facilities for luggage storage and lost and found is located in basement of the North Convention Centre.

Suitcases (except cabin trolleys) are not allowed in the halls.

EASD Community Plaza:
The EASD Community Plaza is located in Hall 10 and includes the EASD Member Lounge, the EASD/EFSD and Diabetologia Booth, e-Poster Viewing Stations, seating areas and charging stations for mobile devices.

Opening hours EASD Booth and Member Lounge:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Opening Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>10 September 2024</td>
<td>08:00 - 18:30</td>
</tr>
<tr>
<td>Wednesday</td>
<td>11 September 2024</td>
<td>08:00 - 18:30*</td>
</tr>
<tr>
<td>Thursday</td>
<td>12 September 2024</td>
<td>08:00 - 18:30</td>
</tr>
<tr>
<td>Friday</td>
<td>13 September 2024</td>
<td>08:00 - 15:00</td>
</tr>
</tbody>
</table>

*Member Lounge will close at 18:00 on Wednesday, 11 September 2024

Exhibition - Opening Hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Opening Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday</td>
<td>10 September 2024</td>
<td>09:00 - 16:30</td>
</tr>
<tr>
<td>Wednesday</td>
<td>11 September 2024</td>
<td>09:30 - 16:30</td>
</tr>
<tr>
<td>Thursday</td>
<td>12 September 2024</td>
<td>09:30 - 16:30</td>
</tr>
</tbody>
</table>

Hotels:
For individual accommodation, please use the Hotel Booking Page provided by our official hotel booking partner INTERPLAN Congress, Meeting & Event Management AG.

For group accommodation, please use the Hotel Booking Page provided by our official hotel booking partner INTERPLAN Congress, Meeting & Event Management AG or contact them directly by email: hotels.easd@interplan.de

Security:
Any suspicious or unidentified items onsite at the meeting venue are to be reported immediately to the nearest staff member. Security staff are on duty to ensure that all persons entering the venue are wearing a badge. For your safety, it is strongly advised to leave all your valuables in a safe at your hotel.
Insurance:
The registration fees do not include the insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate insurance especially with regards to travel.

Travel

Special Iberia airlines fares:
A 15% discount for bookings made directly on the Iberia website. Discount is only valid for round trips operated by Iberia, Iberia Express and Air Nostrum within the period 2 - 20 September 2024. Please enter the promotional code EASDIF24 in the designated field during the payment process.

Special Renfe train fares:
A 5% discount for travelling to Madrid, Spain on AVE (High Speed)-Long Distance trains. Discount is valid for travel between 7 and 15 September 2024.

Visit the Renfe website and select the train of your choice by checking any of the available options. Then select the Congress/Events (Congresos/Ferias) fare from the fare drop-down menu on the Discount and Promotion Section of the Passenger Information page. Enter the authorization number 052404685 in the box indicating authorization number (not valid for discount code box).

If purchasing from a Renfe ticket office, travel agent/shop, please bring a printed copy of the voucher.

Transportation

Registered delegates will receive a free pass to the Madrid City Transportation System to easily travel to/from the congress venue.

The public transport card covers the metropolitan area (Zona A) and is valid for 5 days.

By metro, the venue can be reached using metro line 8. Get off at the Feria de Madrid subway station, access the IFEMA Convention Center at the south entrance and take the hallway through the convention center down to the north entrance.
Information for online attendance via the Virtual Meeting platform

Registered delegates can access the Virtual Meeting platform by using the MyEASD account connected to the registration (respective email is provided on the registration confirmation).

The Virtual Meeting platform can be accessed directly or via the EASD website www.easd.org.

Technical requirements:

Delegates must ensure at their own expense that they meet the technical requirements necessary for following the EASD Annual Meeting virtually.

In addition to the necessary hardware, the following requirements will be needed:

- A stable internet connection with a minimum of 5 MBITs (data speed) to follow the online programme,
- A browser in an up-to-date version e.g. Chrome®, Firefox® or Safari®.

EASD recommends the participation via PC/Mac Computers and a resolution of Full HD 1920x1080 pixels or higher. Cookie and Pop-Up blocking measures may lead to problems. On smart phone/tablet devices only basic viewing features are being supported. It is recommended to use the Safari® browser for Apple® devices.

Please note: When using the Safari® browser on Apple® devices, you will need to enable pop-ups. Pop-ups are disabled by default in the Safari® browser. Please go to the settings of your Safari® browser and enable pop-ups.

For further instructions how to enable pop-ups, please see here.

EASD is not responsible if delegates are unable to successfully access the virtual meeting platform if they do not fulfil the technical requirements.

EASD Virtual Meeting App

The EASD Virtual Meeting app provides access to the programme, speakers, floorplans, live sessions, on-demand content and other opportunities.

App will be available to download from the Apple Store and Google Play shortly before the Annual Meeting begins.
Speakers and Chairpersons

All speakers and chairpersons are expected to attend the EASD Annual Meeting in Madrid, Spain, in person to participate live at the time indicated in the programme.

Speakers’ Lounge:

The Speakers’ Lounge is located in Hall 9 on the 1st floor. All speakers are asked to check their presentations at the Speakers’ Lounge at least three hours before the scheduled presentation time. If the presentation is scheduled in the morning, speakers are kindly asked to check their presentation at the Speakers’ Lounge the day before.

Speakers’ Lounge - Opening Hours:

<table>
<thead>
<tr>
<th>Day</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td>8 September 2024</td>
<td>12:00 - 18:00</td>
</tr>
<tr>
<td>Monday</td>
<td>9 September 2024</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>Tuesday</td>
<td>10 September 2024</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Wednesday</td>
<td>11 September 2024</td>
<td>07:00 - 19:00</td>
</tr>
<tr>
<td>Thursday</td>
<td>12 September 2024</td>
<td>08:00 - 19:00</td>
</tr>
<tr>
<td>Friday</td>
<td>13 September 2024</td>
<td>08:00 - 14:00</td>
</tr>
</tbody>
</table>

Short Oral Discussions Events:

Short Oral Discussions rank equally with Oral Presentations. All Short Oral Discussions will take place during six events which will be held on Tuesday, Wednesday and Thursday

<table>
<thead>
<tr>
<th>Event A</th>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Oral Discussions Event A</td>
<td>Tuesday</td>
<td>12:30 - 13:30</td>
</tr>
<tr>
<td>Short Oral Discussions Event B</td>
<td>Tuesday</td>
<td>13:45 - 14:45</td>
</tr>
<tr>
<td>Short Oral Discussions Event C</td>
<td>Wednesday</td>
<td>12:45 - 13:45</td>
</tr>
<tr>
<td>Short Oral Discussions Event D</td>
<td>Wednesday</td>
<td>14:00 - 15:00</td>
</tr>
<tr>
<td>Short Oral Discussions Event E</td>
<td>Thursday</td>
<td>12:45 - 13:45</td>
</tr>
<tr>
<td>Short Oral Discussions Event F</td>
<td>Thursday</td>
<td>14:00 - 15:00</td>
</tr>
</tbody>
</table>

Disclaimer

All efforts will be made to adhere to the programme as provided. However, EASD and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Meeting, for any case beyond their reasonable control. EASD and the local conference organisers are not liable for any other loss or inconvenience caused as a result of such changes.
Programme Committee

Tina Vilsbøll, Denmark, Chair
Leszek Czupryniak, Poland
Eelco De Koning, Netherlands
Fiona Gribble, United Kingdom
Marit E. Jørgensen, Greenland
Tomasz Klupa, Poland
Timo Müller, Germany
Patrick Schrauwen, Netherlands
Matthias Tschöp, Germany

Sofia Carlsson, Sweden
Dana Dabelea, USA
Lena Eliasson, Sweden
Niels Jessen, Denmark
Janaka Karalliedde, United Kingdom
Beatriz Merino Antolin, Spain
Niina Sandholm, Finland
Tsvetalina Tankova, Bulgaria
Daniël van Raalte, Netherlands
**Abstracts**

1814 abstracts were received by the Association and 1064 abstracts were accepted for inclusion. All abstracts were reviewed anonymously and scored by the Abstract Review Committee members.

The Programme Committee members designed the programme and created Oral and Short Oral Discussion sessions upon the accepted abstracts.

**Publication of Abstracts**

Accepted abstracts are published in the Abstract Volume by Diabetologia. Abstracts are also available online.

**Embargo Policies**

Information contained in abstracts may not be released until 1 July 2024 when the abstracts are published online. Oral Presentations are under embargo until the commencement of the speaker’s presentation. Short Oral Discussion Presentations are under embargo until 12:30 CEST on Tuesday, 10 September 2024.

**Abstract Review Committee**

In addition to the members of the Programme Committee, the Abstract Review Committee comprises the following members:

- Alice Adriaenssens, United Kingdom
- Paloma Alonso-Madalena, Spain
- Francesca Amati, Switzerland
- Andreas Andersen, Denmark
- Caroline Bonner, France
- Christoffer Clemmensen, Denmark
- Miriam Cnop, Belgium
- Rumyana Dimova, Bulgaria
- Samy Hadjadj, France
- Sofie Hædersdal, Denmark
- Irina Kowalska, Poland
- Sanna Lehtonen, Finland
- Timo Otonkoski, Finland
- Nicolae M. Panduru, Romania
- Kashyap A. Patel, United Kingdom
- Lorenzo Piemonti, Italy
- Thomas Stulnig, Austria
- Tricia Tan, United Kingdom
- German Tapia, Norway
- Florian Toti, Albania
- Daniel R. Witte, Denmark
- Dorota Zozulinska, Poland
## Tuesday, 10 September 2024

<table>
<thead>
<tr>
<th>TIME</th>
<th>MADRID HALL</th>
<th>LONDON HALL</th>
<th>BERLIN HALL</th>
<th>VIENNA HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Presidential Address</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>56th Claude Bernard Lecture</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>OP 1</td>
<td>OP 2</td>
<td>OP 3</td>
<td>OP 4</td>
</tr>
<tr>
<td>12:00</td>
<td>OP 7</td>
<td>OP 8</td>
<td>OP 9</td>
<td>OP 10</td>
</tr>
</tbody>
</table>
| 12:30  | Short Oral Discussion Sessions  
            Event A                                 |             |             |             |
| 13:00  |                                                |             |             |             |
| 13:45  | Short Oral Discussion Sessions  
            Event B                                 |             |             |             |
<p>| 14:00  |                                                |             |             |             |
| 15:15  | 39th Camillo Golgi Lecture                       | Adipose tissue control of energy and glucose metabolism | A paradigm change for basal insulin replacement? Results from the QWINT programme of insulin efsitora alfa | Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management and future directions |
| 16:15  |                                                |             |             |             |
| 17:15  | 39th Camillo Golgi Lecture                       | Adipose tissue control of energy and glucose metabolism | A paradigm change for basal insulin replacement? Results from the QWINT programme of insulin efsitora alfa | Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management and future directions |
| 18:15  |                                                |             |             |             |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>SYDNEY HALL</th>
<th>SOFIA HALL</th>
<th>CAIRO HALL</th>
<th>SPOTLIGHT STAGE</th>
<th>PROGRAMME</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>OP 5</td>
<td>OP 6</td>
<td>LBA OP 1</td>
<td>12:00</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>OP 11</td>
<td>OP 12</td>
<td>LBA OP 2</td>
<td>16:45</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td>The forgotten few or many? Delivering diabetes care to people at the margins of society</td>
<td>Amylin for treatment of metabolic diseases</td>
<td>Youth-onset type 2 diabetes: a key challenge for the future</td>
<td>17:15</td>
<td>18:15</td>
</tr>
</tbody>
</table>
### Wednesday, 11 September 2024

<table>
<thead>
<tr>
<th>TIME</th>
<th>MADRID HALL</th>
<th>LONDON HALL</th>
<th>BERLIN HALL</th>
<th>VIENNA HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:30</td>
<td>FLOW: the first dedicated kidney outcomes trial with GLP-1 RA, semaglutide, in patients with type 2 diabetes and CKD</td>
<td>18th Albert Renold Lecture (09:00 - 10:00)</td>
<td>Emerging topics in the etiology of type 1 diabetes</td>
<td>EASD/EASL/EASO symposium: a new joint guideline for metabolic dysfunction-associated steatotic liver diseases (MASLD)</td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td>OP 13</td>
<td>OP 14</td>
<td>OP 15</td>
<td>OP 16</td>
</tr>
<tr>
<td>12:45 - 13:45</td>
<td>Short Oral Discussion Sessions Event C</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>Short Oral Discussion Sessions Event D</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>OP 19</td>
<td>LBA OP 3</td>
<td>OP 20</td>
<td>OP 21</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>59th Minkowski Lecture</td>
<td>Taking a COMBINED approach: insulin icodex and semaglutide</td>
<td>Addressing the lack of treatment options to reduce the morbidity/mortality gap in type 1 diabetes</td>
<td>EASD/ESSM Symposium: When sex is ex (for her or for him)</td>
</tr>
<tr>
<td>Hall</td>
<td>Hall</td>
<td>Hall</td>
<td>Hall</td>
<td>Time</td>
</tr>
<tr>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>EASD/ESC</strong> Symposium: Impact of type 2 diabetes prevention on cardiovascular disease</td>
<td>Artificial intelligence and diabetes technology in diabetic complications: Can they shape the future to improve outcomes?</td>
<td>Exercise in diabetes: from bench to clinical practice</td>
<td>09:00 10:30</td>
<td></td>
</tr>
<tr>
<td><strong>OP 17</strong></td>
<td><strong>OP 18</strong></td>
<td><strong>EASD General Assembly</strong></td>
<td></td>
<td>10:45 12:15</td>
</tr>
<tr>
<td><strong>Short Oral Discussion Sessions</strong> Event C</td>
<td><strong>EASD e-Learning Expert Session</strong></td>
<td><strong>Help! I need somebody: Managing complex clinical cases in the Emergency Room</strong></td>
<td></td>
<td>12:45 13:45</td>
</tr>
<tr>
<td><strong>Short Oral Discussion Sessions</strong> Event D</td>
<td><strong>EASD e-Learning Expert Session</strong></td>
<td><strong>EASD Early Career Academy Symposium: Work-Life-Balance</strong></td>
<td></td>
<td>14:00 15:00</td>
</tr>
<tr>
<td><strong>OP 22</strong></td>
<td><strong>OP 23</strong></td>
<td><strong>OP 24</strong></td>
<td></td>
<td>15:30 17:00</td>
</tr>
<tr>
<td><strong>Neuroendocrine control of food intake, body weight and glucose metabolism</strong></td>
<td><strong>Mitochondria: Implications in insulin sensitivity</strong></td>
<td><strong>What can we learn about diabetes from population isolates?</strong></td>
<td></td>
<td>17:30 18:30</td>
</tr>
<tr>
<td><strong>Wednesday, 11 September 2024</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Thursday, 12 September 2024

<table>
<thead>
<tr>
<th>TIME</th>
<th>MADRID HALL</th>
<th>LONDON HALL</th>
<th>BERLIN HALL</th>
<th>VIENNA HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00 - 10:30</td>
<td>The rise of GIP: from biology to medicine</td>
<td>How is precision medicine advancing our understanding of diabetes aetiology and will it make a difference?</td>
<td>Rising Star Symposium (08:50 - 10:30)</td>
<td>Novel approaches for prediction of microvascular complications - from tears to DNA and MRI</td>
</tr>
<tr>
<td>10:45 - 12:15</td>
<td>OP 25</td>
<td>LBA OP 4</td>
<td>OP 26</td>
<td>OP 27</td>
</tr>
<tr>
<td>12:45 - 13:45</td>
<td>Short Oral Discussion Sessions Event E</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00 - 15:00</td>
<td>Short Oral Discussion Sessions Event F</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 - 17:00</td>
<td>OP 31</td>
<td>LBA OP 5</td>
<td>OP 32</td>
<td>OP 33</td>
</tr>
<tr>
<td>17:30 - 18:30</td>
<td>Diabetes Prize for Excellence Lecture</td>
<td>The promise of GIP and GIPR antagonism: bridging the gap</td>
<td>The use of Automated Insulin Delivery (AID) around physical activity and exercise in type 1 diabetes: a position statement of the EASD and ISPAD</td>
<td>Diabetes and cancer: connecting the dots</td>
</tr>
</tbody>
</table>
### Thursday, 12 September 2024

<table>
<thead>
<tr>
<th>SYDNEY HALL</th>
<th>SOFIA HALL</th>
<th>CAIRO HALL</th>
<th>SPOTLIGHT STAGE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Old and new” islets for type 1 diabetes</td>
<td>EASD/JDRF Symposium: Do devices really help the person with diabetes?</td>
<td>12th East-West-Forum: Involving the public and patients in shaping diabetes care and research</td>
<td></td>
<td>09:00 - 10:30</td>
</tr>
<tr>
<td>OP 28</td>
<td>OP 29</td>
<td>OP 30</td>
<td></td>
<td>10:45 - 12:15</td>
</tr>
<tr>
<td>Short Oral Discussion Sessions Event F</td>
<td>EASD e-Learning Expert Session</td>
<td>EUDF Symposium</td>
<td></td>
<td>14:00 - 15:00</td>
</tr>
<tr>
<td>OP 34</td>
<td>OP 35</td>
<td>OP 36</td>
<td></td>
<td>15:30 - 17:00</td>
</tr>
<tr>
<td>EASD/EASO Symposium: Obesity and diabetes: the intertwined syndemic</td>
<td>EASD Early Career Academy Symposium: ERC funding</td>
<td>Insulin secretion in type 1 diabetes</td>
<td></td>
<td>17:30 - 18:30</td>
</tr>
</tbody>
</table>
### Friday, 13 September 2024

<table>
<thead>
<tr>
<th>TIME</th>
<th>MADRID HALL</th>
<th>LONDON HALL</th>
<th>BERLIN HALL</th>
<th>VIENNA HALL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Centennial Anniversary Prize Lecture</td>
<td>Prospective study to evaluate individual effects on the relationship of glucose and HBA1c: design, results, and clinical implications</td>
<td>From monogenic to oligogenic forms of diabetes: a continuum?</td>
<td>The sky is the limit</td>
</tr>
<tr>
<td>10:30 - 11:30</td>
<td>OP 43</td>
<td>OP 44</td>
<td>OP 45</td>
<td>OP 46</td>
</tr>
<tr>
<td>12:00 - 13:00</td>
<td>OP 50</td>
<td>OP 51</td>
<td>OP 52</td>
<td>OP 53</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Metabolic medicine 2030: What the future will bring</td>
<td>Can we receive consensus on how glucagon secretion is regulated?</td>
<td>Diabetologia Symposium: Diabetes Technology: a lifelong companion</td>
<td>Heterogeneity of type 2 diabetes: Will seeing type 2 diabetes in HD...</td>
</tr>
</tbody>
</table>
### Friday, 13 September 2024

<table>
<thead>
<tr>
<th>SYDNEY HALL</th>
<th>SOFIA HALL</th>
<th>CAIRO HALL</th>
<th>SPOTLIGHT STAGE</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shift from proliferative diabetic retinopathy to early intervention of diabetic eye disease</td>
<td>Generation of pancreatic islets from stem cells</td>
<td>EASD Early Career Academy Symposium: From Rising Star to Principal Investigator</td>
<td></td>
<td>09:00 - 10:00</td>
</tr>
<tr>
<td>OP 47</td>
<td>OP 48</td>
<td>OP 49</td>
<td>Double jeopardy: Could SGLT2 inhibitors and/or GLP1RAs improve glycaemic outcomes and QoL in type 1 diabetes?</td>
<td>10:30 - 11:30</td>
</tr>
<tr>
<td>OP 54</td>
<td>OP 55</td>
<td>OP 56</td>
<td>Type 1 diabetes and kidney failure: additional donor pancreas or islet transplantation should be the standard treatment of hyperglycaemia</td>
<td>12:00 - 13:00</td>
</tr>
<tr>
<td>Metabolic disease and mental illness</td>
<td>Targeting obesity to treat heart failure: dawn of a new era</td>
<td>EASD/ADA Symposium: Consensus report: Transition from paediatric to adult diabetes care</td>
<td></td>
<td>13:30 - 15:00</td>
</tr>
</tbody>
</table>
09:00 - 09:30  
**Madrid Hall**

**Presidential Address**

**Speaker:** Chantal Mathieu, Belgium  
President EASD/EFSD

09:30 - 10:15  
**Madrid Hall**

**56th Claude Bernard Lecture**

The Claude Bernard Prize recognises an individual's innovative leadership and lifetime achievements in diabetes research.

**Chair:** Chantal Mathieu, Belgium

**Speaker:** Roy Taylor, UK:  
*The aetiology of type 2 diabetes: an experimental medicine odyssey*

Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine at Newcastle University.

He founded the Newcastle Magnetic Resonance Centre in 2006 to further his research into the nature of type 2 diabetes. He was then able to confirm the predictions of his 2008 Twin Cycle Hypothesis of aetiology, showing type 2 diabetes to be a simple, reversible condition of excess fat within liver and pancreas. This required development of an effective dietary method to achieve the necessary weight loss. Subsequently he applied this knowledge to clinical practice, demonstrating that short term diabetes was most easily reversed to normal, that non-obese people with the condition also responded to weight loss and also, in a collaboration with Prof Michael Lean, that durable remission could be achieved in routine primary care. The totality of the research programme has led to practical application in NHS England with the national ‘NHS Type 2 Diabetes Path to Remission’ programme now successfully in place.

Between 1986 and 2000, Professor Taylor developed the national system now used for screening for diabetic eye disease and established the profession of retinal screeners, with major reduction in blindness due to diabetes across the UK.

He has published books in lay language explaining type 2 diabetes (eg ‘Life Without Diabetes’) plus training books on retinal screening. He has been invited to deliver several named lectures including the 2012 Banting Lecture of Diabetes UK. He received the 2023 Robert Turner Award for Research Impact and was the co-recipient of the 2024 Rank Prize for Nutrition. Professor Taylor was made MBE in the King’s 2023 New Year Honours.
10:30 - 12:00

**Madrid Hall**

**OP 01**  
New mechanisms and outcomes of treatments for diabetic kidney disease

1 Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT-2 inhibitors or GLP-1 receptor agonists under routine care: the DARWIN-Renal study  
G. Fadini, E. Longato, M. Morieri, S. Del Prato, A. Avogaro, A. Solini, Italy

2 Extracellular vesicles as messengers: how canagliflozin improves diabetic podocytes ferroptosis  
G. Qin, X. Fan, Y. Song, F. Guo, S. Ma, M. Shao, W. Zhang, Y. Luo, F. Wei, W. Guo, Y. Zhao, China

3 Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted magnetic resonance imaging and total kidney volume in patients with type 2 diabetes  
L. Vernstrøm, S. Gullaksen, S. S. Sørensen, S. Ringgaard, C. Laustsen, H. Birn, K. Funck, E. Laugesen, P. L. Poulsen, Denmark

4 Gastric bypass and sleeve gastrectomy improve albuminuria more than iSGLT-2/GLP-1RA based medical therapy: a randomised clinical trial  
J. P. Valderas, C. A. Boza, C. Le Roux, Chile, Ireland

5 SGLT2-inhibitor treatment for nephroprotection can be targeted using eGFR / albuminuria categories and risk scores: precision medicine in type 2 diabetes  
T. Jansz, K. Young, R. Hopkins, B. Shields, A. T. Hattersley, R. Oram, J. Dennis, UK

6 Effect of empagliflozin on urinary albumin excretion and hypoxic injury biomarkers of early phase diabetic kidney disease (EUROBEAT study)  

10:30 - 12:00

**London Hall**

**OP 02**  
Which day of the week is your insulin day?

7 Safety, tolerability, and pharmacodynamics properties of a novel once-weekly insulin GZR4 in healthy subjects  
8 Effects of insulin Efsitora alfa on frequency and severity of hypoglycaemia under conditions of increased hypo risk compared to glargine in type 2 diabetes
T. Heise, G. Andersen, E. J. Pratt, J. Leohr, T. Fukuda, Q. Wang, C. Kazda, J. Bue-Valleskey, R. Bergenstal, Germany, USA

9 No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec vs once-daily basal insulin in type 1 diabetes: ONWARDS 6
H. Sourij, R. Bracken, M. Asong, L. Carstensen, S. Kehlet Watt, A. Philis-Tsimikas, Austria, UK, Denmark, USA

10 Associations between mean fasting glucose levels and adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive type 2 diabetes: post hoc analysis of ONWARDS 5
H. Bajaj, A. M. Donatsky, S. Engberg, J. H. Martiny, A. Vianna, L. Lingvay, Canada, Brazil, USA

11 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline sodium-glucose cotransporter-2 inhibitor use: ONWARDS 1-5
R. Goldenberg, K. O. Bangsgaard, A. Fu, M. Kellerer, S. B. Søgaard, T. Vilsboell, Canada, Denmark, Germany

12 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1-5
T. Vilsboell, K. O. Bangsgaard, A. Fu, M. Kellerer, S. B. Søgaard, R. Goldenberg, Denmark, Germany, Canada

10:30 - 12:00 Berlin Hall

OP 03 Liver: the master regulator

13 Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD

14 Osteoprotegerin regulates hepatic glucose metabolism and insulin sensitivity through mTORC1 signalling pathway
S. Qiu, G. Yang, M. Yang, China
15 Investigating whole-body fructose catabolism in vivo using stable isotopes to identify new anti-obesity targets
M. Rios-Morales, F. Westerbeke, D. Van Harskamp, B. Groen, M. Nieuwdorp, Netherlands

16 Increased postprandial succinate levels are associated with hepatic gluconeogenesis regulation via SUCNR1
A. Marsal-Beltran, L. Salmerón-Pelado, A. Ribas-Latre, M.-M. Rodríguez-Peña, C. Núñez-Roa, M. Repollés-de-Dalmay, E. Novoa, R. Nogueiras, R. Bosch, J. Vendrell, V. Ceperuelo-Mallafré, S. Fernández-Veledo, Spain

17 Whole-body insulin sensitivity is lower after 4-week high fructose compared to 4-week high saturated fat consumption in overweight individuals
K. H. Roumans, P. M. Van Lier, E. Phielix, B. Havekes, P. Schrauwen, V. B. Schrauwen-Hinderling, Netherlands

18 Cytoskeleton protein Leupaxin promote hepatic gluconeogenesis through activating HNF4α transitional activity
Z. Zhijian, L. Xiaomin, L. Fang, P. Yongde, China

10:30 - 12:00 Vienna Hall

OP 04 Beyond glucose in diabetes and prediabetes

19 Effects of a randomised controlled dietary intervention high in unsaturated fat, plant protein and fiber on intrahepatic lipid levels at 12 and 36 months

20 Slower liver growth in-utero predicts the risk of prediabetes at 18 years of age, a DOHaD jump from birth size to organogenesis: novel human data in the Pune Maternal Nutrition Study (PMNS)

21 Excessive free fatty acids sensing in pituitary lactotrophs elicits liver steatosis by decreasing prolactin levels
Y. Bi, X. Ji, H. Yin, China

22 The effect of 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on cardiac markers and mitochondrial function
23 Prolactin deficiency drives diabetes-associated cognitive dysfunction by inducing microglia-mediated synapse loss
Y. Bi, Z. Zhang, J. Jiang, J. Wang, China

24 When does metabolic memory starts? Insights from the AMD Annals initiative
G. Russo, A. Nicolucci, G. Lucisano, M. Rossi, A. Ceriello, F. Prattichizzo, V. Manicardi, A. Rocca, P. Di Bartolo, S. De Cosmo, G. Di Cianni, R. Candido, AMD Annals Study Group, Italy

10:30 - 12:00
Sydney Hall

OP 05 Can you change what you are by what you eat?

25 Unlocking the potential of urolithins: novel approaches to inhibit IAPP aggregation in diabetes
S. G. Ferreira, A. F. Raimundo, N. Saraiva, C. N. Santos, R. Menezes, Portugal, Spain

26 Effects of a hypocaloric time-restricted feeding diet programme in individuals with metabolic dysfunction-associated steatotic liver disease: preliminary data of a randomised controlled trial
S. Tsitsou, T. Bali, M. Adamantou, A. Saridaki, K.-A. Poulia, E. Petsiou, E. Papakonstantinou, E. Cholongitas, Greece

27 A fasting-mimicking diet programme reduces liver fat and inflammation/fibrosis measured by MRI-derived biomarkers in patients with type 2 diabetes

28 Effects of 12-week supplementation with coffee diterpene cafestol in healthy subjects with increased waist circumference: a randomised, placebo-controlled trial

29 Meal timing, its relation to metabolism, and heritability in German adult twins
O. Pivovarova-Ramich, J. Vahlhaus, B. Peters, S. Hornemann, A.-C. Ost, M. Kruse, A. Busjahn, A. Pfeiffer, Germany
30 Liver fat as a key target in dietary management of type 2 diabetes and prediabetes using novel diet therapies: a randomised clinical trial (The NAFLDiet study)

10:30 - 12:00

Sofia Hall

OP 06 Maternal influences and prediction in type 1 diabetes

31 Is the relative protective effect of maternal vs paternal type 1 diabetes on risk of type 1 diabetes explained by differences in predisposing genes potentially induced by selective foetal loss?

32 Maternal type 1 diabetes confers long-term relative protection against type 1 diabetes in the offspring: results from five cohort studies

33 Maternal psychosocial stress and risk of childhood-onset type 1 diabetes
L. C. Stene, A.-K. Rantala, M. C. Magnus, G. Tapia, T. Skrivarhaug, N. A. Lund-Blix, K. Størdal, the HEDIMED Investigators, Norway, Finland

34 Trajectory of type 1 diabetes risk shifts after age 10 years between at-risk males and females

35 Screening and monitoring for presymptomatic type 1 diabetes: the DiaUnion project
J. Hviid Klæbel, A. Lind, S. Hamdan, M. N. Scherman, F. Kristensen, J. C. Antvorskov, D. N. Agardh, F. Pociot, Denmark, Sweden

36 Population screening for type 1 diabetes and celiac disease: autoimmunity screening for kids (ASK)
M. Rewers, C. Geno Rasmussen, B. Frohnert, L. Yu, K. Simmons, A. Steck, H. O'Donnell, M. Stahl, E. Liu, USA
10:30 - 12:00

**Cairo Hall**

**LBA OP 1**  **TBA**

Late breaking abstracts
### Short Oral Discussions Event A

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Station</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 - 13:30</td>
<td>Short Oral Discussion Area</td>
<td>SO 001</td>
<td>Genetic insights into type 2 diabetes: from risk variants to personalized treatment strategies</td>
<td>115</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 007</td>
<td>Global perspectives on type 2 diabetes: prevalence, risk factors, and predictive tools</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 013</td>
<td>Prevention of type 2 diabetes</td>
<td>128</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 019</td>
<td>Catching signals to follow the right pathway in islets</td>
<td>134</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 025</td>
<td>Breaking bad: destruction of beta cells</td>
<td>139</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 031</td>
<td>All the reasons why exercise is good!</td>
<td>145</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 037</td>
<td>New approaches in carbohydrate metabolism</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 043</td>
<td>Inflammation and beta cell homeostasis</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 049</td>
<td>Novel clinical insights into adipose tissue function</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 055</td>
<td>Improving metabolism through nutrition</td>
<td>169</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 061</td>
<td>Novel incretins: focus on kidney, liver and cardiovascular system</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 067</td>
<td>Breaking away with tradition or how to give insulin differently</td>
<td>181</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 073</td>
<td>Diabetes technology - but at a higher level</td>
<td>188</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 079</td>
<td>From microbiology to MRI in diabetic foot disease</td>
<td>194</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 085</td>
<td>Clinical data and emerging markers in diabetic foot disease and neuropathy</td>
<td>200</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 091</td>
<td>A new look at well-known drugs in type 2 diabetes</td>
<td>206</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SO 097</td>
<td>Pathogenesis of diabetes complications</td>
<td>212</td>
</tr>
</tbody>
</table>
12:30 - 13:30  Cairo Hall

EASD e-Learning expert session

Chair:     TBA
Speaker:   TBA

12:45 - 13:30  Spotlight Stage

Islet networks regulating insulin secretion: a debate

Chair:     TBA
Speaker:   TBA
## Short Oral Discussions Event B

**13:45 - 14:45**  
**Short Oral Discussion Area**  
**Page**

<table>
<thead>
<tr>
<th>SO</th>
<th>Station</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 002</td>
<td>Station 1</td>
<td>Epigenetics and gestational diabetes: from maternal health to newborn outcomes</td>
<td>116</td>
</tr>
<tr>
<td>SO 008</td>
<td>Station 2</td>
<td>Advances type 1 diabetes: genetic, biomarker, and machine learning approaches</td>
<td>122</td>
</tr>
<tr>
<td>SO 014</td>
<td>Station 3</td>
<td>Early factors and family determinants of diabetes</td>
<td>129</td>
</tr>
<tr>
<td>SO 020</td>
<td>Station 4</td>
<td>Holding hands with alpha cells in the islets</td>
<td>135</td>
</tr>
<tr>
<td>SO 026</td>
<td>Station 5</td>
<td>Pregnancy and type 1 diabetes</td>
<td>140</td>
</tr>
<tr>
<td>SO 032</td>
<td>Station 6</td>
<td>Insulin action in peripheral tissues</td>
<td>146</td>
</tr>
<tr>
<td>SO 038</td>
<td>Station 7</td>
<td>Novel pharmacological approaches for the treatment of obesity and diabetes</td>
<td>152</td>
</tr>
<tr>
<td>SO 044</td>
<td>Station 8</td>
<td>Lipid signatures and ectopic fat</td>
<td>158</td>
</tr>
<tr>
<td>SO 050</td>
<td>Station 9</td>
<td>Understanding and combating adipose tissue dysfunction</td>
<td>164</td>
</tr>
<tr>
<td>SO 056</td>
<td>Station 10</td>
<td>Thinking outside the box to treat obesity and diabetes</td>
<td>170</td>
</tr>
<tr>
<td>SO 062</td>
<td>Station 11</td>
<td>Hot of the press novel incretins</td>
<td>176</td>
</tr>
<tr>
<td>SO 068</td>
<td>Station 12</td>
<td>Playing with food intake and energy expenditure</td>
<td>183</td>
</tr>
<tr>
<td>SO 074</td>
<td>Station 13</td>
<td>It is very hard to beat the system - or is it?</td>
<td>189</td>
</tr>
<tr>
<td>SO 080</td>
<td>Station 14</td>
<td>Diabetic kidney disease: clinical insights from childhood to frailty</td>
<td>195</td>
</tr>
<tr>
<td>SO 086</td>
<td>Station 15</td>
<td>Novel markers and predictors for neuropathy in diabetes</td>
<td>201</td>
</tr>
<tr>
<td>SO 092</td>
<td>Station 16</td>
<td>Divination from a glass ball or something more? Predictive models, biomarkers, genome analysis</td>
<td>207</td>
</tr>
<tr>
<td>SO 098</td>
<td>Station 17</td>
<td>Cancer and diabetes</td>
<td>213</td>
</tr>
</tbody>
</table>
13:45 - 14:45 Cairo Hall

EASD e-Learning expert session

Chair: TBA
Speaker: TBA

13:45 - 14:30 Spotlight Stage

Global concepts and mechanisms of preventing type 2 diabetes: Can prediabetes remission reduce global diabetes incidence?

Chair: TBA
Speaker: TBA
15:15 - 16:45 Madrid Hall

**OP 07 Cardiovascular complications in type 1 diabetes: burden and mechanisms**

37 Rapid vs slow plasma glucose decline has no impact on systolic function in individuals with type 1 diabetes

38 Effects of rapid vs slow plasma glucose decline on haemostasis in individuals with type 1 diabetes

39 Coronary arteries assessment in asymptomatic high risk patients with type 1 diabetes using optical coherent tomography
M. Dubsky, R. Roland, N. Marhefková, P. Wohlfahrt, V. Karmazin, P. Novodvorsky, J. Kautzner, M. Haluzik, M. Pazdernik, Czech Republic

40 Automated insulin delivery systems and vascular reactivity in type 1 diabetes: a prospective study
R. Lupoli, C. P. Petrosino, C. Rainone, G. Vallefuoco, I. L. Calcaterra, M. N. Di Minno, L. Bozzetto, Italy

41 Incidence and risk of myocardial infarction subtypes in type 1 diabetes
P. Smidtslund, V. Harjutsalo, V. Thorn, F. Jansson Sigfrids, P.-H. Groop, L. M. Thorn, Finland

42 Whole genome sequencing reveals genetic variation associated with coronary artery disease in individuals with type 1 diabetes
A. A. Antikainen, J. Haukka, A. Syreeni, S. Mutter, V. Harjutsalo, P.-H. Groop, N. Sandholm, Finland

15:15 - 16:45 London Hall

**OP 08 Genetics and epigenetics in type 2 diabetes**

43 Blood-based epigenetic markers associate with future macrovascular events in individuals with type 2 diabetes
S. Garcia-Calzon, A. Maguolo, A. Perfilyev, M. Maziarz, E. Ahlqvist, I. Gonçalves, C. Ling, Spain, Sweden, Italy
44 An updated meta-analysis of epigenome-wide association study of incident type 2 diabetes reveals 234 novel CpG sites

45 Allelic expression imbalance in pancreatic islets indicates parent-of-origin effects on type 2 diabetes risk
   J. Andersson, G. Hatem, M. Maziarz, M. Lehtovirta, L. Hakaste, T. Tuomi, R. Prasad B, Sweden, Finland

46 Beta cell dysfunction polygenic risk associates with risk of gestational diabetes and postpartum abnormal glucose intolerance in Chinese

47 Loss-of-function mutations of the GIP receptor impair GIP-mediated insulin secretion

48 Change in telomere length and its implications in type 2 diabetes: the Fremantle Diabetes Study Phase II
   M. L. Huang, C.-H. Yang, W. Davis, K. Peters, A. J. Jenkins, T. Davis, Australia

15:15 - 16:45 Berlin Hall

OP 09 Drugs you thought you knew all about, but what else do they do?

49 The effect of sodium-glucose cotransporter-2 inhibitors on graft survival and cardiorenal outcomes in patients with diabetes and heart transplantation
   C.-M. Hwu, F.-S. Yen, J.-Y. Huang, C.-C. Hsu, W.-Y. Cheng, J. C.-C. Wei, Taiwan

50 Efficacy and safety of canagliflozin in children and adolescents with type 2 diabetes: a multicentre, randomised, double-blind, parallel-group, phase 3 trial
   S. R. Ali, U. Nadgir, J. Gogate, W. Shaw, S. Fonseca, J. Antunes, USA
51 Sodium-glucose cotransporter 2 inhibitor use and risk of dementia and parkinson's disease among patients with type 2 diabetes

52 Cardiovascular effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists combination therapy in adults with type 2 diabetes
P. Htoo, D. J. Wexler, H. Tesfaye, S. Schneeweiss, R. Glynn, C. Shay, N. Schmedt, L. Koeneman, J. M. Paik, E. Patorno, USA, Germany

53 Metformin reduces fasting blood glucose independently of endogenous glucose production by promoting glycolysis and glucose clearance in well-controlled type 2 diabetes
T. Sarabhai, T. LaMoia, S. Friesl, M. Jonuscheit, V. Schrauwen-Hinderling, K. Petersen, G. Shulman, M. Roden, Germany, USA

54 Impact of timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes
C. Xie, P. Iroga, Y. Sun, W. Huang, M. J. Bound, J. Grivell, K. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

15:15 - 16:45 Vienna Hall

OP 10 Hypothalamic regulation of systems metabolism

55 Prolactin act on POMC neurons to regulate lipid metabolism of liver
Y. Zhu, Y. Bi, China

56 Influence of insulin sensitivity on food cue evoked brain response in children

57 Regulation and mechanism of hypothalamic MST1 signalling on energy homeostasis and glucose/lipid metabolism
M. Yang, L. Li, China

58 A hypothalamus-liver-skeletal muscle axis controlled by JNK1 and FGF21 mediates olanzapine-induced insulin resistance in an intraperitoneal treatment in male mice
V. Ferreira, C. Folgueira, A. Montes, A. B. Hitos, R. J. Davis, G. Sabio, P. Rada, Á. M. Valverde, Spain, USA
59 In vivo phenotyping of glucose-dependent insulinotropic polypeptide receptor neurocircuits in distinct hypothalamic nuclei
N. S. Figueredo Burgos, A. Roberts, A. Adriaenssens, F. Reimann, UK

60 Brain-to-periphery crosstalk: exploring sympathetic innervation and dopamine signalling during diet-induced obesity or caloric restriction in male Wistar rats

15:15 - 16:45 Sydney Hall

OP 11 Risk factors and treatment opportunities in neuropathy and hypertension

61 Understanding the impact of diabetic peripheral neuropathy and neuropathic pain on quality of life and mental health in people with diabetes
M. Borbjerg, A.-M. L. Wegeberg, A. Nikontovic, C. D. Moerch, N. Ejskjaer, C. Brock, P. Vestergaard, J. Røikjer, Denmark

62 Impact of diabetes on heart rate variability among acutely admitted patients
R. Hadad, A. V. Hviid, M. H. Domínguez, F. E. Nielsen, B. S. Larsen, O. Wendelboe, A. Sajadieh, S. B. Haugaard, Denmark

63 A prognostic tool to predict the risk of 5-year all-cause mortality in diabetic patients with hypertension: evidence from two perspective cohorts
Y. Liu, H. You, J. Yuan, S. Wu, Y. Wu, W. Yang, China

64 Neuropathic pain symptoms in patients with painful diabetic neuropathy followed for 12 months after treatment with high concentration (179 mg) capsaicin patch: a retrospective cohort study
M. Eerdekens, M. A. Überall, S. Engelen, T. Fajri, S. Allen, R. Freitas, L. Garcia Guerra, T. Quandel, Germany, France, USA, Portugal, Spain

65 Risk factor phenotypes for cardiovascular autonomic neuropathy based on indices of heart rate variability in type 1 diabetes
B. Braffett, L. El ghormli, I. Bebu, C. Martin, R. Pop-Busui, DCCT/EDIC Research Group, USA

66 Blood pressure polygenic risk scores associate with treatment-resistant hypertension in individuals with type 1 diabetes
R. Lithovius, H. Sánez Tähtisalo, A. Antikainen, S. Mutter, P.-H. Groop, K. Kontula, T. Hiltunen, N. Sandholm, Finland
**15:15 - 16:45**

**OP 12  Fatal attraction: immune cells and beta cells**

67 Beta cell extracellular vesicle surface PD-L1 is induced by IFN-α treatment and correlates with residual C-peptide in plasma of children with recent-onset type 1 diabetes

68 T cells drive beta cell senescence in type 1 diabetes
J. Pipella, P. Thompson, Canada

69 Insulitis and exocrinitis in antibody-positive non-diabetic individuals: role of HLA genotypes individuals: role of HLA genotypes
E. Larger, M. Diedisheim, D. Dubois-Laforgue, R. Mallone, France

70 The Hippo pathway terminal effector YAP potentiates enteroviral infection in human islets
F. Atawneh, S. Geravandi, H. Liu, O. Zabad, H. Pahwa, M. Madduri, A. Pugliese, A. Ardestani, K. Maedler, Germany, USA, UK

71 An mRNA vaccine induces immune tolerance and protects against disease in NOD mice
L. P. Pallo, V. Ng, S. Chen, J. Zaifman, A. Nguyen, P. Singh, S. Zhang, Y. C. Tam, H. C. Denroche, C. B. Verchere, Canada

72 Verapamil in combination with low-dose anti-thymocyte globulin reverses hyperglycaemia in newly diagnosed diabetic NOD mice
P.-J. Martens, M. Viaene, L. Degroote, C. Mathieu, C. Gysemans, Belgium

**15:15 - 16:45**

**Cairo Hall**

**LBA OP 2  TBA**

Late breaking abstracts
39th Camillo Golgi Lecture

The Camillo Golgi Prize recognises outstanding contributions in the field of histopathology, pathogenesis, prevention and treatment of the complications and comorbidities of diabetes mellitus.

Chair: Chantal Mathieu, Belgium

Speaker: Rodica Pop-Busui, USA: TBA

Rodica Busui, MD, PhD is the Larry D. Soderquist Professor of Diabetes, Vice Chair Clinical & Health Outcomes Research Department of Internal Medicine, Director Clinical Research Caswell Diabetes Institute at the University of Michigan, and an international leader in the field of diabetes and diabetes complications.

Her research interests involve chronic complications of diabetes, including diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure, cardiovascular disease, as well as use of novel technologies for diabetes management.

She has been PI and member of the Steering Committee in many landmark diabetes clinical trials funded by NIH or Pharma including: ACCORD, DCCT/EDIC, PERL, BARI-2D, GRADE, DEVOTE, REPLACE-BG, WISDM, MOBILE, SOUL. She also designed and leads several investigator-initiated studies to unveil disease modifying agents for diabetic complications, and on the use of diabetes technologies to improve patients’ outcomes and diabetes care delivery funded by NIDDK and Pharma. She is the Chair of the Steering Committee of the NIDDK Diabetes Foot Consortium.

Dr. Busui has published more than 300 peer-reviewed manuscripts and book chapters, and had been a member of the EASD since 1993. She received awards for her research and advancement of diabetes care from many organizations including the American Diabetes Association (ADA), the Fulbright Foundation, the Harvard Medical School, the Romanian Diabetes Society, and the University of Michigan. She has been an elected member of the ADA Clinical Practice Committee, chaired the 2017 ADA Position Statement on Diabetic Neuropathy, the ADA Diabetes & Cardiovascular Disease Interest Group, and the ADA/ACC Heart Failure in Diabetes Consensus.

Dr. Busui is the 2023 President for Medicine and Science of the American Diabetes Association.
17:15 - 18:15  
London Hall

Adipose tissue control of energy and glucose metabolism

Chair: Andreas L Birkenfeld, Germany  
Speaker: Alice Williamson, UK:  
**Novel candidate genes regulating glucose metabolism**

Niklas Mejhert, Sweden:  
**Adipocyte subpopulations and insulin sensitivity**

Laurie J. Goodyear, USA:  
**Exercise remodeling of adipose tissue**

---

17:15 - 18:15  
Berlin Hall

A paradigm change for basal insulin replacement? Results from the QWINT programme of insulin efsitora alfa

Chair: Rory J. McCrirmon, UK  
Speaker: Stefano Del Prato, Italy:  
**Introduction to once-weekly insulins**

Harpreet S. Bajaj, Canada:  
**Background on the efsitora alfa phase 3 QWINT program**

Carol Wysham, USA:  
**Efficacy and safety of efsitora as a weekly basal insulin compared to insulin degludec in insulin-naïve adults with type 2 diabetes (QWINT-2)**

Richard Bergenstal, USA:  
**Efficacy and safety of insulin efsitora alfa as a weekly basal insulin compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy (QWINT-5)**

Melanie J. Davies, UK:  
**Implications for clinical care**

Cees J. Tack, Netherlands:  
**Commentary**
17:15 - 18:15  
**Sydney Hall**

**Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management and future directions**

*Chair:* TBA  
*Speaker:* TBA

17:15 - 18:15  
**Sydney Hall**

**The forgotten few or many? Delivering diabetes care to people at the margins of society**

*Chair:* Didac Mauricio, Spain  
*Speaker:* Giuseppe Maltese, UK:
  *The many faces of ageing with diabetes*

Andrzej W. Kokoszka, Poland:
  *Stabilising glucose in unstable minds*

Alice Rickford, UK:
  *Diabetes without a safe house*

17:15 - 18:15  
**Sofia Hall**

**Amylin for treatment of metabolic diseases**

*Chair:* Eelco De Koning, Netherlands  
*Speaker:* Thomas Lutz, Switzerland:
  *Exploring Amylin’s role in type 2 diabetes and obesity*

Kirsten Raun, Denmark:
  *Amylin analogues MoA: unveiling the mechanisms of action*

Ania M. Jastreboff, USA:
  *Clinical insights*
Youth-onset type 2 diabetes: a key challenge for the future

Chair: Tsvetalina Tankova, Bulgaria
Speaker: Orit Pinhas-Hamiel, Israel:
Risk of long-term complications in youth-onset type 2 diabetes

Allison L. B. Shapiro, USA:
Brain and cognitive health in youth onset type 2 diabetes

Amy Shah, USA:
Management of youth onset type 2 diabetes: Should it be different?
09:00 - 10:30  
**Madrid Hall**

**FLOW: the first dedicated kidney outcomes trial with GLP-1 RA, semaglutide, in patients with type 2 diabetes and CKD**

*Chair:* TBA  
*Speaker:* TBA

09:00 - 10:00  
**London Hall**

**18th Albert Renold Lecture**

The Albert Renold Prize recognizes outstanding achievements in the field of pathophysiology and treatment of diabetes mellitus.

*Chair:* Francesco Giorgino, Italy  
*Speaker:* Lori Sussel, USA:  
**Regulation of islet cell lineages in health and diabetes**

*Lori Sussel* is the Research Director of the Barbara Davis Diabetes Center (BDC) and Director of the NIDDK-funded University of Colorado Diabetes Research Center (DRC). She received her graduate degree from Columbia University Medical School and pursued a postdoctoral fellowship at the University of California, San Francisco.

Dr. Sussel’s research has been funded by throughout her career by the National Institutes of Health (NIH), Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA). Her research focuses on the molecular regulation of pancreatic islet cell differentiation and function, with a focus on understanding how beta cell dysfunction contributes to type 1 and type 2 diabetes.

Her research programme combines advanced molecular biology techniques, mouse models and human stem cell models to understand the molecular mechanisms that determine the differentiation of the pancreatic islet lineages during fetal development and maintenance of alpha and beta cell function in the adult. These studies have identified several novel proteins, long non-coding RNAs and molecular mechanisms that are involved in islet cell fate decisions during pancreas development and in maintaining the function and/or identity of the beta cell in the adult.
09:00 - 10:30  
**Berlin Hall**

**Emerging topics in the etiology of type 1 diabetes**

*Chair:* Lars C. Stene, Norway  
*Speaker:* Heikki A. Hyöty, Finland:  
**The exposome**  
Teresa Rodriguez-Calvo, Germany:  
**The virus hypothesis**  
Randi K. Johnson, USA:  
**The diet**

09:00 - 10:30  
**Vienna Hall**

**EASD/EASL/EASO symposium: a new joint guideline for metabolic dysfunction-associated steatotic liver diseases (MASLD)**

*Chair:* TBA  
*Speaker:* TBA

09:00 - 10:30  
**Sydney Hall**

**EASD/ESC Symposium: Impact of type 2 diabetes prevention on cardiovascular disease**

*Chair:* Dana Dabelea, USA; Francesco Cosentino, Sweden  
*Speaker:* Amanda I. Adler, UK:  
**Glycaemic control and CVD prevention**  
Mark Espeland, USA:  
**Cardiovascular effects of lifestyle interventions**  
Simon J. Griffin, UK:  
**Impact of metformin on CVD**  
Darren K. McGuire, USA:  
**Opportunities for the future**
09:00 - 10:30  Sofia Hall

Artificial intelligence and diabetes technology in diabetic complications: Can they shape the future to improve outcomes?

Chair: Piya Sen Gupta, UK
Speaker: Tomas Griffin, Ireland:
Using diabetes technology in people on dialysis or with impaired vision: What is possible?

Sufyan Hussain, UK:
When does technology not help? What more is needed?

Navdeep Tangri, Canada:
Can Artificial Intelligence predict kidney failure and related complications?

09:00 - 10:30  Cairo Hall

Exercise in diabetes: from bench to clinical practice

Chair: Juleen R. Zierath, Sweden
Speaker: Lauren M. Sparks, USA:
Exercise as medicine and prevention of disease

John P. Thyfault, USA:
Exercise to control hepatic lipid metabolism

Mikel Izquierdo, Spain:
How to prescribe physical activity in individuals with diabetes and physical frailty and sarcopenia

Dominique Hansen, Belgium:
How to prescribe physical activity in individuals with diabetes and chronic coronary syndrome and/or heart failure
10:45 - 12:15 Madrid Hall

**OP 13**  GLP-1-based polypharmacology: we are not done yet!

73 CagriSema driven weight loss in diet-induced obese rats prevents counter-regulation of weight loss associated reduction in energy expenditure

74 Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study
A. Gasiorek, A. Heydorn, K. Kirkeby, C. Key, S. Toubro, L. H. Schefe, K. Dahl, J. B. Hjerpsted, A. Vegge, Denmark, USA

75 CagriSema improves insulin sensitivity in diet-induced obese rats
A. Secher, C. L. Brand, K. Raun, Denmark

76 Survodutide and semaglutide both induce weight loss but show different effects on food preference and dyslipidaemia in the free choice diet-induced obese hamster model
F. Briand, R. Augustin, K. Bleymehl, B. Bajrami, T. Zimmermann, T. Klöckener, T. Klein, France, Germany

77 Impact of GLP-1/GIP receptor signalling on human pancreatic adipose tissue organoids
E. Lorza-Gil, O. Strauss, E. Ziegler, L. Sandforth, A. Sandforth, F. Berlth, S. Singer, A. Mihaljevic, A. Birkenfeld, F. Gerst, Germany

78 Petrelintide induced potent additional weight loss in combination with either semaglutide or tirzepatide in DIO rats
B. Vestergaard, C. Wenander, J. Skarbaliene, J. Griffin, Denmark, Switzerland

10:45 - 12:15 London Hall

**OP 14**  Incretins: How many targets do you need?

79 Short-acting glucagon-like peptide-1 receptor agonist therapy delays gastric emptying during insulin-induced hypoglycaemia as well as euglycaemia in type 2 diabetes
80 Neither exogenous nor endogenous glucose-dependent insulinotropic polypeptide affects appetite or energy intake acutely in healthy older people

81 Novel unimolecular tetra-agonist peptides targeting GLP-1, GIP, amylin, and calcitonin receptors with enhanced metabolic benefits in animal models of obesity
C. M. Rondinone, M. P. Valdecantos, P. Rada, A. Valverde, S. Ghosh, USA, Spain

82 Characterising the pharmacology of glucagon receptor agonism in a dual GCGR/GLP-1R agonist
T. Kloeckener, T. Zimmermann, P. Haebel, B. Bajrami, R. Augustin, Germany

83 Effects of Liraglutide on GLP-1, GIP and glucagon concentrations in persons with type 2 diabetes with multiple daily insulin injections during a 24-week period

84 Effects of endogenous and exogenous glucose dependent insulinotropic polypeptide on blood pressure, heart rate, gastric emptying and blood glucose responses to oral glucose in healthy older people

10:45 - 12:15

Berlin Hall

OP 15   Cardiovascular risk in patients with type 1 diabetes: What do we know today, how can we modify it tomorrow?

85 All-cause and cause-specific mortality, cardiovascular diseases, and prognostic factors in adult-onset type 1 diabetes
Y. Wei, T. Andersson, T. Tuomi, T. Nyström, S. Carlsson, Sweden, Finland
86 Preclinical carotid atherosclerosis is independently associated with incident cardiovascular events in patients with type 1 diabetes

87 People with type 1 diabetes living with overweight or obesity are at increased cardiovascular risk: insights from the SFDT1 cohort

88 Increased body mass index and risk of developing cardiovascular complications in a cohort of people with type 1 diabetes
E. Soto-Pedre, L. D. Petty, R. J. McCrimmon, E. R. Pearson, UK

89 Evaluation of the Steno-risk in predicting cardiovascular events in young type 1 diabetes and its association with the progression of microvascular complications progression
I. C. Paliares, P. M. Dualib, L. S. Torres, P. M. Aroucha, J. R. De Sá, S. A. Dib, Brazil

90 Cumulative glycaemic exposure is associated with coronary artery disease in type 1 diabetes: a call for action
R. Bergdal, V. Harjutsalo, P.-H. Groop, S. Mutter, the FinnDiane Study Group, Finland, Australia

10:45 - 12:15    Vienna Hall

OP 16  Emerging risk factors and treatment options for diabetic eye disease

91 Semaglutide does not affect central retinal thickness beyond the effect explained by glycaemic change: continuous glucose monitoring in persons with type 2 diabetes
S. Gullaksen, L. Vernstrøm Hald, S. Skovgaard Sørensen, K. Funck, L. Petersen, T. Bek, E. Laugesen, P. Poulsen, Denmark

92 Is early worsening of diabetic retinopathy a concern when starting hybrid closed loop therapy in people with type 1 diabetes?
93 Diabetes-related microvascular complications and periodontitis: Health in Central Denmark
F. V. Bitencourt, A. Andersen, L. Bjerg, A. Sandbæk, H. Li, G. G. Nascimento, R. Spin-Neto, M. A. Peres, F. R. Leite, Denmark, Singapore

94 Impact of sleep duration at night on microvascular complications in patients recently diagnosed with type 2 diabetes
M. S. Johansen, J. V. Stidsen, P. Asyaei, F. N. Pedersen, J. Grauslund, M. H. Olsen, K. Højlund, T. B. Olesen, Denmark

95 Pericyte MDM2-knockout prevents retinal fibrosis in the development of diabetic retinopathy via regulating ITGB8-TGF-β1 axis
J. Lin, Y. Chen, Z. Xu, B. Krämer, Germany

96 Topical administration of sitagliptin prevents neurodegeneration in an experimental model of steroid-induced glaucoma: clinical implications for treating diabetic macular oedema

10:45 - 12:15 Sydney Hall

OP 17 Type 2 diabetes prediction

97 Screening for type 2 diabetes and population mortality over 20-year follow-up (ADDITION-Cambridge): a cluster-randomised controlled trial

98 A multi-country study of trends in the incidence of end-stage kidney disease among people with diabetes
J. W. Sacre, J. I. Morton, L. Chen, M. E. Pavkov, E. W. Gregg, J. E. Shaw, D. J. Magliano, GLOBODIAB Writing Group, Australia, USA, UK

99 How frequently is early-onset type 2 diabetes misclassified in South Asian and White individuals?
S. A. Jones, H. Cheng, S. Pandya, C. Goodall, S. Misra, UK

100 Diabetes medication is not associated with cancer occurrence in type 2 diabetes patients: a study of the entire Danish population 1996-2022
B. Carstensen, S. Friis, F. Persson, V. Kosjerina, M. Gamborg, L. S. Mørch, Denmark
101 Remnant cholesterol and incident type 2 diabetes: a community-based 14-year prospective cohort study
Y.-C. Hwang, J. Jun, I.-K. Jeong, K. Ahn, H. Chung, Republic of Korea

102 Screening for type 2 diabetes is cost-effective: evidence from a pilot screening study in Denmark
N. C. Mateu, P. Rossing, K. Neergaard, T. Thybo, Denmark

10:45 - 12:15    Sofia Hall

OP 18   How to blow the low

103 Real-world burden of severe hypoglycaemic events in type 1 diabetes in Germany
R. Ziegler, Q. Zhang, P. Callahan, C. Vetter, E. Garal-Pantaler, A. De Remigis, L. Chen, W. Rathmann, Germany, USA

104 Association of type 1 diabetes duration or duration of advanced technology utilisation with severe hypoglycaemic event frequency

105 Residual C-peptide is associated with new and persistent impaired awareness of hypoglycaemia in type 1 diabetes
R. Varkevisser, T. Sas, H.-J. Aanstoot, B. Wolffenbuttel, M. Van der Klauw, Netherlands

106 A single experimental hypoglycaemic event induces acute and prolonged transcriptional changes in circulating monocytes of people with type 1 diabetes and healthy controls

107 Pathophysiological mechanisms of postprandial hypoglycaemia after gastric bypass in type 2 diabetes

108 Metoclopramide improves hypoglycaemic counterregulation in diabetic rats
<table>
<thead>
<tr>
<th>Event</th>
<th>Station</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 003</td>
<td>Station 1</td>
<td>The many facets of weight and type 2 diabetes risk</td>
<td>117</td>
</tr>
<tr>
<td>SO 009</td>
<td>Station 2</td>
<td>Treatment of type 1 diabetes</td>
<td>123</td>
</tr>
<tr>
<td>SO 015</td>
<td>Station 3</td>
<td>Genetics and biomarkers for prediction of type 2 diabetes</td>
<td>130</td>
</tr>
<tr>
<td>SO 021</td>
<td>Station 4</td>
<td>Insulin service providers for the body</td>
<td>136</td>
</tr>
<tr>
<td>SO 027</td>
<td>Station 5</td>
<td>Gestational diabetes: clinical perspective</td>
<td>141</td>
</tr>
<tr>
<td>SO 033</td>
<td>Station 6</td>
<td>Understanding insulin sensitivity: What can we learn from human studies?</td>
<td>147</td>
</tr>
<tr>
<td>SO 039</td>
<td>Station 7</td>
<td>Improving metabolic outcome by bariatric surgery</td>
<td>153</td>
</tr>
<tr>
<td>SO 045</td>
<td>Station 8</td>
<td>Preclinical advances to better understand energy, glucose and lipid metabolism</td>
<td>159</td>
</tr>
<tr>
<td>SO 051</td>
<td>Station 9</td>
<td>Metabolic alterations in obesity and diabetes-linked co-morbidities</td>
<td>165</td>
</tr>
<tr>
<td>SO 057</td>
<td>Station 10</td>
<td>Novel therapeutic avenues for metabolic disease</td>
<td>171</td>
</tr>
<tr>
<td>SO 063</td>
<td>Station 11</td>
<td>More combo's less insulin!</td>
<td>177</td>
</tr>
<tr>
<td>SO 069</td>
<td>Station 12</td>
<td>HbA$_1c$ vs CGM: a tie break?</td>
<td>184</td>
</tr>
<tr>
<td>SO 075</td>
<td>Station 13</td>
<td>A lesson in diabetes geography</td>
<td>190</td>
</tr>
<tr>
<td>SO 081</td>
<td>Station 14</td>
<td>Advances in diabetic kidney disease from cells to histology</td>
<td>196</td>
</tr>
<tr>
<td>SO 087</td>
<td>Station 15</td>
<td>Clinical studies on the crosstalk between neuropathy and other systems</td>
<td>202</td>
</tr>
<tr>
<td>SO 093</td>
<td>Station 16</td>
<td>A non-classical look at type 1 diabetes</td>
<td>208</td>
</tr>
<tr>
<td>SO 099</td>
<td>Station 17</td>
<td>A non-traditional look at type 1 diabetes</td>
<td>214</td>
</tr>
</tbody>
</table>
12:45 - 13:45      Cairo Hall

EASD e-Learning expert session

Chair: TBA
Speaker: TBA

13:00 - 13:45      Spotlight Stage

Help! I need somebody: Managing complex clinical cases in the Emergency Room

Chair: Stephen Thomas, UK
Speaker: Stephen Thomas, UK: Diabetic ketoacidosis in end stage kidney disease
 Aoife M. Egan, USA: Glycaemic emergencies in pregnancy
 Daniel Morganstein, UK: New cancer drug induced hyperglycaemic emergencies
## Short Oral Discussions Event D

<table>
<thead>
<tr>
<th>14:00 - 15:00</th>
<th>Short Oral Discussion Area</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SO 004 - Station 1</strong></td>
<td>Diet, lifestyle, and metabolic health: insights into diabetes risk and prevention</td>
<td>118</td>
</tr>
<tr>
<td><strong>SO 010 - Station 2</strong></td>
<td>Complications of type 1 diabetes</td>
<td>124</td>
</tr>
<tr>
<td><strong>SO 016 - Station 3</strong></td>
<td>Molecular predictors of type 1 diabetes</td>
<td>131</td>
</tr>
<tr>
<td><strong>SO 022 - Station 4</strong></td>
<td>Cells in attacking mode and beta cell victims</td>
<td>137</td>
</tr>
<tr>
<td><strong>SO 028 - Station 5</strong></td>
<td>Biomarkers and mechanisms in gestational diabetes</td>
<td>142</td>
</tr>
<tr>
<td><strong>SO 034 - Station 6</strong></td>
<td>Novel mechanisms of insulin resistance</td>
<td>148</td>
</tr>
<tr>
<td><strong>SO 040 - Station 7</strong></td>
<td>Now the brown fat talks</td>
<td>154</td>
</tr>
<tr>
<td><strong>SO 046 - Station 8</strong></td>
<td>What’s new on white fat function?</td>
<td>160</td>
</tr>
<tr>
<td><strong>SO 052 - Station 9</strong></td>
<td>Preclinical advances to understand glucose metabolism</td>
<td>166</td>
</tr>
<tr>
<td><strong>SO 058 - Station 10</strong></td>
<td>SGLT2 inhibition: focus on the heart and the kidneys</td>
<td>172</td>
</tr>
<tr>
<td><strong>SO 064 - Station 11</strong></td>
<td>Incretins have more effects than you can imagine</td>
<td>178</td>
</tr>
<tr>
<td><strong>SO 070 - Station 12</strong></td>
<td>De-combining CGM and insulin in type 2 diabetes</td>
<td>185</td>
</tr>
<tr>
<td><strong>SO 076 - Station 13</strong></td>
<td>Up or down and back</td>
<td>191</td>
</tr>
<tr>
<td><strong>SO 082 - Station 14</strong></td>
<td>Predicting and treating renal complications. What’s new in 2024?</td>
<td>197</td>
</tr>
<tr>
<td><strong>SO 088 - Station 15</strong></td>
<td>Fatty liver in diabetes: pathways and relationships</td>
<td>203</td>
</tr>
<tr>
<td><strong>SO 094 - Station 16</strong></td>
<td>Cohorts, trials and cardiovascular disease</td>
<td>209</td>
</tr>
<tr>
<td><strong>SO 100 - Station 17</strong></td>
<td>Correlates of fatty liver disease in diabetes</td>
<td>215</td>
</tr>
</tbody>
</table>
14:00 - 15:00 Cairo Hall

EASD e-Learning expert session

Chair: TBA
Speaker: TBA

14:00 – 14:45 Spotlight Stage

EASD Early Career Academy Symposium: Work-Life-Balance

Chair: Alexandra M. Smink, Netherlands
Panelists: Anna Krook, Sweden
Benoit Gauthier, Spain
15:30 - 17:00    Madrid Hall

**OP 19  Prediction and prognosis of type 1 diabetes**

109 Pioglitazone amplifies the decrease in HbA1c and prevents the increase in plasma ketone caused by dapagliflozin in type 1 diabetes patients
R. DeFronzo, M. Abdul-Ghani, G. Baskoy, A. Nakhleh, S. Abdelgani, F. Al-Mulla, M. Abu-Farha, F. Alajmi, T. Alessa, N. Shehadeh, USA, Israel, Kuwait,

110 Pancreatic imaging biomarkers of increased fibro-inflammation, low volume and low fat characterise type 1 diabetes: a UK Biobank study
H. Thomaides-Brears, E. Jackson, A. Triay-Bagur, F. McCann, T. Mahon, H. Al-Mossawi, M. Pansini, UK, Switzerland

111 Mortality and factors associated with it in Finnish patients with type 1 diabetes
E. Putula, T. Kauppala, S. Vanhamäki, J. Haapakoski, T. Laatikainen, S. Metso, Finland

112 Influence of the type 1 diabetes genetic risk score on response to immunotherapies for type 1 diabetes prevention

113 Islet Antigen-2A (IA-2A) autoantibody positivity increases risk of progression within and across established stages of type 1 diabetes

114 Risk of developing type 1 diabetes in individuals with other autoimmune conditions
S. Edelman, D. Agardh, N. Cui, L. Hao, X. Li, M. Wieloch, L. Meneghini, USA, Sweden, France
OP 20  Are you afrAID?
115 Quality-of-life benefits for adults living with type 1 diabetes using the Omnipod 5 System compared with insulin pump therapy: results from a randomised controlled trial
J.-P. Riveline, E. Renard, R. S. Weinstock, T. T. Ly, The OP5-003 Research Group, France, USA

116 Early real-world performance of the Omnipod® 5 automated insulin delivery (AID) system in 9,900 people with type 1 diabetes in Europe
E. G. Wilmot, T. Biester, F. M. Campbell, D. Deiss, J. Elliott, F. Gibb, J. Kröger, L. M. Huyett, J. J. Méndez, I. Hadjiyianni, L. R. Conroy, T. T. Ly, UK, Germany, USA

117 Real-world glycaemic and person-reported outcomes one year after Tandem Control IQ™ initiation in children and adults with type 1 diabetes

118 Sustained 1-year improvement of glucose control under free-life hybrid closed-loop insulin therapy in children with type 1 diabetes: national observatory of closed-loop in France (OB2F)
E. Renard, J.-P. Riveline, J.-B. Julla, F. Dalla-Vale, A. Spiteri, L. Mathivon, J.-F. Gautier, E. Bonnemaison, France

119 Glucose control in free-life under hybrid closed loop 6 and 12 months after initiation from a nation-wide survey
120 Impact on GRI and other metrics in type 1 adult patients switching to advanced hybrid closed-loop systems: a one-year real-life experience

15:30 - 17:00 Vienna Hall

OP 21 Cardiovascular risk in diabetes: in search of the holy grail

121 Atherosclerotic cardiovascular disease in familial hypercholesterolemia and diabetes: a nationwide registry study
D. Eriksson Hogling, K. Littmann, G. Kindborg, J. Brinck, Sweden

122 Association of plasma concentrations of MGO-apoB_{3184-3194}, a signature peptide of glycated apoB100, with cardiovascular events in people living with type 2 diabetes

123 The importance of muscle health in type 2 diabetes: adverse muscle composition and all-cause mortality
J. Linge, M. Petersson, O. Dahlqvist Leinhard, Sweden

124 Reduction in ischaemic events with icosapent ethyl in patients with diabetes and prior CABG: REDUCE-IT diabetes-prior CABG

125 Risk prediction of type 2 diabetes complications using metabolomic data from the whole UK Biobank cohort
K. Schut, S. Kerminen, L. Jostins-Dean, P. Wurtz, J. C. Barrett, Finland

126 Diabetes and trends in survival after acute myocardial infarction, 2011 to 2020
P.-S. Song, M. Kim, S. Lee, Republic of Korea
15:30 - 17:00  Sydney Hall

OP 22  Actions of incretins on the brain and pancreas you might not know about

127 Single-dose GLP-1-based pancreatic gene therapy durably maintains body composition and glycaemia after semaglutide withdrawal in a murine model of obesity

128 Brain circuitry activated by cagrilintide, semaglutide and CagriSema in mice
T. A. Lutz, G. Lommi, C. Le Foll, A. Secher, K. Raun, M. Hankir, Switzerland, Denmark

129 A trans-ancestry GLP1R candidate locus study for mental and physical health
M. M. Hayman, R. J. Strawbridge, P. Welsh, UK

130 Assessing GLP1 receptor occupancy in the CNS and pancreas using PET
A. Khalil, I. Velikyan, M. Bossart, M. Wagner, O. Eriksson, Sweden, Germany

131 Retatrutide, an agonist of GIP, GLP-1, and glucagon receptors, improves markers of pancreatic beta cell function and insulin sensitivity

132 Direct contact between endosomal GLP-1R, ER VAP-B and the AKAP SPHKAP triggers PKA-dependent MIC19 phosphorylation and beta cell mitochondrial remodelling

15:30 - 17:00  Sofia Hall

OP 23  Why exercise?

133 Effects of exercise intensity on the insulin sensitivity and lipid composition in skeletal muscle under the same calorie consumption exercise
S. Kakehi, Y. Tamura, T. Funayama, R. Kawamori, H. Watada, Japan
134 Myofiber Piezo1 regulates muscle hypertrophy and metabolism in response to exercise
T. Inoue, Y. Hirata, K. Nomura, N. Kuramoto, T. Nishigaki, K. Hozumi, K. Sugawara, W. Ogawa, Japan

135 Exercise-induced exosomes contribute to the sustained metabolic changes after cessation of exercise training in insulin resistance states

136 Effects of light-intensity physical activity snacking on cardiometabolic parameters in young adults with overweight/obesity: a randomised controlled crossover trial
S. Sanfilippo, O. Moser, P. Zimmermann, J. Schierbauer, A. Grothoff, N. Wachsmuth, T. Voit, A. Rössler, H. K. Lackner, S. Hoffmann, Germany, Austria

137 The response in insulin sensitivity to different modalities of acute exercise
N. S. Nielsen, J. O. Hvidemose, R. Aarvig, N. G. Skougaard, J. P. Hartmann, K. Husted, R. J. Loos, R. M. Berg, M. Ried-Larsen, Denmark

138 Integrated analysis of the skeletal muscle methylome and transcriptome following exercise in females with type 2 diabetes and normal glucose tolerance
K. MacGregor, J. Zierath, A. Krook, Sweden

15:30 - 17:00 Cairo Hall

OP 24 Islets forever: survival of the beta cells

139 Covid-19 and type 1 diabetes in Denmark: a longitudinal study on beta cell function
M. Bjerregaard-Andersen, P. Emilie Petersen, K. Kolnes, M. Bangshaab, A. Razvan Andries, J. Da Silva, E. Carvalho, T. Krarup Hansen, P. Vestergaard, F. Pociot, K. Højlund, C. B. Juhl, Denmark, Portugal

140 Regular at-home monitoring of stimulated dried blood spot C-peptide levels can detect changes in beta cell function early in individuals with recently diagnosed type 1 diabetes
A. E. Hendriks, M. L. Marcovecchio, P. Barker, M. Evans, C. Mathieu, on behalf of the INNODIA consortium, UK, Belgium
141 Characterisation of residual proinsulin and C-peptide after 50 years of insulin dependence: the Joslin Medalist study

142 Assessment of beta cell function and glucose metabolism after near total pancreatectomy: implications of 80% pancreas reduction
L. Soldovieri, G. Di Giuseppe, M. Zidda, M. Brunetti, G. Ciccarelli, S. Moffa, F. Cinti, A. Mari, G. Quero, S. Alfieri, A. Giaccari, T. Mezza, Italy

143 EGFR inhibitor erlotinib downregulates high fat mediated beta cell inflammation, lipid accumulation and augments insulin secretory function
O. Mukherjee, S. Nag, S. Mandal, N. Das, R. Kundu, India

144 Role of autophagy and intermittent fasting in beta cell mass and identity in K_ATP-induced neonatal diabetes
E. Castelblanco, Z. A. Shyr, I. Ramirez-Sotero, M. S. Remedi, USA
17:30 - 18:30  

**Madrid Hall**

**59th Minkowski Lecture**

The Minkowski Prize recognises research which contributes to the advancement of knowledge concerning diabetes mellitus.

*Chair:* Chantal Mathieu, Belgium

*Speaker:* Elisa De Franco, United Kingdom:  
**Finding the missing pieces of the puzzle: gene discovery in neonatal diabetes to gain new insights into beta cell biology**

**Elisa De Franco** studied medical biotechnologies at the University of Turin, Italy, followed by an EU-funded PhD fellowship at the University of Exeter.

She is currently a Senior Research Fellow in Exeter and the recipient of a Diabetes UK RD Lawrence Fellowship and an EFSD/Novo Nordisk Future Leader award.

Dr. De Franco’s research uses genome sequencing to discover genes essential for beta-cell development and function. Her work has been recognised by multiple awards, including the EASD Rising Star award in 2018 and the ISPAD Young Investigator Award in 2020.

She has published over 80 papers, including first-author publications in the Lancet and Nature Genetics.
**17:30 - 18:30 London Hall**

**Taking a COMBINEd approach: insulin icodex and semaglutide**

**Chair:** Athena Philis-Tsimikas, USA

**Speaker:** Liana K. Billings, USA:  
*Defining the needs for a weekly fixed ratio combination treatment in type 2 diabetes*

Linong Ji, China:  
*Basal insulin intensification by switching to once weekly IcoSema (COMBINE 1)*

Ildiko Lingvay, USA:  
*Intensification with IcoSema in a GLP-1RA experienced population (COMBINE 2)*

Liana K. Billings, USA:  
*IcoSema as an alternative to basal bolus treatment (COMBINE 3)*

---

**17:30 - 18:30 Berlin Hall**

**Addressing the lack of treatment options to reduce the morbidity/mortality gap in type 1 diabetes**

**Chair:** Daniel H. van Raalte, Netherlands

**Speaker:** Rory McCrimmon, UK:  
*Cardiovascular and kidney disease in type 1 diabetes*

Anand Srivastava, USA:  
*Which treatment options in type 2 diabetes could be harnessed for type 1 diabetes?*

Peter Rossing, Denmark:  
*Design of cardiovascular outcome trial in type 1 diabetes*
17:30 - 18:30  
**Vienna Hall**

**EASD/ESSM Symposium: When sex is ex (for her or for him)**

*Chair:* Leszek Czupryniak, Poland; Giovanni Corona, Italy  
*Speaker:* Aleksandra Uruska, Poland  
**Is it the body?**

Marieke Dewitte, Netherlands:  
**Is it the mind?**

Zdravko A. Kamenov, Bulgaria:  
**Is it the drugs?**

17:30 - 18:18:30  
**Sydney Hall**

**Neuroendocrine control of food intake, body weight and glucose metabolism**

*Chair:* Nicolai J. Wewer Albrechtsen, Denmark  
*Speaker:* Daniela Cota, France:  
**Hypothalamic responses to energy surfeit in the regulation of energy balance**

Ruben Nogueiras, Spain:  
**Regulation of glucose metabolism by neddylation**

Gregory R. Steinberg, Canada:  
**GFD15 regulation of food intake**
**17:30 - 18:30 Sofia Hall**

**Mitochondria: Implications in insulin sensitivity**

**Chair:** Piero Marchetti, Italy

**Speaker:** Marc Liesa-Roig, Spain:
*Mitochondrial dynamics and insulin resistance*

Paola Venditti, Italy:
*Role of mitochondria in muscle insulin resistance*

Gerald I. Shulman, USA:
*Novel liver-targeted mitochondrial protonophores in the treatment of type 2 diabetes*

Arun Sanyal, USA:
*Therapeutic potential of mitochondrial uncouplers in the treatment of insulin resistance*

**17:30 - 18:30 Cairo Hall**

**What can we learn about diabetes from population isolates?**

**Chair:** Marit E. Jorgensen, Greenland

**Speaker:** Torben Hansen, Denmark:
*Diabetes in Arctic Inuit*

Carlos A. Aguilar-Salinas, Mexico:
*Indigenous Mexicans*

Leslie J. Baier, USA:
*Pima Indians*
09:00 - 10:30 Madrid Hall

The rise of GIP: from biology to medicine

Chair: Timo D. Müller, Germany
Speaker: Michael A. Nauck, Germany:
GIPR/GLP-1R dual agonists: from discovery to approval

Alice E. Adriaenssens, UK:
Central effects of GIPR agonism in control of feeding behaviour

Ruth Gimeno, USA:
Pharmacological use

09:00 - 10:30 Madrid Hall

How is precision medicine advancing our understanding of diabetes aetiology and will it make a difference?

Chair: TBA
Speaker: TBA
Rising Star Symposium

The EASD Rising Star Symposium and EFSD Rising Star Fellowship Programme aims to identify promising and innovative young researchers who are developing their research activities in Europe.

Chair: Tina Vilsbøll, Denmark
Speaker: Georgia Colleluori, Italy: Inter-organ crosstalk in glucose homeostasis

Cintia Folgueira-Cobos, Spain: Unravelling the central role of p38α and its implications in metabolic disorders

Sini Marjut Heinonen Finland: Novel targets to activate adipose tissue metabolism for the treatment of obesity

Borja Martinez-Tellez, Spain: Revelling a new brown fat depot in young women with type 2 diabetes
**09:00 - 10:30**

**Vienna Hall**

**Novel approaches for prediction of microvascular complications - from tears to DNA and MRI**

*Chair:* Niina Sandholm, Finland  
*Speaker:* Ulrik B. Andersen, Denmark:  
  *Kidney imaging is the next biomarker in diabetic kidney disease*

Rama Natarajan, USA:  
  *DNA methylation is the next biomarker in diabetic kidney disease*

Martina Kropp, Switzerland:  
  *Tear metabolomics reveal the next biomarker in diabetic retinopathy*

---

**09:00 - 10:30**

**Sydney Hall**

**“Old and new” islets for type 1 diabetes**

*Chair:* Eelco De Koning, Netherlands  
*Speaker:* James A. M. Shaw, UK:  
  *Clinical outcome assessment of donor islet transplantation*

Timothy J. Kieffer, Canada:  
  *Ensuring safety of stem cell-derived islet products*

Trevor W. Reichman, Canada:  
  *Update of clinical stem cell-derived islet trials*
09:00 - 10:30 Sofia Hall

EASD/JDRF Symposium: Do devices really help the person with diabetes?

*Chairs:* Tadej Battelino, Slovenia; Aaron J. Kowalski, USA

*Speaker:* Lutz Heinemann, Germany: 
**Connected insulin pens: What are the benefits?**

Mark Evans, UK: 
**What risks to foresee with connected medical devices in diabetes?**

Thomas Danne, Germany: 
**Automated insulin delivery technologies: What is there on the horizon?**

09:00 - 10:30 Cairo Hall

12th East-West-Forum: Involving the public and patients in shaping diabetes care and research

*Chairs:* Apostolos Tsapas, Greece; Daisuke Yabe, Japan

*Speaker:* Sean Dinneen, Ireland: 
**Building capacity for high quality public and patient involvement in research: the PPI Ignite Network**

Yusuke Arai, Japan: 
**People with type 1 diabetes and their families in diabetes research**

Ingrid Willaing Tapager, Denmark: 
**User involvement in diabetes prevention, research and care**

Haruka Nakada, Japan: 
**Situation of PPI in the field of cancer in Japan**
10:45 - 12:15    Madrid Hall

**OP 25  Incretin receptor agonists: better and better**

145 Comparative efficacy and tolerability of incretin-based therapies for adults with overweight or obesity: a network meta-analysis

146 Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial
H. M. Colhoun, S. E. Kahn, P. M. Brown, E. T. Olesen, R. Bravo, J. Deanfield, A. Goudev, G. Latkovskis, M. Lehrke, A. M. Lincoff, N. Rathor, C.-C. Wu, I. Lingvay, On behalf of the SELECT investigator group, UK, USA, Denmark, Bulgaria, Latvia, Germany, Taiwan

147 ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study
L. Ji, H. Zhou, X. Li, X. Xu, A. Wong, Y. Zu, X. Song, Y. Zhang, S. Lin, X. Zhang, Y. Zhang, China

148 A phase 3 evaluation of cAMP signalling biased GLP-1 analogue ecnoglutide in adults with type 2 diabetes

149 Efficacy and safety of mazdutide in Chinese participants with overweight or obesity (GLORY-1)
L. Ji, H. Jiang, H. Li, J. Tian, D. Liu, Y. Zhao, W. Qiu, Y. Bi, J. Gu, Z. Liu, H. Deng, Y. Wang, L. Li, L. Qian, The GLORY-1 Investigators, China

150 A triple GIP, GLP-1 and glucagon receptor agonist, retatrutide, decreases inflammatory CV risk biomarkers in people with overweight or obesity, with or without type 2 diabetes
10:45 - 12:15  London Hall

LBA OP 4   TBA
Late breaking abstracts

10:45 - 12:15  Berlin Hall

OP 26   Love goes through the stomach: new roles for GLP-1

151 Alpha-lipoic acid's role in improving GLP-1 agonist treatment tolerability in young overweight patients with prediabetes
L. Jashi, T. Peshkova, T. Shervashidze, R. Kvanchakhadze, K. Dundua, L. Beridze, Georgia,

152 Higher GLP-1R expression in the pituitary of males with type 2 diabetes compared to females determined by [68Ga]Ga-NODAGA-exendin-4 PET/CT imaging
S. Tokgöz, L. Deden, R. I. Meijer, C. Tack, B. E. De Galan, M. Boss, M. Gotthardt, Netherlands

153 Serum GLP-1 and thrombospondin-2 predict improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy

154 Serotonin is a potent stimulator of GLP-1 secretion from the rat perfused intestine
T. A. Cookson, I. M. Modvig, J. J. Holst, Denmark

155 Insulin resistance elicits GLP-1 secretion from pancreatic alpha cells in mice
G. Di Giuseppe, S. Lind Jepsen, J. Vergara Ucin, D. Bjørklund Andersen, B. Hartmann, A. Giaccari, J. J. Holst, T. Mezza, Italy, Denmark

156 Lipidated interleukin-22 reduces body weight through reduced food intake and increased fecal energy loss in a complementary manner to GLP-1 receptor agonists
M. Van de Bunt, D. Haß, M. Rohm, A. Kjølbye, R. Jorgensen, Denmark, Germany
10:45 - 12:15   Vienna Hall

**OP 27  Predictors of diabetic kidney disease progression from omics to ethnicity**

157 Redefining the eGFR-albuminuric relationship using genetics: setting stage for precision monitoring
C. H. Naaman, T. W. Hansen, F. Persson, P. Rossing, T. S. Ahluwalia, Denmark

158 Impact of ethnicity on faster progression of kidney function loss and onset of advanced chronic kidney disease in an ethnically diverse cohort of people with type 2 diabetes
T. Aloabid, J. Karalliedde, S. Ayis, M. O’Connell, UK

159 Proteomic changes prior to onset and progression of albuminuria and end-stage kidney disease in type 1 diabetes
S. Mutter, E. Valo, E. Dahlström, V. Harjutsalo, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland, Australia

160 Association between serum REG Iα and progression of diabetic kidney disease: a prospective cohort study
N. Huang, S. Chen, Z. Shu, L. Li, China

161 Albuminuria trajectories over six years and their determinants in type 2 diabetes: the Fremantle Diabetes Study Phase II
W. A. Davis, T. M. Davis, Australia

162 HbA$_1c$ variability is independently associated with progression of diabetic kidney disease in people with type 1 diabetes
A. Muthukumar, L. Badawy, A. Mangelis, P. Vas, S. Thomas, A. Gouber, S. Ayis, J. Karalliedde, UK

10:45 - 12:15   Sydney Hall

**OP 28  New kids on the block: stem cell islets**

163 Metabolic maturation of stem cell derived beta cells upon murine engraftment
E. Vähäkangas, T. Barsby, H. Montaser, S. Eurola, P. Katajisto, J. Saarimäki-Vire, T. Otonkoski, Finland

164 Pro-inflammatory stimuli induce profound transcriptome and translatome changes in iPSC-derived beta cells that mimic type 1 diabetes beta cell gene signatures
165 Recruitment of thymic regulatory T cells to stem cell-derived beta cells expressing CCL22

166 Knock-out of the activating ligand repertoire of human stem cell-derived beta cells avoids chronic allogeneic rejection by NK cells in a diabetic humanised IL-15 NOG mouse model
G. Siracusano, R. Chimienti, M. Certo, C. Volpi, G. Lunetta, L. Perani, A. Palmisano, T. Canu, R. Melzi, F. Deambrogio, V. Sordi, M. Malnati, L. Piemonti, Italy

167 Multi-omic analysis reveals a dual role of PTPN2 in protecting beta cells from inflammatory-induced cell death and promoting stem cell-derived beta like cell maturation
V. Vandenbempt, J. Negueruela, F. Ribeiro-Costa, M. Nunes, S. Singh, L. Martelotto, E. Gurzov, Belgium, Australia

168 Monoclonal antibodies against the immune checkpoints B7-H3 and CD155 enhance engraftment of iPSC-derived pancreatic progenitors into mice humanised with allogeneic PBMCs
R. Chimienti, G. Siracusano, C. Volpi, M. Certo, G. Lunetta, F. Deambrogio, V. Sordi, L. Piemonti, Italy

10:45 - 12:15 Sofia Hall

OP 29 More on hormones

169 Postprandial secretion of GLP-1 and GIP is reduced in recent-onset type 2 diabetes but increased in steatotic liver disease
M. Huttasch, T. Mori, S. Kahl, G. Heilmann, N. Trinks, M. Schön, S. Trenkamp, Y. Kupriyanova, V. Schrauwen-Hinderling, N. J. Wewer Albrechtsen, V. Burkart, R. Wagner, M. Roden, for the GDS group, Germany, Denmark

170 Disparities in GLP-1 and GIP responses to small intestinal glucose infusion between people with well- and poorly-controlled type 2 diabetes
Y. Sun, C. Xie, M. Bound, K. L. Jones, M. Horowitz, R. Young, C. K. Rayner, T. Wu, Australia
171 Human GLP-1R expression in several organs outside the pancreas assessed by a biodistribution study of radiolabeled exendin PET/CT imaging

172 Blocking the effects of endogenous GIP increases fasting plasma glucose levels in individuals with obesity
F. Koefoed-Hansen, H. Kizilkaya, M. Helsted, N. Sørum, F. Dela, M. M. Rosenkilde, J. Holst, B. Hartmann, F. K. Knop, L. Gasbjerg, Denmark

173 Nutrient sensing mechanisms in human cholecystokinin-secreting cells
M. Santos-Hernandez, N. Guccio, C. Alcaino, C. A. Smith, F. Reimann, F. M. Gribble, UK

174 The effect of hepatic fat content on the hepatic response to glucagon during postprandial conditions
H. E. Christie, S. Mohan, A. M. Egan, A. Vella, USA

10:45 - 12:15 Cairo Hall

OP 30 Causes and consequences of gestational diabetes

175 The effect of a reduced energy diet upon maternal weight and pregnancy outcomes in women with gestational diabetes: the DiGest trial

176 Reduction of type 2 diabetes can be achieved by lifestyle intervention in young women with previous gestational diabetes

177 Achievement of glycaemic control after gestational diabetes diagnosis is associated with a risk of obesity in the offspring similar to that in children of individuals without gestational diabetes
178 Effectiveness of a family-based health promotion intervention on type 2 diabetes risk markers in women with prior gestational diabetes: 1-year follow-up from the Face-it RCT

179 Partitioned polygenic scores and extremes of polygenic risk provide mechanistic insights into type 2 diabetes and gestational diabetes in British Pakistani and Bangladeshi populations

180 Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study from Denmark
M. H. Christensen, C. A. Vinter, T. B. Olesen, M. H. Petersen, E. A. Nohr, K. H. Rubin, M. S. Andersen, D. M. Jensen, Denmark
# Short Oral Discussions Event E

<table>
<thead>
<tr>
<th>12:45 - 13:45</th>
<th>Short Oral Discussion Area</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 005 - Station 1</td>
<td>Unraveling monogenic diabetes: from genetic variants to innovative diagnostic tools</td>
<td>119</td>
</tr>
<tr>
<td>SO 011 - Station 2</td>
<td>Disease progression and mortality in diabetes</td>
<td>125</td>
</tr>
<tr>
<td>SO 017 - Station 3</td>
<td>Long-term complications and outcomes in type 2 diabetes: vascular health, kidney function, and mortality</td>
<td>132</td>
</tr>
<tr>
<td>SO 023 - Station 4</td>
<td>Keeping islet cell identity under different circumstances</td>
<td>137</td>
</tr>
<tr>
<td>SO 029 - Station 5</td>
<td>On the young ones...</td>
<td>143</td>
</tr>
<tr>
<td>SO 035 - Station 6</td>
<td>Non-insulin hormones</td>
<td>149</td>
</tr>
<tr>
<td>SO 041 - Station 7</td>
<td>Towards a better understanding of the adipose tissue - liver axis</td>
<td>155</td>
</tr>
<tr>
<td>SO 047 - Station 8</td>
<td>Novel mechanisms regulating energy and glucose metabolism</td>
<td>161</td>
</tr>
<tr>
<td>SO 053 - Station 9</td>
<td>Oral agents to control glucose metabolism</td>
<td>167</td>
</tr>
<tr>
<td>SO 059 - Station 10</td>
<td>Pleiotropic effects of SGLT2 inhibition</td>
<td>173</td>
</tr>
<tr>
<td>SO 065 - Station 11</td>
<td>Advanced real life in type 1 diabetes</td>
<td>179</td>
</tr>
<tr>
<td>SO 071 - Station 12</td>
<td>How universal can CGM be?</td>
<td>186</td>
</tr>
<tr>
<td>SO 077 - Station 13</td>
<td>Continuous monitoring of CGM</td>
<td>192</td>
</tr>
<tr>
<td>SO 083 - Station 14</td>
<td>The four M’s of microvascular complications: MRI, Mitochondria, Models, and iMaging</td>
<td>198</td>
</tr>
<tr>
<td>SO 089 - Station 15</td>
<td>Brain matters in diabetes</td>
<td>204</td>
</tr>
<tr>
<td>SO 095 - Station 16</td>
<td>Other complications of type 2 diabetes</td>
<td>210</td>
</tr>
<tr>
<td>SO 101 - Station 17</td>
<td>MASLD: now an established complication of diabetes</td>
<td>216</td>
</tr>
</tbody>
</table>
12:45 - 14:15  Sofia Hall

EFSD Future Leaders Symposium

Chair: Fatima Bosch, Spain

13:00 - 13:45  Spotlight Stage

Pro & Contra: Will next generation obesity drugs make bariatric surgery obsolete?

Chair: Matthias Blüher, Germany

Speaker: Francesco Rubino, UK: Pro

Louis J. Aronne, USA: Contra
## Short Oral Discussions Event F

### 14:00 - 15:00 Short Oral Discussion Area Page

<table>
<thead>
<tr>
<th>Station</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO 006</td>
<td>Station 1: Advancements in predicting type 1 diabetes</td>
<td>120</td>
</tr>
<tr>
<td>SO 012</td>
<td>Station 2: Health interactions and risks in diabetes: from cancer</td>
<td>127</td>
</tr>
<tr>
<td>SO 018</td>
<td>Station 3: Diabetes management and outcomes: societal, behavioral,</td>
<td>133</td>
</tr>
<tr>
<td></td>
<td>and clinical influences</td>
<td></td>
</tr>
<tr>
<td>SO 024</td>
<td>Station 4: Improving islet transplantation</td>
<td>138</td>
</tr>
<tr>
<td>SO 030</td>
<td>Station 5: Investigating impact of gestational diabetes</td>
<td>144</td>
</tr>
<tr>
<td>SO 036</td>
<td>Station 6: Keeping your beta cells alive</td>
<td>150</td>
</tr>
<tr>
<td>SO 042</td>
<td>Station 7: How lifestyle affects our health</td>
<td>156</td>
</tr>
<tr>
<td>SO 048</td>
<td>Station 8: Novel mechanisms controlling glucometabolic health</td>
<td>162</td>
</tr>
<tr>
<td>SO 054</td>
<td>Station 9: Improving metabolism via the gut</td>
<td>168</td>
</tr>
<tr>
<td>SO 060</td>
<td>Station 10: Novel incretins: it is all about clinical outcomes</td>
<td>174</td>
</tr>
<tr>
<td>SO 066</td>
<td>Station 11: Pumping without bumping</td>
<td>180</td>
</tr>
<tr>
<td>SO 072</td>
<td>Station 12: The future of diabetes science is here</td>
<td>187</td>
</tr>
<tr>
<td>SO 078</td>
<td>Station 13: More stress on distress</td>
<td>193</td>
</tr>
<tr>
<td>SO 084</td>
<td>Station 14: Mechanisms and treatment for microvascular complications;</td>
<td>199</td>
</tr>
<tr>
<td></td>
<td>nerves, eyes, and blood vessels</td>
<td></td>
</tr>
<tr>
<td>SO 090</td>
<td>Station 15: Skeletal muscles and subcutaneous adipose tissue: important players in diabetes management</td>
<td>205</td>
</tr>
<tr>
<td>SO 096</td>
<td>Station 16: A non-traditional look at type 2 diabetes</td>
<td>211</td>
</tr>
<tr>
<td>SO 102</td>
<td>Station 17: Addressing risk and consequences of liver pathology in diabetes</td>
<td>217</td>
</tr>
</tbody>
</table>
14:00 - 15:00  Cairo Hall

**EASD e-Learning expert session**

*Chair:* TBA  
*Speaker:* TBA

**14:00 – 14:45  Spotlight Stage**

**EUDF Symposium: AI-Driven clinical decision support systems:** Potential, concerns and what should it bring to people living with diabetes?

*Speaker:*  
Stefano Del Prato, Italy:  
*Welcome and introduction*

Alfonso Galderisi, USA:  
*Implications of using AI-CDSS in diabetes care*

Peter E.H. Schwarz, Germany:  
*What should AI-CDSS deliver in diabetes care? TBA*
15:30 - 17:00  
Madrid Hall

**OP 31  Macrovascular outcomes of diabetes: a holistic view**

181 The relationship between serum HDL-cholesterol, cardiovascular disease and mortality in community-based people with type 2 diabetes: the Fremantle Diabetes Study phase II  
T. M. Davis, W. A. Davis, Australia

182 Association between metabolic dysfunction-associated steatotic liver disease and ischemic stroke in patients with type 2 diabetes  
M. Jang, G. Kim, K.-N. Lee, K. Han, R. Oh, S. Cho, J. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, Republic of Korea

183 Risk for cardiovascular disease and all-cause mortality in type 1 compared with type 2 diabetes patients: a nationwide register-based study  

184 Prospective associations between markers of low-grade inflammation and major cardiovascular events and mortality in recently diagnosed type 2 diabetes: a Danish nationwide cohort study  

185 The interaction between type 2 diabetes and chronic kidney disease on heart failure outcomes: observational study from the Swedish Heart Failure and the Swedish National Diabetes Registries  
A. Merolla, V. Valente, L. Benson, U. Dahlström, L. H. Lund, S. Gudbjörnsdottir, F. Cosentino, G. Savarese, G. Ferrannini, Sweden, Italy

186 Prevalence and prognostic significance of diabetes-related complications in patients with newly diagnosed type 2 diabetes in Sweden  
S. Karayiannides, N. Widén, N. Rajamand-Ekberg, S.-B. Catrina, Sweden
15:30 - 17:00  London Hall

LBA OP 5    TBA
Late breaking abstracts

15:30 - 17:00  Berlin Hall

OP 32  Fine tuning CGMing

187 How variable is the glycaemic variability? Analysis of CGM data over one year
E. Schupp, R. Stienstra, C. J. Tack, R. I. Meijer, Netherlands

188 The relationship between time in tight range and the presence of chronic complications in adults with type 1 diabetes: a retrospective cross-sectional real-world study
J. De Meulemeester, S. Charleer, M. Visser, C. De Block, C. Mathieu, P. Gillard, Belgium

189 Inpatient accuracy of continuous glucose monitors in people with type 1 diabetes: a multi-centre retrospective study
R. Wang, A. Connell, C. Chiang, J. Tjahyadi, M. Kyi, S. Fourlanos, Australia

190 Impact of continuous glucose monitoring on hospitalisations in people with type 2 diabetes: real-world analysis

191 Impact of continuous glucose monitoring use on glycated haemoglobin (HbA1c) in people with type 2 diabetes: real-world analysis

192 Time above range and not time below range is associated with mortality in older patients with type 2 diabetes: results from the HYPOAGE study
OP 33  Emerging science in diabetic kidney disease from fasting to autophagy

193 Study of the A<sub>2b</sub> adenosine receptor in profibrotic activation of glomerular parietal epithelial cells in experimental diabetes
C. Jara, D. Moscol, P. D. Sastre, A. Torres-Arevalo, I. Arias, C. Cappelli, R. San Martin, Chile

194 WWP2-induced pericytes to myofibroblast transition contributes to the progression of fibrosis in CKD in diabetes
F. Conserva, A. Cicirelli, G. Sclavo, M. Venneri, R. Franzin, A. Stasi, E. Squicciarino, A. Gallone, M. Fiorentino, F. Pesce, L. Gesualdo, P. Pontrelli, Italy

195 Mechanisms of PERK/ATF4 axis-targeted ATG4B autophagy signalling pathway in promoting diabetic kidney disease
Q. Huang, X. Fei, J. Gong, Y. Chen, X. Wu, China

196 Renal gluconeogenesis maintains body fluids during fasting
K. Kaneko, M. Yamato, H. Katagiri, Japan

197 Is NOX5 potentially a better therapeutic target than NOX4 in renal complications of diabetes?
J. Jha, S. L-Trevino, A. Dai, J. Vincent, J. Meister, M. E. Cooper, K. Jandeleit-Dahm, Australia, Switzerland, Germany

198 Does the expression of glucagon-like peptide-1 receptor on bone marrow derived cells influence the onset and progression of diabetic kidney disease?

OP 34  [B]reaking [F]at

199 Metabolic remodelling in adipose tissue: insights from Roux-en-Y gastric bypass surgery on fructose production
A. Reis-Costa, P. Katsogiannos, M. Pereira, J. Jones, J. Eriksson, Portugal, Sweden
200 Exercise training regulates long noncoding RNAs expression in subcutaneous WAT of obese participants
P. Nigro, T. Caputo, L. K. Simpson, M. M. Columbus, J. Ding, M. F. Hirshman, R. J. Middelbeek, L. J. Goodyear, USA

201 Multi-omics analysis of human brown fat reveals novel candidates for the thermogenic activation of adipose tissue

202 A multi-omics approach to understand the underlying mechanisms of obesity
J. Niu, C. Gieger, A. Peters, S. Sharma, H. Grallert, Germany

203 HOOK1: A potential novel target gene for obesity?

204 Differences in adipose tissue-, liver- and jejunal gene expression between obese patients with and without glomerular hyperfiltration
S. T. Jagroep, M. Koning, V. E. Gerdes, M. Nieuwdorp, A. S. Meijnikman, D. H. Van Raalte, Netherlands

15:30 - 17:00 Sofia Hall

OP 35 Insulin: ready, steady, go!

205 P21-activated kinase: a novel regulator of the FGF1/PDE4D antilipolytic pathway and insulin resistance
J. Seigner, J. Krier, D. Spähn, J. L. Nono, R. Lukowski, A. L. Birkenfeld, G. Sancar, Germany

206 Investigating insulin-lowering mechanisms of SGLT2-inhibition in individuals with postbariatric hypoglycaemia
E. Faggionato, D. Herzig, C. Dalla Man, L. Bally, M. Schiavon, Italy, Switzerland

207 Insulin-degrading enzyme couples glucagon and insulin-mediated regulation of mitochondrial dynamics in hepatocytes
P. Cámara-Torres, S. Hernández de la Red, B. Merino, J. Santo-Domingo, M. De la Fuente, A. Alonso, I. Cózar-Castellano, G. Perdomo, Spain
208 Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes
S. Mäkinen, S. Sree, T. Ala-Nisula, H. Kultalahti, P. Koivunen, H. A. Koistinen, Finland

209 Characterisation of new tissue-specific insulin resistance clusters in persons with and without diabetes and their relationship to comorbidities

210 The gut epithelium-specific mTORC1 activation improves glucose metabolism selectively in male mice

15:30 - 17:00 Cairo Hall

OP 36 Inside information on beta cell regulation

211 Structure, interaction, and nervous connectivity of beta cell primary cilia

212 Somatostatin secretion at synapse like structures triggers primary cilia signalling to modulate beta cell function
C. Incedal Nilsson, O. Dumral, B. Xie, A. Müller, G. Sanchez, M. Solimena, H. Ren, O. Idevall Hagren, Sweden, China, Germany

213 Primary cilia regulate GLP-1 signalling in pancreatic beta cells
I. Melena, L. Zhu, J. Cho, S. Adamson, J. Hughes, USA

214 GPR180 receptor controls insulin production and secretion
M. Antal, P. Makovicky, T. Dahlby, C. Wolfrum, M. Balaz, L. Balazova, Slovakia, Switzerland

215 The type 2 diabetes-associated K+ channel TALK-2 reduces beta cell endoplasmic reticulum Ca2+stores and cytosolic Ca2+ entry, which limit insulin secretion
J. R. Dobson, P. K. Dadi, A. Y. Nakhe, D. A. Jacobson, USA
216 Mitochondrial fission process 1 regulates glucose stimulated insulin secretion in pancreatic beta cells
S. Sarwat, C. Zhang, R. M. Alonso, A. Mihalovits, M. Yang, G. Rutter, T. A. Rodriguez, A. Martinez-Sanchez, UK
17:30 - 18:30

**Diabetes Prize for Excellence Lecture**

The Diabetes Prize for Excellence recognises outstanding achievements in research which has led to significant advances in the understanding, prevention or treatment of diabetes or its complications.

**Chair:** Chantal Mathieu, Belgium  
**Speaker:** Juleen R. Zierath, Sweden:  
*Deconvoluting signals and metabolic rhythmicity of insulin- and exercise-action in type 2 diabetes*

**Juleen R. Zierath** is Professor of Clinical Integrative Physiology at Karolinska Institutet, Stockholm, and Professor and Executive Director at the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen.

She is a member of the Nobel Assembly for Physiology or Medicine, the Royal Swedish Academy of Sciences, EMBO, Academia Europaea and the Keystone Symposia Board of Directors.

Prof. Zierath performs translational research to delineate mechanisms for type 2 diabetes pathogenesis. Her current work is focused on the interaction between circadian rhythms and exercise training and the control of metabolism in diabetes and obesity.
17:30 - 18:30  
**London Hall**

**The promise of GIP and GIPR antagonism: bridging the gap**

*Chair:* TBA  
*Speaker:* TBA

17:30 - 18:30  
**Berlin Hall**

**The use of Automated Insulin delivery (AID) around physical activity and exercise in type 1 diabetes: a position statement of the EASD and ISPAD**

*Chair:* TBA  
*Speaker:* TBA

17:30 - 18:30  
**Vienna Hall**

**Diabetes and cancer: connecting the dots**

*Chair:* Bendix Carstensen, Denmark  
*Speaker:* Cathy J. Bradley, USA:  
**Access to state of the art cancer services: Is diabetes a barrier?**

Magdalena Taube, Sweden:  
**Metabolic surgery and cancer**

Simon Lord, UK:  
**Is there a role for metformin in cancer prevention and therapy?**
17:30 - 18:30  
Sydney Hall

**EASD/EASO Symposium: Obesity and diabetes: the intertwined syndemic**

*Chairs:* Christine Andreasen, Denmark; Volkan D. Yumuk, Turkey

*Speaker:* Gema Frühbeck, Spain:  
*Obesity, an adiposity based chronic disease: clinical implications for diabetes treatment*

Luca Busetto, Italy:  
*The difficulties in obesity definition in terms of anthropometric measures*

Mikael Rydén, Sweden:  
*Management of obesity in people with pre-diabetes to prevent type 2 diabetes*

17:30 - 18:30  
Sofia Hall

**EASD Early Career Academy Symposium: ERC funding**

*Chair:* Jan Gojda, Czech Republic

*Speaker:* Fiona Kernan, Belgium:  
*Annual work programme of ERC funding*

Emma Börjeson, Denmark:  
*How to get your Starting Grant in life science*
17:30 - 18:30 Cairo Hall

Insulin secretion in type 1 diabetes

Chair: James A.M. Shaw, UK

Speaker: Tiinamaija Tuomi, Finland: 
*Residual insulin secretion in individuals with type 1 diabetes*

Sarah J. Richardson, UK: 
*Pancreatic pathology in type 1 diabetes*

Malin Flodstrom Tullberg, Sweden: 
*Impact of coxsackievirus on insulin secretion*
09:00 - 10:00  
Madrid Hall

TBA

Chair: TBA  
Speaker: TBA

09:00 - 10:00  
London Hall

Prospective study to evaluate individual effects on the relationship of glucose and HBA\textsubscript{1c}: design, results, and clinical implications

Chair: TBA  
Speaker: TBA

09:00 - 10:00  
Berlin Hall

From monogenic to oligogenic forms of diabetes: a continuum?

Chair: TBA  
Speaker: TBA

09:00 - 10:00  
Vienna Hall

The sky is the limit

Chairs: Chantal Mathieu, Belgium; Christian Collin, Denmark  
Speaker: Bruce King, Australia: Pilots and passengers: the ups and downs

David Russell-Jones, UK: Flying with diabetes

Julia K. Mader, Austria: Diabetes technology in aviation
09:00 - 10:00  Sydney Hall

Shift from proliferative diabetic retinopathy to early intervention of diabetic eye disease

Chair: Cristina Hernandez, Spain
Speaker: Rafael Simo, Spain:
Neurons at the origin of diabetic retinal disease

Sobha Sivaprasad, UK:
Emerging strategies for early intervention for diabetic retinopathy

09:00 - 10:00  Sofia Hall

Generation of pancreatic islets from stem cells

Chair: Françoise Carlotti, Netherlands
Speaker: Raphael Scharfmann, France:
Lessons learned from embryonic islet formation

Valeria Sordi, Italy:
Generation of stem-cell derived islets from pluripotent stem cells
09:00 - 10:00  Cairo Hall

EASD Early Career Academy Symposium: From Rising Star to Principal Investigator

Chair: Simon Dreher, Germany

Speaker: Ruben Nogueiras, Spain:
Role of p53 family members on hepatic steatosis and insulin sensitivity

Niina Sandholm, Finland:
Dissection of genetic background of diabetic nephropathy in subjects with type 1 diabetes

Hanieh Yaghootkar, UK:
Using human genetics to understand the underlying mechanisms that protect some obese people from type 2 diabetes
10:30 - 11:30  Madrid Hall

OP 37  Protection in islet transplantation

217 Islet transplantation vs insulin alone in patients with type 1 diabetes and a kidney transplant: a French nationwide study on behalf of the Trepid group
M. Maanaoui, R. Lenain, Y. Foucher, F. Buron, S. Lablanche, G. Blanco, S. Caillard, L. Kessler, A. Brodin-sartorius, M. Chetboun, J. Kerr-conte, T. Berney, M.-C. Vantyghem, M. Hazzan, F. Pattou, France

218 Effect of islet transplantation on the incidence of diabetic complications and mortality in patients with unstable type 1 diabetes

219 Ado12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use
A.-L. Gaffuri, X. Gaume, J. Brun, R. Besnard, C. Gautier, O. Jouannot, N. Laurent, R. Eloy, K. Bouzakri, O. Soula, France, USA

220 Functional islet transplantation into immunocompetent diabetic animals using hydrogel encapsulation without the need for immunosuppression
H. Stöver, Canada

10:30 - 11:30  London Hall

OP 38  New insights into CNS regulation of energy and glucose metabolism

221 Effects of activation of peripheral sympathetic nerve on glycaemic control in standard chow- and high-fat-fed rats
D. Sato, L. Miyamoto, R. Banno, M. Kusunoki, Japan

222 Genetic dissection of serum pro-neurotensin implicates its causal effects on brain structure
223 Characterising central cell types accessed by peripherally-administered incretin receptor analogues
A. Roberts, C. Blouet, J. Broichhagen, D. Hodson, A. Adriaenssens, UK, Germany

224 fNIRS demonstrates over activation of the dorsolateral prefrontal cortex following OGTT in youths with obesity and reduced insulin sensitivity
M. Manco, G. Scozia, A. Aureli, D. Menghini, D. Fintini, S. Lasaponara, Italy

10:30 - 11:30                       Berlin Hall

OP 39    Novel insights in monogenic diabetes

225 MODY is polygenic as well as monogenic! Polygenic background strongly contributes to genetically confirmed MODY and clinical cases without a monogenic cause

226 A specific de novo ACTB variant is a novel cause of syndromic neonatal diabetes

227 Last exon truncating variants in INS and PDX1 cause MODY whereas heterozygous WFS1 variants do not cause MODY

228 Impact of SGLT2 inhibition on glucosuria in MODY3

10:30 - 11:30                       Vienna Hall

OP 40    Around liver fat: the fight is on

229 Tirzepatide for treatment of metabolic dysfunction-associated steatohepatitis: relationship between metabolic and histological responses
C. Caussy, M. L. Hartman, M. K. Thomas, K. J. Mather, Y. Tang, R. Loomba, A. J. Sanyal, France, USA
230 Hepatic glucose production is increased in MASH with significant fibrosis even in absence of diabetes
S. Sabatini, P. Sen, F. Carli, S. Pezzica, E. Lembo, C. Rosso, A. Daly, S. Cockel, O. Govaere, T. Hyötyläinen, G. Mingrone, E. Bugianesi, Q. M. Anstee, M. Orešič, A. Gastaldelli, Italy, Finland, UK, Sweden

231 The hepatoprotective HSD17B13 splice variant rs72613567:TA suggests enhanced lactate clearance

232 Genetically determined circulating metabolite levels and risk of metabolic dysfunction-associated steatotic liver disease (MASLD): a mendelian randomisation study
K. Deng, A. V. Vlieg, F. R. Rosendaal, D. O. Mook-Kanamori, K. Willems van Dijk, R. Li-Gao, Netherlands

10:30 - 11:30 Sydney Hall

OP 41 Turning back the biological clock - or merely slowing it?

233 Oral insulin delay of stage 3 type 1 diabetes revisited in HLA DR4-DQ8 participants in the TrialNet oral insulin prevention trial (TN-07)
L. Zhao, G. K. Papadopoulos, J. S. Skyler, D. Geraghty, H. Parikh, B. Kwok, A. Lernmark, USA, Greece, Sweden

234 C-peptide persistence is associated with lower HbA1c, higher time in range and low rates of hypoglycaemia in adults with type 1 diabetes

235 Digital delivery of type 2 diabetes remission programme in the UK: clinically significant weight loss and improved glycaemic control
D. H. Laursen, S. B. Bendsen, S. Johnson, C. Brandt, E. Heath, Denmark, UK

236 Predictive factors for type 2 diabetes remission: insights from a digital twin intervention programme at 18 months
P. Shamanna, M. Dharmalingam, A. Vadavi, A. Keshavamurthy, S. Bhonsley, M. Thajudeen, A. Balasubramanian, S. Joshi, India
10:30 - 11:30  Sofia Hall

**OP 42  New factors in the control of glucose tolerance**

237 Exploring the roles of carbonic anhydrase VIII in hepatic glucose production and its potential for diabetes treatment

238 Glucose-lowering by colesevelam in type 2 diabetes is related to a reduction in circulating serotonin
C. Xiang, C. Xie, W. Huang, K. Jones, M. Horowitz, C. Rayner, T. Wu, China, Australia

239 Genetic deletion of hyaluronan receptor RHAMM improves glucose tolerance and cardiac performance in vivo
A. K. Banah, X. Weng, C. Murdoch, L. Kang, UK

240 Circulating Netrin-4 levels and influencing factors in women with PCOS and the role of anti-insulin resistance therapy
S. Xue, L. Li, China

10:30 - 11:30  Cairo Hall

**LBA OP 6  TBA**

Late breaking abstracts
Double jeopardy: Could SGLT2 inhibitors and/or GLP1RAs improve glycaemic outcomes and QoL in type 1 diabetes?

Chair: Tomasz Klupa, Poland

Speaker: Bruce A. Perkins, Canada:
Yes: benefits overcome risks

Martin Haluzik, Czech Republic:
No: risks overcome benefits
12:00 - 13:00  

**OP 43  Treating type 1 diabetes: What else does the future hold?**

241 A novel small-molecule activator of Lyn kinase for the treatment of type 1 diabetes  
H. Huang, Q. Wang, J. Buteau, Canada

242 ILC3 stimulation by a novel FFAR2 agonist ameliorates type 1 diabetes in C57BL/6 mice  

243 Efficacy of semaglutide and tirzepatide by insulin delivery in overweight and obese adults with type 1 diabetes  
J. Snell-Bergeon, F. Dong, G. Kaur, D. Renner, H. Akturk, S. Garg, USA

244 Dapagliflozin reduces endogenous glucose production during a period of acute insulin deprivation and development of ketoacidosis in people with type 1 diabetes  
E. Svehlikova, W. Regittnig, C. Gatschelhofer, V. Höller, G. Fluhr, B. Lackner, C. Magnes, A. Eberl, T. R. Pieber, Austria

---

12:00 - 13:00  

**OP 44  The unforgettable alpha cells**

245 Patch-seq reveals alpha cell electrical dysfunction linked to alterations in identity, paracrine signalling, metabolism, immune response, and mTOR activity in type 1 diabetes  
T. Dos Santos, X. Q. Dai, C. Ellis, A. Bautista, R. C. Jones, J. Camuñas-Soler, S. Quake, P. E. MacDonald, Canada, USA, Sweden

246 Glucagon induced CREB-dependent delta cell hyperactivity underlies impaired glucagon secretion in recurrent hypoglycaemia  
R. Gao, S. Acreman, J. Ma, P. Rorsman, Q. Zhang, UK, Sweden, Portugal

247 The effect of obesity on the alpha cell response to amino acids in the presence of hyperglycaemia  
S. Mohan, F. Boscolo, H. Christie, A. Egan, M. Laurenti, C. Dalla Man, A. Vella, USA, Italy

248 The glucagon-like peptide-1 receptor antagonist, exendin (9-39) amide, improves the impaired glucagon response to hypoglycaemia in the non-obese diabetic mouse model of type 1 diabetes  
T. G. Hill, A. Clark, C. Miranda, P. Rorsman, UK, Sweden
12:00 - 13:00  
Berlin Hall

**OP 45  How smart an insulin pen can be?**

249 Improvement in time in range after smart insulin pen initiation in Austria  
J. K. Mader, N. V. Hartvig, A. Kaas, N. N. Knudsen, Y. Winhofer, Austria, Denmark

250 Real world results from the first 845 European InPen smart MDI system users: behaviour has a substantial effect on outcomes  

251 Multinational analysis of factors associated with missed bolus insulin injections using smart pen data  
F. J. Ampudia-Blasco, M. L. Jensen, A. Kaas, N. N. Knudsen, R. Nishimura, Spain, Denmark, Japan

252 Enabling continuous glucose monitoring users with multi-horizon glucose predictive capabilities: the Accu-Chek®SmartGuidePredict App  
P. Herrero, M. Androrrà, N. Babion, H. Bos, M. Koehler, Y. Klopfenstein, P. Lustenberger, A. Peak, C. Ringemann, T. Glatzer, Spain, Germany, Netherlands, Switzerland

---

12:00 - 13:00  
Vienna Hall

**OP 46  Pregnancy: taking care of the future**

253 Placental expression of glucose transporters mRNA (GLUT-1, GLUT-3 and GLUT-4) and transcriptome profiling with microarrays in pregnant patients with diabetes  
R. Sibiak, P. Gutaj, U. Mantaj, L. Adamczak, M. Blatkiewicz, M. Rucinski, E. Wender-Ozegowska, Poland

254 Impact of gestational diabetes on infant fat and fat-free mass: findings from a prospective cohort study (PEAPOD)  
P. Saravanan, N. Periyathambi, Y. Weldeselassie, S. Pandya, C. Bagias, N. Sukumar, UK

255 Myoinositol modulates endothelial extracellular vesicles release in gestational diabetes  
M. Baldassarre, F. Carrieri, P. Di Tomo, N. Di Pietrantonio, D. De Bellis, P. Lanuti, A. Pandolfi, A. Consoli, G. Formoso, Italy
256 Maternal HbA\textsubscript{1c} and BMI and risk of congenital malformations in type 1 diabetes: a cohort study
I. H. Thorius, J. Petersen, L. N. Husemoen, A. N. Alibegovic, M.-A. Gall, P. Damm, E. Mathiesen, Denmark

12:00 - 13:00

**Sydney Hall**

**OP 47** Inflammatory mechanisms regulating systems metabolism

257 Soluble CD52 suppresses hepatic chronic inflammation in obese mice
T. Wada, Y. Miyazawa, Y. Onogi, H. Tsuneki, T. Sasaoka, Japan

258 Integrating immune-inflammatory profile to define endotypes of type 2 diabetes
B. T. Vuong, J. B. Julla, M. Diedisheim, C. Bleriot, F. Alzaid, C. Potier, K. Khider, A. Bonnefond, L. Potier, F. Ginhoux, J. F. Gautier, N. Venteclef, France

259 The RAGE antagonist Azeliragon prevents adiposity and metaflammation in diet-induced obese mice
R. Mastrocola, E. Porchietto, P. I. Rivas Navarrete, J. L. Scheijen, E. Aimaretti, C. Ceccopieri, M. Aragno, C. Cifani, C. Schalkwijk, M. Collino, Italy, Netherlands, Poland

260 Vildagliptin: the good guy in improving pancreatic beta cell function by lowering pro-inflammatory macrophage accumulation and polarisation
S. Nag, S. Mandal, O. Mukherjee, R. Kundu, India

12:00 - 13:00

**Sofia Hall**

**OP 48** Managing diabetic foot disease: clinical studies and omics predictors

261 A single centre, randomised controlled trial on the efficacy of regenerating tissue agents technology in diabetic foot ulcers
G. Samakidou, I. Eelftheriadou, I. A. Anastasiou, O. Kosta, A. Tentolouris, K. Evangelou, N. Tentolouris, Greece
262 Elevated triglyceride levels correlate with a unique swap and plasma biomarker profile in diabetic foot ulcers

263 Novel proteomic markers of diabetic foot ulcer healing time

264 Care pathway and risk of amputation after diabetic foot ulcer: data from the French national claim data (SNDS)
J.-B. Bonnet, C. Duflos, H. Huguet, S. Tournayre, A. Avignon, A. Sultan, France

12:00 - 13:00 Cairo Hall

LBA OP 7  TBA
Late breaking abstracts
12:15 - 12:45  Spotlight Stage

Type 1 diabetes and kidney failure: additional donor pancreas or islet transplantation should be the standard treatment of hyperglycaemia

Chair: Lorenzo Piemonti, Italy
Speaker: Thierry Berney, France: Pro

Anne Wojtusciszyn, Switzerland: Con
13:30 - 15:00  
Madrid Hall

Metabolic medicine 2030: What the future will bring

*Chair:* Matthias H. Tschöp, Germany  
*Speaker:* Anette-Gabriele Ziegler, Germany:  
The future of type 1 diabetes therapy

David A. D'Alessio, USA:  
The future of type 2 diabetes therapy

Matthias Blüher, Germany:  
The future of obesity therapy

13:30 - 15:00  
London Hall

Can we receive consensus on how glucagon secretion is regulated?

*Chair:* Anders Tengholm, Sweden  
*Speaker:* Patrik Rorsman, UK:  
The KATP-channel and glucagon secretion

Jakob G. Knudsen, Denmark:  
Fatty acids as regulator of glucagon secretion

Danielle Dean, USA:  
Amino acids as regulators of glucagon secretion
13:30 - 15:00  Berlin Hall

Diabetologia Symposium: Diabetes Technology: a lifelong companion

*Chair:* Anna Krook, Sweden

*Speaker:* Helen R. Murphy, UK:
**Benefits, barriers and pitfalls of diabetes technology use in pregnancy**

Marc D. Breton, USA:
**Use of technology in children with type 1 diabetes**

Alan J. Sinclair, UK:
**The use of diabetes in technology in older people**

Hood Thabit, UK:
**Technology use in hospitalised inpatients**

Partha Kar, UK; Chantal Mathieu, Belgium:
**Panel discussion**

13:30 - 15:00  Vienna Hall

Heterogeneity of type 2 diabetes: Will seeing type 2 diabetes in HD…

*Chair:* Shivani Misra, UK

*Speaker:* John Dennis, UK:
**… help choose the best treatment?**

Tuomas O. Kilpeläinen, Denmark:
**… improve diabetes prevention efficacy?**

Emma Ahlqvist, Sweden:
**… be the obvious way to see it?**
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
<th>Chair</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 15:00</td>
<td>Sydney Hall</td>
<td>Metabolic disease and mental illness</td>
<td>TBA</td>
<td>TBA</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Sofia Hall</td>
<td>Targeting obesity to treat heart failure: dawn of a new era</td>
<td>TBA</td>
<td>TBA</td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td>Cairo Hall</td>
<td>EASD/ADA/ISPAD Symposium: Consensus report: Transition from paediatric to adult diabetes care</td>
<td>TBA</td>
<td>TBA</td>
</tr>
</tbody>
</table>
Short Oral Event A  Tuesday, 12:30 - 13:30

SO 001 Genetic insights into type 2 diabetes: from risk variants to personalized treatment strategies

265 The diabetes-associated genetic variants rs111669836 and rs17791513 modulate the incretin effect in individuals with normal glucose tolerance

266 Combining next-generation sequencing and metabolic phenotyping to elucidate reduced mitochondrial respiration in type 2 diabetes

267 Effect of fetal alpha-ketoglutarate dependent dioxygenase (FTO) gene obesity risk variant on maternal postload glucose levels at OGTT during pregnancy

268 Multiple genetic factors: the key to detect early type 2 diabetes
L. Alonso, M. A. Pérez, C. Salvoro, L. Ruiz, J. L. Berral, J. R. González, I. Morán, D. Torrents, Spain

269 Genetic susceptibility to beta cell dysfunction and adipose tissue mediated insulin resistance modifies the benefit of physical activity on type 2 diabetes
X. Zhou, G. D. Carrasquilla, M. R. Christiansen, R. A. Smit, R. J. Loos, T. O. Kilpeläinen, J. Merino, Denmark

270 Dissecting the causal association between spleen iron concentration and type 2 diabetes using mendelian randomisation
M. A. Abdalla, M. AbuFarha, J. Abubaker, M. Abdulghani, F. Almulla, Kuwait, UK, USA

271 Genome-wide association analysis of age of diabetes diagnosis in Hong Kong Chinese
272 Genetic markers of response to treatment of type 2 diabetes with novel antihyperglycaemic drugs: prospective interventional genetic association study
G. Tonin, V. Dolžan, J. Klen, Slovenia

273 Insulin levels in pregnant women with obesity are associated with higher abdominal fat deposition in newborns and with DNA methylation in cord blood

274 Investigating DNA methylation of metabolic and inflammatory genes with therapeutic potential for obesity: a cohort study in south African women
A. Shaik, F. Essop, C. Pheiffer, T. Willmer, South Africa

275 Risk of gestational diabetes and neonatal outcomes in migrants: a retrospective cohort study
F. Citro, N. Placenza, M. Aragona, L. Battini, P. Marchetti, C. Bianchi, A. Bertolotto, Italy

276 Identification of epigenetic marks shared between mothers with gestational diabetes and their offspring, and their association with newborn anthropometric variables
T. Linares-Pineda, N. Peña-Montero, A. Piserra, M. Estébanez Prieto, M. Suárez-Arana, M. Molina Vega, M. Picón César, S. Morcillo Espina, Spain

277 Epigenome-wide association study identifies a specific panel of DNA methylation signatures associated with gestational diabetes
C. Thirumoorthy, S. Kuldeep, M. Deepa, P. Nikhil, S. Sharma, G. Ball, H. Grallert, U. Ram, R. Anjana, M. Balasubramanyam, V. Mohan, P. Saravanan, G. Kuppan, India, Germany, UK

278 Exploration of epigenetic loci in individuals with and without diabetes from Northern Ireland
279 First-trimester DNA methylome profiling identifies novel predictors of gestational diabetes in Indian women

280 Identifying novel predictors of gestational diabetes in early pregnancy through DNA methylome profiling and artificial neural networks
S. Sharma, G. Ball, T. Chinnasamy, M. Deepa, K. Sharma, P. Nikhil, H. Grallert, U. Ram, R. Anjana, M. Balasubramanyam, V. Mohan, P. Saravanan, G. Kuppan, Germany, UK, India

Short Oral Event C Wednesday, 12:45 - 13:45

SO 003 The many facets of weight and type 2 diabetes risk

281 Obesity measures and risk of diabetes, early-onset diabetes: insights from a large cohort study
W. Zheng, L. He, K. Qiu, W. Zhang, Q. Liu, Y. Ren, W. Kong, T. Zeng, China

282 Is weight reduction associated with a lower risk of diabetes in middle-aged non-diabetic overweight people who gained 10 kg or more weight from age 20? A population-based cohort study of Japanese
M. Noguchi, A. Oyama, H. Iso, Japan

283 Associations between chronotype waist circumference, visceral fat, liver fat, and incidence of type 2 diabetes

284 Dissociation of static and dynamic associations of liver fat content and visceral fat mass with insulin resistance and type 2 diabetes risk
285 Birthweight and risk of chronic kidney disease after being diagnosed with type 2 diabetes

286 Amelioration of the thrifty (‘thin-fat’) phenotype in Indians by socioeconomic development and a primordial micronutrient intervention: Escaping the curse?
C. S. Yajnik, R. Wagh, S. Otiv, P. C. Yajnik, R. Ladkat, D. Bhat, K. Kumaran, C. H. Fall, India, UK

287 Severe insulin resistant diabetes shows increased visceral adipose tissue volume as compared to other diabetes endotypes

288 Lifetime healthcare costs of female obesity: modelling of England Data shows that quality of life must be included to show the cost-effectiveness of GLP-1 analogues
A. Heald, M. Stedman, M. Whyte, M. Rutter, M. Gibson, UK

Short Oral Event D Wednesday, 14:00 - 15:00

SO 004 Diet, lifestyle, and metabolic health: insights into diabetes risk and prevention

289 Food consumption associated with the risk of islet autoimmunity and type 1 diabetes

290 The associations of plasma carotenoids and alpha-tocopherol concentrations with fasting glucose in adults in Cameroon
C. M. Mba, A. Koulman, F. K. Assah, J. C. Mbanya, N. J. Wareham, UK, Cameroon

291 Plasma metabolomics of meat intake: a Swedish population-based study
292 The role of remnant cholesterol in prediabetes exceeds low-density lipoprotein cholesterol in different metabolic states
L. He, W. Zheng, K. Qiu, W. Kong, T. Zeng, China

293 Meat intake, gut microbiota and biomarkers of cardiometabolic health in the population-based Swedish CardioPulmonary bioImage Study

294 Alcohol consumption, genetic susceptibility to diabetes, and risk of LADA and type 2 diabetes: findings from a Swedish case-control study and the Norwegian HUNT study

295 The effects of Mediterranean-style diet with or without high intensity interval exercise on metabolic variables in overweight post-menopausal women: a randomised control trial
R. Churm, A. Tan, S. L. Prior, M. D. Campbell, R. Bracken, UK

296 Risk of type 2 diabetes according to patterns of lifestyle combination among middle-aged Korean men: findings based on the Korean Genome and Epidemiology Study (KoGES) cohort
H. Lim, I. Lee, Republic of Korea

Short Oral Event E Thursday, 12:45 - 13:45

SO 005 Unraveling monogenic diabetes: from genetic variants to innovative diagnostic tools

297 Motilin and Semaphorin 4C: an exciting new blood test for MODY

298 Genetic spectrum of monogenic diabetes in Slovakia: 20 years of experience
299 A recessive HNF1A variant associated with young-onset diabetes induces beta cell dysfunction and bias towards alpha cell differentiation  
I. Cherkaoui, Q. Du, C. Dion, H. Leitch, D. M. Egli, S. Misra, G. Rutter, 
Canada, USA, UK

300 Integrating biomarkers with clinical features improves discrimination in MODY calculator  
J. Knupp, P. Cardoso, T. J. McDonald, K. Patel, A. Jones, E. R. Pearson, 
A. T. Hattersley, T. J. McKinley, B. Shields, UK

301 Biomarker selection testing plus targeted next-generation sequencing identifies 2.0% monogenic diabetes amongst individuals with young-onset diabetes in a sub-Saharan African setting  
J. C. Katte, M. Y. Dehayem, A. B. Chetcha, K. Colclough, A. T. Hattersley, 
T. J. McDonald, A. G. Jones, E. Sobngwi, UK, Cameroon

302 Heterozygous HNF1A-MODY mice exhibit hyperglucagonemia preceding insulin secretory defects  
I. Louvet, A. Acosta-Montalvo, M. Moreno-Lopez, J. Thevenet, M. Chiral, 
N. Delalleau, V. Gmyr, J. Kerr-Conte, F. Pattou, M. Pontoglio, C. 
Saponaro, A. Liston, C. Bonner, France, Belgium, UK

303 Early onset diabetic phenotype and impaired beta cell maturation in two novel MIDY mouse models  
M. Schmidtke, A. Harten, A.-L. Amend, G. K. Przemeck, M. Hrabě de 
Angelis, Germany

304 MDFiNE (monogenic diabetes finder-north east): pilot of a novel digital search tool to enhance diagnostic rates for monogenic diabetes  
A. Al-Sharefi, R. Haines, A. Porter, M. Houseman, V. Kumar, C. 
Bradshaw, A. Curry, F. Haque, S. Tee, UK

Short Oral Event F Thursday, 14:00 - 15:00

SO 006 Advancements in predicting type 1 diabetes

305 Polygenic risk scores for pre-selection of children for population-based primary prevention trials and islet autoantibody screening  
J. Zapardiel-Gonzalo, C. Winkler, F. Haupt, N. Friedl, K. Hatzikotoulas, 
A.-G. Ziegler, E. Bonifacio, Germany
306 A multi-omics integration approach does not discern endotypes in childhood type 1 diabetes
A. Petrelli, V. Codazzi, N. Baldoni, G. M. Scotti, A. Giovenzana, A. Rigamonti, G. Frontino, C. Bechi Genzano, I. Marzinotto, V. Lampasona, P. Fiorina, A. Giustina, M. Battaglia, M. Morelli, R. Bonfanti, Italy, Belgium

307 Enhancing precision of metabolic staging to predict progression to stage 3 type 1 diabetes
S. Hummel, C. Winkler, M. Köger, A. Weiβ, J. Stock, F. Reinmüller, M. Kohls, P. Achenbach, E. Bonifacio, A. G. Ziegler, Fr1da Study Group, Germany

308 Discovery of multi-omics signatures in children and adolescents with recent-onset type 1 diabetes
H. Tan, T. Yue, Y. Shi, L. Pan, D. Zheng, Y. Ding, S. Luo, X. Zheng, J. Weng, China

309 Neutrophil enriched circulating miRNAs identify individuals at risk for stage 3 type 1 diabetes onset in a specific timeframe
E. Pedace, M. Toniolli, G. Grieco, D. Fignani, G. Licata, A. Berteramo, M. Bruttini, A. Mori, M. Marcovecchio, C. Mathieu, G. Sebastiani, F. Dotta, Italy, UK, Belgium

310 Continuous glucose monitoring in children with presymptomatic early stage type 1 diabetes

311 Screening children for paediatric diabetes in the UK (ELSA Study): accessing underserved communities
L. Quinn, S. M. Greenfield, A. Richter, R. Dias, P. Narendran, UK

312 Development, validation, and applicability of a miRNA-based dynamic risk score (DRS) for type 1 diabetes
A. Hardikar, M. Joglekar, W. Wong, P. S. Kunte, on behalf of the PREDICT T1D Study Group, Australia

Short Oral Event A
Tuesday, 12:30 - 13:30

SO 007 Global perspectives on type 2 diabetes: prevalence, risk factors, and predictive tools

313 Type 2 diabetes in Greenland: prevalence and risk factors
M. Harder, P. Bjerregaard, M. E. Joergensen, N. Senftleber, S. Byberg, T. Hansen, Denmark
314 Understanding pathophysiological heterogeneity in populations before diagnosis of type 2 diabetes through multi-omics profiling

315 The effects of baseline haemoglobin A1c on diabetes incidence by low socioeconomic, immigration status, and ethnic origin
G. S. Fazli, L. Lipscombe, B. Shah, L. C. Rosella, C. Kenaschuk, D. Thiruchelvam, F. Ali, C. Ke, G. L. Booth, Canada

316 Modified cardiovascular health metrics including psychosocial stress, and incident diabetes and cardiovascular disease: a population-based cohort study
S. Han, N. Lee, Y. Choi, H. Kim, K.-W. Lee, Republic of Korea

317 Prevalence and trends of diabetes in Thi-Qar, Southern Iraq

318 Bioelectrical phase angle as a marker for incident type 2 diabetes and glycaemic deterioration: results from the MONICA/KORA studies

319 Performance of the 1h OGTT in predicting type 2 diabetes in Asians

320 Identifying high risk adults for progression to diabetes for early intervention using Hong Kong territory-wide electronic health records and machine learning algorithm
T. Chen, A. Yang, M. Shi, S. Lau, H. Wu, C. Wong, N. Lui, C. Ma, P. Kong, O. Luk, C. Chan, Y. Chow, China

Short Oral Event B Tuesday 13:45 - 14:45

SO 008 Advances type 1 diabetes: genetic, biomarker, and machine learning approaches

321 Automatic immune phenotyping of type 1 diabetes samples from a validation study using a machine learning analysis workflow
J. Vera-Ramos, B. Prietl, V. Pfeifer, L. Herbsthofer, T. Pieber, Austria
322 Detecting pre-clinical type 1 diabetes in adults: using type 1 diabetes genetic risk to enrich for islet autoantibodies in a general population
N. Thomas, K. Gillespie, A. E. Long, A. Hill, D. Fraser, T. J. McDonald, R. Oram, UK

323 Mir-150-5p and mir-375-3p are increased in plasma of young children (<7y) with recent onset stage 3 type 1 diabetes
M. Toniolli, G. E. Grieco, S. Auddino, M. Bruttini, A. Mori, G. Licata, L. Nigi, C. Formichi, C. Mathieu, N. Morgan, G. Sebastiani, F. Dotta, Italy, Belgium, UK

324 Postprandial C-peptide in provider-diagnosed pediatric type 1 diabetes and type 2 diabetes

325 Reshaping the diagnostic algorithm to improve differentiation between type 1 and type 2 diabetes

326 Higher circulating anti-GAD levels are associated with higher levels of C-peptide and proinsulin, and show a similar decline in a cross-sectional cohort of 444 individuals with type 1 diabetes

327 Smoking, GAD65 autoimmunity and risk of adult-onset diabetes in the EPIC-InterAct case-cohort study
E. Keysendal, Sweden

328 Continuous glucose monitoring in first degree relatives with stage 2 diabetes
L. Marcovecchio, J. Tajes, K. Dovc, E. Hendriks, C. Mathieu, T. Battelino, on behalf of the INNODIA consortium, UK, Belgium, Slovenia

Short Oral Event C Wednesday, 12:45 - 13:45

SO 009 Treatment of type 1 diabetes
329 Clinical characteristics of malnutrition related insulin requiring ketotic resistant diabetes in India
S. Gupta, S. Gupta, K. Gupta, R. Mutkure, P. Bamrah, S. S. Gupta, India
330 Multimorbidity disease clusters and their association with increased mortality in type 1 diabetes

331 Exploring HLA genotype variations in type 1 diabetes: implications for precision medicine and immunotherapy response

332 Prevalence of actionable HbA\textsubscript{1c} levels in immune mediated inflammatory diseases: Is HbA\textsubscript{1c} screening warranted for early pre-diabetes detection?
L. D. Ferguson, C. Celis-Morales, J. Anderson, N. Sattar, UK

333 Glucocorticoid-induced diabetes among adults hospitalised in the Oxford University Hospitals NHS Foundation Trust (England, United Kingdom): a matched cohort study
R. Golubic, H. Mumbole, R. Coleman, R. Rea, R. Caleyachetty, R. Mathur, A. Adler, UK

334 Factors predicting persistently high HbA\textsubscript{1c} levels in adults with type 1 diabetes
H. L. Lee, L. L. Chan, L. E. Watson, R. J. Jalleh, P. Lee, C. Shoubridge, A. T. Zimmermann, Australia

335 Multi-omics profiling of extended honeymoon unveils new therapeutic targets

336 Contrasting autoantibody and risk profiles in at-risk adult vs paediatric populations

Short Oral Event D Wednesday, 14:00 - 15:00

SO 010 Complications of type 1 diabetes

337 Comparison of serum creatinine and cystatin C based eGFR and their prediction of incident moderate albuminuria in individuals with type 1 diabetes
P.-H. Groop, L. Thorn, V. Harjutsalo, Finland
338 Incidence of diabetic foot complications in a type 1 and type 2 diabetes population: a Danish register-based cohort study
A. Akerkar, P. Falberg Rønn, V. Kosjerina, C. Stevns Hansen, A. Hulman, A. Rasmussen, P. Rossing, T. S. Ahluwalia, Denmark

339 Characteristics of above 65-year-olds with type 1 diabetes in the Finnish Diabetic Nephropathy Study
E. Franzén, S. Satuli-Autere, M. Eriksson, A. Ylinen, P.-H. Groop, L. Thorn, Finland

340 Exploring the association between oxidative stress biomarkers, inflammation, and carotid intima-media thickness in young people with type 1 diabetes and initial microvascular complications
V. Kumar, S. Prasad, N. Kumar, India

341 Severity of diabetes-related complications and quality of life in people with type 1 diabetes: findings from the SFDT1 cohort study

342 Interacting effects of HLA DR3DQ2 and DR4DQ8 on diabetic phenotype and comorbidity in LADA patients: a HUNT study
V. Grill, B. E. Lønnnum, E. Soergjerd, I. K. Hals, Norway

343 Prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years after diagnosis by decade of diagnosis: a cross-sectional, real-world observational study
A. Lavens, L. Crenier, C. De Block, P. Oriot, J.-C. Philips, M. Vandenburgue, A. Verhaegen, A.-S. Vanherwegen, F. Nobels, C. Mathieu, Belgium

344 Population with type 1 diabetes is ageing rapidly in Finland: national registry study on diabetes-related complications from 2014 to 2021
H. Vessari, E. J. Peltonen, E. Pimiä, I. Iso-Mustajärvi, I. Vauhkonen, H. Luoto, T. Saukkonen, Finland

Short Oral Event E Thursday, 12:45 - 13:45

SO 011 Disease progression and mortality in diabetes

345 Time trends in mortality in people treated for diabetes in the entire France before and during the COVID-19 pandemic: a nationwide study from 2013-2021
E. Cosson, M. Guion, S. Goria, S. Fosse-Edorth, France
346 Prediction of disease progression with artificial intelligence algorithms in patients with type 2 diabetes in Finland: the initial screening for associations

347 Mendelian Randomisation provides evidence that higher BMI, but not mild hyperglycaemia, may be a causal risk factor for severe infection

348 Diabetes and incident stroke and mediation by microvascular dysfunction: pooled analysis of three population-based studies

349 Sex differences in the characteristics, comorbidities, pharmacotherapy and prevalence of diabetes-related complications in patients with newly diagnosed type 2 diabetes in Sweden
N. Rajamand Ekberg, N. Widén, S. Karayiannides, S. Catrina, Sweden,

350 Cross-sectional associations of 24h blood pressure with retinal arteriolar narrowing and urinary albumin excretion are modified by (pre)diabetes: The Maastricht Study

351 Glucose levels at hospital admission are associated with mortality beyond the admission
N. Cheung, P. McElduff, G. Fulcher, S. Middleton, The NSW Emergency BGL Trialists, Australia

352 Vaccinome landscape in nearly 620.000 patients with diabetes
SO 012 Health interactions and risks in diabetes: from cancer survival to chronic conditions

353 Association between gastrectomy and the risk of type 2 diabetes in gastric cancer survivors: a nationwide cohort study
G. Kim, M. Jang, K.-D. Han, J. Kim, Republic of Korea

354 Glucocorticoid treatment and hyperglycaemia in people living with chronic obstructive pulmonary disease: systematic review and meta-analysis
R. Golubic, H. Mumbole, R. Coleman, N. Rahman, R. Caleyachetty, A. Adler, UK

355 Clinical phenotyping of people living with type 1 diabetes according to their levels of diabetes-related distress: results from the SFDT1 cohort study

356 Sarcopenia and frailty is associated to higher mortality risk in individuals with type 2 diabetes: Insights from the UK Biobank study

357 Circulating inflammatory markers and all cause death in type 2 diabetes: evidence for an intertwined relationship with tryptophan metabolism
C. Menzaghi, A. Marucci, M. Mastroianno, G. Di Ciaccia, M. Armillotta, L. Salvemini, D. Mangiacotti, A. Fontana, S. De Cosmo, O. Lamacchia, M. Copetti, V. Trischitta, Italy

358 Prevalence of pre-heart failure among individuals with type 2 diabetes within primary care: insights from the Mexico cohort iCaReMe registry

359 The association between asthma and type 2 diabetes: a systematic review and meta-analysis including 17 million individuals
N. N. Nguyen, D. S. Ho, M. T. Nguyen, T. D. Nguyen, T. Q. Tran, Y.-C. Chen, Taiwan, Viet Nam
360 The survivors of pulmonary tuberculosis are at risk of newly developed type 2 diabetes
J. Yoo, C. Kim, C. Hwang, C. Yim, Republic of Korea

Short Oral Event A  
Tuesday, 12:30 - 13:30

SO 013 Prevention of type 2 diabetes

361 Using a machine learning-based model to categorise progression risks and customise interventions for prediabetes: a post-hoc analysis of DPP and DPPOS
S. Wang, Q. Huang, Y. Luo, Z. Lian, Y. Luo, L. Ji, X. Zou, China

362 Metabolically unhealthy and low skeletal muscle mass: crucial contributors to diabetes, particularly early-onset diabetes
L. He, W. Zheng, K. Qiu, W. Zhang, Q. Liu, Y. Ren, W. Kong, T. Zeng, China

363 Prediabetes management in Indian adults: a quasi-experimental study on effectiveness of integrated intensive lifestyle intervention
M. Ganla, P. Tripathi, D. Tiwari, N. Kadam, A. Vyawahare, B. Sharma, T. Kathrikolly, B. Saboo, India

364 RCT on effects of guided self determination in primary health care, to reduce risk of coronary heart disease and prediabetes
E. Arnardottir, A. K. Sigurdardottir, T. C. Skinner, M. Graue, B.-C. H. Kolltveit, Iceland, Denmark, Australia, Norway

365 Can we screen for type 2 diabetes using voice? Findings from the Colive Voice study

366 A part for the whole: using the post-breakfast glucose response pattern in real-life to predict the daily glucose profile in non-diabetic individuals
A. Giosuè, V. Skantze, R. Giacco, M. Vitale, G. Costabile, R. E. Bergia, W. W. Campbell, G. Riccardi, R. Landberg, Italy, Sweden, USA

367 Diurnal glucose responses to meals with different carbohydrate content and glycaemic index and their effects on beta cell dysfunction: the OmniCarb trial
Y. Heianza, V. Carey, L. J. Appel, F. M. Sacks, L. Qi, USA
368 The conundrum of what determines return to normal glucose handling in people with non-diabetic hyperglycaemia: prospective analysis of outcomes in 1,367 men
F. Wilkinson, A. Innes, B. Kelly, J. Sarginson, B. Ollier, A. Heald, UK

Short Oral Event B  Tuesday, 13:45 - 14:45

SO 014 Early factors and family determinants of diabetes

369 Maternal age at delivery and type 2 diabetes in adult offspring: longitudinal sibling comparison register study
V. Ahuja, A. Hiyoshi, H. Backman, D. Simmons, S. Montgomery, Sweden, Australia

370 Using multistate models and polygenic risk scores to understand cardiometabolic disease in British Pakistani and Bangladeshi populations: showcasing the Genes and Health cohort

371 Parent-of-origin effects in the lifecourse evolution of cardiometabolic traits
R. H. Wagh, G. Hatem, P. S. Kunte, C. S. Yajnik, R. Prasad B, India, Sweden, Australia

372 Environmental neglect: endocrine disruptors as under appreciated but potentially important diabetogens in HNF1A-MODY cell model
T. A. Legøy, L. Unger, J. Paulo, L. Ghila, S. Chera, Norway, USA

373 Weight gain and ethnic background as determinants of HbA\textsubscript{1c} 11-years after pregnancy: the STORK-Groruddalen follow-up study
C. Waage, C. Sommer, I. Mdala, S. Lee-Ødegård, A. M. Brænd, A. K. Jenum, K. I. Birkeland, Norway

374 Impact of family history of young-onset type 2 diabetes on utility of 1-hour post-load plasma glucose in predicting risk of incident diabetes
C. O, B. Fan, J. Ho, E. S. Lau, J. N. Lui, E. Y. Chow, A. P. Kong, R. C. Ma, A. O. Luk, J. C. Chan, Hong Kong
375 Trajectories of glucose excursions in early childhood and the risk of abnormal glucose tolerance in adolescence
Y. Zhang, E. S. Lau, C. H. Tam, N. Y. Ng, A. Yang, A. Y. Tsang, C. L. Yuen, H. Wu, E. Y. Chow, A. O. Luk, A. P. Kong, C. Wang, J. C. Chan, W. Tam, R. C. Ma, Hong Kong

**Short Oral Event C**

**Wednesday, 12:45 - 13:45**

**SO 015 Genetics and biomarkers for prediction of type 2 diabetes**

376 Sex-specific associations of contaminant and essential metals with fasting plasma glucose: a cross-sectional analysis of the Hong Kong school children cohort
A. Yang, T. Chen, H. Tam, H. Cheung, C. Ma, P. Kong, Y. Chow, H. Chan, C. Chan, China

377 Impact of glucocorticoids on islet function: role of SRD5A1 as a modulator of glucocorticoids bioavailability
O. K. Tijani, C. Saponaro, M. Moreno-Lopez, I. Louvet, A. Acosta, V. Gmry, A. Coddeville, J. Kerr Conte, F. Pattou, C. Bonner, S. Espiard, France

378 Gut microbiota clusters and metabolic health: characterising associations in a large cohort study

379 Prediction of oral glucose tolerance test response by fasting glycosaminoglycans-bound protein levels
M. Alonso-Sampedro, O. Lado-Baleato, S. Lopez-Gonzalez, A. Gonzalez-Quintela, F. Gude, Spain

380 Subgroups of adult diabetes show phenotypic differences before diabetes onset
L. Hakaste, M. Andersen, H. Maalmi, J. Vangipurapu, T. Ozgumus, A. Mollsten, Prediabetic Phenotype Working Group, E. Ahlqvist, T. Tuomi, Finland, Denmark, Germany, Norway, Sweden

381 Association of coagulation factor levels and thrombin generation potential with the incidence of type 2 diabetes: mediating role of glycoprotein acetylation
J. Han, A. Van Hylckama Vlieg, R. De Mutsert, F. R. Rosendaal, J. H. Van der Velde, S. C. Boone, E. Winters -van Eekelen, S. Le Cessie, R. Li-Giao, Netherlands
382 Type 2 diabetes and 2-h postload glucose are inversely associated with endothelial glycocalyx thickness: The Maastricht Study
X. Zhao, C. Schalkwijk, B. Kroon, M. Schram, B. Houben, Netherlands

383 Role of glucagon in the development of type 2 diabetes in 548 participants with prediabetes: a post-hoc analysis of two randomised controlled trials
M. Csanalosi Artigas, S. Kabisch, C. Honsek, A. Sachno, M. Kemper, C. Gerbracht, U. Dambeck, M. A. Osterhoff, M. O. Weickert, A. F. Pfeiffer, Germany

**Short Oral Event D  Wednesday, 14:00 - 15:00**

**SO 016 Molecular predictors of type 1 diabetes**

384 Effect of the autoimmune-associated C1858T variant of PTPN22 on neutrophil activation and function in type 1 diabetes patients
A. Fierabracci, A. Cudini, E. Belcastro, S. Petrini, R. Schiaffini, V. D’Oria, M. Scarsella, A. Lo Russo, Italy

385 Inflammation in the exocrine and endocrine pancreas is potentiated by the Hippo pathway effector YAP and associated with type 1 diabetes
H. Pahwa, S. Geravandi, H. Liu, M. K. Madduri, O. Zabad, F. Atawneh, A. Pugliese, K. Maedler, A. Ardestani, Germany, USA, UK

386 Genetic underpinnings of pediatric onset type 1 diabetes in the Canary Islands
I. Marcelino-Rodriguez, Y. Novóa Medina, S. González Barbuzano, R. Molina Suarez, N. Martel Suarez, I. García de Pablo, P. Pedrianes Martin, O. Guillen Diaz, M. Alberiche Ruano, A. Corrales, A. M. Wägner, M. Boronat, C. Flores Infante, Spain

387 The TEAD activator TT-10 promotes human beta cell regeneration and protects from diabetes induction

388 Continuous glucose monitoring metrics can replace HbA1c in composite scores assessing beta cell function
A. L. Carr, A. Lam, P. N. Taylor, A. Lindqvist, J. Ludvigsson, U. Hannelius, C. M. Dayan, P. A. Senior, Canada, UK, Sweden
389 The type 1 diabetes candidate genes PTPN2 and BACH2 cooperate for the modulation of the JAK/STAT and MAPKs pathways in human beta cells

390 Role of ZNF808 in early pancreatic cell fate specification

391 Loss of RFX6 function impairs islet development, resulting in hypoplastic islet organoids derived from iPSCs, while maintaining pancreatic progenitor formation
E. M. Abdelalim, N. Aldous, A. K. Elsayed, B. Memon, S. Ijaz, H. Sikander, Qatar, Germany

**Short Oral Event E**

**Thursday, 12:45 - 13:45**

**SO 017 Long-term complications and outcomes in type 2 diabetes: vascular health, kidney function, and mortality**

392 Incidence rates of vascular complications in a cohort of people with type 2 diabetes from the Swedish National Diabetes Register
S. Khare, K. Boye, J. Lebrec, K. T. Ranta, A. Toll, B. K. Bjerregaard, R. Cordtz, B. Eliasson, J. Redig, UK, USA, France, Finland, Sweden, Denmark

393 Glomerular filtration rate decline predicts all cause mortality and mediates the effect of tryptophan metabolism on the risk of death in patients with type 2 diabetes
C. Menzaghi, O. Lamacchia, M. Copetti, M. Mastroianno, C. Corsano, A. Fontana, V. Trischitta, S. De Cosmo, Italy

394 Association of glycaemic control with intraocular pressure in a large general population: results from the UK Biobank
Q. Liu, P. Welsh, C. Celis-Morales, N. Sattar, UK, Chile

395 Association between kidney function and mortality in type 2 diabetes patients: a 10-year prospective cohort study

396 Prevalence and long term mortality of burnt-out diabetes in end stage kidney disease
J. Navarrete, R. J. Galindo, R. McCoy, P. Vellanki, L. Peng, G. Umpierrez, USA
397 Genes involved in the manifestation of proliferative diabetic retinopathy in people with diabetic retinopathy
Q. Liu, A. Aman, C. Celis-Morales, P. Welsh, UK, Chile

398 Temporal trajectories of hospitalisations for traditional and non-traditional complications in people with type 2 diabetes in Hong Kong

399 Microvascular disease incidence over a 34-year period among Chinese with newly diagnosed diabetes and impaired glucose tolerance: the China Da Qing Diabetes and IGT Study 1986-2020
Q. An, X. Qian, S. Zhou, X. Li, S. He, X. Feng, J. Xu, Y. Chen, G. Li, China

Short Oral Event F, Thursday, 14:00 - 15:00

SO 018 Diabetes management and outcomes: societal, behavioral, and clinical influences

400 Initiation of cardioprotective glucose-lowering drugs according to sex and educational level: a Danish nationwide cohort study
E. Calderon, L. Bjerg, A. A. Isaksen, A. Sandbæk, K. L. Funck, E. L. Grove, Denmark

401 Clinical implications of intentional weight loss in people living with type 2 diabetes: a CPRD Aurum database study
C. Kruse, U. C. Braae, E. Nørtoft, P. N. Kristensen, N. F. Nielsen, Denmark

402 Racial and ethnic differences in pharmacy dispensing of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes

403 Cytokine profiling according to glycaemic status and COVID-19 severity in patients with diabetes
D.-H. Lee, Y. Kim, K. Yoo, Republic of Korea

404 Trends in physical activity before and after the COVID-19 pandemic shelter-in-place mandate among adults with prediabetes in an integrated health care system in northern California
L. A. Rodriguez, M. Yassin, O. Duru, R. S. Neugebauer, S. D. Brown, Y. Castellon-Lopez, J. Schmittdiel, USA
405 What is the impact of structural changes in society on diabetes self-management and HbA1c trajectories? A cohort study during the COVID-19 pandemic in people with diabetes at outpatient clinics
M. G. Rasmussen, E. Just-Østergaard, J. V. Stidsen, I. Willaing, G. S. Pedersen, Denmark

406 Treatment discontinuation among users of SGLT2 inhibitors and GLP-1 receptor agonists in a national population of patients with type 2 diabetes
C.-E. Lim, B. Pasternak, B. Eliasson, P. Ueda, Sweden

407 Routine clinical features are associated with short-term discontinuation of GLP1-RA but are of limited utility to predict individuals unlikely to tolerate therapy

**Short Oral Event A  Tuesday, 12:30 - 13:30**

**SO 019 Catching signals to follow the right pathway in islets**

408 Regulating the pancreatic beta cell functionality through nanotopographical cues: focus on organelles organisation and crosstalk
A. Galli, N. Dule, E. Maffioli, P. Marciani, M. Castagna, P. Milani, C. Lenardi, G. Tedeschi, C. Perego, Italy

409 Targeting SIKs for improving beta cell function and glycaemic control
K. Loh, Australia

410 Turnover of mRNA mediated by RNA modification regulates pancreatic beta cell function and identity
Y. Tara, T. Yamamoto, Japan

411 Ca2+-dependent oscillations of cytoplasmic pH in glucose-stimulated pancreatic beta cells
O. Dyachok, A. Tengholm, Sweden

412 EPDR1, an obesity-induced protein in human islets, maintains mitochondrial function by promoting mitophagy flux in beta cells
F. A. Munoz, M. Fex, T. Moritz, H. Mulder, L. R. Cataldo, Sweden, Denmark
413 A dual GLP-1/GIP agonist may encompass most of the beneficial effects of both incretins on pancreatic beta cell signalling and survival
M. A. Ravier, N. Zaïmia, S. El Mallem, F. Playe, S. Costes, France

414 Pyruvate kinase controls cAMP production and amplifies insulin secretion downstream of the GLP-1 receptor in beta cells
H. R. Foster, R. E. Kirchner, S. L. Lewandowski, M. E. Capozzi, J. E. Campbell, M. J. Merrins, USA

415 Exploring sonic hedgehog signalling and HNF1A crosstalk in HNF1A-MODY stem cell islets
L. Unger, T. Legøy, S. Chera, L. Ghila, Norway

Short Oral Event B Tuesday, 13:45 - 14:45

SO 020 Holding hands with alpha cells in the islets

416 Sex differences in the plasma glucagon responses to a high carbohydrate meal and a glucose drink in type 2 diabetes
W. Huang, C. Xie, K. L. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

417 Circadian rhythms of pancreatic alpha and beta cell dynamics and protein landscape
C. Jiménez-Sánchez, V. Petrenko, N. Phillips, M. Stolovich-Rain, Y. Dor, Y. Wu, C. Dibner, Switzerland, Israel

418 Using engineered pseudoislets to study the role of gap junction channels in human islet function
C. H. Levitt, T. Gaia Oliveira, C. Birznieks, D. Bell, R. K. Benninger, USA

419 Semaphorin signalling alters the function of islet alpha and beta cells

420 Characterisation of the secretion of glucagon from the pancreas of GCGKRO alpha cells in mice
J. Vergara Ucin, D. B. Andersen, J. J. Holst, Denmark

421 Ghrelin and LEAP2 affect insulin and glucagon secretion in mouse but not in human islets, and their effects in mouse islets are mediated by somatostatin
Y. Murdasov, P. Gilon, Belgium
422 Urocortin-3 regulates glucagon secretion through an inhibitory beta to δ to alpha cell axis in mice, but not in rats
J. Vergara Ucin, D. B. Andersen, G. Di Giuseppe, T. Mezza, J. J. Holst, Denmark, Italy

423 Regulation of alpha cell glucagon exocytosis by TMEM55A
X. Liu, A. F. Spigelman, S. Duckett, T. Dos Santos, P. E. MacDonald, Canada

**Short Oral Event C**  **Wednesday, 12:45 - 13:45**

**SO 021 Insulin service providers for the body**

424 Cav1.3 calcium channel regulates pancreatic beta cell gene transcription, electrical activity, and insulin release

425 Islet sodium/potassium ATPase as a key transducer of secretagogue signal strength
M. Dickerson, P. Dadi, J. R. Dobson, S. Behera, D. A. Jacobson, USA

426 Roles of Exophilin5 in insulin vesicle fusion without stable docking to the plasma membrane
H. Wang, China

427 Altered BAG3/insulin colocalisation is associated with reduced 1st phase insulin secretion in humans
M. Brunetti, G. Di Giuseppe, V. Damiani, E. Di Piazza, L. Soldovieri, G. Ciccarelli, A. Mari, V. De Laurenzi, A. Giaccari, T. Mezza, Italy

428 Mitochondrial AASS-dependent lysine metabolism potentiates insulin secretion
L. Cataldo, Denmark

429 NCK1 modulates pancreatic beta cell insulin secretion in a sex-dependent manner
L. Monteillet, N. Jouvet, C. Baldwin, J. Estall, Canada

430 Investigating the role of N6-methyladenosine on chromatin-associated RNA (caRNA) in regulating transcription in human pancreatic beta cells
N. Shukla, C.-W. Ju, C. He, R. N. Kulkarni, USA
Short Oral Event D  Wednesday, 14:00 - 15:00

**SO 022 Cells in attacking mode and beta cell victims**

431 Tolerisation for treating type 1 diabetes
M. Garcia Toscano, A. Crespo Barreda, A. Dorronsoro Gonzalez, J. Van der Velden, T. Gerritzen, P. De Haan, Spain, Netherlands

432 Characterising lymphocytes in newly diagnosed type 1 diabetes patients during and after treatment with the JAK inhibitor baricitinib

433 Activated human T cells express glutamic acid decarboxylase 67 and secrete endogenous GABA
Z. Jin, B. Birnir, Sweden

434 Human fecal microbiome transplantation alters the incidence of diabetes in non-obese diabetic mice
R. Minab, E. Rampanelli, N. Hanssen, C. Fuhri Snethlage, D. Van Raalte, B. O. Roep, B. Vallance, M. Nieuwdorp, B. Verchere, Canada, Netherlands

435 Type 1 diabetes onset is prevented in offspring of NOD mouse mothers treated with statins
S. Muntoni, E. Schirru, R. Rossino, M. F. Marongiu, C. Catia, F. Manchinu, L. Atzori, M. Piludu, M. Pala, F. Secci, M. Zoledziewska, S. Uzzau, F. Pili, F. Cucca, M. Congia, Italy

436 The maternal and fetal metabolic and immune landscape of gestational diabetes
R. Nanan, D. Ni, Australia

Short Oral Event E  Thursday, 12:45 - 13:45

**SO 023 Keeping islet cell identity under different circumstances**

437 The role of MafB transcription factor in endocrine cell differentiation
S. Bsharat, L. Brouty, I. Artner, K. Achanta, Sweden

438 Conversion of human alpha cells into insulin-producers
C. Renaud, E. Bru-Tari, K. Furuyama, F. Thorel, P. Herrera, Switzerland, Japan

439 Mitochondrial fission promotes loss of beta cell identity
K. Rivera, E. Montanya, Spain
440 Roux-en-Y-gastric bypass induces a significant reduction of pancreatic noradrenergic innervation and beta cell redifferentiation, leading to remission of type 2 diabetes
A. Avolio, C. Morciano, S. Gugliandolo, U. Capece, A. Splendore, M. Brunetti, T. Mezza, S. Moffa, G. Di Giuseppe, G. Ciccarelli, L. Soldovieri, A. Giaccari, F. Cinti, Italy

441 Pleiotrophin deletion, islet architecture, and function: insights into high-fat diet effect

442 Periodic fasting-mimicking diet increases Insulin* and BRN4* cells in murine endocrine pancreas

443 Impact of NOTCH2 polymorphisms on endocrine pancreas development and type 2 diabetes risk
D. Matas-Aguado, M. Hernanz, M. Mirasierra, M. Vallejo, U. B. Pajvani, A. Bartolomé, Spain, USA

444 High-resolution 3D calcium time course imaging sheds new light on beta cell heterogeneity
J. K. Briggs, E. Jin, M. J. Merrins, R. K. Benninger, USA

**Short Oral Event F, Thursday, 14:00 - 15:00**

**SO 024 Improving islet transplantation**

445 Females undergoing islet transplantation using CNI-based immunosuppression may be at higher risk of progressing to reduced kidney function

446 Development of high-throughput platform for KIR genotyping and expression analysis to infer the outcome of islet transplantation according to recipient/donor KIR/HLA mismatches
R. Chimienti, G. Siracusano, G. Lunetta, C. Volpi, M. Certo, S. Tentori, R. Melzi, R. Biassoni, R. Caldara, M. Malnati, L. Piemonti, Italy

447 Islet allotransplantation into pre-vascularised Sernova Cell Pouch™: interim results
P. Witkowski, N. Wojcik, S. Gondek, J. Tomecki, K. Milejczyk, B. Juengel, L. Wang, J. J. Fung, R. Barth, USA
448 Porous hydrogel microcarriers with human islet organoids for diabetes modelling
J. Li, L. Li, China

449 Injectable self-healing hydrogel encapsulation of pancreatic islets for diabetic cell therapy
Z. Huan, L. Li, China

450 From aesthetic medicine to islet transplantation: nanofat improves the success of islet transplantation
S. Wrublewsky, A. Weinzierl, M. Menger, M. Laschke, E. Ampofo, Germany

451 Meal-like stimulation protocol of beta cells in islets-on-chip and a human in-silico simulator

Short Oral Event A Tuesday, 12:30 - 13:30

SO 025 Breaking bad: destruction of beta cells

452 The crosstalk between the JAK/STAT and MAPKs pathways is essential for STAT1 activation in human beta cells

453 Unveiling the methylglyoxal contribution to beta cell failure and glucose intolerance in Glo1KD mice
C. Nigro, A. Leone, I. Prevenzano, A. Nicolò, M. Longo, D. Conza, A. Croce, F. Beguinot, C. Miele, Italy

454 Recovery of human beta cell functional damage induced by cytokines and glucotoxicity
M. Tesi, M. Suleiman, R. Semeraro, C. De Luca, E. Bosi, S. Del Guerra, A. Magi, F. Cardarelli, M. Cnop, D. Eizirik, L. Marselli, P. Marchetti, Italy, Belgium

455 Long non-coding RNA MALAT1 prevents hypoxia damage in human islets via HIF1A
W. K. Wong, N. H. PHAM, V. Saini, T. Loudovaris, H. E. Thomas, A. A. Hardikar, M. V. Joglekar, Australia

456 Concentration-dependent dual effects of ROS on insulin secretion mechanisms
X.-Q. Dai, A. F. Spigelman, K. Suzuki, P. E. MacDonald, Canada
457 The organisational and activational effects of testosterone contribute to diabetes development and progression in a mouse model of beta cell endoplasmic reticulum stress
L. F. Daniels Gatward, L. Doherty, A. J. King, UK

458 Perilysosomal Ca\(^{2+}\) overload and mechanistic target of rapamycin C1 activation impair autophagic degradation in beta cell lipotoxicity
K.-S. Park, H. T. Nguyen, A. Wiederkehr, C. B. Wollheim, Republic of Korea, Switzerland

459 IAPP and beta cell dysfunction in diabetes: a cross-sectional study
E. B. Alves, A. Gomes, R. Andrade, J. F. Raposo, R. T. Ribeiro, R. Menezes, Portugal

**Short Oral Event B, Tuesday 13:45 - 14:45**

**SO 026 Pregnancy and type 1 diabetes**

460 Maternal glycaemic and neonatal outcomes in pregnant women with type 1 diabetes treated with an advanced hybrid closed-loop vs non-algorithmic approach
V. Resi, A. Gaglio, Y. Pigotskaya, V. Grancini, E. Orsi, Italy

461 Impact of pre-eclampsia and hypertensive disorders of pregnancy on cardiovascular disease risk and all-cause mortality in women with type 1 diabetes
K. Rimpeläinen, D. Gordin, M. M. Klemetti, F. Jansson Sigfrids, V. Harjutsalo, P.-H. Groop, L. Thorn, Finland

462 Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster-acting insulin aspart or insulin aspart: a secondary analysis of the CopenFast trial
J. C. Søholm, S. K. Nørgaard, K. Nørgaard, T. D. Clausen, P. Damm, E. Mathiesen, L. Ringholm, Denmark

463 Sensor-derived glycaemic metrics in women with type 1 diabetes using insulin degludec vs other basal insulin analogs during pregnancy: a post hoc analysis of the CopenFast trial
J. C. Søholm, S. K. Nørgaard, K. Nørgaard, T. D. Clausen, P. Damm, E. Mathiesen, L. Ringholm, Denmark

464 Impact of birthweight on neonatal complications in babies born to patients with type 1 diabetes
A. Vambergue, E. Gnana, M. Lemaitre, E. Cailliau, F. Toulali, F. Baudoux, M. Niyitegeka, D. Subtil, France
465 Time in Tight Range in pregnant women with type 1 diabetes: Are stricter targets achievable with hybrid closed loop systems?
O. Bitterman, A. G. Napoli, C. Giuliani, R. Fresa, Italy

466 The relationship between good glycaemic control achieved in different stage of pregnancy and the risk of complications rate in patients with preexisting diabetes
N. G. Asatiani, R. B. Kurashvili, E. Shelestova, S. Kublashvili, Georgia

467 Pregnancy after gastric bypass surgery and traits associated with maternal hypoglycaemia
T. Linder, D. Eppel, G. Kotzaeridi, A. Piersanti, M. Morettini, A. Tura, C. S. Göbl, Austria, Italy

**Short Oral Event C  Wednesday, 12:45 - 13:45**

**SO 027 Gestational diabetes: clinical perspective**

468 The trends of development of diabetes in women with previous gestational diabetes thus increasing their risk of diabetes: a 15-year clinical observational study
A. Mukunda, J. Chacko James, A. Nayak, L. Varadhan, UK

469 Abnormal glucose values at the various OGTT time points and neonatal outcomes in pregnancies complicated by gestational diabetes

470 The prevalence of gestational diabetes more than doubled during the last decade: a nationwide study in France
E. Cosson, E. Lebreton, L. Tang, S. Fosse-Edorth, N. Regnault, France

471 Clinical profile of women requiring insulin therapy during gestational diabetes
S. Nouira, T. Ach, R. Khochteli, O. Zarrouk, A. Ben Abdelkrim, M. Chaieb, K. Ach, Tunisia

472 Performance of the Monash gestational diabetes risk scoring tool in identifying women at-risk of developing gestational diabetes across four countries involved in the Bump2Baby and Me study
473 Risk of gestational diabetes in twin pregnancy: a retrospective case-control study
C. Bianchi, F. Citro, T. Belcari, L. Battini, P. Marchetti, M. Aragona, A. Bertolotto, Italy

474 Joint association of maternal preconceptional overweight and gestational diabetes on offspring adiposity trajectory from birth to 11 years

475 Effect of diagnosing and management of early gestational diabetes using HbA1c of 42-47mmol/L
S. Pandya, N. Periyathambi, Y. Weldeselassie, N. Sukumar, V. Patel, P. Saravanan, UK

**Short Oral Event D**

**Wednesday, 14:00 - 15:00**

**SO 028 Biomarkers and mechanisms in gestational diabetes**

476 Cannabidiolic acid mitigates postpartum development of metabolic dysfunction-associated steatotic liver disease in a lean mouse model of gestational diabetes

477 Pregnancy in an obese and gestational diabetes context: epigenetic regulation of adipose tissue
P. Corrales, G. Llaurado, P. Fernández García, N. Vilanova, M. Ballesteros, D. Sánchez-Infantes, A. Megia, G. Medina Gómez, Spain

478 The effect of maternal thyroid function and lipid metabolism in early pregnancy on the risk of gestational diabetes
M. Zhi, X. Zhu, L. Li, China

479 Gestational diabetes is associated with activation of circulating innate lymphoid cells

480 The effect of bile acid-RNA methylation on intergenerational inheritance of diabetes by microbiotavertical transmission
H. Yuan, Q. Xie, China
481 Serum resistin and adipocyte fatty acid binding protein level in different trimesters of gestational diabetes
T. Ferdousi, S. Jahan, M. A. Hasanat, Bangladesh

482 Long-term multi-omics signatures from gestational diabetes in postpartum women

483 From womb to weight gain: the connection between foetal biomarkers and child growth
N. Kabbani, M. Blüher, H. Stepan, T. Ebert, W. Kiess, M. Vogel, R. Baber, U. Lößner, A. Tönjes, S. Schrey-Petersen, Germany

Short Oral Event E Thursday, 12:45 - 13:45

SO 029 On the young ones...

484 Real-world total daily insulin dose in 14,358 young individuals with type 1 diabetes in the US: data from the T1D Exchange Quality Improvement Collaborative

485 Screening for autoimmune thyroid disease, celiac disease and type 1 diabetes using multiplex ADAP assays: TRIAD2023 study
S. Hamdan, M. N. Scherman, A. Lind, D. Agardh, Sweden

486 Cytokine signature of diabetic ketoacidosis in children and adolescents
A. Rewers, Z. Chaffin, S. Ghetti, D. Tancredi, A. Mahon, S. Gilles, B. Ander, J. Dadra, N. Glaser, USA

487 Patterns of insulin discontinuation in youth with new onset type 2 diabetes presenting with and without diabetic ketoacidosis
P. Vellanki, A. L. Westbrok, C. Sinha, D. Hsia, S. Hao, USA

488 Distinct cord blood lipid signatures and its insights into childhood metabolic health
J. Zheng, X. Xiao, J. Zhang, China
489 Using maternal glycosylated haemoglobin as well as glucose tolerance tests identified significantly more mothers with high birth weight in their offspring

490 Performance of Automated Insulin Delivery systems during a winter ski camp in children and adolescents with type 1 diabetes: the InSki trial

491 The function of 1,5 anhydroglucitol in assessing beta cell and glucose intolerance in women with gestational diabetes
D. Quansah, C. Jimenez-Sanchez, J. Puder, P. Maechler, Switzerland

**Short Oral Event F**

**Thursday, 14:00 - 15:00**

**SO 030 Investigating impact of gestational diabetes**

492 Can we encourage severe weight restriction in women with obesity and gestational diabetes?
S. Pandya, N. Periyathambi, Y. Weldeselassie, N. Sukumar, V. Patel, P. Saravanan, UK

493 Is 1 year post-partum follow-up after gestational diabetes useful for investigating glycaemic changes?
A. Gaglio, Y. Pigotskaya, V. Grancini, E. Orsi, V. Resi, Italy

494 Continuous glucose monitoring metrics and suboptimal pregnancy outcomes in women with gestational diabetes: secondary analysis of the DiGest trial

495 Heterogeneity of metabolic phenotype and pregnancy outcome in gestational diabetes characterised by isolated fasting hyperglycaemia or isolated post-load hyperglycaemia
Y. Gong, Y. Liu, Q. Wang, C. Li, R. Kang, J. Wang, T. Wei, Q. Wang, X. Li, X. Zheng, Y. Ding, China

496 Low mid-pregnancy serum albumin levels associated with higher incidence of postpartum diabetes in women with gestational diabetes
Y. Su, N. Li, M. Lai, J. Yang, G. Liang, Y. Wang, China
497 Comparison of glycaemic responses following meal tolerance testing during early and late second trimester with oral glucose tolerance characteristics in overweight pregnant women

498 Foetal abdominal obesity and adverse pregnancy outcomes in women with gestational impaired glucose tolerance
W. Kim, Republic of Korea

499 Prediction of gestational diabetes in early pregnancy by fasting and dynamic parameters of glucose metabolism
C. Göbl, L. Weidinger, G. Kotzaeridi, T. Linder, T. Fischer, M. Todesco Bernasconi, M. Kunze, N. Ochsenbein-Koelble, B. Winzeler, I. Hösli, E. Huhn, A. Tura, Austria, Switzerland, Germany, Italy

Short Oral Event A  Tuesday, 12:30 - 13:30

SO 031 All the reasons why exercise is good!

500 The effects of pre-meal and post-meal exercise on postprandial glucose excursions in women with type 1 diabetes: the MERIT1D study
P. Acosta Manzano, J. Wenninger, J. Lex, A. Gjergji, M. Flor-Alemany, P. Birnbaumer, G. Tschakert, P. Hofmann, M. N. Van Poppel, Austria, Spain

501 Myokine secretion and metabolic pathways under resting and contractile conditions in primary human myotubes: A matter of oxygen level?
L. Mennens, N. Hoebers, J. W. Jocken, K. Verboven, G. H. Goossens, Netherlands, Belgium

502 Sex-related differences in cardiorespiratory capacity and ventilatory function in people with type 1 diabetes
L. Brugnara, H. Marí, V. Ribas, S. Murillo, J.-M. Servitja, A. Novials, Spain

503 CEFIP-deficient mice exhibit compromised physical fitness but improved glucose tolerance associated with enhanced exercise-inducible insulin sensitisation

504 Does better cardiorespiratory fitness extend the duration of partial clinical remission in adults with type 1 diabetes?
505 Carbohydrate ingestion before or during exercise on gastrointestinal mediated glucose metabolism in type 1 diabetes
O. M. McCarthy, S. Tawfik, M. Bechmann Christensen, K. Birch Kristensen, A. Ranajn, S. Schmidt, B. Hartmann, J. J. Holst, S. Bain, K. Noergaard, R. Bracken, Denmark, UK

506 The exerkine meteorin-like protein is a mediator of the protective effects of exercise against cytokine-induced human beta cell death

507 GDF15 is dispensable for the insulin-sensitising effects of chronic exercise
A. Labour, L. Frassin, M. Lac, C. Moro, France

Short Oral Event B  Tuesday, 13:45 - 14:45

SO 032 Insulin action in peripheral tissues

508 Physical and functional interactions between angiotensin converting enzyme 2 and GLUT4 in 3T3L1 adipocytes
H. Sato, T. Fukushima, G. W. Gould, M. Kanzaki, Japan, UK

509 Reduced insulin-induced capillary recruitment as a key defect in glucose extraction in type 2 diabetes
A. C. Hesp, L. Snel, B. Ariëns, A. H. Hulst, J. Hermanides, L. A. Schwarte, P. R. Schober, R. W. Ten Kate, D. Van Raalte, Netherlands, Austria

510 The role of insulin on the hepatic translatome
P. D. Teixeira, R. Meurs, G. Lucibello, G. Ursino, D. Gatfield, G. Ramadori, R. Coppari, Switzerland

511 Hepatic insulin clearance is associated with pancreatic fat fraction in ketosis-prone diabetes
P. Vellanki, D. A. Reiter, S. J. Edwards, E. E. Ray, O. Oladejo, D. Stefanovski, USA

512 The oxidized linoleic acid metabolite 9-hydroxyoctadecadienoic acid promotes metabolic adaptions in skeletal muscle
X. Yu, A. Krook, J. R. Zierath, N. J. Pillon, Sweden

513 Metabolic adaptations in the maintenance of body weight and glycaemia in food-restricted mice with physical exercise
S.-P. Chen, Z. Boudra, N. Kassis, J. Vily Petit, O. Viltart, G. Mithieux, C. Magnan, C. Cruciani-Guglielmacci, France
514 Investigating the role of TSC22D4 phosphorylation in metabolic control
S. Demir, J. Szendrödi, S. Herzig, B. Ekim, Germany

515 Genetic variation at RAB3GAP2 is associated with skeletal muscle capillary density
B. A. Mir, K. Ström, N. Oskolkov, S. Kalamajski, O. Ekström, P. Franks, O. Hansson, Sweden

**Short Oral Event C Wednesday, 12:45 - 13:45**

**SO 033 Understanding insulin sensitivity: What can we learn from human studies?**

516 Impact of low-calorie diets and bariatric surgery on organ-specific insulin sensitivity in the liver and skeletal muscle
M. Mori, Y. Takeshita, D. Matsubara, M. Okumura, S. Tokuno, H. Goto, Y. Nakano, T. Takamura, Japan

517 Measures of insulin clearance, insulin sensitivity, and insulin secretion and association with incident diabetes in older adults: a cardiovascular health study
S. Sarma, M. Biggs, D. Siscovick, J. Barzilay, R. Retnakaran, C. Kramer, L. Djousse, J. Ix, K. Jorge, K. Mukamal, USA, Canada

518 NPH increases the risk of insulin resistance in type 1 diabetes
L. V. Silva, Liana C França, Paulo Z Silvano, Robson Barth, Gustavo J dos Santos., Brazil

519 Insulin resistance is associated with 31 diseases and all-cause mortality in females in the UK Biobank: a prospective cohort study
J. Wu, Y. Song, China

520 Assessing the cardiovascular implications of insulin resistance and adipose tissue distribution: a hospital-based investigation into the role of ectopic fat deposition
N. Kumar, A. Sinha, S. Jha, India

521 Plasma metabolomics and transcriptional profiling of adipose tissue in humans with inherited insulin resistance
P. M. Møller, R. Kruse Sørensen, A. B. Hansen, K. Brusgaard, J. Havelund, N. J. Færgeman, K. Højlund, Denmark
522 In monozygotic twin pairs discordant for BMI, six months of exercise training modulate microbiota composition and stimulate colon insulin sensitivity in leaner twins

523 Estimation of muscle and hepatic insulin sensitivity in type 1 diabetes adults using clinical and research biomarkers
A. S. Januszewski, J. R. Snaith, G. Kowalski, C. Bruce, D. J. Holmes-Walker, A. J. Jenkins, J. R. Greenfield, Australia

**Short Oral Event D**  **Wednesday, 14:00 - 15:00**

**SO 034 Novel mechanisms of insulin resistance**

524 Elucidating the molecular mechanisms of obesity-induced insulin resistance: the role of NEDD4-2 in calcium homeostasis

525 Ramulus mori alkaloids improve intestinal oxidative stress and inflammation by regulating the gut microbiota and circle metabolites in PCOS
S. Geng, Y. Wang, China

526 Impact of therapeutic use of levothyroxine in treatment on insulin resistance in untreated primary hypothyroidism patients
N. Kumar, S. Jha, A. Sinha, India

527 The mechanism of hepatic selenoprotein S deficiency aggravating insulin resistance based on transcriptomics
J. Du, L. Qiao, L. Men, X. Xie, China

528 Pharmacological intervention in insulin resistance: the role of angiotensin-II-receptor blockers in correcting intracellular Ca\(^{2+}\) dysregulation

529 Multi-omics reveals tissue-specific mechanisms of hyperinsulinaemia and sucrose-induced insulin resistance
530 Unravelling the paracrine role of endothelial IGF-1R in basal hepatic insulin signalling  

531 Impact of elevated branched-chain amino acid levels on insulin signalling and metabolic function: a preliminary in vitro study  

**Short Oral Event E**  
**Thursday, 12:45 - 13:45**

**SO 035 Non-insulin hormones**

532 Serum 25-hydroxy vitamin D level is associated with elastography detected liver fibrosis in patients with type 2 diabetes, in a gender dependent pattern  
X. Wu, N. Huang, L. Li, China

533 Pander interplay with il-6 in regulation of GLP-1 secretion  
X. Cao, Z. Li, L. Pei, F. Lai, N. Chen, C. Xu, S. Liang, China

534 Age-related changes in glucagon secretion and effects of preservation of beta cell function on muscle mass in people with type 2 diabetes  
K. Motohashi, S. Tokumoto, Y. Sogawa, S. Kaneko, Japan

535 Upregulation of portal GLP-1r density by targeted administration of dihydrotestosterone induces remission in a large animal model of type 2 diabetes  
C. Malbert, R. Allouche, M. Horowitz, K. Jones, France, Australia

536 Fragmentation of circulating IGFBP-2 upon obesity and bariatric surgery  
F. Picard, J. Faramia, S. Miard, Canada

537 The gut peptide Neurotensin stimulates the release of pancreatic polypeptide in healthy young men  

538 Use of LC-MS/MS to quantify metabolically important pancreatic and enteroendocrine hormones in human plasma  
C. Bannon, A. Punnoose, R. Kay, P. Fletcher, L. Moreno Lopez, F. Reimann, F. M. Gribble, UK
539 The separate and combined effects of glucose-dependent insulinotropic polypeptide and alanine on plasma glucose during fasting in healthy individuals

Short Oral Event F Thursday, 14:00 - 15:00

SO 036 Keeping your beta cells alive

540 Irisin restores the secretory function of pancreatic beta cells in experimental and human type 2 diabetes
N. Marrano, A. Borrelli, G. Biondi, M. Rella, L. Roberto, L. Vincenti, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, A. Natalicchio, Italy

541 Persistence of beta cells secreting proinsulin in long-standing patients with minimal residual insulin secretion
E. Larger, F. Bonnet, S. Daclin, R. Mallone, J. Guibourdenche, France

542 Prediction of insulin requirement in type 2 diabetes patients using a glucagon test

543 Variability in beta cell function trajectories following surgical-induced beta cell mass reduction
R. Bizzotto, G. Di Giuseppe, C. Rossi, L. Soldovieri, F. Cinti, S. Moffa, M. Brunetti, G. Ciccarelli, S. Alfieri, G. Quero, A. Mari, A. Giaccari, T. Mezza, Italy

544 HMB, lysine, and arginine: a combination of ingredients that potentiates the glucose-stimulated insulin secretion via ERK1/2 activation in pancreatic beta cells
J. M. López-Pedrosa, M. Manzano, R. Salto, M. D. Girón, P. Bueno-Vargas, R. Rueda, Spain

545 Improvement of beta cell function and glucagon secretion by dietary weight loss of >10 kg in patients with type 2 diabetes
E. Lalama, J. Zhang, B. Schuppelius, K. Rüther, M. Csanalosi-Artigas, N. Kraenkel, S. Kabisch, K. Mai, E. Latz, A. Christ, D. Trico, A. Mari, A. F. Pfeiffer, Germany, Italy

546 Hormone characteristics of post-acute pancreatitis diabetes: insulin resistance accompanied by dysregulated glucagon and pancreatic polypeptide secretion
Y. Lv, L. Li, China
547 Non-targeted metabolomic profiling reveals novel metabolite biomarkers of post-acute pancreatitis diabetes compared with type 2 diabetes
Y. Lv, L. Li, China

Short Oral Event A Tuesday, 12:30 - 13:30

SO 037 New approaches in carbohydrate metabolism

548 Gut microbial flora and development of diabetes and obesity in rodents
Z. Boudra, S.-P. Chen, I. Raho, C. Cruciani-Guglielmacci, C. Magnan, France

549 Diabetes in the outcome of chronic pancreatitis: specific features course and therapy
K. Amikishieva, A. Ametov, A. Shabunin, E. Pashkova, Russian Federation

550 Ace2 modulates diabetes-associated gluconeogenesis in the kidneys
T. J. Block, C. Tikellis, M. C. Thomas, Australia

551 Experienced blood glucose regulation after menopause: a cross-sectional survey in women with type 1 diabetes
E. M. Speksnijder, S. Simsek, P. H. Bisschop, D. J. Stenvers, S. E. Siegelaar, Netherlands

552 Modulation of gut microbiota homeostasis as a strategy to prevent diabetes progression: the role of dietary carbohydrate quality
J. M. López-Pedrosa, M. Manzano, M. T. García-Corcoles, R. Rueda, Spain

553 Relative contributions of fasting vs postprandial hyperglycaemia to overall glycaemic control in newly-diagnosed type 2 diabetes before and following 3 months’ treatment
Y. Sun, Y. Luo, C. Xie, J. Ma, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia, China

554 Characteristics of glucokinase regulatory protein missense mutations with distinct effects on hepatic lipid metabolism suggest a gene regulatory function of glucokinase
S. Langer, D. Jagdhuhn, R. Waterstradt, J. Gromoll, M. Müller, M. G. Rees, A. L. Gloyn, S. E. Baltrusch, Germany, USA
**Short Oral Event B**

**SO 038 Novel pharmacological approaches for the treatment of obesity and diabetes**

**555 Dual amylin and calcitonin receptor agonist treatment increases proton leak of skeletal muscle in obesity rat model**
E. A. Petersen, I. Blom, S. Cubranovic, S. Larsen, M. A. Karsdal, K. Henriksen, A. T. Larsen, Denmark, Poland, Switzerland

**556 The dual amylin and calcitonin receptor agonist KBP-336 induces significant weight loss with preserved muscle function and strength**
A. T. Larsen, K. Mohamed, E. Petersen, M. A. Karsdal, K. Henriksen, Denmark, Switzerland

**557 Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study**
S. Heymsfield, J. Suschak, J. Kasper, J. Gutierrez, S. Tomah, L. Johansson, E. Johansson, J. Yang, S. Keeton, M. Roberts, M. Harris, S. K. Browne, USA, Sweden

**558 Petrelintide significantly reduces fat mass while preserving lean mass and selectively reducing intake of high fat diet in DIO rats**
B. Vestergaard, T. Baader-Pagler, J. Griffin, Denmark, Germany

**559 The novel Cannabinoid receptor 1 inverse agonist, INV-347, improves metabolic outcomes in obese mice**
A. Vivoli, F. Paré, V. Facca, G. Gaucher, G. Crater, G. Lim, Canada

**560 FGF21 gene therapy: a single administration treatment strategy to treat severe obesity and associated comorbidities**

**561 No clinically relevant QTc prolongation with cagrilintide: a thorough QT study in healthy participants**
M. B. Gabe, R. Fuhr, A. Sinn, A. Eliassen, K. K. Berthelsen, A. B. Kuhlman, T. A. Bækdal, A. B. Nejad, Denmark, Germany

**562 Amino acids plasma levels do not correlate with lean mass loss in weight matched DIO mice treated with survodutide or semaglutide**
K. Klepac-Bartl, M. Pereira, T. Zimmermann, W. Rist, B. Bajrami, T. Kloechner, T. Klein, Germany
SO 039 Improving metabolic outcome by bariatric surgery

563 Impact of pre-surgery post prandial hypoglycaemia on metabolic outcomes after surgery: a 2yr follow-up study
L. Bonvicini, D. Moriconi, P. Troia, C. Moretto, M. Nannipieri, Italy

564 Changes in beta cell mass in remission of type 2 diabetes after Roux-en-Y gastric bypass surgery, quantified in vivo by $^{68}$Ga-exendin-4 PET/CT

565 Gastro-intestinal effects of metformin on glucose homeostasis and enterohormone secretions after bariatric surgery
M. Hirlemann, A. Willemetz, L. Ribeiro-Parenti, T. Bertrand, J. Movassat, C. Carette, M. Le Gall, France

566 Effects and safety of bariatric surgery in obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study

567 Sleeve gastrectomy alters intestinal morphology and the number and localisation of incretin-producing cells

568 Assessment of the quality of life in patients with morbid obesity and type 2 diabetes after bariatric surgery
Z. Shamansurova, E. Adilkhodjaeva, U. Bozorov, Uzbekistan

569 Ultra-processed food consumption and indicators of adiposity in South Asia: findings from the South Asia Biobank in Bangladesh, India, Pakistan, and Sri Lanka

570 Comparative analysis of DNA methylation patterns in adipose tissue and blood following bariatric surgery: insights into inflammatory state reflection
L. Müller, A. Hoffmann, S. H. Bernhart, A. Gosh, J. Zhong, W. Sun, H. Dong, F. Noé, C. Wolfrum, A. Dietrich, L. Massier, M. Blüher, P. Kovacs, R. Chakaroun, M. Keller, Germany, Switzerland, Sweden
571 Canagliflozin or acarbose vs placebo to ameliorate post-bariatric hypoglycaemia: the HypoBar I randomised clinical trial

**Short Oral Event D**

**Wednesday, 14:00 - 15:00**

**SO 040 Now the brown fat talks**

572 Acute cold exposure differentially affects fasting and postprandial hormone secretion in participants with obesity compared to leans
M. Monfort-Pires, T. Saari, M. U-Din, F. Acosta Manzano, J. Örling, S. E. Zaidi, M. Karjalainen, K. Pohjanoksa, A. Tornio, K. A. Virtanen, Finland

573 Higher brown adipose tissue glucose uptake is related to better glycaemic control
T. Saari, M. Karjalainen, J. Örling, A. K. Kirjavainen, M. Monfort-Pires, F. M. Acosta, M. U-Din, K. A. Virtanen, Finland

574 Neuronostatin modulates proliferation and differentiation of rat primary brown preadipocytes
M. Krążek, T. Wojciechowicz, J. Fiedorowicz, M. Z. Strowski, K. W. Nowak, M. Skrzypski, Poland, Germany

575 Adipocyte-specific deletion of PGC-1 co-activators disrupts brown adipose tissue secretory function and induces glucose intolerance
J. A. Villena, M. Velilla, N. Tellez, R. Pardo, Spain

576 Analysis of age-related metabolic changes in thermogenic adipocytes
J. Heida, S. Gohlke, T. Schulz, Germany

577 Serotonin transporter expression relates to cold-stimulated brown fat metabolism in adult humans
M. U-Din, J. R. Raiko, T. Niemi, T. Fromme, O. Eskola, M. Klingenspor, P. Nuutila, K. A. Virtanen, Finland, Germany
Short Oral Event E Thursday, 12:45 - 13:45

SO 041 Towards a better understanding of the adipose tissue - liver axis

578 A clinically relevant variant of SHP-1 preserves glucose homeostasis and hepatic insulin sensitivity during aging despite B cell infiltration and matrix deposition
B. Laborit Labrada, K. Bellmann, M. Pineault, M. Schwab, A. Kumar, M. Laplante, M. C. Morisette, A. Marette, Canada

579 Impact of sarcopenic obesity on metabolism-associated fatty liver disease (MAFLD) and glucose metabolism
J. Xia, China

580 Impact of hepatic steatosis and senescence on dynamic glucagon secretion: A potential mechanism of hypoglycaemic risk in metabolic dysfunction-associated steatotic liver disease?

581 The impact of exercise training on hepatic fibrosis based on serum proteomic analysis
Z. Cai, Q. Wang, X. Zhou, C. Ni, H. Wang, X. Wang, Y. Yuan, Z. Sun, China

582 P62-mediated proteasomal degradation of perilipin 1 enhances anti-obesity effects by boosting lipolysis in white adipose tissue
S.-H. Go, J.-Y. Yun, Y. Cho, E. Koh, Republic of Korea

583 Adaptive metabolic responses facilitate blood-brain barrier repair in ischaemic stroke via BHB-mediated epigenetic modification of ZO-1 expression
Y. Huang, R. Li, Y. Liu, China

584 Early dynamics in ectopic fat in multiple organs during individualised weight loss in obese individuals with non-alcoholic fatty liver disease and the metabolic syndrome
M. Ulanowska, M. Gjela, A. Askeland, R. W. Rasmussen, P. Vestergaard, J. Brøndum Frøkjær, M. Mellergaard, A. Handberg, Denmark

585 Age-related epigenetic marks in muscle and liver have functional and clinical consequences in subjects before and after obesity surgery
A. Khamis, M. Boissel, L. Ning, L. Maurin, V. Raverdy, B. Staels, L. Philippe, F. Pattou, A. Bonnefond, P. Froguel, France, UK
Short Oral Event F  

Thursday, 14:00 - 15:00

SO 042 How lifestyle affects our health

586 Exercise training does not reverse the obesity-induced increase in insulin-stimulated brain glucose uptake but improves cognition in MZ-twin pairs discordant for BMI  

587 Impact of the time-restricted eating on the lipid metabolism in subjects with high diabetes risk  

588 The correlation between households food insecurity and obesity in youth in the United States: findings from the NHANES 2017-2018 survey  
S. Gheibi, A. Mokari-Yamchi, A. Faghfouri, Netherlands, Iran, Islamic Republic of

589 Long-term effects of sweeteners and sweetness enhancers consumption after weight loss on the gut microbiota composition in individuals with overweight or obesity: the SWEET study  
M. Pang, J. Bastings, A. Umanets, M. Maurer-Sost, L. Kjølbæk, A. Martinez, Y. Manios, S. Navas-Carretero, E. Feskens, J. A. Harrold, J. C. Halford, T. Adam, G. Goossens, A. Raben, E. E. Blaak, Netherlands, Denmark, Spain, Greece

590 Maternal over-nutrition exacerbated offspring hepatic lipid accumulation via butyrate-AMPK-pHDAC5 pathway  
J. Zheng, J. Zhang, L. Zhang, S. Zhang, China

591 The role of weight loss and diabetes duration for the remission of human type 2 diabetes in response to three months of very low caloric formula diets  
B. Schuppelius, E. Lalama, J. Zhang, K. Rüther, M. Csanalosi, S. Kabisch, K. Mai, A. F. Pfeiffer, Germany

592 Skeletal muscle mitochondria respond differently to weight loss induced by bariatric surgery or caloric restriction  
593 Effect of time restricted feeding (TRF) on REV/ROR alpha gene on CYP11a1 protein expression in the ileum epithelium cells and rhythmic abundance of gut microbiota in pre-diabetic mice
B. Anjum, K. Ahmad, S. Tiwari, R. Sinha, M. Godbole, India

Short Oral Event A, Tuesday, 12:30 - 13:30

SO 043 Inflammation and beta cell homeostasis

594 The effect of ketogenic diet vs Mediterranean diet on clinical and biochemical markers of inflammation in patients with obesity and psoriatic arthritis

595 Omega-3 fatty acids partially reverts the inflammation and insulin resistance in the hippocampus of obese and diabetic mice through GPR120 receptor

596 A deeper understanding of the role of circulating cell free DNA in obesity: a potent immune activator
P. Apalaki, C. M. Cheimonid, K. Stratigi, G. Chatzinikolaou, M. Karaglani, G. Tarapatzi, M. Panagopoulou, E. A. Chatzaki, Greece

597 Exploring the molecular mechanisms underlying the role of GRK2 in macrophage activation
R. Santos-Clemente, F. Mayor Jr, I. García-Higuera, Spain

598 Transfer RNA fragments induced during obesity hold regulatory functions in islet macrophage activation and beta cell homeostasis
C. Cosentino, R. Klein, V. Menoud, A. Galli, F. Brozzi, S. Poddar, C. Guay, R. Regazzi, Switzerland

599 The transcription factor p53 regulates adipose tissue macrophages’ phenotype and their capacity to handle lipids
J. Jager, I. Mucel, M. Gaudfrin, J. Frère, J. Gilleron, J.-F. Tanti, M. Cormont, France

600 Role of miRNAs and tRNA fragments in senescence-induced deregulation of pancreatic beta cell function
C. Guay, V. Menoud, C. Aguayo-Mazzucato, S. Bonner-Weir, R. Regazzi, Switzerland, USA
601 Impact of liver fat content on serum levels of plasminogen activator inhibitor-1, fibroblast growth factor 21 and cerebral microcirculation in type 2 diabetes and obesity

**Short Oral Event B**

**TUESDAY, 13:45 - 14:45**

**SO 044 Lipid signatures and ectopic fat**

602 Association of serum sclerostin levels in type 1 and type 2 diabetes with low muscle density and high visceral fat: the Diafall study
N. Rasmussen, A. Vestergaard Kvist, J. Van den Bergh, P. Vestergaard, Denmark, Netherlands

603 Lipid signature of changes women with gestational diabetes in response to puerperal exclusive breastfeeding
L. Li, J. He, X. Cui, C. Ji, China

604 Expression of adipocytokines in human peri-pancreatic adipose tissue and correlations with beta cell function
M. Suleiman, G. Gambino, M. Tesi, C. De Luca, R. Del Testa, S. Del Guerra, L. Marselli, P. Marchetti, L. Rossi, Italy

605 Lipolysis-dependent lipids secretion mediate adipose tissue and pancreas crosstalk in early stages of insulin resistance
F. Almeida-Oliveira, J. M. Alves, P. H. Melo, N. Pereira, T. T. Gonçalves, A. M. Pinto, A. Saghatelian, S. Offermanns, L. O. Leiria, Brazil, Germany, USA

606 Risk factors for predicting visceral fat in type 2 diabetes individuals with normal body mass index
Y. Li, M. Jiao, Y. Yang, W. Tao, Y. Feng, X. Wang, China

607 Characterisation of extracellular matrix remodelling in adipose tissue of diet-induced obese mice using an untargeted proteomics approach
D. Sarnobat, X. Weng, R. Stimpson, L. Kang, UK

608 Defective G-CSF in the secretome of epicardial adipose cells favors apoptosis and cellular stress of cardiac progenitor cells in human obesity
G. Palma, C. Caccioppoli, R. D’Oria, V. Genchi, I. Calderoni, T. Bottio, A. Braun, G. Santarpino, A. Cignarelli, A. Natalicchio, L. Laviola, A. Pezzolla, A. M. Valverde, F. Giorgino, S. Perrini, Italy, Spain
609 12,13-diHOME protects against obesity-related kidney disease by regulating PLIN5-mediated lipid metabolism
X. Sun, K. Zhang, W. Zhang, H. Qiu, J. Shi, J. Zhang, C. Kan, F. Han, N. Hou, Z. Guo, China

Short Oral Event C  Wednesday, 12:45 - 13:45

SO 045 Preclinical advances to better understand energy, glucose and lipid metabolism

610 Combinations of the mitochondrial protonophore TLC-6740 and/or the ACC2 inhibitor TLC-3595 provide additive glycaemic benefits to glucagon-like-peptide-1 receptor agonist in db/db mice
A. Vijayakumar, N. Sroda, E. Murakami, S. Weng, R. P. Myers, G. M. Subramanian, G. I. Shulman, USA

611 TLC-6740, a liver-targeted mitochondrial protonophore, increases energy expenditure and lipid utilisation in obese mice
A. Vijayakumar, N. Sroda, E. Murakami, S. Weng, G. I. Shulman, R. P. Myers, G. M. Subramanian, USA

612 Characterisation of intestinal K/I cells utilising GIP/CCK double reporter mice

613 Intergenerational and transgenerational inheritance of obesity in a mouse model of childhood obesity: role of germline small non-coding RNAs
M. Mourin, F. Palmieri, I. Palacios-Marin, M. Ramon-Krauel, C. Lerin, J. Jimenez Chillaron, Spain

614 Modelling type 2 diabetes remission: the NONcNZO10/LtJ polygenic mouse model is ideal to study de novo lipogenesis

615 IGF2 deficiency promotes obesity by inhibiting testosterone synthesis through suppression of autophagy
X. Lin, C. Zhou, W. Gui, F. Wu, China

616 Lipoxins-mediated restoration of lymphatic functions in an experimental model of obesity
M. Clark, Y. Subashi, K. Fujita, S. Tavajoh, A. Peluzzo, B. E. Suur, M. Quiding-Järbrink, S. Karaman, S. Lange, E. Börgeson, Denmark, Finland, USA, Sweden
617 The impact of early vs postponed statin therapy after ovarian cycle loss on insulin resistance parameters in a prediabetes model
M. Hüttl, I. Markova, H. Malinska, D. Miklankova, K. Cerna, T. Hlinka, J. Pitha, Czech Republic

**Short Oral Event D**

**Wednesday, 14:00 - 15:00**

**SO 046 What's new on white fat function?**

618 Decoding transcriptional regulatory circuits associated with energy expenditure in human adipocytes and implications for diabetes risk

619 Association between longitudinal changes of targeted metabolites and of insulin clearance in non-diabetic individuals: an IMI DIRECT study

620 The sartorius fat fraction is independently associated with myocardial fibrosis in Chinese patients with obesity
Z. Wang, J. Yue, Q. Lu, Y. Qi, H. Zhao, M. Jiang, J. Bu, J. Ma, China

621 Transcriptomic reveals new keys in the subcutaneous adipose depot remodeling after bariatric surgery
E. Martínez, P. Fernández García, D. Rodríguez, S. Martínez, M. Álvarez Antolínez, M. Ros, P. Corrales-Cordon, D. Sánchez-Infantes, Spain

622 Extracellular vesicles mediate the communication of adipose tissue with hypothalamus and involved in maintaining energy homeostasis
J. Wang, Y. Bi, China

623 Subcutaneous adipose tissue aromatase expression and oestrogen signalling: potential contributors to insulin resistance in men with obesity and type 2 diabetes

624 Metabolic function of MLKL, the mediator of necroptosis, in adipose tissue
V. Pistorio, J. Tokgozoglu, P.-A. Soret, V. Steunou, L. Serfaty, V. Ratziu, J. Gautheron, France
625 Analysing epigenetic contributions to diabetes and obesity across generations in families with metabolic disorder
A. Shankar, S. Kumar, A. Das, India

**Short Oral Event E**

**SO 047 Novel mechanisms regulating energy and glucose metabolism**

626 Role of endoplasmic reticulum stress activation in diabetes related intestinal barrier dysfunction
F. De Vito, A. Facciolo, E. Suraci, R. Marasco, F. Luzzia, M. L. Hribal, G. Sesti, F. Andreozzi, T. V. Fiorentino, Italy

627 ARHGEF3 plays multifaceted roles in adipogenesis through its interplay with YAP and PPARγ
M.-S. Yoon, Republic of Korea

628 Role of FKBP5 in adipose tissue function: implications for obesity and insulin sensitivity

629 Olfactory system is a target to control lipid and glucose homeostasis in mice
M. Sugiyama, H. Tsuneki, T. Yamagishi, K. Onishi, T. Wada, T. Sasaoka, Japan

630 Targeting BRD4-HK2 reverses perivascular adipose tissue meta-inflammation shift and rescues cardiometabolic vascular dysfunction
A. Mengozzi, S. Costantino, A. Mongelli, E. Duranti, S. A. Mohammed, E. Gorica, F. Cappelli, C. M. Matter, S. Taddei, S. Masi, F. Ruschitzka, A. Virdis, F. Paneni, Italy, Switzerland

631 Hypothalamic fibroblast growth factor-1 regulates energy homeostasis
H. Shin, J. Suh, Republic of Korea

632 The DNER/NOTCH-1 couple contributes to adipose tissue inflammation and insulin resistance in obesity

633 Multilevel involvement of Alx3 in the regulation of glucose-induced insulin secretion
M. Mirasierra, A. Bartolomé, M. Vallejo, Spain
Short Oral Event F    Thursday, 14:00 - 15:00

SO 048 Novel mechanisms controlling glucometabolic health

634 Longitudinal analysis of microbial metabolites in a prediabetes mouse model
M. V. Joglekar, N. H. Pham, M. Thanki, E. Alvandi, W. K. Wong, A. Hardikar, Australia

635 Subcutaneous adipose tissue expression of the Notch signalling pathway genes in relation to insulin sensitivity, obesity, and markers of adipogenesis
N. Matulewicz, M. Dobrzycka, M. Stefanowicz, P. Mysliwiec, J. Dadan, I. Kowalska, M. Karczewska-Kupczewska, Poland

636 Unravelling p53’s role in AGE-induced adipose tissue dysfunction
N. Kavin, N. Kislev, D. Benayahu, Israel

637 B cell-derived Nociceptin contributes to immune cell trafficking and insulin resistance in obesity
S. Puente-Ruiz, A. Hoffmann, P. Czechowski, M. Blüher, N. Klöting, F. Wunderlich, J. Brüning, A. Jais, Germany

638 Deletion of miR-494 promotes skeletal muscle mitochondrial biogenesis and extends a healthy lifespan in mice

639 The LMK-235, an HDAC inhibitor, prevented diabetic skeletal muscle atrophy
K.-W. Lee, S. Park, Y. Kim, Y. Kim, S.-E. Choi, Y. Son, T. Kim, S. An, N. Lee, J. Jeon, S. Han, H. Kim, D. Kim, Republic of Korea

640 N-acetylaspartylglutamic acid: A novel hippocampal compensatory mechanism against glucose intolerance in obesity?
B. Caramelo, V. Mendes, A. Cortez, T. Monteiro-Alfredo, J. Sereno, J. Martins, M. Castelo-Branco, P. Matafome, B. Manadas, Portugal, Brazil

641 The NPY/melanocortin system in white adipose tissue is regulated by ghrelin and leptin and is impaired in patients with insulin resistance
Short Oral Event A  
Tuesday, 12:30 - 13:30

SO 049 Novel clinical insights into adipose tissue function

642 Liver fat content, regulated by BMI, as a potential marker for subclinical myocardial remodelling and dysfunction in obese adults
X. Wan, J. Yue, Q. Lu, H. Zhao, S. He, Y. Qi, M. Yang, J. Che, M. Jiang, J. Bu, J. Ma, China

643 In type 2 diabetes, epicardial adipose tissue displays enhanced senescence of mesenchymal stem cells
G. Ferraro, S. Cabaro, S. Romano, R. De Martino, V. D'Esposito, V. Parisi, M. F. Di Tolla, F. Mormone, C. Morelli, F. Oriente, D. Leosco, F. Beguinot, P. Formisano, Italy

644 Body fat distribution differs between people with autoimmune diabetes and healthy controls
R. Amendolara, R. Risi, A. Balena, M. Watanabe, D. Masi, L. D'Onofrio, L. Gnessi, R. Buzzetti, E. Maddaloni, Italy

645 The serum-derived extracellular vesicle lipidome is altered in people with type 2 diabetes

646 Sodium-glucose cotransporter 2 inhibitors attenuate cellular senescence through regulation of TonEBP expression in obesity and diabetic kidneys
S. KIM, J. Kim, J. Bae, M. Lee, Y. Kang, D. Yi, D. Kim, Republic of Korea

647 Correlation between of IGF2 and testosterone in overweight and obese adolescent boys
C. Zhou, D. Wu, X. Lin, China

648 Metabolic dysfunction-associated fatty liver disease and obesity can modify the inflammation and complement activation in type 2 diabetes
E. Sipter, L. Barkai, K. Babayigit, D. Csuka, Z. Prohaszka, N. Hosszufalusi, Hungary

649 Circadian rhythmicity in human subcutaneous und visceral adipocytes
O. Pivovarova-Ramich, L. Meyer, V. Lange, C. Dibner, Germany, Switzerland
**Short Oral Event B**

**Tuesday, 13:45 - 14:45**

**SO 050  Understanding and combating adipose tissue dysfunction**

650 Plakoglobin ablation in adipocytes exacerbates high-fat diet induced weight gain
F. Abou Azar, F. Paré, W. Shou, G. Lim, Canada, USA

651 SVEP1-based peptide modulates adipose tissue dysfunction and insulin resistance via macrophage-driven inflammation inhibition
N. Kislev, N. Kavin, D. Benayahu, Israel

652 Novel genotype profiles in digenic triallelic obesity: coexistence of ciliopathy syndromes with PSCK1 mutations
S. Dagdelen, N. Basmaci, S. H. Oguz, Turkey

653 CLDN1 and its novel role in adipose tissue physiopathology: studies in a mice aging model
P. Fernández-Garcia, P. Corrales, M. Martín-Taboada, J. Tarascó, S. Pellitero, M. Ros, R. Cereijo, F. Villarroya, G. Medina, D. Sánchez-Infantes, Spain

654 Empagliflozin, an SGLT2 inhibitor, prevented palmitate-induced lipotoxicity through enhanced fatty acid oxidation and reduced stress signals
T. Kim, Y. Kim, S. Park, Y. Kim, S.-E. Choi, Y. Son, S. An, J. Jeon, N. Lee, S. Han, H. Kim, D. Kim, K.-W. Lee, Republic of Korea

655 Adipose Angptl8 controls glucose and energy metabolism and its suppression in mice improves diet induced obesity

656 Early liver lipidome markedly contributes to the development of diabetes mediated by an active adipose-liver interaction
R. Sehgal, M. Jähnert, M. Lazaratos, T. Speckmann, M. Ouni, W. Jonas, A. Schürmann, Germany

657 Regulation of adipogenesis by 14-3-3ζ scaffold protein occurs via modulation of chromatin accessibility in the initial phases of adipocyte differentiation
S. Rial, Z. You, A. Vivoli, D. Sean, A. Al-khoury, G. Lavoie, M. Civelek, A. Martinez-Sanchez, P. P. Roux, T. T. Durcan, G. Lim, Canada, France, USA, UK,
658 Changes in human serum VEGFb levels by preferential oil intake might be related to fatty acid effects on adipocyte’s VEGFb gene methylation, expression and protein levels
W. Oualla-Bachiri, A. Lago-Sampedro, S. Valdés, C. Maldonado-Araque, I. González-Molero, G. Rojo-Martínez, S. Garcia-Serrano, E. Garcia-Escobar, Spain

**Short Oral Event C**

**Wednesday, 12:45 - 13:45**

**SO 051 Metabolic alterations in obesity and diabetes-linked co-morbidities**

659 Association between diabetes and sarcopenic obesity in older outpatients in Vietnam
T. N. Nguyen, H. T. Nguyen, T. X. Nguyen, H. T. Vu, Viet Nam

660 Identification of transcriptome alterations in the central amygdala of rats with painful diabetic neuropathy
X. Nie, China

661 Cardio-metabolic risk in patients with grade III obesity before and after weight loss
A. Penesová, L. Kubanova, M. Páleník, J. Babjakova, I. Hric, V. Bielík, Slovakia

662 Exploring inflammatory resolution pathways in patients with elevated systemic inflammation and cardiometabolic diseases

663 The anti-senescence effect of DPP-IV inhibitor gemigliptin on vascular tissue
M.-K. Kim, J. Park, Republic of Korea

664 Patient in a dish: mimicking patient phenotypes in 3D adipocyte spheroids

665 The efficacy and safety of liraglutide 3.0 mg for weight management as an add-on treatment in obese adolescents with type 1 diabetes
N. Elbarbary, S. Abouelnasr, Egypt
666 Adipose tissue in patients with morbid obesity with or without chronic kidney disease: differences in circulating adipocytokines, miRNAs, isomiRs and adipose tissue gene expression
R. Vila Bedmar, M. Martin-Taboada, B. Lanzón, I. González de Pablos, L. Torres, P. Corrales, P. Gomez-Rodríguez, E. Rodríguez-Cuéllar, E. Morales, G. Medina-Gómez, Spain

**Short Oral Event D**       **Wednesday, 14:00 - 15:00**

**SO 052 Preclinical advances to understand glucose metabolism**

667 Acetyl-coa carboxylase 1 phosphorylation at serine1215 by AMPK-activated protein kinase plays a critical role in embryonic development and glucose homeostasis in mice
J. Cantley, V. A. Morfin, R. B. Bakar, D. G. Hardie, UK

668 FFA-fetuin-a mediated lipid accumulation and insulin secretory defect in pancreatic beta cells: dissecting the possible crosstalk of CD36 and TLR4
R. Kundu, S. Mandal, S. Nag, India

669 Cytoskeletal protein Leupaxin promote hepatic gluconeogenesis through activating HNFA4α transitional activity
X. Luo, Fang Liu, Guoqiang Li, Caizhi Liu, Min Tang, Yueyin Yang, Xiaoying Ding, Yufan Wang, Xinran Ma, Yan Lu, Zhijian Zhang, Yongde Peng, China

670 ITIH5 is required for adipocyte differentiation and diet-induced obesity by modulating PI3K/AKT signalling
J. Li, D. Li, L. Li, China

671 Metabolic syndrome and hepatic steatosis in a diet-induced minipig model
Y. Eckstein, A. Blutke, B. Dobenecker, S. Fiedler, S. Renner, Germany

672 The relationship between glucagon and VFA in type 2 diabetic patients
P. Huang, X. Zhao, Y. Sun, T. Xu, Y. Gu, China
Short Oral Event E  
Thursday, 12:45 - 13:45

SO 053 Oral agents to control glucose metabolism

673 Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study

674 Effect of acarbose on glycaemic status and variability in patients of type 1 diabetes: a randomised, placebo controlled study
A. Rizvi, M. Mittal, R. Shukla, M. K. Garg, India

675 Distinct effects of imeglimin on insulin, GLP-1 and GIP secretion compared to metformin: a randomised controlled trial
M. Imura, R. Usui, Y. Hamamoto, Y. Omori, Y. Kurotobi, H. Kuwata, H. Tatsuoka, K. Shimomura, K. Murotani, Y. Yamada, Y. Seino, Japan

676 Polychemotherapy to induce remission of newly diagnosed type 2 diabetes: the MIRACLE trial

677 Chronic treatment of alfa-glucosidase inhibitor alters intestinal morphology and sugar transport gene expression under high-sucrose diet feeding

678 A multicenter, randomised controlled trial in individuals with type 2 diabetes to evaluate the efficacy of imeglimin on time in range
M. Ueda, Y. Hirota, K. Yokota, K. Kouyama, M. Mihara, S. Nakajima, K. Miyakoda, W. Ogawa, Japan

679 Machine learning methods to identify C-peptide as a clinical predictor of glycaemic response to sulphonylureas in type 2 diabetes

680 Efficacy and safety of sitagliptin in preserving bone mineralisation in women with type 2 diabetes: the SLowDOWN randomised clinical trial
**Short Oral Event F**  
**Thursday, 14:00 - 15:00**

**SO 054 Improving metabolism via the gut**

681 Effect of microencapsulated oral sodium butyrate on GI signs, SIBO and diabetic control: a randomised, placebo controlled study  
E. Franek, P. Panufnik, M. Wieciek, P. Szwarc, M. Kaniewska, K. Lewandowski, G. Rydzewska, Poland

682 Weight-independent effects of very low-carbohydrate vs Mediterranean diet on glucose tolerance and free-living glucose control in individuals at risk for type 2 diabetes  

683 Replacing sugar with isomaltulose reduces postprandial blood glucose response in school children: results from a double-blind, randomised, controlled cross-over study  
L. Schweitzer, S. Theis, Germany

684 Effects of well and poorly absorbed low-calorie sweeteners on insulin secretion and sensitivity in type 2 diabetes  
C. Xie, T. Li, M. Bound, J. Grivell, Y. Sun, K. L. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

685 Gut microbiome composition is linked with Mediterranean diet adherence and blood glucose control in adults with type 1 diabetes  
J. Abuqwider, E. Pasolli, G. Scidà, A. Corrado, G. Costabile, A. Rivellese, D. Ercolini, F. De Filippis, L. Bozzetto, Italy

686 Canola oil as a source of GPCR ligands regulating carbohydrate metabolism  
A. K. Drzazga, P. Bernat, G. Dabrowski, E. Gendaszewska-Darmach, M. M. Rosenkilde, M. Koziolkiewicz, Poland, Denmark

687 Impact of starch digestibility modulation on glycaemic variability and control and the cardiometabolic profile in type 2 diabetes  
M. Chisbert, A.-L. Castell, L. Van Den Berghe, N. Feugier, C. Cuerq, O. Brack, M. Laville, A. Meynier, S. Vinoy, J.-A. Nazare, France

688 Finding the sweet spot: comparing lower carbohydrate diets for the management of type 2 diabetes using CGM and time in range  
**Short Oral Event A**  
**Tuesday, 12:30 - 13:30**

**SO 055 Improving metabolism through nutrition**

689 Time restricted eating improves glycaemic variability, independently of energy intake, in adults at risk of type 2 diabetes  
K. A. Bowden Davies, J. Pratt, A. Sanderson, N. Hodson, S. Joanisse, A. H. Heald, K. Smith, W. Peeters, D. J. West, UK

690 Postprandial glucose control with different hybrid closed-loop systems in adults with type 1 diabetes  
G. Scidà, A. Corrado, J. Abuqwider, G. Annuzzi, L. Bozzetto, Italy

691 Joint association of diet quality scores physical activity status with all-cause mortality among individuals with or without diabetes  
C. Liu, Z. Xin, L. Hua, China

692 A low-intensity structured weight management programme with partial diet replacement for type 2 diabetes in Chinese population: an open-label, randomised wait-list controlled trial  
C. Yuan, Community Health Service Centers in Hongkou District, Y. Ding, W. Xiang, J. Pan, H. Yu, G. Zong, China, USA

693 Co-existence of food insecurity and obesity in type 2 diabetes is associated with worse glycemic control in Bangladesh  
M. Kamruzzaman, M. Horowitz, K. L. Jones, C. Marathe, Australia, Bangladesh

694 The effect of a dietary intervention on insulin sensitivity in type 1 diabetes and the role of dietary advanced glycation end-products: a 12-week randomised clinical trial  
H. Kahleova, T. Znayenko-Miller, N. D. Barnard, USA,

695 A randomised controlled trial on low, moderate and high carbohydrate diet in adults with type 1 diabetes: 3-month preliminary results from the DANCE study  
A. A. Barouti, A. Björklund, Sweden

696 Six-year follow-up of an intensive lifestyle intervention in persons with type 2 diabetes: an extension study of the U-TURN randomised trial  
M. Ried-Larsen, M. Y. Johansen, K. Karstoft, K. Hansen, N. Pilmark, C. S. MacDonald, R. Christensen, T. Almdal, A. Vaag, B. K. Pedersen, C. G. Durrer, Denmark, Sweden
Short Oral Event B  Tuesday, 13:45 - 14:45

SO 056 Thinking outside the box to treat obesity and diabetes

697 Enhancing glucose homeostasis via oral administration of milk-derived extracellular vesicles
S. Weksler-Zangen, R. Lax, M. Musseri, S. Reif, R. Golan, Israel

698 The plant-based substance TOTUM-63 reduces fasting plasma glucose and HbA1c in people with prediabetes or type 2 diabetes: a 24-week, 600-people randomised controlled trial (REVERSE-IT)

699 Durable effects of duodenal ablation using electroporation combined with Semaglutide to eliminate insulin therapy in patients with type 2 diabetes; 24-month results

700 Dorzagliatin in combination with sitagliptin improves insulin sensitivity and beta cell function in patients with type 2 diabetes
Y. Zhang, L. Feng, J. Zhang, H. Liu, M. Jiang, L. Chen, D. Liu, China

701 Vicious cycle-breaking lipid nanoparticles remodelling intercellular crosstalk to reverse pancreatic fibrosis
W. Hui, L. Li, L. Qi, China

702 Diet-driven succinate production by intestinal microbiota stimulates GLP-1 secretion by colonic enteroendocrine cells via SUCNR1

703 RKER-065, a novel ActRII-Fc ligand trap, increased lean mass and improved fat mass loss in obese mice treated with semaglutide
704 Safety of teplizumab in stage 2 and stage 3 type 1 diabetes: integrated analysis of clinical trials

**Short Oral Event C**

**Wednesday, 12:45 - 13:45**

**SO 057 Novel therapeutic avenues for metabolic disease**

705 An optimised methylglyoxal scavenging peptide improves insulin sensitivity and glucose tolerance in mice with diet induced obesity independent of food intake or weight loss
S. Brings, M. Campos, W. Mier, S. Herzig, J. Szendrődi, P. P. Nawroth, T. Fleming, Germany

706 Discovery and characterisation of HDM1005, a novel dual GLP-1 and GIP receptor agonist for the treatment of type 2 diabetes and obesity
C. Jiang, N. Zhang, L. Teng, L. Guo, H. Pan, Z. Zhang, Z. Dong, D. Liu, China

707 Characterisation of AZD6234, a novel amylin receptor selective agonist peptide, in rodent models of weight loss and aversion

708 Berberine ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
L. MacConell, A. Liberman, A. Flyer, K. Liu, USA, China

709 Ultrasound combined with microbubbles has no therapeutic effect on atherosclerotic plaques of the aorta in diabetic ApoE⁻/⁻ mice
A. Korn, S. Simsek, M. D. Fiet, I. S. Waas, K. Kooiman, H. W. Niessen, P. A. Krijnen, Netherlands
710 SYNCHRONIZE™-CVOT: study design of a phase 3, randomised, event-driven, CV outcome trial of survodutide in adults living with overweight or obesity, and CVD, CKD or with risk factors for CVD
M. N. Kosiborod, S. Wharton, C. Le Roux, E. Platz, M. Brueckmann, A. M. Jastreboff, S. Ajaz Hussain, S. D. Pedersen, A. Unseld, E. Startseva, L. M. Kaplan, on behalf of the SYNCHRONIZE(TM)–CVOT trial committees and investigators, USA, Canada, Ireland, Germany

711 Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
S. Gan, L. Ji, J. Ma, Z. Cheng, N. T. Gunn, G. W. Neff, K. Liu, L. MacConell, China, USA

712 Exploring the mechanism behind the novel FGF1 analogue in treating metabolic syndrome-related conditions in db/db mouse model

Short Oral Event D Wednesday, 14:00 - 15:00

SO 058  SGLT2 inhibition: focus on the heart and the kidneys

713 Long-term maintenance of coronary flow reserve improvement in type 2 diabetes patients after dapagliflozin treatment: results from the 4-years DAPAHEART follow-up study

714 Cardiovascular outcomes with SGLT2 inhibitors in patients with atrial fibrillation and type 2 diabetes
S. Kim, Y. Cho, Y. Suh, D. Seo, Y. Kim, S.-H. Shin, Republic of Korea

715 Cardiovascular, kidney outcomes and mortality by SGLT2 inhibitors in patients with type 2 diabetes undergoing percutaneous coronary intervention
H.-S. Kwon, Republic of Korea

716 Sodium glucose cotransporter-2 inhibitors reduce salt-sensitivity of blood pressure in type 2 diabetes
M. Chiriacò, L. Sacchetta, L. Nesti, N. Cimbalo, L. Santoni, S. Gallo, S. Baldi, D. Tricò, A. Natali, Italy
717 **Empagliflozin limits AKI incidence and severity following cardiac surgery: an open-label phase IV randomised pilot study**

718 **Empagliflozin’s heart shield: unlocking Sirtuins and ncRNA regulators for myocardial infarction recovery**
A. Nowak, Z. Wicik, C. Eyileten, S. Ahmadova, J. Siller-Matula, D. Von Lewinski, H. Sourij, M. Postula, Poland, Austria

719 **The effect of SGLT2-inhibition on the kidney perfusion, diffusion and oxygenation in patients with type 2 diabetes**

720 **Impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy**

### Short Oral Event E  
**Thursday, 12:45 - 13:45**

**SO 059 Pleiotropic effects of SGLT2 inhibition**

721 **Effect of dapagliflozin on serum metabolome in patients with type 2 diabetes**
V. Tsimihodimos, A. Dimou, E. Bairaktari, S. Filippas-Ntekouan, Greece

722 **Effect of sotagliflozin, a dual SGLT 1 and 2 inhibitor, on continuous glucose monitoring in basal insulin-treated type 2 diabetes**
M. Hardin, A. Peters, A. K. Carroll, M. Davies, M. Girard, J. Buse, M. Davies, H. Bajaj, P. Banks, J. Rosenstock, USA, UK, Canada

723 **Glucagon as a potential promoter of sodium-glucose co-transporter 2 induced ketogenesis via effect on lipolysis**
E. Svehlikova, W. Regitting, C. Gatschelhofer, V. Höller, G. Fluhr, B. Lackner, C. Magnes, A. Eberl, T. R. Pieber, Austria

724 **Haematocrit trends and risk of erythrocytosis in persons with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors in real world clinical practice**
A. R. Gosmanov, D. E. Gemoets, USA
725 Characteristics of Sodium Glucose Co-Transporter 2 inhibitor associated diabetic ketoacidosis among hospitalised patients and compared to all hospital prescriptions
N. S. Lau, V. W. Wong, J. H. Lam, Australia

726 Transient elevation of minerals and bone resorption during 48-week treatment with an SGLT2 inhibitor tofogliflozin in people with type 2 diabetes
S. Tokuno, Y. Takeshita, M. Okumura, H. Goto, Y. Nakano, T. Takamura, Japan

727 Empagliflozin increases the probability of higher C-peptide levels during follow-up in patients with type 2 diabetes: a retrospective cohort study
D. Cuevas-Ramos, R. Flores-Cárdenas, F. González-Valdivia, M. A. Gómez-Sámano, P. Almeda-Valdés, S. Rodríguez-Carranza, F. J. Gómez-Pérez, Mexico

728 An alteration of intestinal morphology and sugar transporters by long-term administration of SGLT2 inhibitor

Short Oral Event F Thursday, 14:00 - 15:00

729 Long-term safety of dapagliflozin or saxagliptin in paediatric patients with type 2 diabetes: 104-week follow-up of the phase 3 T2NOW trial
N. Shehadeh, P. Galassetti, N. Iqbal, C. Karlsson, J. Monyak, J. Ostridge, M. Bolin, T. Barrett, Israel, USA, Sweden, UK

730 Effects of triple-hormone receptor agonist retatrutide on lipid profiling in participants with obesity

731 Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes: a systematic review and meta-analysis
E. Rebelos, I. Anastasiou, N. Tentolouris, T. Karagiannis, A. Tsapas, E. Ferrannini, A. Liakos, Greece, Italy

732 Efficacy and safety of HS-20094 in patients with type 2 diabetes: a randomised double-blind, placebo-controlled, phase 2 trial
L. Liu, X. Shi, Z. Cheng, W. Song, Z. Wang, F. He, Y. Cui, J. Zhang, China
733 A phase 2 study of mazdutide 9 mg in Chinese adults with BMI≥30 kg/m²
H. Jiang, L. Ji, Y. Zhang, Z. Cheng, S. Pang, X. Li, W. Qiu, Q. Ma, Z. Liu, Y. Wang, H. Deng, L. Qian, China

734 Mazdutide reduces body weight in adults with overweight or obesity: a multiple-dose study
S. N. Bhattacha, L. Tham, Y. Li, L. Chua, S. Ng, Y. Tang, H. Ibriga, W. Ni, M. K. Thomas, K. J. Mather, USA

735 Optimising use of SGLT2 inhibitors and GLP1 receptor agonists across patients with type 2 diabetes
M. Evans, P. McEwan, V. Foos, R. Jenkins, G. Roberts, M. Jones, J. Chen, UK, USA

736 Phase 1 topline safety, efficacy, and pharmacokinetics of oral ecnoglutide

**Short Oral Event A**

**Tuesday, 12:30 - 13:30**

**SO 061 Novel incretins: focus on kidney, liver and cardiovascular system**

737 Retatrutide, an agonist of GIP, GLP-1 and glucagon receptors, improves lipoprotein biomarkers associated with cardiovascular risk in participants with obesity or overweight

738 Utreglutide (GL0034), a novel GLP-1RA, increases liver FGF-21 and demonstrates significant efficacy on weight loss, HbA₁c, and triglycerides in db/db mice
R. Thennati, V. Burade, M. Natarajan, A. Garcia-Ocaña, G. Rutter, R. E. Pratley, B. Thorens, T. Vilsbøll, India, USA, UK, Canada, Switzerland, Denmark

739 Effects of Orforglipron, a novel oral GLP-1 receptor agonist, on metabolic dysfunction-associated steatotic liver disease related biomarkers
A. Sanyal, R. Loomba, Y. Lin, K. Duffin, J. M. Wilson, H. Banerjee, K. J. Mather, C. Kazda, M. König, USA
740 Orforglipron, an oral GLP-1RA, improves CV risk biomarkers in patients with obesity
K. Mather, S. Wharton, J. Rosenstock, Y. Lin, K. Duffin, J. Wilson, H. Banerjee, C. Kazda, M. Konig, USA, Canada

741 Effect of tirzepatide on kidney parameters in people with excess body weight and type 2 diabetes: a post-hoc analysis of the SURMOUNT-2 trial

742 Glucagon-like peptide-1 receptor agonist exendin-4 improves chronic kidney disease through restoration of lysosomal function and autophagy

743 Effect of retatrutide on kidney parameters in people with type 2 diabetes and/or obesity: a post-hoc analysis of two phase 2 trials

744 Improvement of liver steatosis by mazdutide in Chinese participants with overweight or obesity: an exploratory analysis of GLORY-1
L. Gao, L. Ji, H. Jiang, Y. Zhang, L. Lv, J. Gu, Z. Liu, H. Deng, Y. Wang, L. Qian, China

Short Oral Event B Tuesday, 13:45 - 14:45

SO 062 Hot of the press novel incretins

745 GLP-1 and glucagon receptor agonist mazdutide improves markers of metabolic function in adults with overweight or obesity
L. Tham, S. N. Bhattachar, Y. Li, L. Chua, S. Ng, Y. Tang, H. Ibriga, W. Ni, M. K. Thomas, USA

746 Development of a once-a-month formulation of semaglutide from an innovative injectable and biodegradable hydrogel

747 Efficacy and safety of efsubaglutide alfa as add-on to metformin in patients with type 2 diabetes
Q. Wang, Y. Bao, S. Chen, J. Zhou, D. Anwar, W. Jia, China
748 A multicenter, blinded, placebo-controlled, randomised single- and multiple-ascending dose study of orforglipron, an oral GLP-1 receptor agonist, in Japanese patients with type 2 diabetes
K. Ohwaki, C. Nakamura, R. Nasu, K. Takenouchi, T. Hirase, Japan

749 A phase 1, randomised, double-blind trial of the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral small molecule GSBR-1290 in Japanese and non-Japanese healthy volunteers
B. Coll, L. J. Seman, H. Yue, A. Barth, L. Ibarra, M. Bach, USA

750 WITHDRAWN

751 Safety, tolerability and metabolic effects of once weekly GL0034 (Utreglutide) in individuals with obesity: a multiple ascending dose study
R. Thennati, V. Burade, M. Nagarajan, P. Shahi, R. Nagaraja, S. Agrawal, T. Duvauchelle, A. Garcia-Ocana, G. Rutter, R. E. Pratley, B. Thorens, T. Vilsbøll, India, France, USA, UK, Canada, Switzerland, Denmark

752 WITHDRAWN

Short Oral Event C Wednesday, 12:45 - 13:45

SO 063 More combo’s less insulin!

753 The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Events Reporting System (FAERS) database
I. Caruso, L. Di Gioia, S. Di Molfetta, M. Caporusso, A. Cignarelli, G. Sorice, L. Laviola, F. Giorgino, Italy

754 Tirzepatide as an add-on for participants with inadequate glycaemic control using basal insulin: pooled subgroup analysis of SURPASS-5 and -6
A. Rodriguez, H. Bajaj, L. K. Billings, M. Liu, J. A. Levine, H. Patel, USA, Canada

755 Near-normoglycaemia and insulin regression induced by tirzepatide in basal insulin-treated type 2 diabetes
H. Patel, S. Tofé, C. Wysham, V. T. Thieu, J. Kiljanski, C. Lee, H. Wang, J. Rosenstock, USA, Spain
756 Body weight reduction with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials
L.-E. García-Pérez, A. Chao, R. Taylor, D. Mojdami, T. Forrester, F. Chigutsa, R. Malik, USA

757 Predictors of achieving and sustaining glycaemic control and weight loss with tirzepatide in individuals with type 2 diabetes and increased cardiovascular risk (SURPASS-4)

758 Efficacy and safety of tirzepatide in participants who achieved fasting serum glucose targets at 52 weeks in SURPASS-3 and SURPASS-4
A. Y. Kwan, A. Cheng, J. Green, J. M. Maldonado, M. Liu, R. Silva, USA, Canada

759 Insulin therapy DE-intensificAtion with iGlarLixi: the IDEAL randomised controlled trial
M. Haluzík, L. Thieme, I. Laňková, A. Veselá, E. Záhumenský, T. Edelsberger, M. Löblová, F. Hrubý, M. Mráz, P. Novodvorský, Czech Republic

**Short Oral Event D**  
**Wednesday, 14:00 - 15:00**

**SO 064 Incretins have more effects than you can imagine**

760 Blocking glucagon receptor improves hyperglycaemia to larger extent after bariatric surgery
G. Angelini, S. Russo, A. Gastaldelli, G. Mingrone, M. Salehi, Italy, USA

761 Effects of empagliflozin vs sitagliptin on exercise macronutrient oxidation rates in type 2 diabetes
L. Santoni, L. Nesti, N. Pugliese, S. Frascerra, D. Tricò, M. Chiriacò, L. Sacchetta, S. Baldi, A. Natali, Italy

762 The central vs peripheral mediated effects of liraglutide enhancement on insulin secretion is dependent on the stage of diabetes
763 Corneal nerve loss and regeneration after GLP-1 therapy in children with simple and monogenic obesity

764 Intestinal L-cell timekeepers: roles in GLP-1 secretion in physiology and type 2 diabetes
A. D. Biancolin, C. Dibner, Switzerland

765 Semaglutide normalises increased cardiac myocyte calcium transients in a rat model of high fat diet-induced obesity

766 Elucidation of a new mechanism of action of GLP-1 focusing on pancreatic islet blood flow: investigation by in vivo imaging

767 Organ-on-a-chip recapitulating the gut-islets axis for endocrine hormones secretion regulators evaluation
J. Sun, L. Ling, China

Short Oral Event E Thursday, 12:45 - 13:45

SO 065 Advanced real life in type 1 diabetes

768 Real world experience using advanced closed-loop hybrid systems vs other automated insulin delivery systems for pregnant women with type 1 diabetes
A. Gómez, D. Henao, D. Parra, B. Grassi, M. N. Serrano, M. Rondon, Colombia, Chile,

769 Hybrid closed loop in adolescents and young adults with type 1 diabetes: a real world study
M. Ung, A. Penfornis, C. Amadou-Kerangoarec, J. Eroukhmanoff, France

770 Real-world experience of Omnipod 5 hybrid closed loop system in a UK Diabetes centre
S. Hussain, C. Willis, L. Anthony, J. Pichierri, C. Hume, M. Ford-Adams, R. Amin, R. Abraham, P. Choudhary, S. Greene, UK
771 Open-label, descriptive, sequential study in type 1 diabetes patients to evaluate the Mylife™-Dose app with ISCI and compare it to a hybrid continuous insulin infusion system (CamAPS): Dose Human Loop study

772 Switch of open-source automated insulin delivery system - AndroidAPS to commercially available AID systems in type 1 diabetes: the extension of the CODIAC study
D. Q. Do, A. Hásková, L. Radovnická, E. Horová, J. Konecná, G. Grunberger, C. Parkin, M. Prazny, J. Šoupal, Czech Republic, USA

773 Characteristics associated with decreased time in range in people with type 1 diabetes using automated insulin delivery systems
R. Bem, D. Vávra, M. Kahle, M. Dubsky, M. Haluzik, Czech Republic

774 Use of an advance hybrid closed loop system during marathon running: case series and clinical implications
M. T. Onetto, B. Grassi, D. Montt, C. Berget, K. Strodthoff, Chile, USA

775 GLP-1 receptor agonist effects in people with type 2 diabetes using MiniMed™ advanced hybrid closed-loop therapy
J. J. Shin, A. S. Rhinehart, A. Keiter, H. Ma, T. L. Cordero, R. A. Vigersky, IMPACT2 Study Group, USA

Short Oral Event F Thursday, 14:00 - 15:00

SO 066 Pumping without bumping

776 Insulin pump therapy in type 1 diabetes: a real-world study of mortality and clinical outcomes
A. Iqbal, S. Haughton, D. Riley, M. F. Arshad, S. Azmi, R. A. Malik, U. Alam, UK, Qatar

777 Efficacy and safety of the Omnipod 5 System compared with insulin pump therapy in adults with type 1 diabetes: sub-analysis of French participants in a randomised controlled trial
A. Penfornis, E. Renard, R. S. Weinstock, J.-P. Riveline, C. Thivolet, T. T. Ly, The OP5-003 Research Group, France, USA
778 HbA₁c outcomes across gender, ethnicity, deprivation and age with hybrid-closed loop in the association of British clinical diabetologist’s audit of the NHS England pilot

779 Management of prolonged aerobic exercise in people with type 1 diabetes on hybrid closed-loop systems: a randomised controlled study
A. Corrado, G. Scidà, J. Abuqwider, L. Bozzetto, G. Annuzzi, Italy

780 Simplified meal announcement in adolescents with type 1 diabetes using the MiniMed 780G: 18-month follow-up analysis
G. Petrovski, J. Campbell, M. Pasha, K. Hussain, Sidra Diabetes Group, Qatar

781 Postprandial insulin strategy for improving glycaemic control after a missed meal bolus in persons with type 1 diabetes users of the Advanced Hybrid Closed Loop (AHCL) Minimed 780G™ system
B. A. Grassi, M. Onetto, G. Mora, N. Tapia, M. Castro, N. Kurtz, R. Vigersky, O. Cohen, Chile, USA, Switzerland

782 Real-world performance of the MiniMed™ 780G safe meal bolus feature

783 Clinical and economic impact of lifelong use of AID by different patient patient groups from the Swedish health care perspective
J. Jendle, M. Syleouni, G. Brusaferri, A. Khan Miron, Sweden, Switzerland

**Short Oral Event A**

**SO 067 Breaking away with tradition or how to give insulin differently**

784 Efficacy and safety of once-weekly insulin icodect vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5
A. Y. Cheng, P. Rossing, M. Benamar, C. Laugesen, P. H. Nielsen, H. S. Bajaj, Canada, Denmark
785 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5  
I. Lingvay, K. O. Bangsgaard, C. Desouza, M. Fragao-Marques, A. Navarria, A. Vianna, USA, Denmark, Brazil

786 Impact of age on the efficacy and safety of once-weekly insulin icodec vs once-daily insulin in type 2 diabetes: ONWARDS 1-5  
A. G. Vianna, C. Desouza, C. Laugesen, M. Fragao-Marques, P. H. Nielsen, S. Shaikh, I. Lingvay, Brazil, USA, Denmark, India

787 No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes: ONWARDS 1-5  
M. C. Riddell, S. Heller, M. Asong, L. Carstensen, S. Kehlet Watt, V. C. Woo, Canada, UK, Denmark

788 Pharmacokinetic and pharmacodynamic properties of a novel once-weekly insulin analogue GZR4 in people with type 2 diabetes  
X. Wang, F. Guo, C. Tang, C. Huang, C. Hao, J. Zhao, A. He, T. Xie, Y. Li, W. Chen, Z.-R. Gan, China

789 Evaluation of the pharmacokinetic profile of insulin efsitora alfa (efsitora) administered subcutaneously at different injection sites  
J. Leohr, S. Suriyapperuma, A. Ghosh, D. Waters, T. Fukuda, USA

790 Efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drug(s): the SoliD randomised controlled trial  
Y. Li, W. Gu, L. Chen, H. Kuang, J. Du, A. Alvarez, F. Lauand, E. Souhami, J. Zhang, W. Xu, Q. Du, Y. Mu, M. Liu, China, Spain, France

791 Soli-switch: efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes  
M. Haluzík, S. Lim, K. Cypryk, A. Alvarez, F. Lauand, V. Corp-dit-Genti, O. S. Bakiner, Czech Republic, Republic of Korea, Poland, France, Turkey
Short Oral Event B  
TUESDAY, 13:45 - 14:45

**SO 068 Playing with food intake and energy expenditure**

792 Duodenal jejunal bypass liner treatment for type 2 diabetes and obesity: comparison between 9 and 12 months implantation using data from a worldwide registry
R. E. Ryder, R. Lopez-Gonzalez, C. Lazzara, J. P. Gebelli, L. Munro, H. Frydenberg, J. Stein, T. Battelino, S. Fishman, J. Byrne, C. De Jonge, J.-W. Greve, R. Cohen, M. Yadagiri, P. Sen Gupta, UK, Spain, Australia, Germany, Slovenia, Israel, Netherlands, Brazil

793 Recurrent postprandial hypoglycaemia after gastric bypass impairs hypoglycaemia awareness and dietary habits in type 2 diabetes

794 Experience of bariatric surgery in patients living with type 1 diabetes
A. Soghomonian, P. Darmon, E. Disse, A. Dutour, France

795 Advancing individualised treatment and data-driven healthcare management: benefits of the national Danish diabetes digital PROMS-tool
N. Ejskjaer, Presented on behalf of the VBS-PRO-DIA Research Team (VBHC-PROMS-DIABETES) Aalborg, Denmark, Denmark

796 Evaluating the impact of a digital twin intervention on type 2 diabetes remission at 18 months: a cluster-specific analysis
S. Joshi, M. Dharmalingam, A. Vadavi, A. Keshavamurthy, S. Bhonsley, M. Thajudeen, A. Balasubramanian, P. Shamanna, India

797 Gender based impact of personalised coaching in diabetes management through sugarfit’s diabetes reversal and management programme
C. Mehra, A. Mattilda Raymond, S. Kumar, A. Sequeira, S. Mehra, India, USA

798 Demographic differences in adherence to physical activity and screen time recommendations among youth: insights from NHANES 2017-2018
A. Mokari-Yamchi, K. Brazendale, A. Faghfouri, S. Gheibi, Iran, Islamic Republic of, USA
799 Further phenotyping of eating disorders and diabulimia is required in persons living with type 1 diabetes: results from SFDT1, a French national cohort

Short Oral Event C  Wednesday, 12:45 - 13:45

SO 069 HbA1c vs CGM: a tie break?

800 Predictors of discordance between CGM and HbA1c: lower haemoglobin glycation is associated with a higher risk of proliferative diabetic retinopathy

801 The link between age, sex, fasting plasma glucose and glycated haemoglobin (HbA1c)

802 Analytical performance of 10 HbA1c point-of-care devices in a comparative evaluation study
P. Singh, B. Vetter, E. Lenters-Westra, Switzerland, Netherlands

803 The combined effect of CGM with anti-diabetes medications and the association with improved HbA1c in people with type 2 diabetes not on insulin
P. Nemlekar, K. Hannah, G. J. Norman, USA

804 Average glucose and HbA1c display a nonlinear and variable relationship: implications for clinical practice
Y. Xu, T. Dunn, R. Bergenstal, R. Ajjan, USA, UK

805 Personalised adjustment to improve accuracy of HbA1c at reflecting hyperglycaemic exposure in different racial groups: a prospective clinical study
P. Choudhary, T. Dunn, Y. Xu, R. Ajjan, UK, USA

806 Feasibility of calibration-free intradermal glucose monitoring using a sensor microarray
M. Christiansen, N. Bhavaraju, S. Sattayasamitsathit, A. Campbell, R. Gottlieb, A. VandenBerg, K. Nogueira, M. Brister, R. Yang, J. Tangney, USA
Short Oral Event D       Wednesday, 14:00 - 15:00

**SO 070 De-combining CGM and insulin in type 2 diabetes**

807 Association of educational level with clinical presentation and pharmacological treatment in 10,020 individuals with recently diagnosed type 2 diabetes

808 Insulin therapy de-intensification with iGlarLixi (IDEAL) randomised controlled trial: CGM-related outcomes

809 Efficacy and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy
A. Cheng, D. Mauricio, R. Ritzel, M. E. Al-Sofiani, T. Bailey, M. Mabunay, M. Bonnemaire, M.-M. Lydie, S. Mimouni, M. Davies, Canada, Spain, Germany, Saudi Arabia, USA, Singapore, France, Algeria, UK

810 Cost-effectiveness of Dexcom real-time continuous glucose monitoring vs self-monitoring of blood glucose in patients with type 2 diabetes on intensive insulin therapy in Estonia
S. Ilham, H. Alshannaq, G. J. Norman, USA

811 Frontier - Freestyle Libre use in Ontario among patients with type 2 diabetes in the IC/ES database - evidence from real-world practice: patients aged ≥66 years on basal insulin ± GLP-1 RA
S. Harris, Y. Poon, R. Rabasa-Lhoret, A. Ratzki-Leewing, Canada

812 A prospective cohort study with continuous glucose monitoring and education in type 2 diabetes and prediabetes

813 Association of CGM use with glycaemic outcomes for people with type 2 diabetes: a multi-centre observational longitudinal study
O. Ebekozien, A. Mungmode, O. Odugbesan, M. Basina, S. Tsai, R. Weinstock, USA
814 Long-term improvement in Time In Range and Time in Tight Range with Dexcom CGM use in adults with type 2 diabetes not treated with insulin: real-world data
J. E. Layne, L. Jepson, A. Carite, R. Bergenstal, USA

**Short Oral Event E**

**Thursday, 12:45 - 13:45**

**SO 071 How universal can CGM be?**

815 Hypoglycaemia measured by continuous glucose monitoring in people with insulin-treated type 2 diabetes and chronic kidney disease: post hoc analysis from the HypoMETRICS study

816 Continuous glucose monitoring improves postoperative glucose control in liver transplant recipients with diabetes
M. Mraz, B. Hagerf, M. Protus, L. Nemetova, J. Franekova, V. Svirlochova, P. Girman, E. Kieslichova, M. Haluzik, A. Jabor, Czech Republic

817 Effectiveness of real-time continuous glucose monitoring (Dexcom G6) among cardiac surgery patients: a randomised controlled trial

818 Prospective observational study of real-time continuous glucose monitoring in non-ICU hospitalised people with diabetes
L. Rakotoarisoa, L. Meyer, F. Fall-Mostaine, L. Sluzarek, L. Kessler, France

819 Association of glucose management index with adverse pregnancy outcomes in pregnancies with type 1 diabetes
P. Ling, D. Yang, C. Wang, X. Zheng, S. Luo, H. Deng, X. Yang, W. Xu, J. Yan, J. Weng, China

820 Advanced hybrid closed loop compared to standard insulin therapy in type 1 diabetes during delivery and early postpartum
821 Time in range greater than 60% from the second trimester reduces adverse foetal outcomes in pregnant women diagnosed with type 1 diabetes using automated insulin delivery systems
A. Gómez, D. Henao, B. Grassi, O. Muñoz, M. Rondon, M. García, F. Leon, J. Gómez, M. N. Serrano, Colombia, Chile

822 Health-related quality of life and burden of type 1 diabetes and severe hypoglycaemia in adult continuous glucose monitor users

**Short Oral Event F**

**SO 072 The future of diabetes science is here**

823 Development of highly accurate measurement method of salivary glycated albumin by HPLC
M. Aihara, N. Kubota, T. Yamauchi, Japan

824 Performance data of the first algorithm developed for the BOYDSense breath-based glucose estimation device

825 A gut on a chip platform to monitor GLP-1 secretion dynamics from primary intestinal tissue
W. Huang, C. Xie, C. Xiang, T. Li, R. L. Young, J. Zhao, H. Ebendorff-Heidepriem, C. K. Rayner, T. Wu, Australia

826 Brain functional reorganisation differs in patients with type 1 or type 2 diabetes
W. YuFan, F. Fang, China

827 Risk modelling for personalised screening interval recommendations for diabetic foot and retinopathy: a retrospective cohort study
W. T. Banas, C. A. Sainsbury, A. Manataki, S. Mercer, S. Cunningham, D. J. Wake, UK

828 Evaluation of the potential of LLM-based generative AIs in nutrition education: a comparative study of ChatGPT and Bing for Japanese registered dietitian licensure exam preparation
M. Kosai, Y. Nagamori, Y. Kawai, H. Marumo, M. Shibuya, T. Negishi, A. Sawai, L. Miyamoto, Japan
829 Bridging structured and unstructured data using natural language processing: insights from a French diabetic cohort (CODIA) in a multicentre clinical data warehouse

830 Performance of a safety protocol for scuba diving in type 1 diabetic people: the 20-year experience of Diabete Sommerso®
E. Gamarra, G. Careddu, A. Fazi, V. Turra, A. Morelli, E. Cimino, P. Di Bartolo, C. Camponovo, P. Trimboli, U. Valentini, M. Bonomo, Switzerland, Italy

Short Oral Event A Tuesday, 12:30 - 13:30

SO 073 Diabetes technology - but at a higher level
831 Efficacy of an image-based automated food analysis app in AID users with type 1 diabetes on glucose control: a randomised controlled trial
C. Piazza, L. Kastrati, C. Nakas, D. Herzig, L. Bally, Switzerland, Greece

832 Identification of missed mealtime insulin in type 1 diabetes using connected insulin pens
E. Dassau, H. Wolpert, J. Xue, C. Chen, M. Davidson, A. Boss, J. Johnson, USA

833 Real-world bolus dose timing and glycaemic impact using the Tempo Platform
J. Johnson, J. Xue, D. Duke, M. Davidson, E. Dassau, USA

834 Continuous glucose monitoring in patients with diabetes type 3c: breaking the myth of “labile diabetes”

835 Evaluating a state-of-the-art generative pre-trained transformer model to predict continuous glucose monitoring values at different time intervals
M. E. Shomali, J. Luo, A. Kumbara, A. Iyer, G. Gao, USA
836 Simulated commercial flights and the effects of atmospheric pressure changes on insulin pump delivery  

837 The Hypo-METRICS app: a quantitative assessment of user experience  

838 Relationship of diabetes technology use with prognosis in people with type 1 diabetes awaiting islet or simultaneous islet kidney transplantation  
A. Thant, P. Aung, L. Birtles, M. Greenwood-Morgan, M. Rutter, D. Van Dellen, H. Khambalia, S. Azmi, UK

**Short Oral Event B**  
**Tuesday, 13:45 - 14:45**

**SO 074 It is very hard to beat the system - or is it?**

839 Real-world evidence of healthcare utilisation and costs for type 1 diabetes in Germany: analysis of a statutory health insurance database  
R. Ziegler, Q. Zhang, P. Callahan, C. Vetter, E. Garal-Pantaler, A. De Remigis, L. Chen, W. Rathmann, Germany, USA

840 Implications of healthcare system failures faced by people with diabetes in the United Kingdom  
S. Chanen, T. Bell, P. De Piante, R. Wood, USA

841 Closer collaboration between laboratories and general practices can improve diabetes monitoring and outcomes: effect of a real world trial in UK primary care  

842 Evaluating the effectiveness of same-day screening programme at Steno Diabetes Center north Denmark  
A. Nikontovic, T. Schou Andersen, N. Kragh Madsen, H. Ravn Larsen, D. Juhl Hansen, P. Vestergaard, P. Kronholm, Denmark
843 Detecting unmet psycho-social needs in adult persons with diabetes, first data from our national Danish diabetes PROMS questionnaire (DiaProfil)
A. Nikontovic, L. Nørgaard, L. Havbæk Troelsen, N. Ejskjaer, Denmark

844 Impact of diabetes disease management programme on mortality, hospitalisations, and emergency room visits: a retrospective cohort study
R. Mužik, M. Selvek, B. Saal, I. Tkáč, Slovakia

845 Socioeconomic status and diabetes impact mortality disparities across high income countries: a multinational population-based study

846 Effectiveness and safety of telemonitoring compared with usual care in people with type 2 diabetes treated with insulin: preliminary results from a national multicentre randomised controlled trial
S. Hangaard, T. Kronborg, S. Cohen, A. Kofoed-Enevoldsen2, M. Rasmussen, L. Pedersen, C. Thomsen, T. Aradóttir, S. Kristensen, A. Kaas, H. Bengtsson, C. Dethlefsen, O. Hejlesen, P. Vestergaard, M. Jensen, Denmark, USA

Short Oral Event C Wednesday, 12:45 - 13:45

SO 075 A lesson in diabetes geography
847 The state of carbohydrate metabolism in residents of the de-occupied territories of the Kyiv region
O. Dobrovynska, V. Orlenko, K. Ivaskiva, M. Tronko, Ukraine

848 Switching from sensor augmented pump therapy to mylife CamAPS FX system in a Spanish adult population with type 1 diabetes: impact on glycaemic control and perceived satisfaction
A. Flores Paños, L. Sanchez Canovas, R. Antonio Javier, I. Martin Perez, P. Villalba Armario, L. Marin Martinez, M. Alvarez Martin, A. Pastor Alcaraz, E. Hernandez Alonso, G. Kyriakos, Spain

849 Longitudinal assessment of quality of care in adults with type 1 diabetes in Italy: data from a large, long-term observational cohort
G. Russo, R. Candido, S. De Cosmo, P. Di Bartolo, G. Di Cianni, G. Lucisano, V. Manicardi, A. Nicolucci, A. Rocca, M. Rossi, D. Cucinotta, AMD Annals Study Group, Italy,
850 Glycaemic control is not affected by season in MiniMed 780G system users: a real world study from Italy

851 Real world performance comparison of three hybrid closed loop systems in a semi-rural Welsh cohort
A. Mallipedhi, M. Saeed, A. Zulifiqar, S. Malik, S. Fatima, UK

852 Long-term real-world outcomes of hybrid closed-loop therapy in adults with type 1 diabetes in the UK

853 Elevated type 1 diabetes prevalence in the Faroe Islands: exploring glycaemic management by insulin pump use in a unique remote population
H. Johannesen, M. Petersen, B. Joensen, P. Rasmussen, J. Andreassen, Faroe Islands

854 Impact of mental disorders on the all-cause mortality and cardiovascular disease outcomes in adults with new-onset type 1 diabetes: a nationwide cohort study
S. Kim, G. Kim, S. Cho, R. Oh, J. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, Republic of Korea

**Short Oral Event D**  
**Wednesday, 14:00 - 15:00**

**SO 076 Up or down and back**

855 The suboptimal management of 541 episodes of severe hypoglycaemia underscores the need for improved services: pilot data from the DEKODE hypoglycaemia study

856 Characteristics of nocturnal hypoglycaemic events and their impact on glycaemia in people with type 1 diabetes
M. Eichenlaub, S. Öter, D. Waldenmaier, B. Kulzer, L. Heinemann, R. Ziegler, O. Schnell, T. Glatzer, G. Freckmann, Germany

857 Investigating the impact of symptomatic and asymptomatic hypoglycaemia on heart rate: an analysis of the HypoMetrics dataset
J. J. Thomas, H. Hadid, V. Koutroukas, G. Martine-Edith, P. Choudhary, Hypo-METRICS Consortium, UK
858 Misclassification matters: implementing a clinical prediction model in electronic health records to identify individuals with misclassified diabetes and increased hypoglycaemia and DKA risk
K. G. Young, R. Hopkins, J. Dennis, N. Qureshi, A. Jones, B. Shields, UK

859 Severe hypoglycaemia and diabetic ketoacidosis presenting to a hospital emergency department: young-onset type 2 diabetes has poorer prognosis than type 1 diabetes
S. H. Song, B. M. Frier, UK

860 Clinical presentation and outcomes of DKA in adults with type 1 diabetes on continuous subcutaneous insulin infusion vs multiple daily injection: results from the DEKODE-DKA study
P. Kempegowda, A. Sharma, L. Rengarajan, R. Thayakaran, P. Narendran, K. Dhatariya, DEKODE-DKA working group, UK

861 Diabetic ketoacidosis guidelines have been poorly adopted and implemented in the UK, with an associated lack of improvement in outcomes
A. Buchipudi, A. Sharma, L. Rengarajan, P. Narendran, K. Dhatariya, P. Kempegowda, DEKODE Working Group, UK

862 Aggressive descending mode during short-term intensive insulin therapy achieved better glycaemic control with shorter length of hospital stay in newly diagnosed patients with type 2 diabetes
X. Zhang, X. Huang, Y. Cao, Z. Zhang, Y. Li, Z. Huang, China

Short Oral Event E Thursday, 12:45 - 13:45

SO 077 Continuous monitoring of CGM
863 Population-based study on the implementation of continuous glucose monitoring and severe hypoglycaemia in adults with type 1 diabetes
P. Rodríguez de Vera Gómez, E. Mayoral, R. Ravé García, M. De la Cal Ramírez, G. Umpierrez, M. Martínez-Brocca, Spain, USA

864 Disparities in initiation of continuous glucose monitoring and impact on glycaemic control in children and adolescents with type 1 diabetes
M. K. Borbjerg, A. Kvist, K. M. Mehta, N. Ejskjaer, J. C. Wong, Denmark, USA
865 CGM sensor glucose metrics pre- and post-automated insulin delivery use among adults in the T1D Exchange Online Registry

866 Efficacy of real-time continuous glucose monitoring in adults with diabetic ketoacidosis
M. M. Bogun, C. Wang, P. A. Kurlansky, N. Badeir, G. E. Umpierrez, USA

867 Glucose monitoring profiles in professional football players without diabetes: match analysis and comparison with an active population
K. Skroce, A. Zignoli, N. Mihic, D. Lipman, M. Riddell, H. C. Zisser, Croatia, Italy, Spain, USA, Canada

868 Differences in sensor glucose progression from level 1 to level 2 based on hypoglycaemia awareness, in type 1 and insulin-treated type 2 diabetes: Hypo-METRICS study

869 Insights from two weeks of isCGM usage among individuals with non-insulin treated type 2 diabetes
T. Thybo, E. Nielsen, N. Cayuelas i Mateu, A.-M. Wegener, Denmark

870 Real world evaluation of people with type 2 diabetes with a 180-day implantable CGM system
B. Romarowski, K. Tweden, C. E. Mdingi, F. R. Kaufman, USA

Short Oral Event F Thursday, 14:00 - 15:00

SO 078 More stress on distress

871 Suicide risk comparison among adults with type 1 diabetes, cancer, and the general population: a nationwide cohort study
S. Kim, J. Kim, G. Kim, Republic of Korea

872 Assessment of quality of life, psychological parameters and glycaemic variability in type 1 patients: a real-life experience
E. Resmini, A. V. Cornaghi, V. Turra, G. Massari, S. Dotti, E. Cimino, E. Zarra, M. Sandri, A. Girelli, Italy
873 Prevalence and incidence of elevated diabetes distress and depressive symptoms at 6, 12 and 18-months in people with diabetes: a cox-regression analysis
D. Ehrmann, G. Lehmann, B. Olesen, L.-S. Priesterroth, T. Roos, T. Haak, N. Hermanns, B. Kulzer, Germany

874 Resting-state neuronal communication, but not cortical structure, is associated with increased diabetes distress in adult type 1 diabetes
E. Van Duinkerken, R. G. IJzerman, M. Demuru, M. Klein, F. Barkhof, A. Hillebrand, F. J. Snoek, Netherlands, UK

875 Anxiety and depressive symptoms of type 1 diabetes and severe hypoglycaemia in adult continuous glucose monitor users

876 Can AID systems reduce diabetes-related stress?
B. Kulzer, D. Ehrmann, L. Heinemann, G. Faber-Heinemann, T. Roos, M. Resl, J. Mader, P. Diem, C. Truempy, D. Brandt, N. Hermanns, Germany, Austria, Switzerland

877 Can psychological situation determine advanced hybrid closed-loop system outcomes?
P. Beato Vibora, E. Gil-Poch, F. J. Arroyo-Díez, Spain

878 Associations between sleep patterns and glucose homeostasis in subjects at risk of type 2 diabetes
A. Dardano, G. Daniele, F. Orsolini, U. Faraguna, S. Bruno, G. Giovannini, V. Sancho Bornez, S. Del Prato, Italy

Short Oral Event A Tuesday, 12:30 - 13:30

SO 079 From microbiology to MRI in diabetic foot disease

879 A cluster analysis for stratifying diabetic foot ulcers at baseline: Are those associated with ulcer healing and patient outcome?
R. Naemi, Z. Abbas, UK, Tanzania, United Republic of

880 Survival analysis of diabetic foot ulcer patients: a multicenter cohort study integrating structured and unstructured data from a clinical data warehouse
881 Time in range is closely related to healing time of diabetic foot ulcers
Á. Ortiz Zúñiga, J. Samaniego, F. Cuadra Espinilla, M. Sánchez Bartres, O. Simó Servat, R. Simo, C. Hernández Pascual, Spain

882 Concordance of molecular microbiology and traditional culture techniques for infected diabetic foot ulcer management

883 The use of follow-up MRI in monitoring Charcot Foot and its association with total contact cast treatment duration and long-term outcomes
J. Schoug, E. Uddman, P. Katzman, M. Löndahl, Sweden

884 Hypoxia preconditioned plasma accelerates diabetic wound healing by promoting angiogenesis via increasing growth factors expression
G. Zhou, M. Tao, J. Zhu, S. Li, L. Zhang, China, USA

885 The conjuring of anemia and multidrug resistant bacteria against healing chances in diabetic foot patients
F. Giangreco, E. Iacopi, M. Pogliaghi, A. Leonildi, L. Pieruzzi, S. Barnini, C. Goretti, M. Falcone, A. Piaggesi, Italy

886 Is systematic screening for diabetes effective in reducing perioperative infections in patients undergoing cardiac surgery? The DOCS study
A. Mattina, M. Giusti, E. Conoscenti, M. Morsolini, G. Raffa, A. Mularoni, M. Fazzina, D. Di Carlo, M. Cipriani, F. Musumeci, A. Arcadipane, M. Pilato, P. Conaldi, D. Bellavia, Italy

Short Oral Event B  Tuesday, 13:45 - 14:45

SO 080 Diabetic kidney disease: clinical insights from childhood to frailty

887 Raised prevalence of mental health illnesses and non-white ethnicity in young people with type 2 diabetes and early stage diabetic kidney disease
M. Allen-Taylor, C. Doherty, A. Hodgkinson, A. Rickford, M. Chamley, J. Karalliedde, UK
888 Effect of omega-3 fatty acids supplementation on renal glomerular and tubular integrity and subclinical atherosclerosis in adolescents with type 1 diabetes: a randomised controlled trial
E. Abdelrahman Ismail, S. Abdelaal Mohamed1, N. Elbarbary, Egypt

889 Associations between peripheral augmentation index and renal function decline in adults with type 1 diabetes from the REMOVAL study

890 Cardiac autonomic neuropathy: an independent risk factor for renal decline in diabetic kidney disease
K. Soe, E. J. Robinson, M. A. Oleolo, S. Tesfaye, J. Marques, S. Sourbron, D. Selvarajah, UK, Brazil

891 Decline in kidney function over time in childhood-onset type 1 diabetes

892 Efficacy and safety of finerenone in patients with CKD and type 2 diabetes across the frailty spectrum: a FIDELITY post hoc analysis
P. Rossing, A. Birkenfeld, P. Fioretto, J. B. McGill, S. D. Anker, B. Pitt, A. Scalise, C. Scott, G. Filippatos, Denmark, Germany, Italy, USA, Poland, Spain, UK, Greece

893 Impact of specialised diabetic team intervention on hospitalised patients with type 2 diabetes undergoing kidney transplant
P. Gil, J. Amigó, F. Cuadra, Á. Ortiz Zúñiga, M. Sánchez Bartres, J. García-Arabehety, C. Hernández Pascual, R. Simo, O. Simo-Servat, Spain

**Short Oral Event C**

**Wednesday, 12:45 - 13:45**

**SO 081 Advances in diabetic kidney disease from cells to histology**

894 Histological findings predict kidney failure in diabetes: a retrospective cohort study
K. H. Jensen, M. Blond, F. Persson, I. Bressendorff, D. Hansen, M. Møller, P. Rossing, R. Borg, Denmark

895 circ_0054633 knockdown suppresses hyperglycaemia induced extracellular matrix accumulation in renal mesangial cell by regulating the miR-136-5p/SMAD3 signalling
Q. Jiang, X. W. Zhu, L. Xu, W. Tang, China
896 Nrf2 activation attenuates diabetic kidney disease in preclinical in vitro and in vivo mouse model

897 Plasma fatty acid binding protein 1 and diabetic kidney disease in subjects with type 2 diabetes
M. Giambalvo, D. Lucchesi, M. Capobianco, G. Mancini, S. Del Prato, P. Marchetti, G. Penno, M. Garofolo, Italy

898 The relationship of phenyl sulfate and other factors with renal function status in patients with type 2 diabetes

899 Activation of Hippo pathway alleviates kidney injury in type 2 diabetic mice
Y. Wang, L. Wang, Y. Huang, China, Hong Kong

900 Fibroblast growth factor 23 and diabetic kidney disease phenotypes in type 2 diabetes

901 Urinary cell-free DNA for liquid biopsy in diabetic kidney disease
Y. Liu, W. Li, D. Xie, Y. Chen, X. Wang, China

**Short Oral Event D**

**Wednesday, 14:00 - 15:00**

**SO 082 Predicting and treating renal complications. What’s new in 2024?**

902 Correlation between triglyceride-glucose index and diabetic kidney disease risk in adults with type 1 diabetes
M. Lei, P. Ling, Y. Zhou, J. Lv, Y. Ni, H. Deng, C. Wang, D. Yang, X. Yang, W. Xu, J. Yan, China

903 Length of telomeres in patients with type 2 diabetes with and without chronic kidney disease
Y. Rebrova, Y. Saienko, O. Monashnenko, D. Krasnienkov, V. Korcheva, O. Kot, B. Mankovsky, Ukraine

904 Treating chronic kidney disease with and without diabetes in Danish primary care: results from the Observational ATLAS study
R. Borg, M. K. Lindhardt, T. Saxild, M. Charles, S. Knudsen, Denmark
905 Cystatin C seems to be superior to homocysteine as reliable markers of early diabetic nephropathy
S. Ljubic, A. Jazbec, I. Cudina, M. Tomic, T. Bulum, D. Rahelic, Croatia, Denmark

906 Study of endothelial glycocalyx and vascular function in patients with type 2 diabetes and albuminuria after administration of dulaglutide and dapagliflozin vs DPP-4 inhibitors

907 Effects of the launches of GLP-1 RA and SGLT2i and calendar year on yearly change in eGFR: results from an analysis of 48,363 person-years
S. Katoh, Y. Watanabe, K. Yokoyama, Y. Sakamoto, K. Utsunomiya, R. Nishimura, Japan

908 Association between leisure time physical activity and of risk of end-stage renal disease in people with type 2 diabetes
Y.-J. Lai, Y.-F. Yen, P.-W. Ku, L.-J. Chen, Taiwan

909 Outcomes for MACE, MARE, and mortality in diabetes subgroups with chronic kidney disease
R. Schürfeld, A. Kühnapfel, E. Baratashvili, A. Bachmann, J. Beige, R. Wendt, M. Blüher, M. Stumvoll, A. Tönjes, T. Ebert, Germany

Short Oral Event E

Thursday, 12:45 - 13:45

SO 083 The four M’s of microvascular complications: MRI, Mitochondria, Models, and iMaging
910 Quantitative multi-organ imaging stratifies high risk individuals, with cardiac and abdominal phenotypes in individuals with diabetic retinopathy

911 New insights into the pathogenesis of diabetic kidney disease (DKD): human amylin aggregates as a potential factor in the development of DKD
912 Construction of a prediction model for non-proliferative retinopathy in type 2 diabetes
Y. Liu, C. Wang, J. Qiao, Y. Li, D. Lv, L. Li, Y. Wang, the China National Diabetic Chronic Complications Study Group, China

913 Prevalence of diabetic retinopathy in people with type 2 diabetes and fast progression of kidney function
T. Alobaid, J. Karalliedde, M. O’Connell, S. Ayis, UK

914 Total and trunk body fat are associated with chronic kidney disease progression in type 2 diabetes patients: a prospective study

915 Mitochondrial DNA copy number in patients with type 2 diabetes and chronic kidney disease
Y. Saienko, Y. Rebrova, O. Monashnenko, D. Krasnienkov, V. Korcheva, B. Mankovsky, Ukraine

916 Relationship between serum regenerating protein Iα and estimated glomerular filtration rate decline slope in diabetic kidney disease: a single-centre cohort study
S. Chen, N. Huang, L. Li, China

917 Retinopathy associates with volume loss in the secondary visual cortex in individuals with type 1 diabetes

Short Oral Event F Thursday, 14:00 - 15:00

SO 084 Mechanisms and treatment for microvascular complications; nerves, eyes, and blood vessels

918 Onset and progression of hypertension in diabetes patients: a ten year follow up study applying Markov multistate modelling
P. Goswami, D. T R, A. Kulkarni, Y. Shejul, India

919 The role and mechanism of peripheral angiotensin II type 2 receptor in diabetic neuropathic pain
B. Lu, Y. Bai, China
920 Topical administration of sitagliptin prevents diabetic retinopathy-like lesions in a new non-diabetic experimental model, the TRPV2+/– rat
H. Ramos, J. Augustine, B. M. Karan, C. Hernández, A. W. Stitt, T. M. Curtis, R. Simó, Spain, UK

921 The dual amylin and calcitonin receptor agonist KBP-336 relieves neuropathic pain and improves glucose control in ZDF rats with obesity and diabetes
K. Mohamed, A. Larsen, M. A. Karsdal, K. Henriksen, Denmark, Switzerland

922 Autonomic heart function in prediabetes and type 2 diabetes associates to immune activation
S. B. Haugaard, R. Hadad, A. V. Hviid, O. Wendelboe, A. Sajadieh, Denmark

923 Corneal nerve loss and regeneration after GLP-1 therapy in adults with simple and monogenic obesity
H. Gad, E. Elgassim, I. N. Petropoulos, G. Ponirakis, K. Hussain, T. Elhadd, K. Baagar, R. A. Malik, Qatar, UK

924 Plasma levels of 18β-glycyrrhetinic acid in patients with newly diagnosed type 2 diabetes and its association with blood pressure and blood pressure lowering treatment

Short Oral Event A Tuesday, 12:30 - 13:30

SO 085 Clinical data and emerging markers in diabetic foot disease and neuropathy

925 Prediction of mortality in patients with diabetic foot ulcers based on machine learning
R. Li, H. Zhu, China

926 Thyroid hormone sensitivity index is associated with diabetic peripheral neuropathy in euthyroid patients with type 2 diabetes
W. Wang, Y. Chen, A. Jiang, L. Zhang, China

927 Uncovering the burden: underdiagnosis and undertreatment of diabetic peripheral neuropathy in the northern Danish region
J. Roeikjer, A.-M. Wegeberg, A. Nikontovic, C. Brock, P. Vestergaard, Denmark
928 Metabolic decompensation correlates with worse outcomes in diabetic foot patients
F. Giangreco, E. Iacopi, L. Pieruzzi, C. Goretti, A. Piaggesi, Italy

929 Leveraging artificial intelligence for predicting placebo vs treatment response in painful diabetic neuropathy

930 CODIFI2: randomised controlled trial to compare clinical and cost-effectiveness of swabs vs tissue samples to inform management of infected diabetic foot ulcers

**Short Oral Event B**

**SO 086 Novel markers and predictors for neuropathy in diabetes**

931 Exploring neuroinflammation in diabetic patients: a retrospective analysis of brain imaging data
A. Prakash, S. Ahsan, M. Kumar, India

932 Validation of the histamine-induced axon-reflex flare response in a non-selected population of people with type 1 diabetes
J. Roeikjer, P. Tind, A. Larsen, M. K. Borbjerg, C. D. Mørch, N. Ejskjaer, Denmark

933 Exploring biomarkers for diabetes neuropathy through comprehensive serum proteome analysis

934 Increased advanced glycation end products measured by skin autofluorescence are associated with diminished sciatic nerve structural integrity in type 2 diabetes
935 Attenuation of niacin-induced skin flushing response: a potential clinical adjunctive diagnostic instrument for diabetic peripheral neuropathy
T. Jiang, F. LIU, China

936 Elevated serum Lp-PLA2, a new risk factor, is closely related to diabetic neuropathy in patients with type 2 diabetes
J. Li, H. Lu, Y. Wang, Diabetic Neuropathy Group, China

937 Increased plasma miR27a-3p levels are associated with reduced Netrin-1 and corneal nerve fibre length in diabetic neuropathy
A. Mondal, C. Bose, S. Pramanik, C. Saha, S. Banerjee, B. Mukherjee, L. K. Mondal, R. A. Malik, S. Mukhopadhyay, India, Qatar

**Short Oral Event C**  **Wednesday, 12:45 - 13:45**

**SO 087** Clinical studies on the crosstalk between neuropathy and other systems

938 Diminished renal function is linked to a decline in the structural integrity of the sciatic nerve among individuals with type 1 and type 2 diabetes

939 The association between cardiac autonomic neuropathy and progression of diabetic nephropathy in type 2 diabetic patients

940 Assessment of diabetic autonomic neuropathy using pupillometry and corneal confocal microscopy in patients with diabetes and concurrent sexual dysfunction

941 Does small fibre neuropathy contribute to depression in diabetes? A corneal confocal study

942 Complement activation in diabetic neuropathy: insights from high-resolution resonance imaging and spatial microproteomics
T. Fleming, D. Schwarz, M. Marois, A. Peters, R. Longuespee, D. Helm, Z. Kender, J. Szendroedi, Germany
943 Serum pancreatic regeneration protein Iα potential association between renal injury and metabolic function
Z. Shu, S. Chen, L. Li, China

944 Small fibre damage and autonomic neuropathy are associated with increased mortality after simultaneous pancreas and kidney transplantation in type 1 diabetes
S. Azmi, M. Ferdousi, I. N. Petropoulos, G. Ponirakis, U. Alam, O. Asghar, A. Boulton, T. Augustine, R. A. Malik, UK, Qatar,

945 Periosteal pressure sensitivity a measure of autonomic neuropathy in comparison to other neuropathy measures in people with type 1 diabetes: a DANES cohort study

Short Oral Event D Wednesday, 14:00 - 15:00

SO 088 Fatty liver in diabetes: pathways and relationships
946 Vitamin D3 in the regulation of autophagy and mitochondrial dynamics in non-alcoholic fatty liver disease induced by type 2 diabetes

947 One-hour plasma glucose concentration during the OGTT is a strong predictor of hepatic steatosis in nondiabetic individuals

948 Machine learning approach reveals proteome and lipidome profile in patients with metabolic associated fatty liver disease complicated with poly-vascular plaques
Z. Tu, T. Yue, Y. Ding, X. Zheng, S. Luo, J. Weng, China

949 Antibiotic-induced decline in indoles and their associations with lobular inflammation in patients with metabolic dysfunction-associated steatohepatitis and impaired glucose tolerance
950 Metabolic dysfunction associated steatotic liver disease, but not visceral adiposity, is a strong and independent determinant of increased plasminogen activator inhibitor-1 levels in humans

951 Association between depression and non-alcoholic fatty liver disease according to obese status. The Korean National Health and Nutrition Examination survey 2010-2019
Y. Lyu, S. Kim, Republic of Korea

952 MASLD and MetALD: the amount of liver fat and number of cardiometabolic risk factors in relation to the risk of type 2 diabetes and cardiovascular disease

953 Similar glucagon-stimulated amino acid suppression in obese individuals with and without hepatic steatosis or steatohepatitis
S. Heebøll, G. Wegener, H. Grønbæk, S. Nielsen, Denmark

Short Oral Event E
Thursday, 12:45 - 13:45

SO 089 Brain matters in diabetes

954 Loss of thalamic subnuclei volume is related to widespread cortical thinning in middle-aged people with type 1 diabetes, independent of peripheral microangiopathy
E. Van Duinkerken, L. Loureiro, R. IJzerman, J. Landeira-Fernandez, M. Klein, F. Barkhof, F. J. Snoek, Netherlands, Brazil, UK

955 Risk factors predisposing to dementia in individuals with type 1 diabetes

956 Grey matter reserve modulates the association between diffusion tensor imaging analysis-along the perivascular space index and cognition in patients with type 2 diabetes
X. Yin, Y. Zhang, S. Ge, J. Ma, W. Xia, China

957 Does lipid-lowering drugs reduce the risk of dying from dementia in persons with type 2 diabetes: a Danish population-wide nested case-control study
T. Laurberg, S. B. Graversen, K. N. Horn, H. Støvring, Denmark
958 Age-related decrease of hippocampal insulin sensitivity is linked to unhealthy fat distribution in women

959 Differences in brain anatomy between diabetes endotypes: results from the UK-Biobank
M. Cerrai Ceroni, J. Hummel, K. Prystupa, H. Müller, H. Yamazaki, J. Kassubek, R. Wagner, M. Heni, Italy, Germany, Japan

960 Investigating CR1 as an indicated gene for mild cognitive impairment in type 2 diabetes
X. Zhou, S. Wang, China

961 Effects of aerobic-strength training on glucose metabolism, cognitive functions, and proteome of circulating EVs in patients with Parkinson’s disease

Short Oral Event F Thursday, 14:00 - 15:00

SO 090 Skeletal muscles and subcutaneous adipose tissue: important players in diabetes management

962 Sarcopenia risk in diabetes endotypes
N. Trinks, O. Zaharia, K. Strassburger, S. Schlesinger, R. Wagner, A. Bosy-Westphal, M. Roden, Germany

963 Impact of moderate-to-vigorous physical activity on mortality in sedentary patients with type 2 diabetes using a target trial emulation technique: a nationwide study
S. Park, S. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, G. Kim, Republic of Korea

964 Liver-muscle crosstalk in metabolic dysfunction-associated steatotic liver disease

965 Genetic evidence for causal role of lipodystrophy-like phenotype on diabetes complications of the upper limb
H. D. Green, R. Bala, J. Tyrrell, S. Martin, M. Weedon, I. Barroso, UK, Germany
966 Body fat and muscle contributions to heart failure risk: insights from longitudinal epidemiological and cardiac magnetic resonance studies
S. Xu, K. Wan, Q. Xie, H. Yang, Y. Qu, Y. Zeng, H. Song, China

967 Polygenic risk score for partial lipodystrophy based on clustered phenotypes-modelling and validation in the UK Biobank and Oxford Biobank

968 Differences in cardiac organ damage in individuals with hyperglycaemia and type 2 diabetes identified by 1-hour plasma glucose during an OGTT according to the IDF criteria
A. Riccio, C. M. Cefalo, T. Fiorentino, E. Succurro, F. Andreozzi, A. Sciacqua, G. Sesti, Italy

969 Signs of myocardial fibrosis in patients with type 2 diabetes without cardiovascular disease
I. V. Zubovych, Y. Y. Marushko, Y. A. Saenko, O. G. Halchenko, D. C. Vebs, B. M. Mankovsky, Ukraine

**Short Oral Event A**
**Tuesday, 12:30 - 13:30**

**SO 091 A new look at well-known drugs in type 2 diabetes**

970 Multi-omics analysis of the effect and mechanism of sodium-glucose cotransporter 2 inhibitors on metabolic dysfunction-associated fatty liver disease
J. Chen, J. Du, Q. Sun, M. Zhang, T. Haoming, China

971 Using machine learning to predict dynamic cardiovascular risks and identify the treatment responses of canagliflozin in type 2 diabetes
Q. Huang, X. Zou, E. J. Boyko, L. Ji, China, USA

972 Combination use of SGLT2 inhibitors and pioglitazone on risk of metabolic dysfunction-associated steatohepatitis in patients with type 2 diabetes
C. Lee, D. Lui, L. Mak, C. Fong, C. Cheung, W. Chow, Y. Woo, M. Yuen, W. Seto, K. Lam, Hong Kong

973 The effect of empagliflozin combined with metformin or semaglutide on hyperglycaemic cardiac cells: a pilot study
P. Senesi, A. Ferrulli, B. Bassani, F. Di Marco, A. Bruno, L. Luzi, Italy
974 Role of endogenous GLP-1 on macrovascular stiffness and renal haemodynamics following bariatric surgery
D. Moriconi, R. Bruno, S. Baldi, E. Rebelos, L. Bonvicini, S. Taddei, M. Nannipieri, Italy, France, Greece

975 Metformin added to intensive insulin therapy improves Neuregulin-4 level and subclinical atherosclerosis in youth with type 1 diabetes
E. Abdelrahman Ismail, M. Atef, N. Elbarbary, Egypt

976 Stearate remodels human non-inflammatory macrophages towards the inflammatory M1 immunometabolic profile: A mitigating role of empagliflozin?
G. Cinquegrani, V. Spigoni, F. Fantuzzi, F. Bagnaresi, M. Marinelli, E. Giordano, A. Dei Cas, R. C. Bonadonna, Italy

977 Glucose-dependent insulinotropic polypeptide prevents palmitate-induced apoptosis, but not autophagy and stress kinase activation in human cardiac progenitor cells
I. Calderoni, R. D’Oria, C. Caccioppoli, C. Colabufo, V. A. Genchi, G. Palma, G. Santarpino, A. D. Milano, T. Bottio, A. Leonardini, A. Natalicchio, S. Perrini, A. Cignarelli, F. Giorgino, L. Laviola, Italy

**Short Oral Event B**

**SO 092 Divination from a glass ball or something more?**
**Predictive models, biomarkers, genome analysis**

978 Whole-genome and whole-exome sequencing study of serum apolipoprotein C-III concentrations in individuals with type 1 diabetes
E. Valo, A. Antikainen, J. Haukka, F. Jansson Sigfrids, A. Syreeni, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland, Australia

979 Diabetes type-specific associations between baseline levels of biomarkers of inflammation and changes in depressive symptoms in three intervention studies
C. Herder, A. Zhu, M. Spagnuolo, A. Schmitt, B. Kulzer, M. Roden, D. Ehrmann, N. Hermanns, Germany

980 Construction and evaluation of a diagnostic prediction model for diabetic cardiomyopathy based on mitophagy-related genes
Z. Wang, China
981 A comprehensive analysis of predictive factors for cardiovascular risk in type 2 diabetes: insights from the UK Biobank
M. Lugner, A. Rawshani, B. Eliasson, Sweden

982 Influence of sex and risk factors on myocardial microvascular function in individuals with type 2 diabetes free of overt cardiovascular disease: the DiaHeart study

983 Circadian heart rate fluctuations predict 21-year cardiovascular and all-cause mortality in type 2 and type 1 diabetes

984 Next-generation sequencing supports the role of hyaluronic acid for ischaemic stroke in type 1 diabetes
A. Syreeni, A. A. Antikainen, J. Haukka, V. Harjutsalo, J. Putaala, P.-H. Groop, L. M. Thorn, N. Sandholm, FinnDiane Study Group, Finland

985 From genes to gestation: tracing the genetic footprints of pregnancy
D. Galuška, K. Chalásová, L. Pacal, V. Bartakova, K. Kankova, Czech Republic

Short Oral Event C  
Wednesday, 12:45 - 13:45

SO 093 A non-classical look at type 1 diabetes

986 High-risk individuals with type 1 diabetes demonstrate highly pathological extracellular volume fraction and T1 relaxation times on whole left ventricular cardiac MRI
P. Novodvorský, M. Dubský, N. Marhefková, T. Adla, R. Roland, M. Pazderník, M. Haluzík, P. Garg, Czech Republic, UK

987 Sleep and glucose: unravelling the association between glycaemic variability and sleep disorders among children with type 1 diabetes
N. Salah, A. Abido, H. Rashed, Egypt

988 Prevalence of cognitive impairment in people with diabetes type 1 and 2 and associations to metabolic control and complications
989 Hepatic steatosis with significant fibrosis is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes

990 Beyond hyperglycaemia: double diabetes and adiposity in the population with newly diagnosed type 1 diabetes and its impact on metabolic goals: observations from the prospective InLipoDiab1 study
A. Zawiejska, A. Uruska, A. Duda-Sobczak, M. Miętkiewska-Dolecka, A. Grzelka-Woźniak, J. Flotyńska, D. Zozulinska-Ziółkiewicz, Poland

991 Gastrointestinal symptoms in type 1 diabetes are associated with distinct clinical, fecal microbiome and plasma metabolite profiles

992 Association of remnant cholesterol levels and microvascular complications in adult patients with type 1 diabetes

Short Oral Event D Wednesday, 14:00 - 15:00

SO 094 Cohorts, trials and cardiovascular disease

993 The association between time-in-target haemoglobin A₁c range and cardiovascular disease in a population-based cohort of 68,165 individuals with diabetes in Canada
P. Kaul, L. Chu, D. A. Dover, R. O. Yeung, D. Lau, D. Eurich, P. A. Senior, S. Butalia, Canada, Hong Kong

994 Cardiac phenotypes and cardiovascular risk in patients with type 2 diabetes and chronic coronary artery disease: a Chinese retrospective cohort study
R. Sun, S. Wang, China

995 BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 Sophia study
996 Effect of 10-year intervention on type 2 diabetic patients with central obesity in Beijing community based on cardiovascular risk stratification
X.-L. Zhang, G.-H. Wang, S.-Y. Yuan, Beijing Communities Diabetes Study Group, China

997 Improvement in kidney function mediates part of fenofibrate cardiovascular effects in patients with type 2 diabetes: a post-hoc analysis of the ACCORD-Lipid trial
M. Morieri, H. N. Ginsberg, G. Fadini, A. Avogaro, A. Doria, Italy, USA

998 Screening for previously unknown dysglycaemia and its prognostic impact in patients with coronary artery disease; results from the EUROASPIRE programme
G. Ferrannini, J. Tuomilehto, G. De Backer, K. Kotseva, L. Mellbin, O. Schnell, D. Wood, D. De Bacquer, L. Rydén, Sweden, Finland, Belgium, UK, Germany, Ireland

999 Impact of early detection and treatment of hyperglycaemia in pregnancy: systematic review and meta-analysis of randomised controlled trials
R. Corcoy, M. Balsells, I. Sola, A. García-Patterson, Spain

1000 Suboptimal physician adherence to guideline recommendations in patients with diabetes and established cardiorenal diseases
Z.-Y. Shen, H.-Y. Ou, Taiwan

**Short Oral Event E**

**Thursday, 12:45 - 13:45**

**SO 095 Other complications of type 2 diabetes**

1001 Role of exosomes in human amylin secretion: link between diabetes and Alzheimer’s disease and the protective effects of resveratrol
A. C. Lockwood López, C. González-Blanco, S. Iglesias-Forbes, C. Figaredo, A. García-Aguilar, G. García, C. Guillén, Spain

1002 Burden of diabetic ketoacidosis among people living with type 2 diabetes: a systematic review
C. H. Wysham, Y. Poon, A. Bindal, USA, Canada,

1003 Glycaemic gap as an indicator of prognosis in critically ill patients with diabetes
R. Ahmed, A. Baidya, M. Bera, India
1004 Diabetes and risk of readmission in patients with community-acquired pneumonia

1005 Impaired adaptive responses to hypoxia in patients with diabetes
X. Zheng, A. Di Toro, S. Eliasson Angelstig, C. Xu, I. Botusan, N. Rajamand Ekberg, A. Zhao, B. Yan, Z. Liu, J. Grünler, N. Widén, Q. Deng, N. Xu Landén, L. Bernardi, S.-B. Catrina, Sweden, Italy

1006 Sex differences in mechano-energetics of type 2 diabetic cardiac muscle
M. Rahmani, T. Pham, D. Crossman, A. Taberner, K. Tran, J.-C. Han, New Zealand

1007 Reduced LC3 expression without Beclin 1 alteration in diabetic patients’ right atrial appendage during coronary artery bypass surgery
R. Jha, A. Kumar, P. K. Jha, India

1008 MicroRNA promotes cardiac mitochondrial dysfunction and heart failure by dynamically regulating specific target genes during different disease stage
Q. Su, H. Wade, UK

Short Oral Event F Thursday, 14:00 - 15:00

SO 096 A non-traditional look at type 2 diabetes

1009 Liver steatosis and fibrosis in lean type 2 diabetes patients compared to obese type 2 diabetes patients: Different mechanisms!
W. Tao, L. Li, China

1010 Association between vascular endothelial dysfunction and higher 10-year atherosclerotic cardiovascular disease risk in young-onset type 2 diabetes: a cross-sectional study in China
Y. Hu, S. Shen, S. Liu, J. Zheng, Y. Lei, C. Yan, X. Wu, China

1011 Microrna profile analysis in pericoronary adipose tissue of type 2 diabetes patients with significant coronary artery disease
1012 In-depth microbiological characterisation of urine from subjects with type 2 diabetes
A. Mengozzi, M. Calvigioni, D. Mazzantini, F. Celandroni, E. Biancalana, C. Rossi, E. Ghelardi, A. Solini, Italy, Switzerland

1013 Association between serum uric acid to HDL-cholesterol ratio and incidence of vascular events in type 2 diabetes: a 13-year prospective observation
M. Garofolo, D. Lucchesi, M. Giambalvo, M. Capobianco, G. Mancini, P. Francesconi, S. Del Prato, P. Marchetti, G. Penno, Italy

1014 Prevalence of hepatic fibrosis and effect of PPAR-α/y agonism in type 2 diabetes patients of different ethnicities

1015 Myocardial steatosis and improvement of cardiac function after glycaemic optimisation treatment in newly diagnosed type 2 diabetes subjects
Á. Rosales, P. Gil, T. Julian, A. Teis, B. Pedraz, J. Sanchez, J. Julve, D. Mauricio, A. Perez, N. Alonso, Spain, Germany

1016 Prevalence of sarcopenia in type 2 diabetic and non-diabetic older adults: an observational study
R. Kumar, A. Garg, R. Dewan, A. Kakar, T. Batra, India

**Short Oral Event A Tuesday, 12:30 - 13:30**

**SO 097 Patogenesis of diabetes complications**

1017 Acid-sensing ion channel 1a in the glutamate neuron of the anterior cingulate cortex contributes to diabetes-related pain
A. Jiang, W. Wang, China

1018 Blood monocyte frequency and phenotype are subclinical markers of cardiovascular risk in people with type 2 diabetes
J. Julla, D. Girard, M. Diedisheim, F. Alzaid, J.-F. Gautier, N. Venteclef, France

1019 COX-2 inhibition constrains Oncostatin-M production and granulopoiesis in diabetic mice
M. Albiero, C. Boscaro, A. Rodella, G. P. Fadini, Italy

1020 Eicosapentaenoic acid inhibits lipoprotein(a) oxidation under normal and high glucose conditions in vitro
P. Mason, P. Libby, R. L. Dunbar, D. Bhatt, S. C. Sherratt, USA
1021 Defining the role of NOX5 as a biomarker in the Cardiovascular-Kidney-Metabolic syndrome
J. Pinzon-Cortes, K. C. Sourris, T. J. Block, A. Kincses, J. C. Jha, M. E. Cooper, J. Shaw, K. Jandeleit-Dahm, Australia, Germany

1022 Sestrin2 alleviates obesity-associated heart failure with preserved ejection fraction by modulating the sigma-1 receptor-mediated IRE1α-XBP1 axis and antioxidant system
K. Zhang, J. Zhang, C. Kan, G. Xiong, F. Han, N. Hou, X. Sun, China

1023 Astrocyte SCAP/SREBP2-mediated cholesterol homeostasis imbalance in diabetic cognitive impairment via up-regulating LCN2
K. Liu, W. Zhu, T. Niu, S. Wang, China

1024 The lysine methyltransferase SET7 regulates novel molecular pathways in hyperglycaemia-induced endothelial dysfunction
J. Sánchez Ceinos, D. Sánchez Fernandez, M. Jakobsson, A. Vegvari, F. Cosentino, Sweden

1025 Application of adipose tissue-derived stem cell therapy with a clinically relevant dose does not significantly affect atherosclerotic plaque characteristics in a hyperglycaemia mouse model
A. Korn, S. Simsek, M. D. Fiet, I. S. Waas, H. W. Niessen, P. A. Krijnen, Netherlands

Short Oral Event B Tuesday, 13:45 - 14:45

SO 098 Cancer and diabetes

1026 Circulating levels of interleukin-6 predict risk of obesity-related cancers in patients with recently diagnosed type 2 diabetes
M. D. Bennetsen, J. V. Stidsen, J. S. Nielsen, M. H. Olsen, S. L. Domazet, T. Laurberg, K. Højlund, R. W. Thomsen, T. B. Olesen, Denmark

1027 New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident prostate cancer: a nationwide propensity score-matched cohort study
Y. Cho, S. Kim, M. Kim, S.-H. Go, W. Lee, Y.-J. Kim, C. Jung, Republic of Korea

1028 Increased skin autofluorescence predicts future cancer development
1029 Cancer incidence in Japanese patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists

1030 Associations of alcohol consumption with all-cause mortality and cancer mortality in Korean patients with type 2 diabetes: a nationwide cohort study

1031 Increased risk of pancreatic cancer with diabetes and smoking in non-alcoholic fatty liver disease: a nationwide cohort study
H. Jung, J. Huh, E. Roh, K.-D. Han, J. Kang, S. Lee, S.-H. Ihm, Republic of Korea

1032 Post-authorisation safety study to assess the risk of urinary tract cancer in patients with type 2 diabetes initiating empagliflozin: a multi-country European study
N. Schmedt, A. Alhamdow, G. Tskhvarashvili, L. Saarelainen, X. Qiao, M. Lobier, F. Hoti, Germany, Estonia, Finland

1033 Distinct plasma MALDI-TOF MS spectrum and serum extracellular vesicle profile between pancreatic ductal adenocarcinoma-related diabetes and type 2 diabetes

Short Oral Event C Wednesday, 12:45 - 13:45

SO 099 A non-traditional look at type 1 diabetes

1034 Intestinal fatty acid binding protein is associated with coronary artery disease in long-term type 1 diabetes: the Dialong study
M. Narum, I. Seljeflot, T. J. Berg, K. A. Sveen, Norway

1035 Clustering of type 1 diabetes patients by CGM profiles: higher insulin resistance and risk of MAFLD assessed by surrogate markers in patients with poorly controlled glycaemia
A. Fedulovs, L. Pahirko, J. Sokolovska, Latvia
1036 Type 1 diabetes: Is silent myocardial ischaemia associated with blinded continuous glucose monitoring metrics? Results from a pilot study
A. Cano, O. Giménez-Palop, R. Pareja, L. Albert, V. Arsentales, I. Mazarico, A. Rodríguez-Revuelto, J. Puntí, J. Vendrell, J. M. González-Clemente, Spain

1037 Association of remnant cholesterol levels and the prevalence of the metabolic syndrome in adult patients with type 1 diabetes
M. Kortemeier, S. Tittel, J. Brandts, P. Bramlage, J. Weiskorn, C. Wagner, M. Femerling, M. Huptas, N. Weh, R. Holl, Germany, USA

1038 Non-classical risk factors are associated with preclinical atherosclerosis in younger individuals with type 1 diabetes: insights from over eight hundred cardiovascular risk assessments

1039 The safe management of people with type 1 diabetes and eating disorders study (STEADY) feasibility randomised controlled trial

1040 Risk factors for fractures in patients with type 1 diabetes
S. I. Chisalita, E. Paulsson, E. Gauffin, H. Arnqvist, Sweden

1041 Factors involved in the progression of preclinical atherosclerosis in people with type 1 diabetes

Short Oral Event D Wednesday, 14:00 - 15:00

SO 100 Correlates of fatty liver disease in diabetes

1042 Efficacy of dapagliflozin on hepatic fibrosis and steatosis in patients of type 2 diabetes with non alcoholic fatty liver disease
S. Das, V. Das, B. Prusty, V. Agarwal, D. Sahoo, S. Sahu, D. Meher, A. Choudhury, J. Swain, India

1043 A prospective study on the prevalence of steatotic liver disease and advanced fibrosis in people with type 2 diabetes
D. M. Williams, J. Nagaraj, J. W. Stephens, T. Min, UK
1044 The role and mechanism of IGF2 deficiency in promoting metabolic associated fatty liver disease
W. Gui, C. Zhou, X. Lin, China

1045 Prevalence of metabolic dysfunction associated fatty liver disease in people with type 1 diabetes

1046 Association of non-alcoholic fatty liver disease and liver fibrosis with cardiometabolic risk profile in lean and non-lean patients with type 2 diabetes
H. Yu, L. Li, China

1047 Atherosclerosis rather than arteriosclerosis mediates the incremental association between blood markers of liver fibrosis with cardiovascular risk: a mediation analysis

1048 Implications of steatotic liver disease on cardiovascular disease morbidity and overall survival
I. P. Karhiaho, S. H. Kurki, L. Kullamaa, N. Matikainen, T. Tuomi, Finland

1049 Hepatic fibrosis and not hepatic steatosis determines cardiovascular risk in type 2 diabetes independent from other cardiovascular risk factors: a report from the AleCardio trial

Short Oral Event E Thursday, 12:45 - 13:45

SO 101 MASLD: now an established complication of diabetes

1050 Properties of free fatty acids, not only the circulating levels, are associated with MASLD
S. Ciardullo, M. Vergani, M. Rizzo, A. Oltolini, A. Bongo, E. Muraca, G. Perseghin, Italy

1051 High-fat induced MASLD beyond the liver: metabolic profiling of mice extrahepatic tissues as analysed by $^1$H-NMR
J. G. Silva, L. C. Tavares, G. D. Belew, A. M. Gil, J. G. Jones, Portugal, USA
1052 Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver

1053 Role of small extracellular vesicles in liver and pancreas in MASLD linked to type 2 diabetes
I. Garcia-Martinez, R. Alén, R. Francés, R. Aller, Á. M. Valverde, Spain

1054 The molecular mechanisms of ZBED3 activating ASK1-JNK/p38 signalling pathway to promote NASH progression
Y. Wu, X. Luo, China

1055 Systemic creatine depletion attenuates hepatic steatosis and fibrosis by modulating food intake and energy expenditure in mice
H.-S. Yi, Republic of Korea

1056 Activation of γ-aminobutyric acid receptor type A as a novel first-in-class approach for MASH therapy
E. Rohbeck, L. Koester, J. Eckel, Germany

1057 Efficacy of dodecanedioc acid for insulin resistance and MASH prevention
S. Russo, G. Angelini, G. Mingrone, Italy

**Short Oral Event F**  
**Thursday, 14:00 - 15:00**

**SO 102 Addressing risk and consequences of liver pathology in diabetes**

1058 Is hypoglycaemic treatment better than liver protection? A systematic review and network meta-analysis of randomised controlled trials
Y. Wang, H. Yi, W. Sun, H. Yu, W. Tao, L. Li, China

1059 Metabolic characteristics associated with the bariatric surgery-mediated improvement of liver pathology in Japanese participants with morbid obesity
D. Matsubara, Y. Takeshita, M. Mori, S. Tokuno, M. Okumura, H. Goto, Y. Nakano, T. Takamura, Japan

1060 Increased glycosuria reduces the risk of metabolic associated fatty liver disease in subjects with newly diagnosed diabetes: a cross-sectional study
J. Chen, Z. Sun, J. Yu, X. Zhou, J. Ge, China
1061 Diabetic dyslipidaemia and insulin resistance are more closely associated with liver steatosis than liver fibrosis in type 2 diabetes patients

1062 Gender disparities in metabolic dysfunction associated steatotic liver disease: transcriptomic results from the BARIA longitudinal cohort study
M. Koning, N. M. Hanssen, J. Verheij, M. Doukas, A. Van de Laar, S. Bruin, H. Herrema, V. Gerdes, A. S. Meijnikman, M. Nieuwdorp, Netherlands

1063 Development of a machine learning-based model to identify risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease
W. Zhang, T. Yue, Y. Ding, J. Weng, X. Zheng, S. Luo, China

1064 Mitogen inducible gene 6 (Mig-6), a surrogate for dysglycaemia and dyslipidaemia in type 2 diabetes
B. Mukherjee, C. Bose, S. Kundu, S. Pramanik, C. Saha, A. Mondal, S. Roy, S. Mukhopadhyay, India
### Presenting Authors of Orals and Short Oral Discussions

<table>
<thead>
<tr>
<th>Last Name, Initials, Presentation Number</th>
<th>Last Name, Initials, Presentation Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdalla, M. A.</td>
<td>Antikainen, A. A.</td>
</tr>
<tr>
<td>Abdelalim, E. M.</td>
<td>Apalaki, P.</td>
</tr>
<tr>
<td>Abdelrahman I. E.</td>
<td>Arage, G.</td>
</tr>
<tr>
<td>Abdelsalam, A.</td>
<td>Ariëns, B.</td>
</tr>
<tr>
<td>Abou Azar, F.</td>
<td>Arnardottir, E.</td>
</tr>
<tr>
<td>Abu-Farha, M.</td>
<td>Arni, A. M.</td>
</tr>
<tr>
<td>Abuqwider, J.</td>
<td>Arum, P.</td>
</tr>
<tr>
<td>Acosta Manzano, P.</td>
<td>Atabaki Pasdar, N.</td>
</tr>
<tr>
<td>Acreman, S.</td>
<td>Atawneh, F.</td>
</tr>
<tr>
<td>Ahluwalia, T. S.</td>
<td>Athanasiadou, K. I.</td>
</tr>
<tr>
<td>Ahmad, S.</td>
<td>Athanasopoulos, S.</td>
</tr>
<tr>
<td>Ahmed, R.</td>
<td>Avolio, A.</td>
</tr>
<tr>
<td>Ahmed, S.</td>
<td>Azmi, S.</td>
</tr>
<tr>
<td>Ahuja, V.</td>
<td>Bajaj, H.</td>
</tr>
<tr>
<td>Ai, F.</td>
<td>Balaz, M.</td>
</tr>
<tr>
<td>Aihara, M.</td>
<td>Baldassarre, M.</td>
</tr>
<tr>
<td>Akerkar, A.</td>
<td>Ballesteros-Pla, C.</td>
</tr>
<tr>
<td>Al-Mrabe, A. H.</td>
<td>Banah, A. K.</td>
</tr>
<tr>
<td>Al-Mulla, F.</td>
<td>Banas, W. T.</td>
</tr>
<tr>
<td>Al-Sharefi, A.</td>
<td>Bannon, C.</td>
</tr>
<tr>
<td>Albiero, M.</td>
<td>Barchetta, I.</td>
</tr>
<tr>
<td>Alblas, G.</td>
<td>Barouti, A. A.</td>
</tr>
<tr>
<td>Ali, S. Rana.</td>
<td>Barraud, S.</td>
</tr>
<tr>
<td>Allen, L. A.</td>
<td>Beato Vibora, P.</td>
</tr>
<tr>
<td>Allen-Taylor, M.</td>
<td>Bellido, V.</td>
</tr>
<tr>
<td>Almeida-Oliveira, F.</td>
<td>Bem, R.</td>
</tr>
<tr>
<td>Alobaid, T.</td>
<td>Bennetsen, M. D.</td>
</tr>
<tr>
<td>Alonso, L.</td>
<td>Bergdal, R.</td>
</tr>
<tr>
<td>Alonso-Sampedro, M.</td>
<td>Bergenstal, R. M.</td>
</tr>
<tr>
<td>Álvarez Hernández, E.</td>
<td>Beunen, K.</td>
</tr>
<tr>
<td>Alves, E. B.</td>
<td>Bhagtani, D.</td>
</tr>
<tr>
<td>Amendolara, R.</td>
<td>Bhattacha, S. N.</td>
</tr>
<tr>
<td>Amikishieva, K.</td>
<td>Bi, Y.</td>
</tr>
<tr>
<td>Ampudia-Blasco, F. J.</td>
<td>Bianchi, C.</td>
</tr>
<tr>
<td>An, Q.</td>
<td>Biancolin, A. D.</td>
</tr>
<tr>
<td>Andersson, J.</td>
<td>Bitencourt, F. V.</td>
</tr>
<tr>
<td>Angelini, G.</td>
<td>Bitterman, O.</td>
</tr>
<tr>
<td>Anjum, B.</td>
<td></td>
</tr>
<tr>
<td>Antal, M.</td>
<td></td>
</tr>
<tr>
<td>Last Name, Initials, Presentation Number</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Bizzotto, R. .......................... 543</td>
<td></td>
</tr>
<tr>
<td>Bjerregaard-Andersen, M. ................ 139</td>
<td></td>
</tr>
<tr>
<td>Blangero, F. .......................... 632</td>
<td></td>
</tr>
<tr>
<td>Block, T. J. .......................... 550</td>
<td></td>
</tr>
<tr>
<td>Boateng-Kuffour, A. ...................... 822, 875</td>
<td></td>
</tr>
<tr>
<td>Bódis, K. B. .......................... 209</td>
<td></td>
</tr>
<tr>
<td>Bogun, M. M. .......................... 866</td>
<td></td>
</tr>
<tr>
<td>Bonnet, J.-B. .......................... 264</td>
<td></td>
</tr>
<tr>
<td>Bonvicini, L. .......................... 563</td>
<td></td>
</tr>
<tr>
<td>Borbjerg, M. .......................... 61</td>
<td></td>
</tr>
<tr>
<td>Borbjerg, M. K. ........................ 864</td>
<td></td>
</tr>
<tr>
<td>Borg, R. ............................... 904</td>
<td></td>
</tr>
<tr>
<td>Bosi, E. ............................... 850</td>
<td></td>
</tr>
<tr>
<td>Boudra, Z. ............................. 548</td>
<td></td>
</tr>
<tr>
<td>Bowden Davies, K. A. .................... 689</td>
<td></td>
</tr>
<tr>
<td>Braffett, B. ............................ 65</td>
<td></td>
</tr>
<tr>
<td>Brandts, J. ............................. 992</td>
<td></td>
</tr>
<tr>
<td>Breitfeld, J. ........................... 222</td>
<td></td>
</tr>
<tr>
<td>Briggs, J. K. ........................... 444</td>
<td></td>
</tr>
<tr>
<td>Brings, S. .............................. 705</td>
<td></td>
</tr>
<tr>
<td>Brøssen, J. M. B. ...................... 815</td>
<td></td>
</tr>
<tr>
<td>Brugnara, L. ............................ 502</td>
<td></td>
</tr>
<tr>
<td>Brunetti, M. ............................ 427</td>
<td></td>
</tr>
<tr>
<td>Bsharat, S. ............................. 437</td>
<td></td>
</tr>
<tr>
<td>Buchipudi, A. ........................... 861</td>
<td></td>
</tr>
<tr>
<td>Busch, C. B. E. ........................ 699</td>
<td></td>
</tr>
<tr>
<td>Cai, Z. ................................. 581</td>
<td></td>
</tr>
<tr>
<td>Calderon, E. ............................ 400</td>
<td></td>
</tr>
<tr>
<td>Calderoni, I. ........................... 977</td>
<td></td>
</tr>
<tr>
<td>Callahan, P. ............................ 104</td>
<td></td>
</tr>
<tr>
<td>Cámara-Torres, P. ....................... 207</td>
<td></td>
</tr>
<tr>
<td>Canha, D. ............................... 355</td>
<td></td>
</tr>
<tr>
<td>Cano, A. ............................... 1036</td>
<td></td>
</tr>
<tr>
<td>Cantley, J. ............................. 667</td>
<td></td>
</tr>
<tr>
<td>Cao, X. ................................. 533</td>
<td></td>
</tr>
<tr>
<td>Caramelo, B. ............................ 640</td>
<td></td>
</tr>
<tr>
<td>Cardoso, P. ............................. 407</td>
<td></td>
</tr>
<tr>
<td>Carr, A. L. J. .......................... 388, 445</td>
<td></td>
</tr>
<tr>
<td>Carstensen, B. .......................... 100</td>
<td></td>
</tr>
<tr>
<td>Caruso, I. ............................... 753</td>
<td></td>
</tr>
<tr>
<td>Castelblanco, E. ......................... 144</td>
<td></td>
</tr>
<tr>
<td>Cataldo, L. ............................. 428</td>
<td></td>
</tr>
<tr>
<td>Caussy, C. .............................. 229</td>
<td></td>
</tr>
<tr>
<td>Cen, H. ................................. 529</td>
<td></td>
</tr>
<tr>
<td>Cerrai Ceroni, M. ...................... 959</td>
<td></td>
</tr>
<tr>
<td>Chanen, S. .............................. 840</td>
<td></td>
</tr>
<tr>
<td>Chapeau, D. ............................. 451</td>
<td></td>
</tr>
<tr>
<td>Chen, C.-C. ............................. 898</td>
<td></td>
</tr>
<tr>
<td>Chen, D. ............................... 889</td>
<td></td>
</tr>
<tr>
<td>Chen, J. ............................... 1060</td>
<td></td>
</tr>
<tr>
<td>Chen, S. ............................... 916</td>
<td></td>
</tr>
<tr>
<td>Chen, S.-P. ............................. 513</td>
<td></td>
</tr>
<tr>
<td>Chen, T. ............................... 320</td>
<td></td>
</tr>
<tr>
<td>Chen, W. ............................... 7</td>
<td></td>
</tr>
<tr>
<td>Cheng, A. .............................. 809</td>
<td></td>
</tr>
<tr>
<td>Cheng, A. Y. Y. ........................ 784</td>
<td></td>
</tr>
<tr>
<td>Cherkouï, I. ............................ 299</td>
<td></td>
</tr>
<tr>
<td>Cheung, N. ............................. 351</td>
<td></td>
</tr>
<tr>
<td>Chiriacò, M. ............................ 716</td>
<td></td>
</tr>
<tr>
<td>Chisalița, S. I. ......................... 1040</td>
<td></td>
</tr>
<tr>
<td>Chisbert, M. ............................ 687</td>
<td></td>
</tr>
<tr>
<td>Cho, D.-H. .............................. 939</td>
<td></td>
</tr>
<tr>
<td>Cho, Y. ................................. 673, 1027</td>
<td></td>
</tr>
<tr>
<td>Choudhary, P. ........................... 805</td>
<td></td>
</tr>
<tr>
<td>Christensen, M. H. ..................... 180</td>
<td></td>
</tr>
<tr>
<td>Christiansen, M. ....................... 806</td>
<td></td>
</tr>
<tr>
<td>Christie, H. E. ........................ 174</td>
<td></td>
</tr>
<tr>
<td>Ciardullo, S. ........................... 1050</td>
<td></td>
</tr>
<tr>
<td>Cigler, M. .............................. 837</td>
<td></td>
</tr>
<tr>
<td>Cimbalo, N. ............................. 682</td>
<td></td>
</tr>
<tr>
<td>Cinquegrani, G. ........................ 976</td>
<td></td>
</tr>
<tr>
<td>Cintra, D. E. ........................... 595</td>
<td></td>
</tr>
<tr>
<td>Citro, F. ............................... 275</td>
<td></td>
</tr>
<tr>
<td>Claesson, T. ............................ 917</td>
<td></td>
</tr>
<tr>
<td>Clark, M. ............................... 616</td>
<td></td>
</tr>
<tr>
<td>Claro Brandon, M. ....................... 989</td>
<td></td>
</tr>
<tr>
<td>Colhoun, H. M. ........................ 146</td>
<td></td>
</tr>
<tr>
<td>Coll, B. ............................... 749</td>
<td></td>
</tr>
<tr>
<td>Conserva, F. ............................ 194</td>
<td></td>
</tr>
<tr>
<td>Cookson, T. A. .......................... 154</td>
<td></td>
</tr>
<tr>
<td>Last Name, Initials, Presentation Number</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Corcoy, R. .................................. 999</td>
<td>Ebekozien, O. .................. 484, 813</td>
</tr>
<tr>
<td>Corrado, A. ................................ 779</td>
<td>Eckstein, Y. ................... 671</td>
</tr>
<tr>
<td>Corrales, P. ................................ 477</td>
<td>Edelman, S. .......................... 114</td>
</tr>
<tr>
<td>Cosentino, C. ................................ 598</td>
<td>Eerdekens, M. .......................... 64</td>
</tr>
<tr>
<td>Cosson, E. .................................. 345, 470</td>
<td>Ehrmann, D. ..................... 873</td>
</tr>
<tr>
<td>Costa-Junior, J. M. .......................... 506</td>
<td>Eichenlaub, M. ................... 856</td>
</tr>
<tr>
<td>Crabtree, T. S. J. ........................... 778</td>
<td>Ejskjaer, N. .......................... 795</td>
</tr>
<tr>
<td>Csanalosi Artigas, M. ....................... 383</td>
<td>Elbarbary, N. ..................... 665</td>
</tr>
<tr>
<td>Daggelen, S. .................................. 652</td>
<td>Evans, M. ........................... 735</td>
</tr>
<tr>
<td>Dai, X.-Q. ................................... 456</td>
<td>Fadini, G. ............................ 1</td>
</tr>
<tr>
<td>Daniels Gatward, L. F. ..................... 457</td>
<td>Fagionato, E. ...................... 206</td>
</tr>
<tr>
<td>Dardano, A. .................................. 878</td>
<td>Fagherazzi, G. ..................... 365</td>
</tr>
<tr>
<td>Das, S. ........................................ 1042</td>
<td>Fan, B. .............................. 271</td>
</tr>
<tr>
<td>Dassau, E. .................................... 832</td>
<td>Fan, K. ................................. 836</td>
</tr>
<tr>
<td>Davis, T. M. E. ............................... 181</td>
<td>Fauzi, M. ............................. 237</td>
</tr>
<tr>
<td>Davis, W. A. .................................. 161</td>
<td>Fazli, G. S. ........................... 315</td>
</tr>
<tr>
<td>Dayan, C. ...................................... 704</td>
<td>Fedulovs, A. ....................... 1035</td>
</tr>
<tr>
<td>de Jong, V. D. ...................... .......... 1014</td>
<td>Ferdouisi, M. ....................... 941</td>
</tr>
<tr>
<td>De Meulemeester, J. .......................... 117, 188</td>
<td>Ferdouisi, T. ...................... 481</td>
</tr>
<tr>
<td>De Vito, F. .................................... 626</td>
<td>Ferguson, L. D. ........................ 332</td>
</tr>
<tr>
<td>de Wit, D. F. .................................. 326</td>
<td>Fernández-García, P. ............ 653</td>
</tr>
<tr>
<td>Deden, L. 171, ................................. 564</td>
<td>Ferrannini, G. ....................... 998</td>
</tr>
<tr>
<td>Dei Cas, A. .................................... 676</td>
<td>Ferrara, A. ............................ 177</td>
</tr>
<tr>
<td>Demir, S. ...................................... 514</td>
<td>Ferraro, G. ........................... 643</td>
</tr>
<tr>
<td>Deng, K. ....................................... 232</td>
<td>Ferreira, S. G. ........................ 25</td>
</tr>
<tr>
<td>Deng, Y. ....................................... 474</td>
<td>Ferreira, V. ........................... 58</td>
</tr>
<tr>
<td>Di Giuseppe, G. ............................... 155</td>
<td>Fierabracci, A. ...................... 384</td>
</tr>
<tr>
<td>di Piazza, F. .................................. 250</td>
<td>Figueredo Burgos, N. S. ........ 59</td>
</tr>
<tr>
<td>Diamond, C. ................................... 910</td>
<td>Filatov, E. ............................. 165</td>
</tr>
<tr>
<td>Dickerson, M. .................................. 425</td>
<td>Firmeisz, G. ........................... 267</td>
</tr>
<tr>
<td>Dischinger, U. ................................. 765</td>
<td>Fisher, S. J. ........................... 108</td>
</tr>
<tr>
<td>Do, D. Q. ....................................... 772</td>
<td>Fitzpatrick, A. L. .................. 127</td>
</tr>
<tr>
<td>Dobrovynska, O. ............................... 847</td>
<td>Fleming, T. ........................... 942</td>
</tr>
<tr>
<td>Dobson, J. R. .................................. 215</td>
<td>Flores Paños, A. .................... 848</td>
</tr>
<tr>
<td>Domazet, S. L. ................................ 184</td>
<td>Flotynska, J. ........................... 504</td>
</tr>
<tr>
<td>dos Santos, T. ................................ 245</td>
<td>Foster, H. R. ........................... 414</td>
</tr>
<tr>
<td>Drzazga, A. K. ................................ 686</td>
<td>Franek, E. ............................. 681</td>
</tr>
<tr>
<td>Du, J. ........................................... 527</td>
<td>Franzén, E. ............................. 339</td>
</tr>
<tr>
<td>Dubsky, M. ..................................... 39</td>
<td>Fuhri Snethlage, C. M. ........... 991</td>
</tr>
<tr>
<td>Dyachok, O. ................................... 411</td>
<td>Fumo, A. R. ............................ 964</td>
</tr>
<tr>
<td></td>
<td>Gabe, M. B. N. ...................... 561</td>
</tr>
</tbody>
</table>
Last Name, Initials, Presentation Number

Gad, H. .................. 763, 923  Groop, P.-H. .................. 337
Gaffuri, A.-L. .......... 219  Guay, C. ...................... 600
Gagli, A. .................. 493  Guerrero-Wyss, M. T. ........ 356
Galli, A. ................... 408  Gui, W. ...................... 1044
Galuška, D. ............ 985  Gullaksen, S. .................. 91
Gamarra, E. ............ 830  Gupta, S. ...................... 329
Game, F. .................. 882, 930  Hadad, R. .................... 62
Gan, S. ..................... 711  Hadjadj, S. ................... 122
Ganla, M. ................. 363  Hagelqvist, P. G. ......... 37, 38
Gansmeier, M. .......... 325  Hakaste, L. .................... 380
Gao, L. .................. 744  Haluzik, M. ............... 759, 791
Gao, R. ................... 246  Hamdan, S. .................... 485
Garcia Toscano, M. .... 431  Hameete, A. ................. 314
Garcia-Calzon, S. ...... 43  Han, J. ...................... 381
Garcia-Martinez, I. ... 1053  Han, S. ...................... 316
García-Pérez, L.-E. ... 756  Hangaard, S. ............. 846
Garg, S. ................. 190  Hannelius, U. ............... 331
Garofolo, M. ........... 1013  Harder, M. ................. 313
Gasior, A. ............... 74  Hardikar, A. ............... 312
Gasperikova, D. ........ 298  Hardin, M. ................. 722
Geisler, C. .............. 378  Harer, C. M. ............... 442
Geng, S. .................. 525  Harris, S. ................ 811
Gheibi, S. ............... 588  Haugaard, S. B. ........ 922
Giambalvo, M. .......... 897  Hayman, M. M. E. ........ 129
Giangreco, F. .......... 885, 928  He, J. ...................... 395
Gibb, F. W. ............. 234, 800  He, L ...................... 292, 362
Gil, P. ..................... 893  Heald, A. ................. 288
Giosuè, A. .............. 366  Hecquet, S. K. ............. 945
Go, S.-H. ................. 582  Heebøll, S. ............... 953
Göbl, C. .................. 499  Heerspink, H. ............. 743
Gokulakrishnan, K. .... 279  Heerspink, H. J. L. .... 741
Goldenberg, R. ........ 11  Heianza, Y. ................. 367
Golubic, R. .............. 333, 354  Heida, J. ................. 576
Gómez, A. ............... 768, 821  Heise, T. ................. 8
Gong, Y. ................. 495  Hendriks, A. E. J. ....... 140
Gosmanov, A. R. ....... 724  Hendriksz, M. S. ........ 106
Goswami, P. ............ 918  Hentilä, J. ................. 586
Gourdy, P. ............... 824  Herder, C. ................. 979
Grassi, B. A. .......... 781  Herrera, P. ............... 252
Green, H. D. ........... 965  Hesp, A. C. ............... 509
Grill, V. .................. 342  Heymsfield, S. ............. 557
<table>
<thead>
<tr>
<th>Last Name, Initials, Presentation Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hill, T. G. .......................... 248</td>
</tr>
<tr>
<td>Hirlemann, M. ......................... 565</td>
</tr>
<tr>
<td>Hodgson, S. .......................... 179</td>
</tr>
<tr>
<td>Holland, D. ........................... 841</td>
</tr>
<tr>
<td>Hopkins, R. ........................... 347</td>
</tr>
<tr>
<td>Hornbrinck, E. ......................... 891</td>
</tr>
<tr>
<td>Hornigold, D. ........................ 707</td>
</tr>
<tr>
<td>Hosseini Marnani, E. .................. 80</td>
</tr>
<tr>
<td>Htoo, P. .............................. 52</td>
</tr>
<tr>
<td>Hu, Y. ................................. 1010</td>
</tr>
<tr>
<td>Huan, Z. ............................... 449</td>
</tr>
<tr>
<td>Huang, H. ............................. 241</td>
</tr>
<tr>
<td>Huang, M. L. H. ...................... 48</td>
</tr>
<tr>
<td>Huang, N. ............................. 160</td>
</tr>
<tr>
<td>Huang, P. ............................. 672</td>
</tr>
<tr>
<td>Huang, Q. .............................. 195</td>
</tr>
<tr>
<td>Huang, Q. .............................. 971</td>
</tr>
<tr>
<td>Huang, W. .............................. 416, 825</td>
</tr>
<tr>
<td>Huber, E. .............................. 310</td>
</tr>
<tr>
<td>Hui, W. ................................. 701</td>
</tr>
<tr>
<td>Hukema, F. ............................. 60</td>
</tr>
<tr>
<td>Hummel, S. ............................. 307</td>
</tr>
<tr>
<td>Hussain, S. ............................ 770</td>
</tr>
<tr>
<td>Huttasch, M. .......................... 169</td>
</tr>
<tr>
<td>Hüttil, M. ............................. 617</td>
</tr>
<tr>
<td>Hviid Klæbel, J. ...................... 35</td>
</tr>
<tr>
<td>Hwang, Y.-C. .......................... 101</td>
</tr>
<tr>
<td>Hwu, C.-M. ............................. 49</td>
</tr>
<tr>
<td>Iglesias Fortes, S. ................... 911</td>
</tr>
<tr>
<td>Iliham, S. ............................. 810</td>
</tr>
<tr>
<td>Imura, M. .............................. 675</td>
</tr>
<tr>
<td>Incedal Nilsson, C. ................... 212</td>
</tr>
<tr>
<td>Inoue, T. ............................... 134</td>
</tr>
<tr>
<td>Iqbal, A. ............................... 776</td>
</tr>
<tr>
<td>Ishibashi, R. .......................... 1029</td>
</tr>
<tr>
<td>Jager, J. ............................... 599</td>
</tr>
<tr>
<td>Jagroep, S. T. ........................ 204</td>
</tr>
<tr>
<td>Jalleh, R. J. ........................... 79, 84</td>
</tr>
<tr>
<td>Jang, M. ............................... 182</td>
</tr>
<tr>
<td>Jansz, T. ............................... 5</td>
</tr>
<tr>
<td>Katte, J. C. ........................... 301</td>
</tr>
</tbody>
</table>
Last Name, Initials, Presentation Number

Kaul, P. .......................... 993 Kruse, C. .......................... 401
Kaur, G. .......................... 933 Kuhre, R. E. .......................... 73
Kavin, N. .......................... 636 Kulzer, B. .......................... 876
Kawahara, R. .......................... 210 Kumar, N. .......................... 520, 526
Kempegowda, P. .......................... 860 Kumar, R. .......................... 1016
Kender, Z. .......................... 934 Kumar, V. .......................... 340
Keysendal, E. .......................... 327 Kundu, R. .......................... 668
Khalil, A. .......................... 130 Kwan, A. YM. .......................... 758
Khamis, A. .......................... 585 Kwon, H.-S. .......................... 715
Khare, S. .......................... 392 Kwon, S. .......................... 896
Kim, G. .......................... 353 Laborit Labrada, B. .......................... 578
Kim, H. .......................... 51 Labour, A. .......................... 507
Kim, M.-K. .......................... 663 Lai, Y.-J. .......................... 908
Kim, S.-H. .......................... 524 Lalama, E. .......................... 545
Kim, S. .......................... 580 Lampousi, A.-M. .......................... 294
Kim, S. .......................... 646 Langer, S. .......................... 554
Kim, S. .......................... 714 Larger, E. .......................... 69, 541
Kim, T. .......................... 654 Laterveer, R. .......................... 628
Kim, W. .......................... 498 Lau, N. S. .......................... 725
Kimura, T. .......................... 766 Laurberg, T. .......................... 957
Kislev, N. .......................... 651 Laursen, D. H. .......................... 235
Kizilkaya, H. .......................... 47 Lazzaroni, E. .......................... 352
Klepac-Bartl, K. .......................... 562 Layne, J. E. .......................... 814
Kloeckener, T. .......................... 82 Laye, J. E. .......................... 352
Knupp, J. .......................... 300 Lee, C. .......................... 972
Ko, J. .......................... 812 Lee, D.-Y. .......................... 1030
Koci, M. ........................ 83 Lee, D.-H. .......................... 403
Koefoed-Hansen, F. .......................... 172 Lee, E. Y. .......................... 742
Koene, E. J. C. .......................... 13 Lee, H. L. .......................... 334
Koning, M. .......................... 1062 Lee, K.-W. .......................... 639
Koprivica, I. .......................... 242 Lee, M. H. .......................... 319
Korakas, E. .......................... 906 Legøy, T. A. .......................... 372
Korn, A. .......................... 709, 1025 Lei, M. .......................... 902
Kortemeier, M. .......................... 1037 Leohr, J. .......................... 789
Kosai, M. .......................... 828 Levitt, C. H. .......................... 418
Kosiborod, M. N. .......................... 710 Li, J. .......................... 448
Kountouri, A. .......................... 594 Li, J. .......................... 670
Koutroukas, V. .......................... 868 Li, J. .......................... 936
Krążek, M. .......................... 574 Li, L. .......................... 603
Kragelund Nielsen, K. ........................ 178 Li, R. .......................... 925
Kruit, J. K. .......................... 476 Li, Y. .......................... 606
<table>
<thead>
<tr>
<th>Last Name, Initials, Presentation Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, Y. .................................... 790</td>
</tr>
<tr>
<td>Liarakos, A. L. .......................... 852</td>
</tr>
<tr>
<td>Lietzén, M. ................................ 522</td>
</tr>
<tr>
<td>Lim, C.-E. .................................. 406</td>
</tr>
<tr>
<td>Lim, H. ...................................... 296</td>
</tr>
<tr>
<td>Lin, J. ...................................... 95</td>
</tr>
<tr>
<td>Lin, X. ...................................... 615</td>
</tr>
<tr>
<td>Linares-Pineda, T. ....................... 276</td>
</tr>
<tr>
<td>Linder, T. ................................... 467</td>
</tr>
<tr>
<td>Ling, P. ..................................... 819</td>
</tr>
<tr>
<td>Linge, J. .................................... 123</td>
</tr>
<tr>
<td>Lingvay, I. .................................. 785</td>
</tr>
<tr>
<td>Linn, P. ...................................... 819</td>
</tr>
<tr>
<td>Linge, J. .................................... 940</td>
</tr>
<tr>
<td>Linsakovska, O. ........................... 946</td>
</tr>
<tr>
<td>Lithovius, R. ............................... 66</td>
</tr>
<tr>
<td>Liu, C. ...................................... 691</td>
</tr>
<tr>
<td>Liu, K. ...................................... 1023</td>
</tr>
<tr>
<td>Liu, L. ...................................... 732</td>
</tr>
<tr>
<td>Liu, Q. ....................................... 394, 397</td>
</tr>
<tr>
<td>Liu, X. ...................................... 423</td>
</tr>
<tr>
<td>Liu, Y. ...................................... 63</td>
</tr>
<tr>
<td>Liu, Y. ...................................... 901</td>
</tr>
<tr>
<td>Liu, Y. ...................................... 912</td>
</tr>
<tr>
<td>Ljubic, S. ................................... 905</td>
</tr>
<tr>
<td>Lobato, C. B. ............................... 571</td>
</tr>
<tr>
<td>Lockwood López, A. C. ................. 1001</td>
</tr>
<tr>
<td>Loh, K. ...................................... 409</td>
</tr>
<tr>
<td>López-Pedrosa, J. M. .................... 544, 552</td>
</tr>
<tr>
<td>Lorza-Gil, E. .............................. 77</td>
</tr>
<tr>
<td>Louvet, I. ................................... 302</td>
</tr>
<tr>
<td>Lu, B. ....................................... 919</td>
</tr>
<tr>
<td>Lugner, M. ................................... 981</td>
</tr>
<tr>
<td>Luk, C. ...................................... 530</td>
</tr>
<tr>
<td>Luo, X. ...................................... 669</td>
</tr>
<tr>
<td>Lupoli, R. ................................... 40</td>
</tr>
<tr>
<td>Lutz, T. A. .................................. 128</td>
</tr>
<tr>
<td>Lv, Y. ....................................... 546, 547</td>
</tr>
<tr>
<td>Lyu, Y. ...................................... 951</td>
</tr>
<tr>
<td>Last Name, Initials, Presentation Number</td>
</tr>
<tr>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Milad, C. ............................... 86</td>
</tr>
<tr>
<td>Minab, R. .................................. 434</td>
</tr>
<tr>
<td>Minelli Faiao, V. ........................ 284</td>
</tr>
<tr>
<td>Mir, B. A. .................................. 515</td>
</tr>
<tr>
<td>Mirasierra, M. ............................. 633</td>
</tr>
<tr>
<td>Mohamed, K. ............................... 921</td>
</tr>
<tr>
<td>Mohan, S. .................................. 247</td>
</tr>
<tr>
<td>Mokari-Yamchi, A. ........................ 798</td>
</tr>
<tr>
<td>Møller, P. M. .............................. 521</td>
</tr>
<tr>
<td>Mondal, A. .................................. 937</td>
</tr>
<tr>
<td>Monfort-Pires, M. ........................ 572</td>
</tr>
<tr>
<td>Monteillet, L. .............................. 429</td>
</tr>
<tr>
<td>Moon, S.-J. .................................. 817</td>
</tr>
<tr>
<td>Morciano, C. ............................... 713</td>
</tr>
<tr>
<td>Mori, M. .................................... 516</td>
</tr>
<tr>
<td>Moriconi, D. ............................... 974</td>
</tr>
<tr>
<td>Morieri, M. .................................. 997</td>
</tr>
<tr>
<td>Moser, O. ................................... 490</td>
</tr>
<tr>
<td>Motohashi, K. .............................. 534</td>
</tr>
<tr>
<td>Mourin, M. .................................. 613</td>
</tr>
<tr>
<td>Mraz, M. .................................... 816</td>
</tr>
<tr>
<td>Mužik, R. ................................... 844</td>
</tr>
<tr>
<td>Mueller, A. .................................. 211</td>
</tr>
<tr>
<td>Mukherjee, B. .............................. 1064</td>
</tr>
<tr>
<td>Mukherjee, O. .............................. 143</td>
</tr>
<tr>
<td>Mukunda, A. ................................. 468</td>
</tr>
<tr>
<td>Müller, L. ................................... 570</td>
</tr>
<tr>
<td>Munoz, F. A. ............................... 412</td>
</tr>
<tr>
<td>Muntoni, S. ................................. 435</td>
</tr>
<tr>
<td>Muralidharan, S. ........................... 390</td>
</tr>
<tr>
<td>Murdassov, Y. .............................. 421</td>
</tr>
<tr>
<td>Murray Leech, J. ........................... 225</td>
</tr>
<tr>
<td>Muthukumar, A. ............................ 162</td>
</tr>
<tr>
<td>Mutter, S. ................................... 159</td>
</tr>
<tr>
<td>Naemi, R. .................................... 879</td>
</tr>
<tr>
<td>Nag, S. ...................................... 260</td>
</tr>
<tr>
<td>Nanan, R. .................................... 436</td>
</tr>
<tr>
<td>Narum, M. ................................... 1034</td>
</tr>
<tr>
<td>Nathan, R. ................................... 703</td>
</tr>
<tr>
<td>Navarrete, J. ................................ 396</td>
</tr>
<tr>
<td>Last Name, Initials, Presentation Number</td>
</tr>
<tr>
<td>-----------------------------------------</td>
</tr>
<tr>
<td>Perrier, Q. .................................. 218</td>
</tr>
<tr>
<td>Persad, K. .................................. 855</td>
</tr>
<tr>
<td>Petersen, E. A. ................................ 555</td>
</tr>
<tr>
<td>Petkovic, M. .................................. 262</td>
</tr>
<tr>
<td>Petrelli, A. .................................. 306</td>
</tr>
<tr>
<td>Petrovski, G. ................................ 780</td>
</tr>
<tr>
<td>Piazza, C. .................................. 831</td>
</tr>
<tr>
<td>Picard, F. .................................. 536</td>
</tr>
<tr>
<td>Pinzon-Cortes, J. .......................... 1021</td>
</tr>
<tr>
<td>Pipella, J. .................................. 68</td>
</tr>
<tr>
<td>Pirro, V. .................................. 730</td>
</tr>
<tr>
<td>Pistorio, V. ................................ 624</td>
</tr>
<tr>
<td>Pivovarova-Ramich, O. ........................ 29, 649</td>
</tr>
<tr>
<td>Pliouta, L. .................................. 22</td>
</tr>
<tr>
<td>Prakash, A. ................................ 931</td>
</tr>
<tr>
<td>Puente-Ruiz, S. ............................. 637</td>
</tr>
<tr>
<td>Putcha, V. .................................. 782</td>
</tr>
<tr>
<td>Putula, E. ................................ 111</td>
</tr>
<tr>
<td>Qin, G. ...................................... 2</td>
</tr>
<tr>
<td>Qiu, S. ....................................... 14</td>
</tr>
<tr>
<td>Quansah, D. ................................ 491</td>
</tr>
<tr>
<td>Quinn, L. .................................. 311</td>
</tr>
<tr>
<td>Rahmani, M. ................................ 1006</td>
</tr>
<tr>
<td>Rajamand Ekberg, N. .......................... 349</td>
</tr>
<tr>
<td>Rakotoarisoa, L. ................................ 818</td>
</tr>
<tr>
<td>Ramos, H. .................................. 920</td>
</tr>
<tr>
<td>Rasmussen, M. G. B. .......................... 405</td>
</tr>
<tr>
<td>Rasmussen, N. ................................ 602</td>
</tr>
<tr>
<td>Ravier, M. A. ................................ 413</td>
</tr>
<tr>
<td>Rebelos, E. .................................. 731</td>
</tr>
<tr>
<td>Rebrova, Y. ................................ 903</td>
</tr>
<tr>
<td>Redondo, M. J. ................................ 112, 324</td>
</tr>
<tr>
<td>Reis-Costa, A. ................................ 199</td>
</tr>
<tr>
<td>Renard, E. ................................ 118</td>
</tr>
<tr>
<td>Renaud, C. .................................. 438</td>
</tr>
<tr>
<td>Resi, V. .................................. 460</td>
</tr>
<tr>
<td>Resmini, E. ................................ 120, 872</td>
</tr>
<tr>
<td>Rewers, A. .................................. 486</td>
</tr>
<tr>
<td>Rewers, M. .................................. 36</td>
</tr>
<tr>
<td>Rial, S. .................................. 657</td>
</tr>
<tr>
<td>Riccio, A. .................................. 968</td>
</tr>
<tr>
<td>Riddell, M. C. ................................ 787</td>
</tr>
<tr>
<td>Ried-Larsen, M. .................................. 696</td>
</tr>
<tr>
<td>Rimpeläinen, K. ............................... 461</td>
</tr>
<tr>
<td>Rios-Morales, M. ................................ 15</td>
</tr>
<tr>
<td>Riserus, U. .................................. 30</td>
</tr>
<tr>
<td>Ritz, P. ...................................... 799</td>
</tr>
<tr>
<td>Riveline, J.-P. ................................. 115, 119</td>
</tr>
<tr>
<td>Rivera, K. .................................. 439</td>
</tr>
<tr>
<td>Rizvi, A. .................................. 674</td>
</tr>
<tr>
<td>Roberts, A. .................................. 223</td>
</tr>
<tr>
<td>Roca-Rivada, A. ................................. 389, 452</td>
</tr>
<tr>
<td>Rodríguez, A. ................................ 754</td>
</tr>
<tr>
<td>Rodríguez, L. ................................ 402</td>
</tr>
<tr>
<td>Rodríguez, L. A. ................................ 404</td>
</tr>
<tr>
<td>Rodríguez de Vera Gómez, P. ................ 863</td>
</tr>
<tr>
<td>Rodríguez-Camero, G. .......................... 834</td>
</tr>
<tr>
<td>Roeikjer, J. ................................ 927, 932</td>
</tr>
<tr>
<td>Rohbeck, E. .................................. 1056</td>
</tr>
<tr>
<td>Rohmann, N. .................................. 153</td>
</tr>
<tr>
<td>Romarowski, B. ................................ 870</td>
</tr>
<tr>
<td>Rondinone, C. M. ............................... 81</td>
</tr>
<tr>
<td>Rosales, Á. .................................. 1015</td>
</tr>
<tr>
<td>Rosendo-Silva, D. .............................. 641</td>
</tr>
<tr>
<td>Rossi, C. .................................. 619</td>
</tr>
<tr>
<td>Rossing, P. .................................. 892</td>
</tr>
<tr>
<td>Roumans, K. H. M. ................................ 17</td>
</tr>
<tr>
<td>Ruotolo, G. ................................ 150, 737</td>
</tr>
<tr>
<td>Russo, G. .................................. 24, 849</td>
</tr>
<tr>
<td>Russo, S. .................................. 1057</td>
</tr>
<tr>
<td>Ryder, R. E. J. ................................ 792</td>
</tr>
<tr>
<td>Saari, T. .................................. 573</td>
</tr>
<tr>
<td>Sabatini, S. .................................. 230</td>
</tr>
<tr>
<td>Sacchetta, L. .................................. 793</td>
</tr>
<tr>
<td>Sacre, J. W. .................................. 98</td>
</tr>
<tr>
<td>Saienko, Y. .................................. 915</td>
</tr>
<tr>
<td>Salah, N. .................................. 987</td>
</tr>
<tr>
<td>Salle, L. ...................................... 87</td>
</tr>
<tr>
<td>Samakidou, G. ................................ 261</td>
</tr>
<tr>
<td>Sánchez Ceinos, J. ............................. 1024</td>
</tr>
<tr>
<td>Sandforth, L. .................................. 958</td>
</tr>
<tr>
<td>Sanfilippo, S. ................................ 136</td>
</tr>
<tr>
<td>Santos-Clemente, R. ............................ 597</td>
</tr>
<tr>
<td>Last Name, Initials, Presentation Number</td>
</tr>
<tr>
<td>------------------------------------------</td>
</tr>
<tr>
<td>Santos-Hernandez, M. 173</td>
</tr>
<tr>
<td>Sanyal, A. 739</td>
</tr>
<tr>
<td>Sanz Villanueva, L. 432</td>
</tr>
<tr>
<td>Saponaro, C. 762</td>
</tr>
<tr>
<td>Sarabhai, T. 53</td>
</tr>
<tr>
<td>Saravanan, P. 254</td>
</tr>
<tr>
<td>Sarma, S. 517</td>
</tr>
<tr>
<td>Sarwat, S. 607</td>
</tr>
<tr>
<td>Sato, D. 216</td>
</tr>
<tr>
<td>Sato, H. 508</td>
</tr>
<tr>
<td>Satuli-Autere, S. I. 955</td>
</tr>
<tr>
<td>Sbierski-Kind, J. 479</td>
</tr>
<tr>
<td>Schmedt, N. 1032</td>
</tr>
<tr>
<td>Schmidtké, M. 303</td>
</tr>
<tr>
<td>Schön, M. 266</td>
</tr>
<tr>
<td>Schoug, J. 883</td>
</tr>
<tr>
<td>Schupp, E. 187</td>
</tr>
<tr>
<td>Schuppelius, B. 591</td>
</tr>
<tr>
<td>Schürfeld, R. 909</td>
</tr>
<tr>
<td>Schut, K. 125</td>
</tr>
<tr>
<td>Schweitzer, L. 683</td>
</tr>
<tr>
<td>Scidà, G. 690</td>
</tr>
<tr>
<td>Secher, A. 75</td>
</tr>
<tr>
<td>Seebauer, L. 938</td>
</tr>
<tr>
<td>Sehgal, R. 656</td>
</tr>
<tr>
<td>Seignier, J. 205</td>
</tr>
<tr>
<td>Selvarajah, D. 929</td>
</tr>
<tr>
<td>Semeia, L. 56</td>
</tr>
<tr>
<td>Senesi, P. 973</td>
</tr>
<tr>
<td>Seno, Y. 612</td>
</tr>
<tr>
<td>Shaik, A. 274</td>
</tr>
<tr>
<td>Shamanna, P. 236</td>
</tr>
<tr>
<td>Shamansurova, Z. 568</td>
</tr>
<tr>
<td>Shankar, A. 625</td>
</tr>
<tr>
<td>Sharma, S. 280</td>
</tr>
<tr>
<td>Shehadeh, N. 729</td>
</tr>
<tr>
<td>Shen, Z.-Y. 1000</td>
</tr>
<tr>
<td>Shin, H. 631</td>
</tr>
<tr>
<td>Shin, J. J. 775</td>
</tr>
<tr>
<td>Shomali, M. E. 835</td>
</tr>
<tr>
<td>Shu, Z. 943</td>
</tr>
</tbody>
</table>
Last Name, Initials, Presentation Number

Sun, R. ......................... .994  Tsimihodimos, V. .................. .721
Sun, X. ......................... .609  Tsitsou, S. ....................... .26
Sun, Y. ........................ .170, 553  Tu, Z. .......................... .948
Suur, B. E. ..................... .664  Tuluc, P. ....................... .424
Svehlikova, E. ................ .244, 723  Tuomilehto, J. ................ .176
Svensson, S. I. A. ............ .203  U-Din, M. ..................... .577
Szekely, K. ..................... .587  Ueda, M. ..................... .678
Syreeni, A. ..................... .984  Ukropec, J. ................... .961
Talamonti, E. .................. .560  Ulanowska, M. ............... .584
Tan, H. ........................ .308  Ung, M. ....................... .769
Tao, W. ........................ 1009  Unger, L. ..................... .415
Tapia, G. ....................... . 31  Vähäkangas, E. ............ .163
Tara, Y. ........................ .410  Valderas, J. P. ............. . 4
Tavajoh, S. .................... .662  Valo, E. ...................... .978
Teixeira, P. D. S. ............ .510  Vambergue, A. ............. .464
Templeman, E. ................ .336  van de Bunt, M. ............. .156
Templeman, E. L. ............. .34  van den Burg, E. L. ....... .27
Terva Braake, J. G. .......... .845  Van der Kolk, B. W. ...... .592
Tesi, M. ........................ .454  van der Velde, J. H. P. .... .283
Teunis, C. J. .................. .949  van Duinkerken, E. ....... .874, 954
Tham, L. ........................ .745  Vandenbempt, V. .......... .167
Thant, A. ....................... .838  Vanweert, F. ................. .531
Thennati, R. ................... 738, 751  Varkevisser, R. .......... .105
Thirumoorthy, C. ............ .277  Veefald, S. .................... .537
Thomaides-Brears, H. ...... .110  Vellanki, P. .................. 487, 511
Thomas, A. M. ............... .539  Vera-Ramos, J. ............ .321
Thomas, J. J. C. ............. .857  Vergara Ucin, J. ........... 420, 422
Thomas, M. K. ............... .131  Verma, M. ................... .618
Thomas, N. .................... .322  Verma, S. ................... .124
Thomsen, R. W. ............. .807  Vernstrøm, L. ............... . 3
Thorius, I. H. ................. .256  Vessari, H. ................... .344
Thybo, T. ...................... .869  Vestergaard, B. ............ 558, 78
Tokgöz, S. .................... .152  Vijayakumar, A. .......... 610, 611
Tokuno, S. .................... .726  Vila Bedmar, R. .......... .666
Tomás, A. ...................... .132  Villanueva-Carmona, T. .... .702
Tonioli, M. .................... .323  Villena, J. A. ............... .575
Triatin, R. D. ................. .44  Vilsbøll, T. ................... .12
Trico, D. ....................... .107  Viñals, C. ................... .1041
Trinks, N. ..................... .962  Vinci, C. .................... .164
Villena, S. M. ............... .289  Virtanen, A. ................ .559
<table>
<thead>
<tr>
<th>Last Name, Initials, Presentation Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vuong, B. T.</td>
</tr>
<tr>
<td>Waage, C.</td>
</tr>
<tr>
<td>Wada, N.</td>
</tr>
<tr>
<td>Wada, T.</td>
</tr>
<tr>
<td>Wagh, R. H.</td>
</tr>
<tr>
<td>Wan, X.</td>
</tr>
<tr>
<td>Wang, H.</td>
</tr>
<tr>
<td>Wang, J.</td>
</tr>
<tr>
<td>Wang, K.</td>
</tr>
<tr>
<td>Wang, Q.</td>
</tr>
<tr>
<td>Wang, R.</td>
</tr>
<tr>
<td>Wang, S.</td>
</tr>
<tr>
<td>Wang, W.</td>
</tr>
<tr>
<td>Wang, X.</td>
</tr>
<tr>
<td>Wang, Y.</td>
</tr>
<tr>
<td>Wang, Y.</td>
</tr>
<tr>
<td>Wang, Z.</td>
</tr>
<tr>
<td>Wang, Z.</td>
</tr>
<tr>
<td>Wei, Y.</td>
</tr>
<tr>
<td>Weksler-Zangen, S.</td>
</tr>
<tr>
<td>Wilkinson, F.</td>
</tr>
<tr>
<td>Williams, D. M.</td>
</tr>
<tr>
<td>Wilmot, E. G.</td>
</tr>
<tr>
<td>Wilson, R. B.</td>
</tr>
<tr>
<td>Witkowski, P.</td>
</tr>
<tr>
<td>Wolffenbuttel, B. H. R.</td>
</tr>
<tr>
<td>Wong, W. K. M.</td>
</tr>
<tr>
<td>Wrublewsky, S.</td>
</tr>
<tr>
<td>Wu, H.</td>
</tr>
<tr>
<td>Wu, J.</td>
</tr>
<tr>
<td>Wu, P.</td>
</tr>
<tr>
<td>Wu, X.</td>
</tr>
<tr>
<td>Wu, Y.</td>
</tr>
<tr>
<td>Wysham, C. H.</td>
</tr>
<tr>
<td>Xia, J.</td>
</tr>
<tr>
<td>Xiang, C.</td>
</tr>
<tr>
<td>Xie, C.</td>
</tr>
<tr>
<td>Xu, S.</td>
</tr>
<tr>
<td>Xu, S.</td>
</tr>
<tr>
<td>Xu, W.</td>
</tr>
<tr>
<td>Xu, Y.</td>
</tr>
<tr>
<td>Xue, S.</td>
</tr>
</tbody>
</table>
## Invited Speakers

<table>
<thead>
<tr>
<th>Last Name, First Name</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adler, Amanda I.</td>
<td>49</td>
</tr>
<tr>
<td>Adriaenssens, Alice E.</td>
<td>72</td>
</tr>
<tr>
<td>Aguilar-Salinas, Carlos A.</td>
<td>71</td>
</tr>
<tr>
<td>Ahlqvist, Emma</td>
<td>113</td>
</tr>
<tr>
<td>Andersen, Ulrik B.</td>
<td>74</td>
</tr>
<tr>
<td>Arai, Yusuke</td>
<td>75</td>
</tr>
<tr>
<td>Aronne, Louis J.</td>
<td>84</td>
</tr>
<tr>
<td>Bajaj, Harpreet S.</td>
<td>45</td>
</tr>
<tr>
<td>Bergenstal, Richard</td>
<td>45</td>
</tr>
<tr>
<td>Berney, Thierry</td>
<td>111</td>
</tr>
<tr>
<td>Billings, Liana K.</td>
<td>69</td>
</tr>
<tr>
<td>Blüher, Matthias</td>
<td>84</td>
</tr>
<tr>
<td>Börgeson, Emma</td>
<td>95</td>
</tr>
<tr>
<td>Bradley, Cathy J.</td>
<td>94</td>
</tr>
<tr>
<td>Breton, Marc D.</td>
<td>113</td>
</tr>
<tr>
<td>Busetto, Luca</td>
<td>95</td>
</tr>
<tr>
<td>Colleluori, Georgia</td>
<td>73</td>
</tr>
<tr>
<td>Cota, Daniela</td>
<td>70</td>
</tr>
<tr>
<td>D’Alessio, David A.</td>
<td>112</td>
</tr>
<tr>
<td>Danne, Thomas</td>
<td>75</td>
</tr>
<tr>
<td>Davies, Melanie J.</td>
<td>45</td>
</tr>
<tr>
<td>De Franco, Elisa.</td>
<td>68</td>
</tr>
<tr>
<td>Dean, Danielle</td>
<td>112</td>
</tr>
<tr>
<td>Del Prato, Stefano</td>
<td>45</td>
</tr>
<tr>
<td>Dennis, John</td>
<td>113</td>
</tr>
<tr>
<td>Dewitte, Marieke</td>
<td>70</td>
</tr>
<tr>
<td>Dinneen, Sean</td>
<td>75</td>
</tr>
<tr>
<td>Egan, Aoife M.</td>
<td>58</td>
</tr>
<tr>
<td>Espeland, Mark</td>
<td>49</td>
</tr>
<tr>
<td>Evans, Mark</td>
<td>75</td>
</tr>
<tr>
<td>Flodstrom Tullberg, Malin.</td>
<td>96</td>
</tr>
<tr>
<td>Folgueira Cobos, Cintia</td>
<td>73</td>
</tr>
<tr>
<td>Frühbeck, Gema</td>
<td>95</td>
</tr>
<tr>
<td>Gauthier, Benoit</td>
<td>60</td>
</tr>
<tr>
<td>Gimeno, Ruth</td>
<td>72</td>
</tr>
<tr>
<td>Goodyear, Laurie J.</td>
<td>45</td>
</tr>
<tr>
<td>Griffin, Simon J.</td>
<td>49</td>
</tr>
<tr>
<td>Griffin, Tomas</td>
<td>50</td>
</tr>
<tr>
<td>Haluzik, Martin</td>
<td>105</td>
</tr>
<tr>
<td>Hansen, Torben</td>
<td>71</td>
</tr>
<tr>
<td>Hansen, Dominique</td>
<td>50</td>
</tr>
<tr>
<td>Heinemann, Lutz</td>
<td>75</td>
</tr>
<tr>
<td>Heinonen, Sini M.</td>
<td>73</td>
</tr>
<tr>
<td>Hussain, Sufyan</td>
<td>50</td>
</tr>
<tr>
<td>Hyöty, Heikki A.</td>
<td>49</td>
</tr>
<tr>
<td>Izquierdo, Mikel</td>
<td>50</td>
</tr>
<tr>
<td>Jastreboff, Ania M.</td>
<td>46</td>
</tr>
<tr>
<td>Ji, Linon</td>
<td>69</td>
</tr>
<tr>
<td>Johnson, Randi K.</td>
<td>49</td>
</tr>
<tr>
<td>Kamenov, Zdravko A.</td>
<td>70</td>
</tr>
<tr>
<td>Kerman, Fiona</td>
<td>95</td>
</tr>
<tr>
<td>Kieffer, Timothy J.</td>
<td>74</td>
</tr>
<tr>
<td>Kilpeläinen, Tuomas O.</td>
<td>113</td>
</tr>
<tr>
<td>King, Bruce</td>
<td>98</td>
</tr>
<tr>
<td>Knudsen, Jakob G.</td>
<td>112</td>
</tr>
<tr>
<td>Kokoszka, Andrzej W.</td>
<td>46</td>
</tr>
<tr>
<td>Krook, Anna</td>
<td>60</td>
</tr>
<tr>
<td>Kropp, Martina</td>
<td>74</td>
</tr>
<tr>
<td>Liesa-Roig, Marc</td>
<td>71</td>
</tr>
<tr>
<td>Lingvay, Ildiko</td>
<td>69</td>
</tr>
<tr>
<td>Lord, Simon</td>
<td>94</td>
</tr>
<tr>
<td>Lutz, Thomas</td>
<td>46</td>
</tr>
<tr>
<td>Mader, Julia K.</td>
<td>98</td>
</tr>
<tr>
<td>Maltese, Giuseppe</td>
<td>46</td>
</tr>
<tr>
<td>Martinez-Tellez, Borja</td>
<td>73</td>
</tr>
<tr>
<td>Mathieu, Chantal</td>
<td>28, 113</td>
</tr>
<tr>
<td>McCrimmon, Rory</td>
<td>69</td>
</tr>
<tr>
<td>McGuire, Darren K.</td>
<td>49</td>
</tr>
<tr>
<td>Mejhert, Niklas</td>
<td>45</td>
</tr>
<tr>
<td>Morganstein, Daniel</td>
<td>58</td>
</tr>
<tr>
<td>Murphy, Helen R.</td>
<td>113</td>
</tr>
<tr>
<td>Nakada, Haruka</td>
<td>75</td>
</tr>
<tr>
<td>Natarajan, Rama</td>
<td>74</td>
</tr>
<tr>
<td>Nauck, Michael A.</td>
<td>72</td>
</tr>
<tr>
<td>Nogueiras, Ruben</td>
<td>70, 100</td>
</tr>
<tr>
<td>Perkins, Bruce A.</td>
<td>105</td>
</tr>
<tr>
<td>Pinhas-Hamiel, Orit</td>
<td>47</td>
</tr>
<tr>
<td>Pop-Busui, Rodica</td>
<td>44</td>
</tr>
<tr>
<td>Raun, Kirsten</td>
<td>46</td>
</tr>
<tr>
<td>Last Name, First Name, Page</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td>Reichman, Trevor W. ..........</td>
<td>74</td>
</tr>
<tr>
<td>Richardson, Sarah J. ..........</td>
<td>96</td>
</tr>
<tr>
<td>Rickford, Alice ..............</td>
<td>46</td>
</tr>
<tr>
<td>Rodriguez-Calvo, Teresa ......</td>
<td>49</td>
</tr>
<tr>
<td>Rorsman, Patrik .............</td>
<td>112</td>
</tr>
<tr>
<td>Rossing, Peter ..............</td>
<td>69</td>
</tr>
<tr>
<td>Rubino, Francesco ...........</td>
<td>84</td>
</tr>
<tr>
<td>Russell-Jones, David .......</td>
<td>98</td>
</tr>
<tr>
<td>Rydén, Mikael ..............</td>
<td>95</td>
</tr>
<tr>
<td>Sandholm, Niina. ............</td>
<td>100</td>
</tr>
<tr>
<td>Sanyal, Arun ...............</td>
<td>71</td>
</tr>
<tr>
<td>Scharffmann, Raphael .......</td>
<td>99</td>
</tr>
<tr>
<td>Shah, Amy ..................</td>
<td>47</td>
</tr>
<tr>
<td>Shapiro, Allison L. B. ....</td>
<td>47</td>
</tr>
<tr>
<td>Shaw, James A. M. ..........</td>
<td>74</td>
</tr>
<tr>
<td>Shulman, Gerald I. .........</td>
<td>71</td>
</tr>
<tr>
<td>Simo, Rafael ................</td>
<td>99</td>
</tr>
<tr>
<td>Sinclair, Alan J. ...........</td>
<td>113</td>
</tr>
<tr>
<td>Sivaprasad, Sobha ...........</td>
<td>99</td>
</tr>
<tr>
<td>Sordi, Valeria .............</td>
<td>99</td>
</tr>
<tr>
<td>Sparks, Lauren M. ..........</td>
<td>50</td>
</tr>
<tr>
<td>Srivastava, Anand ..........</td>
<td>69</td>
</tr>
<tr>
<td>Steinberg, Gregory R. ......</td>
<td>70</td>
</tr>
<tr>
<td>Sussel, Lori ...............</td>
<td>48</td>
</tr>
<tr>
<td>Tack, Cees J. ..............</td>
<td>45</td>
</tr>
<tr>
<td>Tangri, Navdeep .............</td>
<td>50</td>
</tr>
<tr>
<td>Taube, Magdalena ..........</td>
<td>94</td>
</tr>
<tr>
<td>Taylor, Roy ..............</td>
<td>28</td>
</tr>
<tr>
<td>Thabit, Hood ...............</td>
<td>113</td>
</tr>
<tr>
<td>Thomas, Stephen ...........</td>
<td>58</td>
</tr>
<tr>
<td>Thyfault, John P. ..........</td>
<td>50</td>
</tr>
<tr>
<td>Tuomi, Tiinamaija ..........</td>
<td>96</td>
</tr>
<tr>
<td>Uruska, Aleksandra .......</td>
<td>70</td>
</tr>
<tr>
<td>Venditti, Paola ............</td>
<td>71</td>
</tr>
<tr>
<td>Willaing, Tapager, Ingrid.</td>
<td>75</td>
</tr>
<tr>
<td>Williamson, Alice .........</td>
<td>45</td>
</tr>
<tr>
<td>Wojtusciszyn, Anne .......</td>
<td>111</td>
</tr>
<tr>
<td>Wysham, Carol .............</td>
<td>45</td>
</tr>
<tr>
<td>Yaghootkar, Hanieh .......</td>
<td>100</td>
</tr>
<tr>
<td>Ziegler, Anette-Gabriele ...</td>
<td>112</td>
</tr>
<tr>
<td>Zierath, Juleen R. ..........</td>
<td>93</td>
</tr>
</tbody>
</table>
Satellite Symposia on the Occasion of the 60th EASD Annual Meeting
PCDE SYMPOSIUM

Mon, 9 September 2024 09:00 - 10:30  Retiro Hall

Chair: TBA
Speaker: TBA
D&CVD SYMPOSIUM

Mon, 9 September 2024 11:00 - 13:00 Retiro Hall

Chair: TBA  
Speaker: TBA
DFSG SYMPOSIUM

Mon, 9 September 2024  13:30 - 15:00  Retiro Hall

Chair: TBA
Speaker: TBA
PSAD SYMPOSIUM

Mon, 9 September 2024  15:30 - 17:30  Retiro Hall

Chair: TBA
Speaker: TBA
INCSG SYMPOSIUM

Tue, 10 September 2024 09:30 - 11:00 Retiro Hall

Chair: TBA
Speaker: TBA
DIABETES INDIA SYMPOSIUM

Tue, 10 September 2024  11:30 - 13:30  Retiro Hall

Chair:  TBA
Speaker:  TBA
DPSON SYMPOSIUM

Tue, 10 September 2024 14:00 - 16:00 Retiro Hall

Chair: TBA
Speaker: TBA

DPSG SYMPOSIUM

Tue, 10 September 2024 14:00 - 16:00 Retiro Hall

Chair: TBA
Speaker: TBA
#dedoc° SYMPOSIUM

**What we wish you knew - and why**

**Tue, 10 September 2024**  
16:30 - 18:30  
Retiro Hall

**Chairs:** Renza Scibilia, Australia; Bastian Hauck, Germany

**Speaker:** TBA
DESG SYMPOSIUM

Wed, 11 September 2024 09:00 - 11:00 Retiro Hall

Chair: TBA
Speaker: TBA
ExPAS SYMPOSIUM

Wed, 11 September 2024 11:30 - 13:30 Retiro Hall

Chair: TBA
Speaker: TBA
EUDF SYMPOSIUM
Diabetes data and registries: Enabling high quality diabetes care

Wed, 11 September 2024  14:00 - 16:00  Retiro Hall

**Chairs:** Stefano Del Prato, Italy; Chantal Mathieu, Belgium

**Speaker:** Stefano Del Prato, Italy: **Welcome and introduction**

Khamlesh Khunti, UK: **Why registries?**

The **different roles of registries in research and diabetes care:**

Juliana Chan, Hong Kong: **Clinical: Hong Kong Diabetes Register**

Anette-Gabriele Ziegler, Germany: **Research: European pre-T1D Registry**

Katarina Eeg-Olofsson, Sweden: **National: Swedish National Diabetes Register**

Olga Kordonouri, Germany: **Care: SWEET Registry**

**Round Table: how to leverage existing research registries for clinical purposes**

The **policy perspective on data and registries:**

Jill Farrington, Denmark: **WHO EURO: How to measure and monitor progress towards the global diabetes targets**

Massimo Massi Benedetti, Italy: **EU Commission: Collaborative Health Information European Framework (CHIEF)**

Hector Bueno, Spain: **JACARDI: Data availability, quality, accessibility and sharing**

Carla Torre, Portugal: **European Regulator: Opportunities and challenges of registries for regulatory decision-making**

Chantal Mathieu, Belgium: **Wrap-up and next steps**
DASG SYMPOSIUM

Wed, 11 September 2024  16:30 - 18:30  Retiro Hall

Chair: TBA
Speaker: TBA
NEUROdiab SYMPOSIUM

Thu, 12 September 2024 09:00 - 11:00 Retiro Hall

Chair: TBA
Speaker: TBA
IDF EUROPE SYMPOSIUM
Personalisation of care - the way forward

Thu, 12 September 2024 11:30 - 13:00 Retiro Hall

Chair: João F. Raposo, Portugal
Speaker: Nebojsa M. Lalic, Serbia:
Welcome and introduction

Juan A. Giménez Bastida, Spain; Cajsa Lindberg, Belgium:
What does personalisation of care mean and what is needed to drive this? - Dialogue between a T2D advocate and T1D advocate

Katharine Barnard-Kelly, UK; Sufyan Hussain, UK; Pinar Topsever, Turkey:
Getting to know healthcare system users, how do you make a science of it? - Conversation between a psychologist, endocrinologist and GP

Antonio Ceriello, Italy; Oliver Schnell, Germany:
Transforming and standardising healthcare systems for optimum personalisation - Conversation between two HCPs from different health systems

Pedro Gullón, Spain:
Breaking barriers - Enabling change - Policy maker’s perspective

Panel discussion and Q&A

Tadej Battelino, Slovenia:
Wrap up and closing remarks
HSRHE-SG SYMPOSIUM

Thu, 12 September 2024  14:00 - 16:00  Retiro Hall

Chair: TBA
Speaker: TBA
IHSG SYMPOSIUM

Thu, 12 September 2024

16:30 - 18:30

Retiro Hall

Chair: TBA
Speaker: TBA
DNSG SYMPOSIUM

Fri, 13 September 2024  09:00 - 11:00  Retiro Hall

Chair:         TBA
Speaker:       TBA
EASD/SFD SYMPOSIUM

Thu, 12 September 2024        11:30 - 13:00        Retiro Hall

Chair:  TBA
Speaker:  TBA
Industry Sessions
on the occasion of the

60<sup>th</sup> ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

9–13 September 2024 • Madrid, Spain

www.easd-industry.com

Organised by

INTERPLAN
media & service gmbh
INDUSTRY SYMPOSIA SCHEDULE

Monday, 9 September 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Madrid Hall</th>
<th>Berlin Hall</th>
<th>Cairo Hall</th>
<th>Sofia Hall</th>
<th>Sydney Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td>Novo Nordisk A/S</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>09:00 – 11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>SANOFI</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>10:30 – 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12:00 – 13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:00 – 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Medtronic International Trading Sàrl</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13:30 – 15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>GSK</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15:30 – 17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>Eli Lilly and Company</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>16:30 – 18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
INDUSTRY SYMPOSIAS SCHEDULE
Monday, 9 September 2024

Vienna Hall

09:00 – 11:00
Roche Diabetes Care GmbH
13:30 – 15:00

Lima Hall

Dexcom
13:00 – 14:30

Mumbai Hall

Boehringer Ingelheim International GmbH
15:00 – 16:30

Warsaw Hall

The Leona M. and Harry B. Helmsley Charitable Trust
09:00 – 18:00

Menarini Group
17:00 – 18:00

All stated times in CEST / Status June 2024, details are subject to change.
INDUSTRY SYMPOSIA SCHEDULE

Tuesday, 10 September 2024

<table>
<thead>
<tr>
<th>Time</th>
<th>Spotlight Stage</th>
<th>Lima Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td><strong>Eli Lilly and Company</strong>&lt;br&gt;12:00 – 12:30</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td><strong>Abbott</strong>&lt;br&gt;14:45 – 15:15</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td><strong>Novo Nordisk A/S</strong>&lt;br&gt;18:30 – 20:00</td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Spotlight Stage

Lima Hall
## INDUSTRY SYMPOSIA SCHEDULE

**Tuesday, 10 September 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:45</td>
<td>Virtual only</td>
<td><strong>iCare</strong> 08:45 – 08:55</td>
</tr>
<tr>
<td>08:55</td>
<td>Warsaw Hall</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Warsaw Hall</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Mumbai Hall</td>
<td></td>
</tr>
<tr>
<td>14:45</td>
<td>Mumbai Hall</td>
<td><strong>Merck KGaA</strong> 18:30 – 19:30</td>
</tr>
<tr>
<td>15:15</td>
<td>Warsaw Hall</td>
<td><strong>Servier medical affairs</strong> 18:30 – 19:30</td>
</tr>
<tr>
<td>18:30</td>
<td>Virtual only</td>
<td><strong>Merck KGaA</strong> 18:30 – 19:30</td>
</tr>
<tr>
<td>19:00</td>
<td>Mumbai Hall</td>
<td><strong>Servier medical affairs</strong> 18:30 – 19:30</td>
</tr>
<tr>
<td>19:30</td>
<td>Warsaw Hall</td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>Warsaw Hall</td>
<td></td>
</tr>
</tbody>
</table>

*All stated times in CEST / Status June 2024, details are subject to change.*
## Industry Symposium Schedule

**Wednesday, 11 September 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Spotlight Stage</th>
<th>Lima Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td></td>
<td>Boehringer Ingelheim and Eli Lilly and Company 07:45 – 08:45</td>
</tr>
<tr>
<td>08:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td><strong>Novo Nordisk A/S</strong> 12:15 – 12:45</td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td><strong>Dexcom</strong> 15:00 – 15:30</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td><strong>Eli Lilly and Company</strong> 17:00 – 17:30</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td>Novo Nordisk A/S 18:45 – 20:15</td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*All stated times in CEST / Details are subject to change.*
<table>
<thead>
<tr>
<th>Time</th>
<th>Mumbai Hall</th>
<th>Beijing Hall</th>
<th>Warsaw Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td>Insulet 07:45 – 08:45</td>
<td>Tandem Diabetes Care, Inc. 08:15 – 08:45</td>
<td>Abbott 07:45 – 08:45</td>
</tr>
<tr>
<td>08:15</td>
<td></td>
<td></td>
<td>08:15</td>
</tr>
<tr>
<td>08:45</td>
<td></td>
<td></td>
<td>08:45</td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td>Institute for Medical and Nursing Education, Inc. (INME) 18:45 – 20:15</td>
<td>Vertex Pharmaceuticals, Inc. 18:45 – 20:15</td>
<td></td>
</tr>
<tr>
<td>19:15</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*All stated times in CEST / Status June 2024, details are subject to change.*
**INDUSTRY SYMPOSIA SCHEDULE**

**Thursday, 12 September 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Spotlight Stage</td>
<td>Medtronic International Trading Sàrl 12:15 – 12:45</td>
</tr>
<tr>
<td>12:45</td>
<td>Lima Hall</td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>Spotlight Stage</td>
<td>Roche Diabetes Care GmbH 15:00 – 15:30</td>
</tr>
<tr>
<td>15:30</td>
<td>Lima Hall</td>
<td></td>
</tr>
<tr>
<td>18:45</td>
<td>Lima Hall</td>
<td>AKH Inc. and Catalyst Medical Education, LLC. 18:45 – 19:45</td>
</tr>
<tr>
<td>19:15</td>
<td>Lima Hall</td>
<td></td>
</tr>
<tr>
<td>19:45</td>
<td>Lima Hall</td>
<td></td>
</tr>
<tr>
<td>20:15</td>
<td>Lima Hall</td>
<td></td>
</tr>
</tbody>
</table>

**Friday, 13 September 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00</td>
<td>Spotlight Stage</td>
<td>Boehringer Ingelheim International GmbH 10:00 – 10:30</td>
</tr>
<tr>
<td>10:30</td>
<td>Lima Hall</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Spotlight Stage</td>
<td>Ypsomed AG 11:30 – 12:00</td>
</tr>
<tr>
<td>12:00</td>
<td>Lima Hall</td>
<td></td>
</tr>
</tbody>
</table>
INDUSTRY SYMPOSIA SCHEDULE

Thursday, 12 September 2024

Mumbai Hall

Warsaw Hall

12:15
12:45
15:00
15:30
18:45
19:15
19:45
20:15

DAIICHI SANKYO EUROPE GmbH
18:45 – 19:45

Novo Nordisk A/S and Echosens
18:45 – 19:15

Novo Nordisk A/S
19:45 – 20:15

All stated times in CEST / Status June 2024, details are subject to change.
MONDAY, 9 SEPTEMBER 2024
09:00 – 11:00
MADRID HALL

INNOVATION IN ACTION: MOVING FORWARD
WITH BASAL INSULINS IN T2D

Chair: Esteban Jodar (ESP)

09:00 – 09:10 Welcome and introduction
Esteban Jodar (ESP)

09:10 – 09:30 Basal insulin treatment in T2D:
where is the innovation taking us?
Athena Philis-Tsimikas (USA)

09:30 – 09:50 Continuous glucose monitoring in T2D:
what is the added value?
Harpreet Singh Bajaj (CAN)

09:50 – 10:00 Q&A
Athena Philis-Tsimikas (USA)
Harpreet Singh Bajaj (CAN)

10:00 – 10:20 Once weekly basal insulins across T2D populations:
what do we know so far?
Monika Kellerer (DEU)

10:20 – 10:40 Once weekly basal insulin in a changing environment
Alice Cheng (CAN)
Harpreet Singh Bajaj (CAN)

10:40 – 11:00 Discussion and Q&A
All faculty

Organised by: Novo Nordisk A/S
MondAy, 9 September 2024  09:00 – 18:00  
WARSAW HALL  

UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN DIABETES  

Welcome and Introduction  
09:00 – 09:15  Welcome and Introduction  
Alvin C. Powers (USA)  

Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes.  
09:15 – 09:45  Alphabet(a) soup: Unraveling cell fate decisions in the islet.  
Lori Sussel (USA)  
09:45 – 10:00  Q&A  
Lori Sussel (USA)  
10:00 – 10:30  Joan Camuñas-Soler (SWE)  
10:30 – 10:45  Q&A  
Joan Camuñas-Soler (SWE)  

Short talks from on submitted abstracts  
11:00 – 11:15  Short talk from on submitted abstracts 1  
11:15 – 11:20  Q&A  
11:20 – 11:35  Short talk from on submitted abstracts 2  
11:35 – 11:40  Q&A  
11:40 – 11:55  Short talk from on submitted abstracts 3  
11:55 – 12:00  Q&A
MONDAY, 9 SEPTEMBER 2024

UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN DIABETES

Understanding and restoring alpha cell function in T1D and T2D: Intrinsic, paracrine, and in vivo consequences in humans.

13:00 – 13:30  Patrik Rorsman (GBR)

13:30 – 13:45  Q&A
Patrik Rorsman (GBR)

13:45 – 14:15  Understanding and restoring alpha cell function in type 1 diabetes
Michael Rickles (USA)

14:15 – 14:30  Q&A
Michael Rickles (USA)

Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia.

Chair: Marjana Marinac (USA)

14:45 – 14:50  Introduction
Marjana Marinac (USA)

14:50 – 15:05  Asger Lund (DNK)

15:05 – 15:20  Richard Liggins (CAN)

15:20 – 15:35  TBD

15:35 – 15:45  Marjana Marinac (USA)

15:45 – 16:30  Discussion session
All Faculty

16:30 – 17:00  Closing Remarks

Poster Session

17:00 – 18:00  Poster Session

Organised by: The Leona M. and Harry B. Helmsley Charitable Trust
MONDAY, 9 SEPTEMBER 2024
10:30 – 12:00
SYDNEY HALL

EARLY USE OF CGM IN TYPE 2 DIABETES

10:30 – 10:45  A Data-Driven Rationale for the Early Deployment of Continuous Glucose Monitoring (CGM)

10:45 – 11:05  Is CGM The Key to Managing Healthcare Utilization in Persons with Diabetes?

11:05 – 11:25  Moving Beyond HbA1c—Optimizing Time-in-Range for Persons with Type 2 Diabetes

11:25 – 11:55  Interactive Case-Based Clinic: Early Application of CGM to Proactively Manage Type 2 Diabetes in the Real World

11:55 – 12:00  Question and Answer Session

Organised by: Abbott Diabetes Care
# PEOPLE, POPULATIONS AND PRACTICE: EXPLORING THE JOURNEY ACROSS DIABETES CARE

## SESSION 1

**Chair:** Stefano Del Prato (ITA)

**10:30 – 10:40 Welcome and introduction**  
Stefano Del Prato (ITA)

**10:40 – 10:50 A case of timing: Current outlook in those with ACSVD with Type 2 diabetes**  
Klaus Parhofer (DEU)

**10:50 – 11:05 Stepping back: Understanding very high CV risk populations**  
Emilio Ortega (ESP)

**11:05 – 11:15 Moving forwards: The importance of proactivity in ASCVD and Type 2 diabetes**  
Manuel Castro Cabezas (NLD)

**11:15 – 11:25 Panel discussion**  
All faculty

**11:25 – 11:30 Meeting close: Summary and conclusions**  
Stefano Del Prato (ITA)

## SESSION 2

**Chair:** Stefano Del Prato (ITA)

**11:30 – 11:35 Welcome and introduction**  
Stefano Del Prato (ITA)

**11:35 – 11:50 Establishing a renewed approach: Recognising needs across Type 2 diabetes**  
Stefano Del Prato (ITA)

**11:50 – 12:15 Navigating simplified paths with insulin-based therapies**  
Rory McCrimmon (GBR)

**12:15 – 12:35 Exploring personalized approaches in basal insulin management**  
Camille Vatier (FRA)

**12:35 – 12:50 The focal point: Empowering self-management**  
Othmar Moser (DEU)  
Virginia Bellido (ESP)

**12:50 – 13:00 Panel discussion**  
All faculty

**13:00 – 13:15 Break**

**13:15 – 14:00 The importance of hypoglycemia in the real world**  
Stewart Harris (CAN)  
Alexandria Ratzki-Leewing (CAN)

**14:00 – 14:30 Break**
BRINGING EARLY AUTOIMMUNE T1D CENTER STAGE:
EXPLORING RECENT ADVANCES AND EXPERT PERSPECTIVES

Chair: Colin Dayan (GBR)

14:30 – 14:35 Welcome
Colin Dayan (GBR)

14:35 – 14:50 Setting the Stage: Autoimmune Pathophysiology of Autoimmune T1D
Colin Dayan (GBR)

14:50 – 14:55 Panel Discussion
All faculty

14:55 – 15:10 Shining a Spotlight on Screening: Clinical and Real-world Experience
Anette Ziegler (DEU)

15:10 – 15:15 Panel Discussion
All faculty

15:15 – 15:30 Taking the Next Step: Management Options for People With Early-Stage Autoimmune T1D
• Monitoring and Education for People with Early-Stage Autoimmune T1D
  Linda DiMeglio (USA)

15:30 – 15:45 Taking the Next Step: Management Options for People With Early-Stage Autoimmune T1D
• The Evolving Treatment Landscape: Preservation of Beta-cell Function
  Emily Sims (USA)

15:45 – 15:55 Panel Discussion
All faculty

15:55 – 16:00 Session Close
Colin Dayan (GBR)

Organised by: SANOFI
MONDAY, 9 SEPTEMBER 2024

12:00 – 13:00

SOFIA HALL

NO SMOKE WITHOUT FIRE –
OBESITY AS AN UNDERLYING CAUSE OF DISEASE

12:00 – 12:05 Welcome and introductions

12:05 – 12:15 Smoke signals – The link between obesity and related comorbidities

12:15 – 12:30 Putting out the fire – Current and future management of obesity

12:30 – 12:45 Inspiring global change – Weight management and health equity/equality

12:45 – 12:55 Q&A
All faculty

12:55 – 13:00 Summary and close

Organised by: AstraZeneca
EMERGING THERAPIES IN HEART AND KIDNEY DISEASE:
BENEFITS AND CLINICAL IMPLICATIONS OF FINERENONE

Chairs: Javier Escalada San Martin (ESP)
        Paola Fioretto (ITA)

12:00 – 12:05  Welcome & introduction
                Javier Escalada San Martin (ESP)

12:05 – 12:25  Finerenone for the spectrum of patients with T2D and CKD:
improving cardiovascular and kidney outcomes
                Paola Fioretto (ITA)

12:25 – 12:45  Real-world benefits of finerenone: from guidelines to clinical
                practice
                Katharina Schuett (DEU)

12:45 – 13:05  Expanding the reach of finerenone: focus on heart failure
                Mikhail Kosiborod (USA)

13:05 – 13:25  Beyond T2D: exploring the role of finerenone in patients with
                T1D and CKD
                Richard Pratley (USA)

13:25 – 13:30  Discussion & close
                All faculty

Organised by:  Bayer AG
THE THREE GS IN THE CONTEXT OF GUT HORMONE MULTIAGONISM

Chair: Melanie Davies (GBR)

13:00 – 13:10 Welcome and introductions
   Melanie Davies (GBR)

13:10 – 13:30 GLP-1 in the context of gut hormone multiagonism
   John Wilding (GBR)

13:30 – 13:50 GIP in the context of gut hormone multiagonism
   Philipp Scherer (USA)

13:50 – 14:10 Glucagon in the context of gut hormone multiagonism
   Eleuterio Ferrannini (ITA)

14:10 – 14:28 Panel discussion
   All faculty

14:28 – 14:30 Wrap up
   Melanie Davies (GBR)

Organised by: Eli Lilly and Company
Organised by:  Dexcom
MONDAY, 9 SEPTEMBER 2024
13:30 – 15:00
SOFIA HALL

OPTIMISING CARDIORENNAL OUTCOMES THROUGH EARLY INITIATION OF SGLT2 INHIBITORS

13:30 – 13:45 Achieving Impactful Goals of Care

13:45 – 14:05 Maximising Cardiorenal Protection With SGLT2 Inhibition in Diverse Patient Populations

14:05 – 14:25 SGLT2Is in Heart Failure, CKD And T2D – What Does The Evidence Say?

14:25 – 14:45 SGLT2i Benefits on Renal Outcomes – Real World Evidence

14:45 – 15:00 SGLT2Is In Clinical Practice

Organised by: AstraZeneca
MONDAY, 9 SEPTEMBER 2024

EXPANDING HORIZONS IN INSULIN THERAPY:
APPLICATIONS OF MINIMED™ 780G SYSTEM AND MDI SOLUTIONS

Chair: Ohad Cohen (CHE)

13:30 – 13:40  Meeting the needs of diverse populations
Ohad Cohen (CHE)

13:40 – 14:00  The MiniMed 780G System Study in Very Young Children with Type 1 Diabetes – First results from the LENNY study

14:00 – 14:20  Using MiniMed™ 780G system in Pregestational Type 1 Diabetes

14:20 – 14:35  The MiniMed 780G system performance in people living with type 2 diabetes requiring insulin treatment

14:35 – 14:50  The Smart MDI system: maximizing the benefits of MDI therapy

14:50 – 15:00  Q&A

Organised by: Medtronic International Trading Sàrl

13:30 – 15:00
SYDNEY HALL
**PREPARE, PREVENT & ACT: ADVANCING IN-TIME GLYCAEMIC CONTROL BY UTILISING THE POWER OF PREDICTION**

**Chairs:** Ana Isabel Chico Ballesteros (ESP)  
Jackie Elliott (GBR)

**13:30 – 13:35 Introduction**  
Jackie Elliott (GBR)

**13:35 – 14:00 Close up: Common yet underrated challenges in daily diabetes therapy**  
Pratik Choudhary (GBR)

**14:00 – 14:25 In focus: Patient-centric innovation taking diabetes therapy to a new level with a novel CGM solution**  
Guido Freckmann (DEU)

**14:25 – 14:50 Spot on: AI-trained predictive algorithms designed for preventive action and improved therapy control**  
Lutz Heinemann (DEU)

**14:50 – 15:00 Discussion & Closing**  
All faculty

Organised by: Roche Diabetes Care GmbH
THE GLUCAGON PHILHARMONIC: ORCHESTRATING METABOLIC HARMONY IN OBESITY, LIVER DISEASE AND HEALTH

Chairs: Melanie Davies (GBR) Josep Vidal (ESP)

15:00 – 15:05 Setting the stage
Melanie Davies (GBR)

15:05 – 15:10 The conductor’s call
Josep Vidal (ESP)

15:10 – 15:20 Tuning in to obesity and scaling the challenge of cardiovascular-renal-metabolic diseases
Josep Vidal (ESP)

15:20 – 15:35 Metabolism overture: Discerning glucagon in ensemble
Daniel Drucker (CAN)

15:35 – 15:55 The allegro of liver health: Accelerating innovations in metabolic management
Mazen Noureddin (USA)

15:55 – 16:10 Concerted care in metabolic health
Ania Jastreboff (USA)

16:10 – 16:30 Moving the conversation
Melanie Davies (GBR)

Organised by: Boehringer Ingelheim International GmbH
EXPLORING THERAPEUTIC MECHANISMS TO IMPROVE ORGAN FUNCTION IN CVRM DISEASE

Chair: Hiddo Heerspink (NLD)

15:30 – 15:35 Introduction
Hiddo Heerspink (NLD)

15:35 – 15:55 Beneficial effects of GLP-1 – weight loss mediated versus direct action?
Carel le Roux (IRL)

15:55 – 16:15 Mechanistic synergies of the actions of SGLT2i’s and GLP1Ra’s on heart and liver
Ildiko Lingvay (USA)

16:15 – 16:35 Mechanistic synergies of the actions of SGLT2i’s and GLP1Ra’s on kidney protection
Hiddo Heerspink (NLD)

16:35 – 16:55 How can we utilize the mechanistic insights to further improve treatments of patients?
All Faculty

16:55 – 17:00 Summary and close
Hiddo Heerspink (NLD)

Organised by: AstraZeneca
ICAN REAL TIME CGM SYSTEM, 
AN OPTION FOR ALL PATIENT GROUPS

Chair: Lutz Heinemann (DEU)

16:00 – 16:05 Welcome and introduction  
Lutz Heinemann (DEU)

16:05 – 16:15 AID systems  
Partha Kar (GBR)

16:15 – 16:30 CGM accuracy assessments  
Guido Freckmann (DEU)

16:30 – 16:40 iCan real time CGM system performance  
Jiangfeng Fei (CHN)

16:40 – 16:55 Current situation of CGM in Spain and new approaches for DM2 management  
Martín Cuesta Hernández (ESP)

16:55 – 17:00 Q&A  
Lutz Heinemann (DEU)

Organised by: Sinocare Meditech Inc.
MONDAY, 9 SEPTEMBER 2024
16:30 – 18:00
SYDNEY HALL

Organised by: Eli Lilly and Company
MONDAY, 9 SEPTEMBER 2024

16:30 – 18:00
CAIRO HALL

EXPERT INSIGHTS ON THE VALUE OF PROTECTION AGAINST VACCINE-PREVENTABLE DISEASE IN PATIENTS WITH DIABETES

16:30 – 16:35  Welcome and Introduction
16:35 – 16:45  Burden and Outcomes of Vaccine-Preventable Diseases in Patients with Diabetes
16:45 – 17:05  Preventing Severe Outcomes of RSV Infection in Patients with Diabetes: A Case Study
17:05 – 17:25  Maintaining Baseline through Herpes Zoster Prevention in Patients with Diabetes: A Case Study
17:25 – 17:40  Preventing RSV and HZ in Patients with Diabetes: Guideline Recommendations and Implementation Considerations
17:40 – 17:50  Panel Discussion
17:50 – 18:00  Q&A and Closing Remarks

Organised by: GSK
TRIPLE PROTECTION OF SGLT2I: ACT2DAY FOR PATIENTS’ FUTURE

**Chairs:** John Wilding (GBR), Xavier Cos (ESP)

**17:00 – 17:02** Introduction  
John Wilding (GBR)

**17:02 – 17:10** Early glycemic control with SGLT-2 inhibitors and its long-lasting benefits  
John Wilding (GBR)

**17:10 – 17:18** Blunting the progression of renal disease in diabetic patients with Canagliflozin: How, when and who?  
Hiddo L. Heerspink (NLD)

**17:18 – 17:26** Getting to the heart of the matter: Canagliflozin cardiovascular benefits in T2D  
David Matthews (GBR)

**17:26 – 17:34** Cardio-renal-metabolic care in T2D: be holistic!  
Apostolos Tsapas (GRC)

**17:34 – 18:00** Round table: addressing barriers for early initiation of the therapy and Closing remarks  
All faculty

Organised by: Menarini Group
TUESDAY, 10 SEPTEMBER 2024
08:45 – 08:55
VIRTUAL ONLY

AI-ASSISTED SCREENING FOR DIABETIC RETINOPATHY – REAL-LIFE OUTCOMES

08:45 – 08:55  Al-assisted screening for diabetic retinopathy – real-life outcomes
Nina Hautala (FIN)

Organised by:  iCare
TUESDAY, 10 SEPTEMBER 2024

12:00 – 12:30
SPOTLIGHT STAGE

BETA-CELL DYSFUNCTION IN T2D – IS IT IRREVOCABLE?

Chair: Jonathan Rachman (GBR)

12:00 – 12:30  Beta-cell dysfunction in T2D – is it irrevocable?
David Matthews (GBR)

Organised by: Eli Lilly and Company
TUESDAY, 10 SEPTEMBER 2024

14:45 – 15:15
SPOTLIGHT STAGE

Organised by: Abbott
TUESDAY, 10 SEPTEMBER 2024
18:30 – 19:30
MUMBAI HALL

THE RIGHT TIME FOR METFORMIN

Chairs: Harry Howlett (GBR)
        Ian Campbell (GBR)

18:30 – 18:35 Welcome & Introduction
        Harry Howlett (GBR)
        Ian Campbell (GBR)

18:35 – 18:50 Early metformin: Diabetes prevention
        Rosangela Rea (BRA)

18:50 – 19:05 Ongoing metformin: Diabetes treatment
        Juliana Chan (CHN)

19:05 – 19:25 Legacy Metformin: UKPDS 91
        Rury Holman (GBR)

19:25 – 19:30 Questions/Answers
        All faculty

Organised by: Merck KGaA
TUESDAY, 10 SEPTEMBER 2024

IMPROVING ADHERENCE, GLYCEMIC CONTROL AND OUTCOMES FOR PEOPLE LIVING WITH DIABETES

Chair: Kamlesh Khunti (GBR)

18:30 – 18:35  Introduction
   Kamlesh Khunti (GBR)

18:35 – 18:47  Achieving early glycemic control for cardio renal protection: is there a link?
   Somia Iqtadar (PAK)

18:47 – 18:59  What to do for people living with diabetes and cardiovascular diseases
   Otavio Berwanger (GBR)

18:59 – 19:11  What about people living with diabetes and dyslipidemia?
   Salah Abusnana (ARE)

19:11 – 19:23  Why therapeutic adherence matter for better outcomes?
   Bart Torbeys (BEL)

19:23 – 19:30  Panel discussion & conclusion
   All faculty

Organised by:  Servier medical affairs
TUESDAY, 10 SEPTEMBER 2024
18:30 – 20:00
LIMA HALL

AT THE CROSSROADS OF SPECIALTIES:
EXPLORING THE TRENDS IN THE HOLISTIC, PERSON-CENTRED
APPROACH IN CARDIOVASCULAR-KIDNEY-METABOLIC DISEASE

Chair: Sue Pedersen (CAN)

18:30 – 18:45 Welcome and introductions: Connecting the dots between cardiovascular, kidney and metabolic diseases
Sue Pedersen (CAN)

18:45 – 19:35 Multidisciplinary care in cardiovascular, kidney and metabolic diseases: A panel discussion across specialties
All Faculty

19:35 – 19:55 Panel Q&A
All Faculty

19:55 – 20:00 Closing
Sue Pedersen (CAN)

Organised by: Novo Nordisk A/S
CONVERSATIONS BETWEEN SPECIALTIES: THE IMPORTANCE OF SGLT2 INHIBITOR INITIATION FOR THE INTERDISCIPLINARY MANAGEMENT OF CARDIO, RENAL AND METABOLIC CONDITIONS

Chair: Silvio Inzucchi (USA)

07:45 – 07:50 Communication between CRM conditions and specialties
Silvio Inzucchi (USA)

07:50 – 08:00 Striking up a conversation on the importance of early treatment
Rikke Borg (DNK)
Richard Hobbs (GBR)

08:00 – 08:10 A breakdown in communication: the consequences of treatment inertia
Rikke Borg (DNK)
Erin Michos (USA)

08:10 – 08:35 Deep in conversation between specialties
All faculty

08:35 – 08:45 Audience Q&A and closing remarks
Silvio Inzucchi (USA)

Organised by: Boehringer Ingelheim and Eli Lilly and Company
**WEDNESDAY, 11 SEPTEMBER 2024**

07:45 – 08:45

MUMBAI HALL

---

Organised by: **Insulet**
WEDNESDAY, 11 SEPTEMBER 2024

Organised by: Abbott
WEDNESDAY, 11 SEPTEMBER 2024

Organised by: Tandem Diabetes Care, Inc.
WEDNESDAY, 11 SEPTEMBER 2024
12:15 – 12:45
SPOTLIGHT STAGE

T2D CARE IN THE DIGITAL ERA: EVIDENCE WITH ONCE-WEEKLY INSULINS, CGM AND OTHER DIGITAL HEALTH TOOLS

Chair:
Harpreet S. Bajaj (CAN)

12:15 – 12:22 Welcome and introduction
Harpreet S. Bajaj (CAN)

12:22 – 12:30 Navigating T2D treatment: combining once-weekly insulins and CGM
André G. Daher Vianna (BRA)

12:30 – 12:38 Data-driven dosing: digital titration tools for managing T2D
Susanne Reger-Tan (DEU)

12:38 – 12:45 Interactive discussion: integrating once-weekly insulins and digital health tools
All faculty

Organised by: Novo Nordisk A/S
WEDNESDAY, 11 SEPTEMBER 2024

15:00 – 15:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

Organised by: Dexcom
THE NEED TO LOOK BEYOND BMI

**Chair:** Rachel Batterham (GBR)

17:00 – 17:02 **Introduction**
Rachel Batterham (GBR)

17:02 – 17:07 **Why do we need to change – Limitations on the current definition of obesity**
John Wilding (GBR)

17:07 – 17:12 **Why is it important to change – Practical implications for the future of obesity management**
Francesco Rubino (GBR)

17:12 – 17:28 **Q&A**
All Faculty

17:28 – 17:30 **Closing**
Rachel Batterham (GBR)

Organised by: **Eli Lilly and Company**
WEDNESDAY, 11 SEPTEMBER 2024
18:45 – 20:15
LIMA HALL

OBESITY MANAGEMENT IN THE SPOTLIGHT:
HOW CAN WE ACHIEVE PATIENT-CENTRICITY?

18:45 – 18:52 Welcome

18:52 – 19:02 Why should obesity be treated as a serious chronic disease?

19:02 – 19:17 Panel discussion
All Faculty

19:17 – 19:27 Looking beyond the numbers: what are the additional benefits of losing weight?

19:27 – 19:42 Panel discussion
All Faculty

19:42 – 19:52 What are the best practical approaches in obesity management?

19:52 – 20:07 Panel discussion
All Faculty

20:07 – 20:15 Key takeaways and closing remarks
All Faculty

Organised by: Novo Nordisk A/S
EMBRACING INNOVATION IN A NEW ERA OF DIABETES CARE: A CME SYMPOSIUM

Chair: Tina Vilsbøll (DNK)

18:45 – 18:55 Introduction
Tina Vilsbøll (DNK)

18:55 – 19:10 Current goals of type 2 diabetes treatment: Is good glycemic control enough?
Kamlesh Khunti (GBR)

19:10 – 19:35 Are current strategies delivering the holistic treatment approach for people living with T2D?
Melanie Davies (GBR)

19:35 – 19:55 Innovative treatment strategies: will they make a difference, or more of the same?
Tina Vilsbøll (DNK)

19:55 – 20:15 Panel discussion
All faculty

Organised by: Institute for Medical and Nursing Education, Inc. (IMNE) // supported by an educational grant from Novo Nordisk A/S
WEDNESDAY, 11 SEPTEMBER 2024
WARSAW HALL
18:45 – 20:15

FROM BURDEN TO BREAKTHROUGH: REIMAGINING TYPE 1 DIABETES TREATMENT WITH CELL-BASED APPROACHES

Chair: Stephanie Amiel (GBR)

18:45 – 18:55  Welcome and Introduction
Stephanie Amiel (GBR)

18:55 – 19:15  Type 1 Diabetes Treatment in the Era of Technology: Improvements in Clinical Care and the Continuing Need for Innovation
Jennifer Sherr (USA)

19:15 – 19:35  A View From the Clinic: Long-term Experience with Islet Cell Therapy for T1D
Peter Senior (CAN)

19:35 – 19:55  The Possibilities of Stem-cell-Derived Islets
Eelco de Koning (NLD)

19:55 – 20:10  Q&A/Panel Discussion
Stephanie Amiel (GBR)

20:10 – 20:15  Summary of Key Takeaways
Stephanie Amiel (GBR)

Organised by:  Vertex Pharmaceuticals, Inc.
THURSDAY, 12 SEPTEMBER 2024
12:15 – 12:45
SPOTLIGHT STAGE

ADDRESSING THE NEEDS OF ALL PEOPLE LIVING WITH
TYPE 1 DIABETES

12:15 – 12:30  The MiniMed™ 780G system addressing the needs
of every population

12:30 – 12:45  Maximizing the benefits of MDI therapy: the Smart MDI system

Organised by:  Medtronic International Trading Sàrl
THURSDAY, 12 SEPTEMBER 2024
15:00 – 15:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

Organised by: Roche Diabetes Care GmbH
THURSDAY, 12 SEPTEMBER 2024
18:45 – 19:15
WARSAW HALL

BREAKING THE BARRIERS: ADDRESSING THE METABOLIC IMPACT
OF MASH WITH MULTIDISCIPLINARY CARE

Chairs: Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

18:45 – 18:47 Introduction
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

18:47 – 18:57 MASH as a metabolic disease
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

18:57 – 19:07 Multidisciplinary care in MASH
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

19:07 – 19:13 Q & A
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

19:13 – 19:15 Summary and close
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

Organised by: Novo Nordisk A/S and Echosens
THURSDAY, 12 SEPTEMBER 2024  
18:45 – 19:45  
LIMA HALL

ENTERING A NEW ERA IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS: EXAMINING THE CLINICAL IMPLICATIONS OF EMERGING DISEASE-SPECIFIC THERAPIES

Chair: Meena Bansal (USA)

Meena Bansal (USA)

18:55 – 19:10 THR-β Agonists and Other Disease-specific Therapies Poised to Change the Paradigm  
Elisabetta Bugianesi (ITA)

19:10 – 19:20 Rising to the Need to Improve Diagnosis in the Era of Disease-specific Therapy

19:20 – 19:40 Clinical Case Challenge: Integrating MASLD/MASH-Specific Therapy into Practice  
Meena Bansal (USA)

19:40 – 19:45 Q&A  
All faculty

Organised by: AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. // supported by an educational grant from Madrigal Pharmaceuticals
THURSDAY, 12 SEPTEMBER 2024
18:45 – 19:45
MUMBAI HALL

CHOLESTEROL LOWERING IN HIGH CARDIOVASCULAR RISK PATIENTS WITH COMORBIDITIES: CLOSING GAPS AND FUTURE OPPORTUNITIES

Chair: Klaus Parhofer (DEU)

18:45 – 18:50 Welcome and introduction
Klaus Parhofer (DEU)

18:50 – 19:00 LDL lowering in patients with diabetes and other metabolic diseases
Luis Masana (ESP)

19:00 – 19:15 Unmet needs: Real-world evidence reveals treatment gaps in patients with diabetes and obesity
Anna Solini (ITA)

19:15 – 19:30 Closing the Gap: Advancing lipid management in high-risk patients with comorbidities
Dirk Mueller-Wieland (DEU)

19:30 – 19:45 Panel discussion and Q&A
All faculty

Organised by: DAIICHI SANKYO EUROPE GmbH
MANAGEMENT OF CKD IN T2D – WHERE ARE WE TODAY?

Chairs: Paola Fioretto (ITA), Jose Luis Górriz (ESP)

19:45 – 19:46 Introduction
Paola Fioretto (ITA)

19:46 – 19:48 Global burden of CKD and T2D
Jose Luis Górriz (ESP)

19:48 – 19:52 Evolution of clinical guidelines in CKD and T2D
Paola Fioretto (ITA)

19:52 – 19:55 Kidney outcome trials in patients with CKD and T2D
Jose Luis Górriz (ESP)

19:55 – 20:15 Discussion: Practical considerations for the management of patients with CKD and T2D – endocrinologist and nephrologist perspectives
Paola Fioretto (ITA)
Jose Luis Górriz (ESP)

Organised by: Novo Nordisk A/S
FRIDAY, 13 SEPTEMBER 2024
10:00 – 10:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

Organised by: Boehringer Ingelheim International GmbH
FRIDAY, 13 SEPTEMBER 2024

11:30 – 12:00
SPOTLIGHT STAGE

ENABLING WOMEN WITH TYPE 1 DIABETES TO ACHIEVE THEIR GOALS WITH AUTOMATED INSULIN DELIVERY

Chair: Helen Murphy (GBR)

11:30 – 11:45 mylife CamAPS FX: a unique solution while planning and throughout pregnancy
Helen Murphy (GBR)

11:45 – 12:00 Application in the clinical practice: insights from a center initiating the journey with mylife CamAPS FX
Pilar Beato Vibora (ESP)

Organised by: Ypsomed AG
SPONSORS LIST

A. Menarini Diagnostics
Abbott
ACON Laboratories Inc.
Ascensia Diabetes Care
AstraZeneca
Bayer AG
Bionime Corporation
Boehringer Ingelheim and Eli Lilly and Company
Boehringer Ingelheim International GmbH
Capteur Protect
CREATION.co
DAIICHI SANKYO EUROPE GmbH
Dexcom
Diabeloop
DiagnOptics Technologies BV
Diamyd Medical AB
ECHOSENS
Eli Lilly and Company
EPS Bio Technology Corp.
Eva Pharma
GC Medical Science Corp.
GSK
iCare
Innovation Zed
Inreda Diabetic
Institute for Medical and Nursing Education, Inc. (IMNE)
Insulet
InsulinSaver AB
i-SENS
Madrigal Pharmaceuticals
Mcentre Co., Ltd
Medtronic International Trading Sàrl
Medtrum Technologies Inc.
Menarini Group
Merck KGaA
MESI, development of medical devices
MicroTech Medical
Nightingale Health
Ningbo Medsun Medical Co., Ltd.
Nova Biomedical
Novo Nordisk A/S
PATIA
ProSciento, Inc.
Roche Diabetes Care GmbH
SANOFI
Servier International / Servier medical affairs
SIBIONICS CGM
Sinocare Meditech Inc.
SOOIL Development Co., Ltd
Syai Health GmbH
Tandem Diabetes Care, Inc.
Vertex Pharmaceuticals, Inc.
Wisepress Medical Bookshop
Ypsomed AG
Yuwell-POCTech
EASD and EFSD Acknowledgements

The European Association for the Study of Diabetes (EASD) is most grateful to the following companies and organisations for their ongoing support of the prestigious prizes awarded on the occasion of the EASD Annual Meeting.

Lilly
The Albert Renold Prize is generously supported by Lilly.
The Minkowski Prize is generously supported by Lilly.

Novo Nordisk
The Camillo Golgi Prize is generously supported by Novo Nordisk.
The Rising Star Symposium and Fellowship is generously supported by Novo Nordisk.

Novo Nordisk Foundation
The Diabetes Prize for Excellence is generously supported by the Novo Nordisk Foundation.

Sanofi
The Claude Bernard Prize is generously supported by Sanofi.
The European Foundation for the Study of Diabetes (EFSD) is greatly indebted to the following companies and organisations for their most generous support of European diabetes research.

**Boehringer Ingelheim**

**EFSD/Boehringer Ingelheim European Research Programme on “Multi-System Challenges in Diabetes”**

This Programme is intended to stimulate and accelerate European research on the interrelation and crosstalk of different organs e.g. heart, kidney, pancreas, gut, liver and brain and related pathophysiology in diabetes, obesity and cardiometabolic disease, and the impact of therapeutic interventions for these complex conditions.

**Japan Diabetes Society**

**EFSD/JDS Reciprocal Travel Research Fellowships**

The objective of these Fellowships is to encourage collaborative research between Europe and Japan in the field of diabetes.

**Lilly**

**EFSD/Lilly European Diabetes Research Programme**

This Programme aims to promote increased European diabetes research and to raise public awareness and political understanding of the magnitude and burden of the disease. Grants are offered for any area of basic or clinical diabetes research.

**EFSD/Lilly Young Investigator Research Award Programme**

The objective of these Young Investigator Research Awards is to encourage innovative research in the field of diabetes and its complications, and to promote excellence in medical education.

**Novo Nordisk**

**EFSD/Novo Nordisk Programme for Diabetes Research in Europe**

This Programme aims to promote high-quality diabetes research in Europe and accepts applications from all fields of clinical and basic diabetes research.
**EASD Rising Star Symposium & EFSD Research Fellowship Programme supported by Novo Nordisk**

This combined EASD/EFSD initiative aims to identify promising and innovative young researchers in basic and clinical diabetes research.

**Novo Nordisk Foundation**

**EFSD/Novo Nordisk Foundation Future Leaders Award Programme**

This Programme is intended to identify outstanding clinical and basic scientists in European diabetes research in the transition from postdoctoral/clinical fellow to a tenured academic appointment in diabetes research in Europe and support them through significant career development awards over 5 years and fostering their development into the leaders of tomorrow.

**Sanofi**

**EFSD and Sanofi European Diabetes Research Programme on autoimmunity in type 1 diabetes**

The Programme is intended to stimulate and accelerate European research aimed at understanding of any aspect of autoimmunity in type 1 diabetes, its pathogenesis, screening and monitoring, its clinical course and its interventions.

In addition, the **EFSD Albert Renold Travel Fellowships** enables young scientists to stay at other institutions in order to learn new techniques in basic or clinical diabetes research.
#EASD2024

POST LIVE AND FOLLOW THE DISCUSSION ON SOCIAL MEDIA